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ABSTRACT 
 
The vast potential of the RNA interference (RNAi) pathway as a new tool for the development of 
therapeutic modalities has been quickly realised since its discovery in 1998. RNAi effector mimics have 
been developed to successfully silence an array of disease-causing genetic elements.  However, 
because of the rapidly mutating genome of viruses such as the human immunodeficiency virus (HIV), 
inhibition of replication cannot be sustained with single RNAi effector mimics.  Instead, a combinatorial 
approach is required, analogous to the cocktail of drugs necessary for successful highly active 
antiretroviral therapy (HAART).  Pioneering studies utilizing long hairpin RNAs (lhRNAs) showed that 
the long double-stranded RNA stem region acts as a Dicer substrate and is processed into multiple 
siRNA species.   This intrinsic combinatorial property of lhRNAs was exploited in this thesis by 
attempting to incorporate three non-contiguous potent siRNA sequences within a single lhRNA stem 
expressed from an RNA Pol III promoter.  Although significant knockdown of three independent HIV 
target sequences was possible, the limitations of this approach became apparent when it was 
observed that human Dicer does not function efficiently as a multiple turnover enzyme.  The generation 
of siRNA products therefore occurred in a gradient, with higher levels of siRNA produced from the base 
of the hairpin stem and decreasing quantities generated towards the loop.  Modifications to the 
configuration of integrated siRNA sequences within the stem region enabled augmented RNAi activity 
of siRNAs in the second position of the hairpin stem.  This led to the notion that further manipulation of 
the structural design of the stem duplex may improve efficacy of up to two siRNAs.  Dual-targeting anti-
HIV lhRNAs encoding only two highly effective siRNAs targeted against non-contiguous sites within the 
tat, nef, LTR and int viral genes were therefore propagated.  The spatial arrangement of two siRNA 
sequences was extensively characterised within dual-targeting lhRNAs by inserting up to three random 
base pairs at the junctions of siRNA encoding sequences and 5 bp preceding the terminal loop 
sequence.  A universally optimal hairpin design was identified which contained a single mismatched 
base pair between two 19 bp + 2 nt siRNA sequences, as well as a terminal extension.  Two powerful 
dual-targeting lhRNA species, lhRNA-tat-nef +1 and lhRNA-LTR-int +1, each capable of producing two 
 A
B
S
T
R
A
C
T
 
vi 
 
potent anti-HIV siRNA products in equal quantities were selected for incorporation into a combinatorial 
RNAi system.  These two effective dual-targeting lhRNAs were combined, adjacent to one another 
within a single RNA Pol III-expressed transcript to create a novel lhRNA-based combinatorial RNAi 
structure. This double lhRNA (dlhRNA) construct served as a precursor for four discrete highly 
functional RNAi effector sequences which were capable of simultaneously silencing four unique HIV 
target sites within the tat, nef, LTR and int genes. Furthermore, the ectopic expression of dlhRNAs did 
not elicit activation of the interferon response, nor did it cause saturation of the endogenous miRNA 
biogenesis pathway in vitro.  In conclusion, the inherent combinatorial RNAi properties of long hairpin 
RNAs were evaluated and the detailed analysis is presented in this thesis.  Structurally optimised dual-
targeting lhRNAs subsequently formed the core components of a novel dlhRNA precursor which meets 
all the requirements for an effective combinatorial RNAi strategy and therefore holds great promise for 
mediating an effective and sustained gene therapy against HIV.  
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CHAPTER 1 
Introduction 
 
1.1 Overview of the introduction 
 
The discovery of the RNA interference (RNAi) pathway and its underlying mechanisms has 
offered researchers a new tool with which to develop novel therapeutics for the treatment of a wide 
array of diseases.  This introductory chapter will explore the intricate network of factors associated with 
this fundamental gene silencing pathway and discuss various mechanisms through which the effectors 
of the pathway are mimicked for sequence specific gene silencing.  The ability of RNAi effector mimics 
to inhibit disease-causing genetic elements and their consequent potential as therapeutic modalities 
will be emphasized.  Given the lack of an effective vaccine or cure for infection by the human 
immunodeficiency virus (HIV), and the current pandemic caused by this virus, strategies for exploiting 
RNAi for the treatment of HIV/acquired immunodeficiency disease (AIDS) will form the focus of this 
thesis.  The rapid evolution of HIV and its consequent ability to develop resistance to single RNAi 
effectors will be addressed, and the need for the simultaneous administration of multiple therapeutic 
modalities to effect prolonged viral inhibition will be highlighted.  Finally, strategies to modify RNAi 
effector mimics for the simultaneous inhibition of multiple gene targets will be discussed, with the 
ultimate aim of designing and developing an RNAi-based combinatorial strategy for the effective long 
term inhibition of HIV gene expression and replication. 
 
1.2 RNA interference  
 
RNA interference (RNAi) is an evolutionary conserved eukaryotic gene silencing pathway and 
represents a fundamental system for intracellular gene expression regulation.  This phenomenon was 
first observed in petunias when exogenously introduced transgenes were shown to suppress 
homologous gene expression, and was termed “co-suppression” (Napoli et al. 1990).  Similar 
 C
H
A
P
T
E
R
 1
 
2 
 
observations were later made in the fungus Neurospora crassa and the phenomenon was termed 
“quelling” (Romano and Macino 1992).  In 1998 Fire and Mello made the seminal discovery that 
double-stranded RNA (dsRNA) was the trigger for such silencing events and described the sequence 
specific silencing mechanism of RNAi in Caenorhabditis elegans (Fire et al. 1998).   
The molecular mechanism underlying RNAi was largely elucidated by several studies conducted 
in Drosophila melanogaster cells (Hammond et al. 2000; Zamore et al. 2000; Elbashir et al. 2001b). 
RNAi was found to be mediated by small dsRNA species that are 21-25 bp in length, which are 
processed from longer dsRNA precursors by an RNase III endonuclease.  These small interfering 
RNAs (siRNAs), together with protein co-factors were found to associate with endonucleases and 
members of the Argonaute protein family, to guide the cleavage of mRNA complementary to one of the 
strands of the siRNA, resulting in sequence specific degradation of target mRNA (Hammond et al. 
2000; Zamore et al. 2000; Elbashir et al. 2001b). 
 
1.3 Biogenesis of small RNAs in humans  
 
Different classes of small RNAs have since been identified and can be distinguished on the basis 
of their biogenesis pathways, their silencing mechanisms and their cellular roles.  To date, three 
classes of eukaryotic small RNAs have been classified: microRNAs (miRNAs), endogenous small 
interfering RNAs (endo-siRNAs) and Piwi-interacting RNAs (piRNAs) [reviewed in (Ghildiyal and 
Zamore 2009; Kim et al. 2009)].  For the purposes of this thesis I will focus on the biogenesis pathway 
of the miRNA class of small RNAs in humans (Figure 1.1).  Today over 700 miRNAs have been 
identified in humans alone (miRBase accessed 2010).  These small RNAs are derived from hairpin-like 
structures transcribed from the genome and regulate endogenous genes at the post-transcriptional 
level and in rare cases at the transcriptional level (Kim et al. 2008).  To harness this pathway for the 
development of therapeutics, an understanding of the intricate biogenesis of miRNAs is imperative. 
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Figure 1.1:  The endogenous mammalian miRNA biogenesis pathway.  Genes encoding miRNAs 
are transcribed by RNA Pol II promoters to form stem loop structures termed Primary miRNAs (pri-
miRNAs) which are flanked by ssRNA sequences.  Pri-miRNAs are recognised and processed by the 
Drosha/DGCR8 microprocessor complex to form Precursor miRNAs (Pre-miRNAs) which are 
transported from the nucleus to the cytoplasm by exportin 5.  Pre-miRNAs are recognised and cleaved 
in the cytoplasm by Dicer to yield miRNAs.  Mature miRNAs assemble into a protein complex known as 
the RNA induced silencing complex (RISC), which guides the effector strand to a complementary 
region within the 3‟ UTR of a mRNA target where, depending on the degree of complementarity 
between the miRNA and mRNA target, can mediate translational suppression, deadenylation or mRNA 
cleavage.  Translationally repressed mRNA targets are often stored in cytoplasmic processing bodies 
(P-bodies). 
 
1.3.1  Expression and processing of primary miRNAs in the nucleus 
 
Genes encoding miRNAs are scattered throughout the genome and may be found in intergenic 
regions, as well as within the introns of protein-coding genes, or the introns and exons of non-coding 
RNAs (Kim and Nam 2006). A large proportion of miRNAs have been found in clusters, usually of two 
or three functionally related miRNAs, and are transcribed as polycistronic units (Yuan et al. 2009).  
MicroRNA genes, with a few exceptions (Borchert et al. 2006), are transcribed by RNA Pol II promoters 
(Cai et al. 2004; Lee et al. 2004), which are responsible for the transcription of messenger RNAs and 
many small nuclear RNAs.  Once transcribed, the RNA folds into a hairpin-like structure consisting of 
an imperfectly paired stem region of approximately 33 bp with an apical loop and single stranded 5‟ 
and 3‟ flanking sequences.  The mature miRNA guide sequence is embedded in either of the 5‟ or the 
3‟ arms of the hairpin duplex.  Primary miRNA (pri-miRNA)-containing transcripts may comprise 
several kb and the pri-miRNA hairpins are excised from the transcript within the nucleus by the RNase 
III enzyme Drosha, to generate a precursor miRNA (pre-miRNA) (Lee et al. 2002b; Lee et al. 2003).  
For this cleavage reaction to occur, Drosha associates with a co-factor known as DiGeorge syndrome 
critical region gene 8 (DGCR8), to form the microprocessor complex (Gregory et al. 2004; Han et al. 
2004; Landthaler et al. 2004).  The complex catalyses the processing of the pri-miRNA stem to yield a 
pre-miRNA with a ~22 bp stem (Zeng et al. 2005; Han et al. 2006) (for further information regarding 
Drosha-mediated cleavage, see section 1.5.1).  Another less common mechanism for the generation of 
pre-miRNA sequences is a Drosha/DGCR8-independent mechanism, first described in Drosophila 
melanogaster and C. elegans (Ruby et al. 2007) and later discovered in mammals (Berezikov et al. 
 C
H
A
P
T
E
R
 1
 
5 
 
2007; Babiarz et al. 2008). The miRNA is encoded by an intronic sequence which, following splicing 
and a debranching, closely resembles the structure of a pre-miRNA.  These structures are termed 
mirtrons and in some cases may require exonucleolytic cleavage of extended 5‟ or 3‟ flanking tails 
before the convergence of the canonical and mirtronic miRNA biogenesis pathways (Babiarz et al. 
2008).   
 
1.3.2  Export of precursor miRNAs from the nucleus and cytoplasmic cleavage 
 
Once nuclear processing of the pri-miRNAs is complete, pre-miRNAs require translocation to the 
cytoplasm.  All non-coding RNAs are dependent on the karyopherin family of nucleocytoplasmic 
transport factors for export from the nucleus (Cullen 2003), and Exportin-5 (Exp-5) was defined as the 
karyopherin responsible for the transport of pre-miRNAs (Yi et al. 2003b; Bohnsack et al. 2004; Lund et 
al. 2004).  Exportin-5 binds directly to the pre-miRNA in the presence of guanosine triphosphate 
(GTP)-bound Ran (RanGTP), and this Exp-5/RanGTP/pre-miRNA heteroternary complex is 
transported to the cytoplasm via nuclear pore complexes.  In the cytoplasm, RanGTP is hydrolysed to 
form RanGDP, resulting in the release of the pre-miRNA (Cullen 2003; Kim 2004).  It was reported that 
Exp-5 may bind to the entire stem region of pre-miR-30 thus protecting this miRNA against 
endonuclease degradation (Zeng and Cullen 2004).  This was confirmed following the recent unveiling 
of the crystal structure of human Exp-5 (Okada et al. 2009).  Exp-5 interacts with RanGTP and this 
duplex folds around the sugar-phosphate backbone of the dsRNA stem region of pre-miRNAs.  
Because both the 5‟ and 3‟ ends of the pre-miRNA are shielded within the Exp-5/RanGTP duplex, the 
pre-miRNA is completely protected against intracellular degradation (Okada et al. 2009).  
The second processing reaction in the biogenesis of miRNAs occurs in the cytoplasm and is 
mediated by the RNase III enzyme Dicer (Bernstein et al. 2001; Hutvagner et al. 2001; Ketting et al. 
2001).  The Piwi Argonaute Zwille (PAZ) domain of the Dicer enzyme recognises and binds the 
terminal 3‟ overhang of the miRNA duplex, and the two RNase III domains catalyse the cleavage of the 
duplex approximately 22-25 nt away from the PAZ/RNA interaction, resulting in the removal of the 
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terminal loop sequence and the generation of a mature miRNA duplex (the structure and cleavage 
mechanism of Dicer is comprehensively addressed in section 1.5.1).  Dicer-generated RNA duplexes 
are generally ~22 bp and contain distinctive characteristics such as 5‟ phosphate and 3‟ hydroxyl 
groups, and 2 nt 3‟ single stranded overhangs (Elbashir et al. 2001b; Elbashir et al. 2001c).  Dicer may 
also associate with two RNA binding proteins: TAR RNA-binding protein (TRBP) (Chendrimada et al. 
2005; Haase et al. 2005; Lau et al. 2009) and the protein activator of PKR (PACT) (Lee et al. 2006), 
which aid in facilitating assembly and later form part of the RNA-induced silencing complex (RISC).   
 
1.3.3 RISC loading 
 
Despite extensive research describing the assembly of the mature RISC complex, the intricacies 
of RISC loading are still debated.  The prevailing mechanistic view is that Dicer interacts with TRPB 
and Ago2 to form the minimal RISC loading complex (Gregory et al. 2005), and the crystal structure of 
this complex has recently been solved (Wang et al. 2009b).  The formation of the RISC loading 
complex facilitates the transfer of the miRNA duplex from Dicer to Ago2, although ultimately only a 
single strand (the guide strand) is retained in the mature/holo RISC complex which may comprise 
additional protein factors as well.  The mechanism by which the passenger strand is removed remains 
a point of contention.  During assembly of mature RISC, Ago2, which is the only human Ago protein 
known to have “slicer” activity (Liu et al. 2004; Meister et al. 2004), has been shown to cleave the 
passenger strand of the miRNA duplex in an ATP-independent manner, resulting in its dissociation 
from the RISC complex and probable degradation (Matranga et al. 2005; Rand et al. 2005; Leuschner 
et al. 2006).  However, the identification of another ATP-dependent helicase, RNA helices A (RHA), 
which associates with the RISC loading complex during the assembly process, supports earlier notions 
that the miRNA duplex is unwound in an ATP-dependent manner before the incorporation of the guide 
strand into mature RISC (Robb and Rana 2007).  Although Ago2 is the only human Ago protein which 
contains intrinsic slicer activity for the cleavage of mRNA targets, the remaining Ago proteins (Ago1, 
Ago3 and Ago4) still form part of mature RISC complexes.  To complicate matters further, current work 
has just shown that Ago1 is also able to cleave the passenger strand of miRNA duplexes (Wang et al. 
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2009a), implicating Ago1 in the duplex dissociation process.  It is a possibility that slightly different 
loading mechanisms proceed according to the nature of the RNA duplex, however further analysis is 
still essential to deduce the exact mechanism by which the active guide strand is incorporated into the 
mature RISC complex.  The guide strand is in most cases selected based on thermodynamic stability 
of the miRNA duplex.  The strand with the more unstably paired 5‟ end is typically retained whilst the 
unselected strand is removed (Khvorova et al. 2003; Schwarz et al. 2003).  In addition to 
thermodynamic asymmetry, certain sequence elements have been shown to also play a distinct role in 
strand selection bias (Hu et al. 2009).  A 5‟ U in the selected strand; a 5‟ C in the eliminated strand as 
well as a higher purine content of the selected strand and the consequent increase in the pyrimidine 
content of the unselected strand may all play a role in strand selection (Hu et al. 2009).  These factors 
must therefore be recognised by the RISC loading complex, which determines the orientation of the 
miRNA duplex (Wang et al. 2009b).  Until recently it has been largely assumed that the eliminated 
passenger strand is degraded upon dissociation from its duplex precursor.  It has however been shown 
in Drosophila that the passenger strand may also be loaded onto Ago proteins to mediate mRNA target 
specific silencing (Czech et al. 2009; Okamura et al. 2009; Ghildiyal et al. 2010).  This observed 
phenomenon remains to be confirmed in humans but given the conservation in the mechanisms 
underlying the RNAi pathway, this possibility should not be disregarded. 
 
1.3.4 The silencing mechanism  
 
The single stranded miRNA guide strand directs the RISC complex to its complementary RNA 
target, usually situated within the 3‟UTR of an mRNA transcript.  Nucleotides at positions 2-8 at the 5‟ 
end of the guide strand are known as the “seed” region and base pairing of the seed region to an 
mRNA target is both essential and sufficient to induce miRNA-mediated gene silencing (Lewis et al. 
2003; Brennecke et al. 2005; Lewis et al. 2005).  In addition to canonical 7-mer seed regions, 8-mer 
and 6-mer sites have also been identified with the latter exhibiting reduced efficacy (Lewis et al. 2005; 
Friedman et al. 2009).  Although the remaining 3‟ sequence of the guide strand has been deemed 
inconsequential, central base pairing at positions 13-17 may supplement seed pairing or compensate 
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for a seed mismatch, thereby contributing to target recognition (Grimson et al. 2007) [For a 
comprehensive review of predicted miRNA targets see (Bartel 2009)].  Silencing of gene expression is 
effected by two primary mechanisms depending on the degree of complementarity between the miRNA 
guide strand and the mRNA target.  Guide strands exhibiting perfect complementarity to their cognate 
target mRNA execute gene repression by Ago2-mediated cleavage of the target RNA (Yekta et al. 
2004).  This is uncommon for many mammalian miRNAs as the majority of miRNA guide strands only 
display partial complementarity with their mRNA targets resulting in translational suppression and 
consequent gene silencing.  The underlying mechanism of translational repression is still disputed; 
however several mechanisms have been described and include:  the inhibition of translational initiation  
(Kiriakidou et al. 2007; Mathonnet et al. 2007); elongation blockage or the dissociation of ribosomes 
(Petersen et al. 2006); co-translational degradation of the nascent polypeptide (Nottrott et al. 2006); or 
deadenylation resulting in decapping and the consequent degradation of the mRNA transcript 
(Wakiyama et al. 2007; Fabian et al. 2009) [reviewed in (Eulalio et al. 2008; Filipowicz et al. 2008; 
Chekulaeva and Filipowicz 2009)].  Furthermore, together with Ago and GW182 proteins, the miRNA 
guide strand-mRNA duplex may be sequestered into cytoplasmic foci known as processing bodies (P-
bodies) which play a role in the degradation and storage of translationally repressed mRNAs (Liu et al. 
2005; Parker and Sheth 2007) (Figure 1.1).  It is intriguing to note that translational suppression of 
miRNAs may be a reversible process.  Repression of CAT-1 mRNA by miR-122 in hepatoma cells was 
observed to be reversed under conditions of stress, and this derepression was accompanied by a 
release of repressed mRNA from P-bodies for active translation (Bhattacharyya et al. 2006). 
 
1.4 Additional RNAi-related pathways in humans 
 
Small interfering RNAs (siRNAs) represent a second class of small RNAs and these RNA 
duplexes closely resemble the structure of mature miRNAs.  In contrast to the miRNA biogenesis 
pathway, siRNA biogenesis is Drosha independent.  Double-stranded RNA transcripts are processed 
by Dicer in the cytoplasm to yield siRNAs.  The siRNA/Dicer/TRBP complex is loaded onto Ago 
proteins and since the guide strand typically exhibits perfect complementarity with its mRNA target, 
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Ago2 cleaves the mRNA which is subsequently degraded.  siRNAs were initially thought to be derived 
from Dicer-mediated cleavage of only exogenous dsRNA precursors such as viruses and transgene 
transcripts.  More recently however, endo-siRNAs have been identified which are generated from 
endogenous sources such as convergent mRNA transcripts, natural sense-antisense duplexes, 
pseudogenes and transposons (Babiarz et al. 2008; Tam et al. 2008; Watanabe et al. 2008).  The 
biological role of endo-siRNAs has yet to be elucidated [reviewed in (Ghildiyal and Zamore 2009; Kim 
et al. 2009)].   
The class of small RNAs most recently identified is that of Piwi-interacting RNAs (piRNAs), which 
are derived from repeat sequences in the genome and function primarily in germ line cells [reviewed in 
(Ghildiyal and Zamore 2009; Kim et al. 2009)].  The biogenesis as well as the function of piRNAs 
remain somewhat unclear although piRNAs, which are distinctly longer than both miRNAs and siRNAs, 
appear to originate from single stranded precursors through a Drosha and Dicer independent 
mechanism (Vagin et al. 2006).  As the name suggests, this class of small RNA associates with the 
PIWI subfamily of Ago proteins and has been shown to cause transcriptional silencing of transposons 
by establishing de novo DNA methylation in murine fetal testes (Aravin et al. 2007; Aravin et al. 2008; 
Kuramochi-Miyagawa et al. 2008).   
Transcriptional gene silencing (TGS) is an RNAi-related pathway originally described in plants 
(Wassenegger et al. 1994; Mette et al. 2000) and later in fission yeast (Volpe et al. 2002) and 
Drosophila (Pal-Bhadra et al. 2002), whereby gene silencing is effected by epigenetic changes at the 
promoter region.  Synthetic promoter-targeted small RNAs have since been used to induce TGS in 
human cells and although the underlying mechanism of TGS in mammalian cells remains unclear, the 
effect is largely mediated by DNA methylation at the promoter and methylation of histone 3 lysine 9 
and 27 (Morris et al. 2004a; Castanotto et al. 2005; Weinberg et al. 2006).  Interestingly, Ago1 and 
Ago2 (Janowski et al. 2006; Kim et al. 2006) as well as Dicer (Ting et al. 2008; Tan et al. 2009) have 
been implicated in the TGS pathway.  In addition to exogenous small RNA-mediated TGS, it has been 
shown that endogenous miRNAs may be encoded by promoter regions and may mediate epigenetic 
changes and TGS of the downstream gene (Kim et al. 2008; Tan et al. 2009).   
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1.5 Key proteins for human RNAi pathways 
 
Despite the existence of distinct classes of small RNAs which differ in both origin and function, 
their biogenesis pathways show some intersection not only with each other but with RNAi-related 
pathways, all of which share a common requirement for certain key RNAi proteins.  These proteins 
include the argonaute proteins and in some cases, the RNase III enzymes Dicer and/or Drosha.  
 
1.5.1 RNase III enzymes 
 
 Drosha and Dicer belong to the RNase III family of proteins and are both critical in the 
biogenesis of certain small RNAs.  RNase III proteins are endonucleases which specifically catalyse 
the hydrolysis of dsRNA.  The first RNase III enzyme was described in E. coli (Robertson et al. 1968) 
but has since been found ubiquitously in eukaryotes.  Both Dicer and Drosha share a common double-
stranded RNA-binding domain (dsRBD) as well as two ribonuclease (RNase III) domains which contain 
the catalytic sites necessary for cleavage of each of the RNA strands (Figure 1.2).  In addition to the 
dsRBD and RNase III domains, Dicer also contains an N terminal helicase domain; a domain of 
unknown function (DUF 283) and a PAZ domain which is shared by Ago proteins (Figure 1.2).   
Dicer is a crucial enzyme for the generation of mature RNAi effectors and a clear understanding 
of the mechanism of Dicer-mediated cleavage is fundamental for the design of RNAi-based therapeutic 
precursors, from which one or more effectors are derived in a Dicer-dependent manner.  A model by 
which Dicer functions has in recent years been gradually pieced together.  Three concurrent structural 
studies determined the three-dimensional crystal structures of the PAZ domains of Drosophila Ago 1 
(Yan et al. 2003) and Ago 2 (Lingel et al. 2003; Song et al. 2003).  The structure of the PAZ domain 
revealed a unique fold, exhibiting a similar topology to the folds found in oligonucleotide / 
oligosaccharide-binding (OB) proteins, which enable this family of proteins to bind single stranded 
nucleic acids.   The binding surface of this PAZ domain fold was found to be conserved between Ago 
and Dicer PAZ domains and furthermore, positively charged residues residing on this surface 
suggested the possibility of binding negatively charged ligands such as nucleic acids. 
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Figure 1.2:  Schematic representation of the functional domains of the human RNase III 
enzymes Dicer and Drosha as well as of the Argonaute proteins.  Human Dicer consists of N 
terminal helicase and DUF 283 domains, a PAZ domain, two RNase III domains and a dsRNA binding 
domain.  Drosha also contains two RNase III domains and a dsRNA binding domain and in addition an 
N terminal proline rich region.  Argonaute proteins share a PAZ domain with Dicer and also contain a 
MID and a PIWI domain. 
 
  Additional assays observed low affinity binding between the PAZ domain and single stranded 
RNA overhangs (Lingel et al. 2003; Song et al. 2003; Yan et al. 2003).  The crystal structure of human 
Ago bound to a 9 bp RNA duplex confirmed that the PAZ domain of Ago and Dicer proteins contains a 
highly conserved RNA binding pocket which serves as the critical factor responsible for binding the 2 nt 
3‟ overhang of siRNAs (Ma et al. 2004) (Figure 1.3).  The conservation of the PAZ domain between 
Dicer and Ago proteins therefore makes sense, since both of these proteins recognise the 3‟ terminal 
structure of siRNAs/siRNA precursors for specific incorporation into the RNAi pathway.  The interaction 
between PAZ and dsRNA is highly specific and the terminal structure as well as the sequence of the 
siRNA ends have a distinct effect on the position and efficiency of Dicer cleavage (Vermeulen et al. 
2005).  Terminal overhangs longer than 3 nt dramatically decreased the efficiency of Dicer processing 
and the overhang sequence, to a lesser extent, also affected Dicer processing with a CA overhang 
resulting in the most efficient cleavage and an AU overhang resulting in the poorest. 
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Figure 1.3:  Schematic illustration of the proposed mechanism by which the functional domains 
of human Dicer interact with dsRNA.  The PAZ domain recognises and binds to the 3‟ single 
stranded overhang and indirectly positions the two RNase III domains at a point along the RNA duplex 
approximately 25 nt away from the PAZ RNA binding pocket.  The catalytic sites within each RNase III 
domain contain cation binding sites and the yellow arrows indicate approximate cleavage positions.  
The N terminal helicase domain is thought to position itself around the alpha helix which connects the 
PAZ and RNase III a domains. 
 
The PAZ domain is connected to the two ribonuclease domains, termed RNase III a and b.  
Zhang et al. proposed a model in which the two RNase III domains form an intramolecular dimer, 
resulting in a single processing centre containing two catalytic sites which function independently of 
one another to each cleave one strand of the dsRNA duplex (Zhang et al. 2004) (Figure 1.3).  This 
model was later confirmed by two studies which analysed the crystal structure of the intact Giardia 
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intestinalis Dicer (Macrae et al. 2006) and the Aquifex aeolicus RNase III (Gan et al. 2006).  The 
Giardia Dicer enzyme contains a PAZ domain and two RNase III domains but lacks any N terminal or 
C terminal domains; however it is still capable of robust dicing activity producing ~25 nt products in 
vitro.  The crystal structure of the intact enzyme showed that the PAZ domain shared a conserved 2 nt 
3‟ RNA binding fold seen in the PAZ domains of Drosophila Ago 1 and 2.  The PAZ domain is directly 
connected to the RNase III a domain by a long alpha helix which is surrounded by N terminal residues.  
The two RNase III domains are linked to form the internal heterodimer described by Zhang et al.  Each 
catalytic site contains two cation binding sites to which divalent metal cations, necessary for hydrolysis, 
may bind (Figure 1.3).  The length between the PAZ-RNA binding fold and the active site within RNase 
III was measured to be 65 Angstroms which is equivalent to 25 nt, corresponding to the length of 
Giardia Dicer products.  This length, which is determined largely by the length of the connector alpha 
helix, is responsible for generating Dicer cleavage products which are consistently uniform in size 
(Macrae et al. 2006). Human Dicer cleavage products are slightly shorter (~21-23 nt), and this 
suggests that the alpha helix in human Dicer may also be slightly shorter. 
Cleavage of dsRNA by these RNase III proteins therefore results in well defined products with 
distinct termini including a 5‟ monophosphate and a 2 nt 3‟ overhang, [reviewed in (MacRae and 
Doudna 2007)].  As mentioned previously, the N terminal of human Dicer consists of DExD/H-box 
helicase domain and the DUF 283 domain.  The function of the DUF 283 domain is as yet unknown.  It 
was proposed that this domain may bind dsRNA (Dlakic 2006), yet this notion was later disputed (Ma 
et al. 2008).  The helicase domain contains binding sites for the direct interaction of Dicer with its 
accessory proteins: TRBP (Chendrimada et al. 2005; Haase et al. 2005) and PACT (Lee et al. 2006).  
Furthermore this domain was recently implicated in the ability of Dicer to process thermodynamically 
unstable RNA stems and in the multiple turnover kinetics of Dicer (Ma et al. 2008; Soifer et al. 2008) 
(discussed further in section 2.4).  Although the mechanism by which Dicer mediates cleavage of 
dsRNA substrates has been largely elucidated, much work is still required to characterise optimal Dicer 
substrates and the ability of human Dicer to effectively process the structures of various RNAi effector 
mimics to yield single or multiple RNAi effectors.  Drosha cleavage requires the action of a co-factor 
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known as DGCR8 which contains a proline binding domain and thus interacts directly with the 
polyproline domain of Drosha (Gregory et al. 2004).   
Two mechanisms for Drosha-mediated cleavage have been proposed.  Zeng et al. proposed a 
model whereby the microprocessor complex binds to the loop sequence of the pri-miRNA and Drosha 
subsequently cleaves the stem ~22 nt from the stem/loop junction (Zeng et al. 2005).  In a conflicting 
model proposed by Han et al. DGCR8 is responsible for recognizing and binding to the junction 
between the single stranded flanking RNA sequences and the double-stranded stem region of the pri-
miRNA.  Drosha then catalyses the processing of the dsRNA stem 11 bp upstream from this junction.  
Both processing models require the presence of ~40 nt single stranded RNA flanking sequences for 
efficient Drosha-mediated cleavage (Han et al. 2006), and result in pre-miRNAs with stem lengths ~22 
bp.  The RNase III family of enzymes is responsible for the cleavage of a multitude of dsRNA 
substrates into functional small RNAs with unique biological roles.  From their respective cleavage 
mechanisms described above, it is evident that the specificity of the Dicer and Drosha enzymes is 
conferred by their accessory domains (PAZ and polyproline domains respectively), which indirectly 
mediate the specific positioning of the relevant RNase III domains for precise cleavage of their 
substrate RNA.  
 
1.5.2 Argonaute proteins  
 
The Argonaute (Ago) proteins constitute the core component of the RNA induced silencing 
complex (RISC) and therefore play an indispensable role in the RNAi pathway [reviewed in (Hutvagner 
and Simard 2008)].  These proteins generally consist of three domains:  a PAZ domain, MID domain 
and a PIWI domain (Figure 1.2).  The PAZ domain, as previously mentioned, is shared by the Dicer 
enzyme and binds to the characteristic 2 nt 3‟ end of small Dicer-generated RNAs (Ma et al. 2004).  
The MID domain binds to the 5‟ phosphate of the small RNA.  Additionally, the MID domain contains an 
MC motif, similar to the cap structure binding motif of the translation initiation factor eIF4E, and this MC 
motif has been shown to be able to bind to the cap of mRNA species and modulate translation 
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(Kiriakidou et al. 2007).  The PIWI domain is located at the C-terminus of Ago proteins, and in some 
cleavage-competent Ago proteins such as mammalian Ago2, harbours a catalytic site for the 
endonucleolytic cleavage of the bound RNA (Liu et al. 2004; Meister et al. 2004).  The Ago proteins are 
divided into two subfamilies which differ in the cells in which they are expressed and hence the small 
RNAs they associate with.  The Ago subfamily of proteins is expressed ubiquitously and associate 
primarily with miRNAs and siRNAs whereas the PIWI subfamily of Ago proteins are expressed mainly 
in the germ cells and associate with piRNAs.  The number of Ago proteins that are present varies 
between species, and in humans there are 4 Ago proteins and 4 PIWI proteins. 
 
1.6 RNAi as a therapeutic   
 
Since its discovery, the RNAi pathway has been widely exploited as a new tool in the 
development of novel therapeutics.  The high specificity required for this gene silencing system 
provides an ideal framework to target disease causing genetic agents, and there are currently a 
number of clinical trials underway which harness different RNAi effector mimics to treat a variety of 
diseases including inherited disorders, viral infections such as HIV, hepatitis B virus (HBV) and 
hepatitis C virus (HCV) as well as different cancers [reviewed in (Castanotto and Rossi 2009)].  Mimics 
of intermediate RNAi effector molecules may be introduced at various stages of the miRNA/siRNA 
biogenesis pathways for gene specific silencing (Figure 1.4).  These mimics are engineered to contain 
guide sequences perfectly complementary to gene targets of interest in order to mediate mRNA 
degradation. 
 
1.6.1 Synthetic siRNA sequences  
 
The most commonly administered RNAi effector mimics are chemically synthesised siRNAs 
which are typically 21mer RNA duplexes designed to mimic endogenous Dicer cleavage products.  The 
guide strand of siRNAs is typically designed to be completely complementary to an mRNA target and 
thus results in Ago2-mediated mRNA cleavage (Figure 1.4).  siRNA duplexes were first introduced into 
 C
H
A
P
T
E
R
 1
 
16 
 
Drosophila cells where they were shown to mediate target RNA degradation and this was the first 
demonstration that siRNA-mediated gene silencing could be uncoupled from the RNase III cleavage 
reactions of siRNA biogenesis (Elbashir et al. 2001b).  Soon thereafter, exogenously introduced 
synthetic siRNAs were introduced into the cytoplasm of mammalian cell lines where they entered RISC 
and directed the cleavage and degradation of specific mRNA sequences (Elbashir et al. 2001a).  The 
use of synthetic siRNAs offers a powerful tool for sequence specific gene silencing and these have 
been widely used to study gene function as well as in the development of potential therapeutics aimed 
at silencing disease associated RNA transcripts.  Chemically synthesised siRNAs with longer duplexes 
(~27 bp) may act as Dicer substrates and have been shown to elicit a stronger gene silencing effect 
than conventional 21mer siRNAs, possibly because Dicer-generated products are incorporated into 
RISC more efficiently (Kim et al. 2005).   
The chemical synthesis of siRNAs allows for the incorporation of certain chemical modifications 
within the duplex which may offer several advantages for the stability and efficacy of exogenously 
introduced siRNAs [reviewed in (Behlke 2008)].  Synthetic siRNAs are subject to degradation by serum 
nucleases in a cellular environment and therefore require chemical modifications for cellular stability.  
Nuclease protection, which does not significantly hamper the RNAi activity of the siRNA, may be 
increased by an array of intrinsic modifications which include the limited incorporation of:  
phosphorothioate linkages within backbone of the passenger (sense) or guide (antisense) strands 
(Chiu and Rana 2003; Choung et al. 2006), locked nucleic acids (LNA) (Elmen et al. 2005; Mook et al. 
2007), or DNA bases (Hogrefe et al. 2006; Ui-Tei et al. 2008b).  Another common means of increasing 
nuclease resistance is by introducing stabilizing moieties to the 2‟ position of the ribose such as 2‟-O-
methyl (Czauderna et al. 2003a; Morrissey et al. 2005; Choung et al. 2006), 2‟-fluoro (Morrissey et al. 
2005), or 2‟-fluoro-β-D-arabinonucleotide (FANA) (Dowler et al. 2006) modifications.  In addition to 
providing nuclease protection to siRNAs, 2‟-O-methyl modifications as well as the substitution of DNA 
bases within the duplex have also been shown to significantly repress activation of an immune 
response (Judge et al. 2006; Robbins et al. 2007) (section 1.7.1).  The strategic placement of 2‟-O-
methyl modifications and DNA bases may also served to reduce off target effects (OTEs) (section 
1.7.2).  More specifically, the addition of a 2‟-O-methyl group to the 5‟ end of the passenger strand 
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blocks its incorporation into RISC thus preventing any OTEs caused by the unintentional incorporation 
of the passenger strand into the RNAi pathway (Chen et al. 2008).  The substitution of the seed region 
of the guide strand with DNA bases allows for siRNA efficacy to be retained, whilst it prevents OTEs 
caused by seed region base pairing with miRNA target sites (Ui-Tei et al. 2008b).  Finally, the 
conjugation of steroid or lipid groups to the siRNA duplex has the potential ability to enhance their 
cellular uptake (Lorenz et al. 2004; Soutschek et al. 2004), and other ligands such as antibody 
fragments (Song et al. 2005; Kumar et al. 2008) or aptamers (Chu et al. 2006; McNamara et al. 2006; 
Zhou et al. 2008b) may enable cell-specific siRNA uptake.  The introduction of single or combinations 
of the modifications described above may therefore offer distinct advantages over expressed RNAi 
effectors, without impairing the efficacy and in some cases even enhancing the potency of the siRNA.  
The placement of introduced modifications should however be carefully considered as the position of 
such modifications within the sense or antisense strands may negatively or positively affect the RNAi 
activity of the siRNA (Czauderna et al. 2003a; Prakash et al. 2005).   
The use of siRNAs can induce potent gene inhibition in a therapeutic context, especially when 
the targeted genes are confined to tissues amenable to topical or localized delivery.  In support of this, 
clinical trials are already underway which use intravitreal injection of siRNAs targeting the vascular 
endothelial growth factor (VEGF) for the treatment of wet age-related macular degeneration (Shen et 
al. 2006; Singerman 2009).   Furthermore, aerosolized siRNAs targeted against the respiratory 
syncytial virus (RSV) can be administered intranasally by inhalation and are also currently undergoing 
clinical trials (DeVincenzo et al. 2008).  Systemic delivery of siRNA-based therapeutics is slightly more 
complicated and a number of obstacles have to be considered and overcome [reviewed in (Tseng et al. 
2009)].  Although chemical modifications to siRNAs may increase their stability and biodistribution, the 
effects of exogenously introduced siRNAs are transient and targeted genes will regain expression 
within relatively short periods of time (Bartlett and Davis 2006).  In a therapeutic setting, repeated 
administration will thus be necessary for sustained inhibition of gene expression.  This may be feasible 
for the treatment of acute infections caused by viruses such as RSV, but is not practical for the 
treatment of chronic diseases such as acquired immunodeficiency disease (AIDS) caused by HIV, for 
which a more stable RNAi-based treatment modality is ideal. 
18 
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Figure 1.4:  The introduction of miRNA precursor mimics into the miRNA biogenesis pathway 
as therapeutic modalities.  Mimics may enter the pathway and exploit the endogenous RNAi 
machinery at various stages of the natural miRNA biogenesis pathway.  (A) The natural endogenous 
miRNA biogenesis pathway (see Figure 1.1 for details).  (B) Pri-miRNA mimics are expressed in the 
nucleus from DNA vectors and enter the canonical miRNA biogenesis pathway at the Drosha cleavage 
step.  (C) shRNA or lhRNA expression cassettes are introduced into the nucleus and the inverted 
repeat sequences encoding the hairpins are generally transcribed by RNA Pol III promoters.  Following 
transcription, the RNA folds into a stem loop structure resembling that of pre-miRNAs and is exported 
to the cytoplasm and processed by Dicer to form siRNAs which are incorporated into RISC.  The guide 
strands of siRNAs are generally designed to be completely complementary to a target gene of interest, 
and Ago2 therefore mediates the cleavage of cognate mRNA species.  (D) Synthetic siRNAs may be 
introduced into the cytoplasm of cells and depending on their length, may act as Dicer substrates 
bypass Dicer cleavage and enter directly into RISC.   
 
1.6.2 Expressed RNAi activators  
 
Pre-miRNA mimics 
In contrast to chemically synthesised siRNAs, RNAi effector mimics may be introduced into the 
nucleus within a DNA vector for intracellular expression.  RNA effector sequences are encoded within 
expressed transcripts as short inverted repeats that fold into stem loop structures which closely mimic 
the structure of endogenous pre-miRNAs and have been termed short hairpin RNAs (shRNAs) (Figure 
1.4).  Brummelkamp et al. first investigated the possibility of endogenously expressing RNAi effector 
sequences within a short hairpin structure.  The RNA Pol III H1 promoter was used to drive expression 
of an shRNA encoding 19 nt guide and passenger strands separated by a loop sequence of 5, 7 or 9 
nt, for the effective inhibition of the endogenous CDH1 gene (Brummelkamp et al. 2002).  The RNA Pol 
III U6 snRNA promoter was subsequently used to express a similar shRNA structure targeted against 
the human lamin A/C gene (Paul et al. 2002).  RNA Pol III promoters such as U6 or H1 are now 
routinely used to drive expression of shRNA sequences since they naturally express small RNAs 
endogenously and result in high levels of constitutively expressed small transcripts.  The promoter 
elements for this class of RNA Pol III promoters are generally upstream from the transcription start site, 
allowing for transcription to occur at a purine residue in position 1.  Pol III driven sequences therefore 
have a clear transcription start site and a termination signal consisting of ≥4  thymidine residues, thus 
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producing transcripts with well defined 5‟ and 3‟ termini. Furthermore, the resulting 3‟ 2-3 nt uridine 
overhang of Pol III-generated transcripts is analogous to the 3‟ overhangs characteristic of RNase III 
processed products, and therefore enables efficient export from the nucleus and allows shRNAs to be 
recognised in the cytoplasm as Dicer substrates.  Dicer cleavage of shRNAs >19 bp yields a single 
mature siRNA which enters into RISC and guides the Ago-mediated target mRNA cleavage as 
previously described (Siolas et al. 2005) (Figure 1.4).   
Ectopically expressed shRNAs have the potential to mediate gene silencing for longer periods 
than synthetic siRNAs since they are continually expressed, resulting in continual replenishment of 
RNA effector sequences.  For this reason shRNAs are effective at a much lower dose than siRNAs and 
moreover, the assimilation of shRNAs into the endogenous RNAi pathway allows for more efficient 
RISC loading, further contributing to their enhanced efficacy (Rao et al. 2009).  These RNAi precursor 
mimics have become powerful tools for the development of novel RNAi-based therapeutics to treat a 
variety of diseases.  However shRNAs bear stems of ~22 bp and are thus able to generate only a 
single siRNA duplex following cleavage.  Although therapeutically viable for the treatment of conserved 
pathological genes, a single therapeutic modality may not be sufficient for repression of rapidly 
mutating genes characteristic of viruses such as HIV and HCV (The emergence of viral escape 
mutants is discussed further in section 1.9.2).   
 
Pri-miRNA mimics 
A further drawback to the use of RNA Pol III expressed shRNAs is the potential for their 
constitutive expression at very high levels to result in unwanted cellular toxicities due to specific and 
non-specific off-target effects (section 1.7).  RNA Pol II promoters drive the expression of most 
endogenous miRNAs and result in longer transcripts containing a 5‟ cap and poly (A) tail.  In addition, 
Pol II promoters are advantageous for the expression of RNAi effector mimics due to their ability to 
drive inducible (Dickins et al. 2007; Wang et al. 2007; Yang and Paschen 2008) and tissue-specific 
(Nielsen et al. 2009; Rhee et al. 2009) expression.  Exploitation of the properties of natural pri-miRNA 
transcripts for the delivery of therapeutic guide strands has therefore recently gained substantial 
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attention.  Guide sequences of choice have been successfully incorporated into expression cassettes 
that encode mimics of natural pri-miRNAs for specific gene inhibition (McManus et al. 2002; Zeng et al. 
2002; Ely et al. 2008; Ely et al. 2009).  The maintenance of the parental miRNA structure is crucial for 
the downstream processing and efficacy of the guide strand (McManus et al. 2002; Zhou et al. 2005).  
The modified hairpin stem is therefore flanked by ~40 nt ssRNA on 5‟ and 3‟ ends, and the original loop 
sequence and symmetrical/asymmetrical mismatches are retained within the stem.  Pri-miRNA mimics 
are Drosha substrates and unlike shRNAs, this upstream processing event is hypothesized to restrict 
over-production of pre-miRNAs thus preventing saturation of downstream pathway components.  In 
comparative studies between shRNAs and pri-miRNA mimics (artificial miRNAs), shRNAs were shown 
to be substantially more potent than miRNAs, albeit due to their elevated expression levels (Boudreau 
et al. 2008).  However, highly expressed shRNAs were also shown to cause saturation of the 
endogenous miRNA pathway and caused neurotoxicity whereas artificial miRNAs at the same effective 
dose caused no symptoms of saturation or toxicity (McBride et al. 2008; Boudreau et al. 2009) (further 
information regarding cellular toxicity caused by saturation effects is provided in section 1.7.3).  To 
date, cellular toxicity as well as saturation of the RNAi pathway have not been caused by ectopic 
expression of pri-miRNA mimics (Ely et al. 2008; Ely et al. 2009; Keck et al. 2009).  However, a limited 
number of miRNA „scaffolds‟ have been studied for their abilities to effectively deliver therapeutic guide 
strands and furthermore, the contribution of the selected miRNA backbone to processing and silencing 
efficacies of the incorporated guide strands has yet to be determined. 
 
1.6.3 Effective design of siRNAs and shRNAs  
 
Regardless of the structure in which guide strands are introduced into target cells, certain 
parameters exist which define an effective guide strand.  It is clearly evident from the large number of 
studies employing RNAi effector sequences that not all siRNAs, shRNAs, or miRNAs are equally 
effective.  This emphasizes the need for careful planning which takes into account these factors which 
are integral for the design of guide sequences incorporated into RNAi effector precursors [reviewed in 
(Pei and Tuschl 2006; Hajeri and Singh 2009)].  There is currently a vast array of computational design 
 C
H
A
P
T
E
R
 1
 
22 
 
tools and algorithms in existence for the prediction of effective guide strands, many of which also aim 
to prevent potential off target effects.  Although very helpful, none of these algorithms is infallible and 
the predicted guide strands still require validation experimentally.  Outlined below are some of the 
common fundamental factors which should be considered when designing RNAi precursor mimics. 
An asymmetrical duplex is key for the incorporation of the guide strand into RISC.  This entails 
sequence asymmetry and the ensuing thermodynamic asymmetry, and the design should take into 
account that generally the strand with the more thermodynamically unstable 5‟ end is retained as the 
guide strand (Khvorova et al. 2003; Schwarz et al. 2003; Bramsen et al. 2009).  Duplex stability should 
also be considered to allow for the passenger strand to be easily removed from the duplex, but 
simultaneously allow for stringent binding to the mRNA target to occur, and generally a guide strand 
with a GC content of 30-50% is optimal (Reynolds et al. 2004).  Guide sequences should contain a 5‟ 
phosphate and a 2 nt 3‟ overhang, characteristic of Dicer products, for efficient incorporation into RISC.  
Furthermore the 3‟ overhang may be chemically modified for the enhanced or impaired selection into 
RISC of the guide and passenger strands respectively (Bramsen et al. 2009).   
G:U mismatches may be introduced into the sense strand of dsRNA duplexes to facilitate 
propagation in E.coli and to aid in sequencing of long inverted repeat sequences (Akashi et al. 2005).  
Targets with strong secondary structures should be avoided, to permit accessibility of the guide stand 
to the miRNA target site (Overhoff et al. 2005; Patzel et al. 2005; Schubert et al. 2005).  Finally, certain 
sequences at specified positions within the guide strand have been reported to potentially augment 
their silencing efficacy.  Although some of these reports contradict one another, sequence preferences 
within the guide strand for which there is a consensus are briefly mentioned.  Sequences which result 
in a thermodynamically unstable 5‟ end include a U or A residue at position 1 and a high A/U content in 
positions 1-7.  In addition, an A or U base at position 10 decreases the stability within the duplex at the 
point of Ago2-mediated cleavage of both the passenger strand and the mRNA target (Reynolds et al. 
2004; Takasaki et al. 2004; Jagla et al. 2005; Shabalina et al. 2006). 
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1.7 Safety concerns of RNAi-based therapeutics 
 
The initial excitement following the discovery of the RNAi pathway and the rush to deliver RNAi-
based therapeutics from bench to bedside has been met with some unforeseen challenges.   
Observations of non-specific gene silencing and cellular toxicities caused by the introduction of 
exogenous RNAi activators into the cellular environment have necessitated the reevaluation of the 
sequence, structure and delivery of RNAi activators, as well as the underlying molecular networks 
causing such non-specific effects. 
 
1.7.1 Non-specific induction of the type-1 interferon response  
 
Before the potential clinical applications of RNAi can be realised, crucial steps to avoid the 
induction of the innate immune response must be taken.  Both siRNAs and shRNAs may be 
recognised intracellularly as foreign agents by different immune receptors present in the cytoplasm and 
in endosomal compartments, thus eliciting a non-specific type I interferon (IFN) response resulting in 
toxic side effects.  Advances in our understanding of the mechanism by which siRNA and shRNA 
sequences/structures trigger such a response have allowed for the safer design of RNAi effectors 
capable of evasion of activators of the type 1 interferon response [reviewed in (Olejniczak et al.)].   
The first cytoplasmic activator of the immune response to be identified was protein kinase R 
(PKR) (Roberts et al. 1976) which recognises long dsRNA generally 30-80 bp in length (Lemaire et al. 
2008).  Upon binding to dsRNA, PKR is autophosphorylated which led to the subsequent 
phosphorylation of the α subunit of the translation initiation factor eIF2, resulting in the global 
repression of protein translation (Dey et al. 2005).  Oligoadenylate synthetase (OAS) is another 
cytoplasmic sensor of foreign agents which recognises long dsRNA 79-80 bp in length, to which the 
outcome is also a universal decrease in protein synthesis (Zilberstein et al. 1978).  For this reason long 
dsRNAs (>30 bp) serving as precursors for siRNA production were considered unsafe due to their 
immunostimulatory potential and the use of shorter siRNA duplexes was therefore thought to represent 
a safer option.   
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Synthetic siRNAs however, were found to induce the IFN pathway by activating cytoplasmic 
retinoic acid inducible gene 1 (RIG-1) (Yoneyama et al. 2004), which activates a signaling cascade 
resulting in IFN and cytokine production.  Upon further investigation it was found that only blunt-ended 
siRNAs activated RIG-1 whereas siRNAs designed to include 2 nt 3‟ overhangs, which are signature 
markers of endogenous Dicer cleavage products, bound but did not activate RIG-1 (Marques et al. 
2006).  RIG-1 also recognises 5‟ triphosphate groups which are found on many viral transcripts and 
thus should be excluded from the design of RNAi effectors (Hornung et al. 2006).   
Furthermore, the mode of delivery of siRNAs may also play a role in immune activation.  
Synthetic siRNAs with or without 3‟ overhangs which are delivered by lipid complexes, are incorporated 
into endosomes where they are also capable of inducing an IFN response by activating toll-like 
receptors 3, 7 an 8 (TLR 3/7/8) which are localized within endosomal compartments (Robbins et al. 
2006).  TLR 7 and TLR 8 recognise certain G/U-rich immunostimulatory sequence motifs which include 
5‟-UGUGU-3‟ (Judge et al. 2005) and 5‟-GUCCUUCAA-3‟ (Hornung et al. 2005).  Although the 
absence of these sequence motifs does not guarantee the prevention of an immune response, every 
effort should be made to exclude these sequences from siRNA duplexes.  As mentioned above 
(section 1.6.1), the inclusion of 2‟-O-methyl groups at one or more bases within the siRNA duplex 
alleviates the immune activation by preventing activation of both TLR 7 and TLR 8 (Judge et al. 2006; 
Robbins et al. 2007).  TLR 3, like TLR 7 and TLR 8, recognises foreign RNA and activates certain 
transcription factors which then promote the expression of pro-inflammatory cytokines (Sen and Sarkar 
2005). However the activation of TLR 3 is sequence independent and 2‟-O-methyl modified siRNAs do 
not prevent TLR 3 recognition.  siRNAs introduced into the cell by electroporation, or derived from 
intracellularly expressed shRNAs, do not traverse the endosomal compartment and may therefore 
reduce the risk of immune stimulation through activation of toll-like receptors.  Importantly, when 
synthetic siRNAs and expressed shRNAs, bearing the same duplex sequence, were compared for their 
immunostimulatory capacity in CD34+ derived immune cells including monocytes and dendritic cells, 
siRNAs induced a strong immune response whereas expressed shRNAs abrogated any 
immunostimulatory effects, thus providing a safer platform for gene specific knockdown (Robbins et al. 
2006). 
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1.7.2 Sequence-specific off-target effects (OTEs) 
 
Another concern for the therapeutic use of RNAi was raised when microarray profiling data 
showed off-target silencing of multiple genes in cells in which siRNAs had been introduced (Jackson et 
al. 2003; Scacheri et al. 2004).  Potential off-target effects were originally predicted by looking for 
target matches in the genome complementary to the entire siRNA guide strand, however it was later 
proved that only partial complementarity of the guide sequence with endogenous cellular genes was 
required for off-target gene silencing (Lewis et al. 2005; Birmingham et al. 2006; Jackson et al. 2006).  
More specifically, base pairing between the seed region at position 2-8 of the 5‟ end of the guide 
strand, and the 3‟UTR of an endogenous gene is sufficient to mediate the unintended translational 
suppression of that gene by mechanisms similar to those used by miRNAs.  Measures to successfully 
prevent such off target effects have included chemical modifications to the duplex (section 1.6.1) as 
well as inclusion of a G:U wobble base pair in the seed region (Ui-Tei et al. 2008a).  Prior to pre-clinical 
and clinical studies using siRNAs however, high throughput screening using predictive algorithms as 
well as microarrays and proteomic arrays (Selbach et al. 2008) should be executed, and potent siRNAs 
should be identified experimentally to minimize the effective dose required. 
 
1.7.3 Saturation of the endogenous miRNA biogenesis pathway  
 
Exogenously introduced RNAi precursors require, to varying extents, the endogenous RNAi 
machinery for their biogenesis and effect.  Competition with natural miRNA precursors for certain vital 
components of the pathway may therefore ensue, leading to saturation of the endogenous miRNA 
biogenesis pathway and a subsequent disruption of natural miRNA function.  An extreme case of 
cellular toxicity was observed in the livers of mice, following the administration of high doses of U6-
expressed shRNAs, ultimately resulting in death (Grimm et al. 2006).  The origin of such toxicity was 
found be the saturation of the exportin-5 karyopherin necessary for nuclear to cytoplasmic transport.  
Highly expressed shRNAs driven from the U6 promoter were also shown to cause severe toxicity in 
lentiviral-transduced human lymphocytes (An et al. 2006) as well as in the striata (McBride et al. 2008) 
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and cerebella (Boudreau et al. 2009) of mice.  Cellular toxicity is in these cases was not necessarily 
attributable to export saturation but possibly saturation of other silencing factors.  Castanotto et al 
showed that synthetic siRNAs as well as shRNAs could also actively compete with each other and with 
endogenous miRNAs for the selection incorporation into RISC (Castanotto et al. 2007).  Constitutive 
expression of exogenously introduced RNAi precursors at high levels may therefore pose a significant 
risk for saturation effects and cellular toxicity.  Since minor deregulation in endogenous miRNA function 
may lead to widespread perturbations in post transcriptional gene regulation, every effort should be 
made to identify potent RNAi activators which are able to mediate their effects at low doses. 
 
1.8 HIV 
 
HIV, the causative agent of AIDS,  is a lentivirus belonging to the Retroviridae family and was first 
isolated in 1983 (Barre-Sinoussi et al. 1983; Gallo et al. 1983).  Each virion contains two copies of the 
RNA genome which are reverse transcribed into cDNA which is then integrated into the human 
genome for expression and thus long term persistence.  HIV has a very high replication rate and 
coupled with the lack of proof-reading ability of the viral reverse transcriptase, HIV is a rapidly evolving 
virus.  More than 25 years following the discovery of this virus, a preventative vaccine or a therapeutic 
cure remain elusive.  Although the success achieved in controlling viremia using a cocktail of 
chemically synthesised antiretroviral drugs has been invaluable; high cost, toxic side effects and the 
failure to remove latent infection have limited the success of these therapeutic modalities.  Novel 
therapies against HIV are urgently required and studies have begun harnessing the RNAi pathway in 
an attempt to develop novel antiviral therapeutics to suppress HIV replication in the long term.  
 
1.8.1 Current epidemic  
 
The Human Immunodeficiency Virus Type 1 (HIV-1) epidemic is presently a major global health 
concern.  As worldwide efforts to create awareness, prevention and treatment programs increase, so 
does the total number of people living with the virus. There were 2.7 million newly infected people in 
 C
H
A
P
T
E
R
 1
 
27 
 
2008 and 2 million AIDS deaths, bringing the total number of people living with HIV as reported at the 
end of 2008 to 33.4 million (UNAIDS 2008).  While all countries are currently fighting the impact of this 
disease, sub-Saharan Africa, and Southern Africa in particular continue to bear the greatest burden of 
people infected with and affected by HIV.  Just over 10% of the world‟s population inhabits sub-
Saharan Africa, yet this region is home to 67% of people living with HIV-1 worldwide (UNAIDS 2008).  
In 2008, new infections in this region totalled more than those in all other regions of the world 
combined.  In South Africa there are an estimated 5.7 million infected individuals which represents the 
largest number of individuals living with the virus in a single country. These patients are infected largely 
with HIV-1 subtype C, which accounts for 56% of all new infections worldwide (UNAIDS 2008).  
 
1.8.2 HIV genome organization 
 
The HIV genome is 9.8 kb in length and consists of nine partially overlapping genes (Figure 1.5 A) 
(Ratner et al. 1985; Sanchez-Pescador et al. 1985; Wain-Hobson et al. 1985).  The gag (group-specific 
antigen); pol (polymerase) and env (envelope) genes encode mainly structural and enzymatic proteins.  
The pr55 Gag protein precursor is processed into the p17 matrix (MA); p24 capsid (CA) and p7 
nucleic-acid binding (NC) structural proteins essential for assembly of viral particles (Ganser-Pornillos 
et al. 2008).  The pr160 Gag-Pol protein precursor is processed into the reverse transcriptase (RT); 
protease (PR) and integrase (IN) enzymes which play important roles in the viral replicative cycle (Hill 
et al. 2005).  Both the Gag and Gag-Pol polyprotein precursors are cleaved by the viral protease into 
their respective subunits (Figure 1.5 B).  The gp160 Env protein is cleaved by cellular proteases into 
the surface gp120 and transmembrane gp41 subunits of the envelope glycoprotein which is necessary 
for binding to the CD4 primary receptor on host cells (Moulard and Decroly 2000).  The tat 
(transcriptional transactivator) and rev (regulator of virion gene expression) genes encode two 
regulatory proteins.  Tat binds to the TAR (transactivation response) element within the R domain of 
the 5‟ long terminal reapeat (LTR) to regulate transcription and Rev mediates the transport of singly 
spliced and unspliced viral transcripts from the nucleus to the cytoplasm (Jeang et al. 1991; Gait and 
Karn 1993; Hope 1999).   
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Figure 1.5:  HIV genome organization.  (A) A representation of the nine genes encoded by the HIV-1 genome.  (B) The gag, pol and env 
genes encode protein precursors (pr55, pr160 and gp160) which require further processing by either viral or cellular proteases to generate 
structural proteins necessary for the formation of a mature virion (C).
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In addition to these five genes, HIV also encodes four accessory genes: nef (negative effector); vif 
(viral infectivity factor); vpr and vpu (viral proteins r and u) which represent critical virulence factors 
(Emerman and Malim 1998; Anderson and Hope 2004).  Proteins coding sequences are flanked on 
either side by 5‟ and 3‟ LTRs.  Each LTR is divided into 3 domains, namely the U3, R and U5 domains.  
The U3 region contains the basal promoter as well as an enhancer sequence and multiple transcription 
factor binding sites (Patarca et al. 1987; Roebuck and Saifuddin 1999).  Transcription initiation occurs 
at the first nucleotide of the R region and this region also encodes the transcriptional response (TAR) 
regulatory stem loop structure to which Tat binds. 
 
1.8.3 The replicative cycle of HIV-1 
 
HIV infects cells of the immune system which express the relevant surface receptors necessary 
for interaction with the HIV transmembrane Env protein.  HIV enters its target cells, which include 
CD4+ T cells; macrophages; monocytes; dendritic cells and microglia (He et al. 1997; Zaitseva et al. 
1997; Rubbert et al. 1998; Ruiz et al. 1998), through interaction of the viral trimeric glycoprotein initially 
with the primary cellular CD4 receptor, and subsequently with the CCR5 or CXCR4 cellular chemokine 
co-receptors, [reviewed in (Doms and Trono 2000)].  The gp120 surface subunit of the Env protein 
initially engages with the cellular CD4 receptor leading to a conformational change in gp120 which 
allows it to bind to a co-receptor (Salzwedel et al. 2000).  Viral tropism is largely determined by the co-
receptor to which it binds.  R5 strains use the CCR5 co-receptor and are able to infect CD4+T cells, 
macrophages and dendritic cells.  X4 strains bind the CXCR4 co-receptor and only infect CD4+ T cells 
(Agrawal et al. 2009).  Co-receptor binding then triggers the interaction of the gp41 transmembrane 
subunit of the Env protein with the host cell membrane.  Fusion of the cellular and viral membranes 
ensues (Campbell and Hope 2008) and the viral core is released into the cellular environment and 
uncoated, releasing the viral genome (Dvorin and Malim 2003).  The viral RNA genome is reverse 
transcribed into cDNA in the cytoplasm by viral RT (Harrich and Hooker 2002) and is then transported 
within the pre-integration complex consisting of viral cDNA; viral RT; matrix protein; integrase and Vpr, 
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to the nucleus.  Nuclear localization signals on Vpr, integrase and matrix mediate import into the 
nucleus in both actively dividing and quiescent cells through the nuclear pores (Bukrinsky et al. 1993; 
Heinzinger et al. 1994; Gallay et al. 1997).  Viral cDNA is subsequently integrated into the host 
genome, usually within active euchromatin (Schroder et al. 2002), to form the provirus.  The provirus is 
flanked by the 5‟ LTR which serves as a promoter for transcription and the 3‟ LTR which provides the 
termination site.  The synthesis of full length transcripts requires the interaction between the regulatory 
Tat protein and the TAR loop.  In the absence of Tat, only short attenuated RNA transcripts are 
produced (Kao et al. 1987).  Tat is a multiply spliced protein synthesised early in the viral life cycle and 
the interaction between Tat and the regulatory TAR loop is enhanced by the positive elongation factor 
(P-TEFb).  Tat binds to the cyclin T1 subunit of P-TEFb and thereby recruits the cyclin dependent 
kinase 9 (CDK9) subunit to the LTR. CDK9 phosphorylates RNA Pol II, enabling the transition of 
initiation to elongation and the consequent synthesis of full length viral transcripts, [reviewed in (Jones 
and Peterlin 1994; Taube et al. 1999)].   
Early phase transcripts encoding the Tat, Rev and Nef proteins are completely spliced and are 
exported from the nucleus by cellular machinery.  Unspliced transcripts including genomic RNA and 
Gag-Pol precursors as well as incompletely spliced mRNAs encoding Env, Vif, Vpr and Vpu, require 
the interaction between the regulatory Rev protein and the Rev responsive element present within 
these transcripts for nuclear export into the cytoplasm, [reviewed in (Pollard and Malim 1998)].  
Following translation, viral proteins together with two copies of the viral genome assemble into 
immature progeny virions within lipid rafts localized at the cell membrane.  Env proteins are processed 
into their respective subunits which also gather at the cell membrane.  Virions are released from 
infected cells through a budding process which results in virus particles coated with the host cell 
membrane containing trimeric Env glycoproteins embedded in the membrane.  Maturation of progeny 
virions occurs following processing of the Gag and Gag-Pol polyprotein precursors extracellularly 
(Ganser-Pornillos et al. 2008).  
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Figure 1.6:  A basic representation of the central steps of the HIV replicative cycle.  HIV virions 
attach to their target cells through binding of the gp120 Env protein primarily to the CD4, and 
subsequently to the CCR5 or CXCR4 host cell receptors.  Receptor binding induces fusion of viral and 
cellular membranes resulting in the release of the viral core and subsequent release of the viral 
genome into the cytoplasm of the host cell.  The viral RNA genome is reverse transcribed and then 
transported into the nucleus where the IN enzyme mediates integration of viral cDNA into the host 
genome.  The integrated provirus serves as a template for the transcription of viral genomic RNA 
copies as well as viral mRNA which is exported to the cytoplasm for translation.  Structural proteins 
and two copies of the RNA genome assemble into virion particles at the cellular membrane and are 
released from the cell by a budding process.      
 
1.8.4 Disease progression and current therapies for the treatment of HIV 
 
HIV-1 infection consists of an initial acute phase followed by a chronic phase.  The acute phase is 
characterised by an increase in viral RNA (viral load) and the consequent decline in CD4+ T cells 
(Clark and Shaw 1993).  The activation of the immune system subsequently results in the suppression 
of viremia to a low steady state level termed the viral setpoint, and an increase in CD4+ T cells.  During 
the chronic phase, viral loads as well as the number of CD4+ T cells may remain constant for several 
years with the patient remaining largely asymptomatic.  However the steady replication of HIV 
eventually overwhelms the immune system, resulting in a gradual rise in viremia and a steady 
reduction in CD4+ T cells until the patient is severely immunocompromised, resulting in increased 
susceptibility to opportunistic infections and the development of AIDS. 
Effective treatment and eradication of HIV continues to present a serious challenge in the struggle 
against infection with this virus.  The first breakthrough in the development of anti-HIV therapeutics 
came in 1987, four years after the isolation of HIV.  The first antiretroviral drug (Ezzell 1987) inhibited 
the viral reverse transcriptase enzyme by acting as a nucleoside analogue, thus preventing the 
complete synthesis of proviral DNA (Furman and Barry 1988).  Additional nucleoside/nucleotide 
reverse transcriptase inhibitors (NRTIs) were subsequently developed (Gershon 1991); however the 
success of the NRTI class of drugs as a monotherapy was short lived.  As a result of the replication 
kinetics of HIV, drug resistant viral variants quickly emerged to expose the limitations of a monotherapy 
to treat HIV infection.  A need for drugs targeting alternative viral components was evident and the 
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class of protease inhibitor drugs was developed soon thereafter.  These drugs inhibit viral protease 
thus preventing the production of mature viral proteins (Venaud et al. 1992).  The advantages of a 
combination therapy were then realised following triple therapy or highly active antiretroviral therapy 
(HAART), initially using a combination of two NRTIs and a protease inhibitor (Hammer et al. 1997; 
Hirsch et al. 1999).  Today there are 25 antiretroviral drugs available in 6 different classes (Zolopa 
2010).  Additional classes of antiretroviral drugs include the non-nucleoside class of reverse 
transcriptase inhibitors (NNRTIs) which function by direct binding and inhibition of the RT enzyme (de 
Bethune 2010); and most recently entry inhibitors which include CCR5 antagonists and fusion 
inhibitors (Tilton and Doms 2010); and integrase inhibitors which prevent integration of the provirus into 
the host chromosome (McColl and Chen 2010).  A novel class of antiretroviral still undergoing clinical 
trial is that of the maturation inhibitors which inhibit cleavage of the capsid precursor (Temesgen and 
Feinberg 2006; Martin et al. 2008).  The increased availability of drugs in recent years to include new 
generation drugs in existing classes, as well as new classes of antiretroviral drugs has greatly 
expanded the possibilities for modification of double and triple therapies.   
 
1.8.5 Drawbacks associated with HAART 
 
HAART has provided significant progress in the quest to decrease viral load and increase CD4+ 
and CD8+ cells in infected patients.  Despite the significant decrease in morbidity and mortality offered 
by HAART, problems associated with these treatment regimens persist.  Toxic side effects caused by 
antiretroviral drugs have been widely observed both in the short and long term and differ between drug 
classes and individual drugs.  Short term adverse effects commonly include, but are not limited to, 
gastrointestinal effects such as nausea and diarrhoea as well fatigue, dizziness and rashes.  In the 
long term, a variety of metabolic disorders such as lipodystrophy, hyperlipidaemia, diabetes mellitus 
and lactic acidaemia commonly occur; and in addition cardiovascular disease, renal dysfunction and 
hepatotoxicity have also been observed [reviewed in (Carr 2003; Mallon 2007; Hawkins 2010)].  In 
addition to severe side effects, and often a consequence thereof, patient compliance continues to pose 
a problem caused by complex regimens necessary for combination therapy (Gardner et al. 2008; 
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Simoni et al. 2008).  The expense of distributing HAART, especially in developing countries where the 
pandemic is most rife is a major problem and finally the emergence of drug resistant strains to various 
antiretroviral drugs continues to represent the foremost setback in the development of an effective long 
term therapy [for a comprehensive review on the molecular mechanism underlying resistance to each 
drug class see (Menendez-Arias 2010)].  The extremely high replication rate of HIV coupled with its 
high mutation rate (Mansky 1996) may actively cause resistance to one or more drugs and 
furthermore, transmission of mutant viral strains may result in minority drug resistance in drug naïve 
patients which substantially increases the risk of first line treatment failure (Paredes et al. 2010).  The 
continual need for the development of new drugs or new drug classes as well as new formulations and 
strategies for existing drugs is an expensive and tedious process involving further clinical trials and 
investigations into potential drug interactions between new and existing drugs.  Resistance testing 
before treatment initiation is therefore ideal for an effective drug regimen to be formulated.  Although 
theoretically possible, the reality is that in sub-Saharan Africa, access even to basic first line 
antiretroviral drugs is limited, and in the majority of cases the practicalities and cost involved in 
diagnosing patients with first line treatment failure and the subsequent administration of second line 
drug formulations is not feasible (Harries et al. 2010).   
The persistence of latent viral reservoirs is another drawback of HAART since although viral 
replication may be effectively suppressed, current drug regimens are incapable of completely 
eradicating the virus.  Despite long term containment of viremia in patients receiving HAART, a latent 
reservoir of virus was identified in resting CD4+ T lymphocytes from which replication competent 
viruses could be isolated (Finzi et al. 1997; Wong et al. 1997).  The underlying molecular mechanisms 
of latency are extremely complex and the exact locations of these latent viral pools are still disputed.  
Memory CD4+ T cells are a well-defined reservoir and are thought to be the main source of residual 
viremia (Chun et al. 1995; Chun et al. 1998; Siliciano et al. 2003).  Latency may occur when activated 
CD4+ T cells become infected with the virus, and soon thereafter make a transition into terminally 
differentiated memory T cells [reviewed in (Lassen et al. 2004; Dahl et al. 2010)].  Viral reservoirs are 
then able to persist and survive for years before potentially re-emerging, and to control viremia, drugs 
therefore need to be taken for life.  Although HAART has been responsible for the transition of a fatal 
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infection into a treatable chronic disease, the limitations of this therapy are obvious and it remains an 
important medical objective to develop alternative novel, and cost effective therapeutic strategies 
 
1.9 Exploitation of the RNAi pathway to develop novel therapeutics 
against HIV 
 
  The RNAi pathway is utilized in many species as a natural defense strategy against foreign 
genetic elements such as transposons and viruses (Ketting et al. 1999; Tabara et al. 1999; Mourrain et 
al. 2000).  Intrinsic cellular defense properties of the RNAi pathway in mammals are still debated.  
However, the obvious interplay between components of the RNAi pathway and several human viral 
pathogens is intriguing (discussed further in section 5.5).  Since this pathway has natural antiviral 
properties in certain species, the mechanism by which RNAi functions offers an attractive tool to exploit 
in the development of antiviral therapeutics in mammalian cells.  In contrast to HAART, RNAi-based 
therapies have the potential to substantially simplify drug regimens, and furthermore, RNAi-based 
therapeutics may be designed to target any one of the viral genes thus eliminating the time consuming 
search for novel drug targets.   
 
1.9.1 RNAi susceptible targets 
 
Incoming viral genomic RNA 
Theoretically, three approaches exist for inhibiting HIV-replication using RNAi and include directly 
targeting the viral genome, targeting host dependency factors or targeting newly synthesised viral 
messenger RNA.  Each mature virion contains two copies of the viral RNA genome which, after fusion, 
are released into the cytoplasm for reverse transcription as described above (section 1.8.3).  Inhibition 
of the incoming viral genomic RNA is an attractive target because synthesis of cDNA and 
establishment of the provirus is prevented, thus inhibiting the replicative cycle of HIV at a very early 
stage.  Several pioneering studies utilizing RNAi to inhibit HIV replication reported successful inhibition 
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of incoming genomic RNA, using siRNA sequences targeted to various genomic sequences including 
gag (Capodici et al. 2002; Novina et al. 2002); tat and rev (Coburn and Cullen 2002); nef and vif 
(Jacque et al. 2002) and the viral LTR (Capodici et al. 2002; Jacque et al. 2002).  However the efficient 
targeting of incoming RNA is controversial and several studies have reported that genomic RNA is not 
susceptible to RNAi, possibly due to its association with capsid, nucleocapsid, RT and possibly other 
proteins which render the genome inaccessible to the RNAi machinery (Hu et al. 2002; Surabhi and 
Gaynor 2002; Nishitsuji et al. 2004; Westerhout et al. 2006a).  Hu et al. made use of siRNA sequences 
targeted against gag or int which were capable of inhibiting HIV >90%, and analysed the inhibition of 
early and late viral targets in isolation.  While the accumulation of viral mRNA transcripts was 
effectively prevented, no degradation of genomic RNA was detected.  Moreover, these results were 
replicated with another retrovirus, Rous sarcoma virus (RSV) (Hu et al. 2002).   
Following these contradictory results, Westerhout et al. investigated the transduction efficiencies 
of lentiviral vectors in the presence or absence of HIV-specific shRNAs as a model of proviral 
integration.  This study reported no difference in transduction efficiencies between control cells and 
cells stably expressing shRNAs targeted to different regions within the HIV-1 genome (Westerhout et 
al. 2006a).  These results provide compelling evidence for inaccessibility of the viral genome to RNAi, 
and although the inhibition of incoming viral RNA is highly desirable for therapeutic purposes, the 
prevention of provirus integration seems unlikely. 
 
Host dependency factors 
 A second possible strategy for the inhibition of HIV replication and an alternative approach for 
the prevention of viral entry is to suppress host cellular genes essential in the replicative cycle of HIV.  
In addition, inhibiting host dependency factors is an attractive strategy for preventing the emergence of 
viral escape mutants.  The most frequently targeted host transcripts encode the primary CD4 receptor 
or the co-receptors CCR5 and CXCR4.  Although the suppression of the CD4 receptor gene may result 
in potent inhibition of viral entry (Novina et al. 2002), complete inhibition of this host factor will abolish 
other intracellular roles it may play and therefore have detrimental effects on the host.  Inhibition of the 
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CCR5 co-receptor is an equally effective strategy at preventing viral entry (Qin et al. 2003) and may 
offer a safer target since people homozygous for the mutant CCR5 allele are resistant to HIV-1 
infection yet exhibit no consequent side effects (Liu et al. 1996; Samson et al. 1996).  In a therapeutic 
context however, down regulation of a single co-receptor is insufficient due to the possible selection of 
minor populations of dual tropic strains and the possibility of co-receptor switching (Delobel et al. 2005; 
Moncunill et al. 2008), both of which will lead to an eventual viral infection.  A combination of cellular 
receptors should therefore be targeted simultaneously.   
Host factor targeting is not limited to host cell receptors and a variety of other host factors have 
been considered for down regulation to inhibit HIV infection.  These factors include, but are not limited 
to, integration factors such as BAF1, Emerin and LEDGF/p75 (Maertens et al. 2003; Jacque and 
Stevenson 2006; Llano et al. 2006); transcription factors such as NF-kB, PAK-1 and cyclin T1 (Surabhi 
and Gaynor 2002; Chiu et al. 2004; Nguyen et al. 2006) and Furin which plays a role in the maturation 
of the Env protein (Nguyen et al. 2006).  In a recent groundbreaking study, an siRNA screen was used 
to identify 250 HIV host dependency factors which are implicated in specific pathways of the viral life 
cycle (Brass et al. 2008).  Similar studies have followed, also using large scale RNAi screens, and 
identified hundreds more potential host factors which are central to the establishment of viral infection 
(Konig et al. 2008; Zhou et al. 2008a; Kok et al. 2009).  These studies have dramatically expanded the 
number of host dependency factors which may be targeted, however the results require further 
validation in T cells and moreover, to prevent disruption of natural endogenous cellular functions of 
these proteins, care should be taken to target only those genes dispensable to the host. 
 
HIV mRNAs 
 The third and most obvious category of RNAi susceptible targets in HIV are the newly 
synthesised viral mRNA transcripts which are exported to the cytoplasm from the nucleus for 
translation.  Transcripts encoding the Rev protein were amongst the first viral transcripts to be 
effectively silenced using RNAi effectors (Coburn and Cullen 2002; Lee et al. 2002a).  Every possible 
HIV transcript has since been targeted for silencing using various RNAi effector mimics with varying 
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degrees of efficacy, but often inhibiting viral replication >90%.  The drawback of this strategy is 
associated with the extraordinarily high rate of error of the viral RT enzyme.  With an error rate of 3 × 
10
-5
 (Mansky 1996), it is not surprising that HIV is a rapidly evolving virus, and in any infected cell, a 
pool of viral variants exist.  It is thus essential to target conserved regions within viral genes to limit the 
emergence of viral mutants which are refractory to RNAi-mediated gene silencing.  However, even 
when targeting conserved sites within the viral genome, mutations may arise under selective pressure, 
rendering the RNAi effector ineffective.   
  
1.9.2 The emergence of viral escape mutants 
 
Viral escape generally occurs through the development of mutations in the targeted sequence.  A 
single mutation within the RNAi targeted site, especially the seed region, is sufficient to protect the 
virus from the silencing effects of RNAi effectors (Gitlin et al. 2002).  The emergence of HIV escape 
mutants were first observed following inhibition of viral replication by stable expression of an shRNA 
targeted to the tat transcript.  After 25 days of exposure of the virus to the shRNA, a point mutation 
within the shRNA target sequence emerged which abrogated the silencing effects of the shRNA 
(Boden et al. 2003a).  Similarly, a stably expressed siRNA sequence targeted against the nef transcript 
was shown to cause potent suppression of viral replication, but only for 23 days, after which resistant 
viral variants arose.  In this case escape mutants emerged due to substitutions or deletions which 
resulted in the modification or the deletion of the target sequence (Das et al. 2004).  Westerhout et al. 
then analysed additional escape variants which emerged following exposure to the shRNA targeted 
against the nef gene (Westerhout et al. 2005).  In five out of nine mutants, partial deletion of the target 
sequence occurred, three mutants acquired single or multiple substitutions within the target sequence, 
and in one mutant, a single nucleotide substitution upstream from the targeted region was found which 
also caused resistance to the RNAi effector.  It was deduced that mutations occurring outside of the 
target region may result in an alternative structural conformation of the RNA which prevents siRNA 
binding and thus reduces RNAi efficacy (Westerhout et al. 2005).  
 C
H
A
P
T
E
R
 1
 
39 
 
The nef gene codes for a non-essential viral accessory protein, yet targeting of essential viral 
genes does not prevent the emergence of viral escape mutants either (Senserrich et al. 2008; von Eije 
et al. 2008).  von Eije et al. performed a large scale analysis of viral evolution following exposure to 
shRNAs against the essential gag, pol and tat/rev genes.  None of these shRNAs was able to abrogate 
viral escape completely, although in contrast to the deletions in the nef gene target, the sequence 
variation of these targets and thus viral escape was limited, presumably to prevent a compromise in 
viral fitness.  Furthermore, a propensity for mutations in certain positions within the target sequences 
was observed.  No escape at the termini of the 19 nt sequences was observed, (at positions 1, 2, 18 
and 19) whilst the central region appeared more prone to mutation, suggesting that the terminal 
nucleotides are either inconsequential for RNAi-mediated silencing or that variation of these 
nucleotides will negatively affect viral fitness (von Eije et al. 2008).   
Targeting conserved regions within essential viral genes may also aid in restricting the emergence 
of viral escape mutants.  A series of shRNAs were designed to target either a poorly conserved region 
within rev, a gag site conserved only across subtype B viral strains, or a highly conserved vif sequence 
(Lee et al. 2005).  Anti-rev shRNAs were capable of incredibly limited inhibition; anti-gag shRNAs 
effectively inhibited only subtype B viral strains whereas anti-vif shRNAs were effective against all viral 
isolates, thus highlighting the advantage of targeting widely conserved sequences.  A further evasion 
mechanism was established following RNAi directed against the TAR loop within the viral LTR.  HIV 
replication was blocked using an shRNA targeted to an RNAi susceptible region within the TAR loop, 
however resistant strains emerged which contained no mutations within the target site.  Mutations were 
however found in alternative sites within the LTR promoter which caused an upregulation in 
transcription as a compensatory mechanism to overcome RNAi-mediated suppression, which served 
as a novel indirect means of escape (Leonard et al. 2008).   
 
Finally, the HIV dosage to which shRNAs are exposed may play an important role in determining 
strong versus weak RNAi effectors.  Nishitsuji et al. showed that while shRNAs targeted against 
integrase were effective at a low viral input, their anti-HIV efficacy was drastically reduced when the 
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viral dosage was increased (Nishitsuji et al. 2006).  This data is supported by a comparative analysis of 
20 shRNAs which used a dose response assay as one of the determinants for shRNA potency.  It was 
shown that while elevated viral dosage will eventually overwhelm any shRNA, the viral input at which 
this occurs is indicative of the shRNA strength (von Eije et al. 2009).  
Large-scale screens may identify potentially powerful siRNAs or shRNAs which upon extensive 
validation may yield a subset of strong, durable RNAi effectors (von Eije et al. 2009).  However, HIV 
has evolved a versatile array of escape mechanisms and to persistently suppress viral replication with 
RNAi, a combination of single RNAi effectors, akin to HAART, is likely to be necessary.       
 
1.10  Combinatorial RNAi 
 
It is evident that when targeting rapidly evolving targets with single RNA effector molecules such 
as siRNAs or shRNAs, mutations within the target sequence will arise within relatively short periods 
following exposure to such effectors, leading to evasion of RNAi-mediated silencing.  To circumvent 
this problem, multiple sites should be targeted simultaneously.  The simultaneous introduction of 
multiple RNAi effectors is known as combinatorial RNAi and is of considerable importance when 
targeting viruses such as HIV. HIV causes chronic infections and thus requires long term treatment, 
and in addition is a highly mutable and thus represents a rapidly evolving target.  Three major 
platforms currently exist for the simultaneous suppression of multiple gene targets, and all three 
strategies have been exploited for the inhibition of HIV.  These approaches include multiple shRNA 
expression cassettes; polycistronic miRNA shuttles and long hairpin RNAs (lhRNAs) (Figure 1.7).   
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Figure 1.7:  Schematic representation of currently utilized combinatorial RNAi strategies. These 
strategies include (A) multiple expressed shRNAs, where multiple siRNA sequences are expressed 
individually from multiple promoters, (B) polycistronic miRNA shuttles, in which multiple siRNA 
sequences are inserted into the natural pri-miRNA backbones within a polycistron, and (C) lhRNAs, 
from which the generation of multiple siRNAs has not been properly characterised. 
 
1.10.1 Multiple expressed shRNAs 
 
Multiple Pol III shRNA expression cassettes may be combined adjacent to one another within a 
single vector (Figure 1.7).  The advantage of this approach is that previously characterised effective 
RNAi effector sequences may be combined into a single vector for the simultaneous inhibition of 
multiple gene targets.  This strategy was investigated by Henry et al. who combined three H1 Pol III 
promoter-driven shRNAs targeted against two sites in the HCV genome and the host cell receptor 
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CD81, within a single DNA vector and showed effective suppression of all three targets (Henry et al. 
2006).  This method has also been successfully used to incorporate 3 (ter Brake et al. 2006) or 4 
(Song et al. 2008) shRNAs targeted to HIV, and up to 6 shRNAs targeted against different proliferation 
and survival pathway factors for the treatment of cancer (Cheng et al. 2009).  In addition, the effects of 
multiple shRNAs are reportedly additive, showing enhanced silencing of several targets in comparison 
to a single shRNA (Gonzalez et al. 2005; ter Brake et al. 2006; Gou et al. 2007; Song et al. 2008).   
In an influential study by ter Brake et al., a lentiviral vector containing four anti-HIV shRNAs in 
tandem was able to suppress viral replication and prevent the emergence of escape mutants for an 80 
day period.  However, it was shown that when multiple shRNAs driven from the same promoter were 
cloned in tandem into a lentiviral delivery vector, recombination of repeat sequences caused deletions 
of one or more of the shRNA cassettes, and the use of multiple different promoters was therefore 
required (ter Brake et al. 2008).  This was recently confirmed by McIntyre et al. who also showed 
significant deletion of individual shRNAs in a lentiviral vector containing up to six H1-driven shRNAs 
(McIntyre et al. 2009b).  Despite the observed synergistic effect, the use of multiple shRNA expression 
cassettes in tandem has been observed to result in a decrease of mature guide strand production 
when compared to single shRNAs (ter Brake et al. 2006; ter Brake et al. 2008).  Of greater concern 
regarding the use of multiple expressed shRNAs however, is the potential for saturating effects on the 
RNAi pathway.  When multiple shRNAs are expressed from strong ubiquitous Pol III promoters, 
competition for strand incorporation into the RISC complex as well as for other components of the 
endogenous miRNA biogenesis pathway may occur, resulting in disrupted gene regulation and cell 
toxicity (Grimm et al. 2006; Castanotto et al. 2007; Boudreau et al. 2008) (section 1.7.3). 
 
1.10.2 Polycistronic miRNA shuttles 
 
A second combinatorial RNAi strategy combines multiple pri-miRNA mimics (described in section 
1.6.2) within a single transcript (Chung et al. 2006; Ely et al. 2009).  Chung et al. demonstrated that 
two tandem modified miR-155 precursors targeting two independent gene sequences could be 
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expressed from a single transcript.  Encouragingly, the knockdown from each miRNA within the 
polycistronic transcript was comparable to that of single pri-miRNA mimics (Chung et al. 2006).  
Similarly, engineered polycistronic miRNAs containing trimeric expression cassettes have been 
successfully used for the inhibition of three different HBV target sequences (Ely et al. 2009).  Three 
effective anti-HBV guide sequences were substituted into three miR-31 backbones in series or 
alternatively into three different tandem miRNA scaffolds including miR-31, miR-30a and miR-122.  
Each trimeric expression cassette was driven from a single CMV promoter and the parental miRNA 
structure and flanking sequences were consistently maintained.  Although effective processing and 
potent knockdown of all three target sequences was achieved both in vitro and in vivo, variability of 
individual miRNA efficacy was observed which correlated with both the sequence and the position of 
each discrete pri-miRNA mimic (Ely et al. 2009).   
Many miRNAs are also found to naturally occur in polycistronic clusters and these pri-miRNA 
precursor structures, if the secondary structures are conserved, may also be manipulated for the 
generation of multiple effector sequences (Aagaard et al. 2008; Liu et al. 2008).  Liu et al. manipulated 
the naturally occurring mir-17-92 polycistron for the inhibition of HIV by inserting antiviral siRNAs into 
the endogenous polycistronic miRNA backbone.  Silencing activity was enhanced in this multimeric 
system and efficient processing of four functional antiviral sequences capable of efficiently inhibiting 
HIV replication was achieved (Liu et al. 2008).  The tri-cistronic miR-106b cluster has also been 
manipulated through substitution of the three endogenous miRNA sequences with siRNA sequences 
targeted against tat and rev.  This construct was effective when tested against an HIV molecular clone; 
however this efficacy was significantly reduced when tested against a more virulent viral strain 
(Aagaard et al. 2008).  Although both engineered and natural polycistronic miRNA shuttles represent a 
potentially viable combinatorial RNAi strategy, much characterisation is still required to determine the 
effects of different endogenous polycistronic miRNA shuttles on the efficacy and processing of effector 
sequences.  Moreover the ability of such constructs to inhibit viral replication in the long term has yet to 
be demonstrated. 
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1.10.3 Long hairpin RNAs  
 
A third strategy for the development of a combinatorial RNAi system, and the focus of this thesis, 
is the use of long hairpin RNAs.  In non-mammalian cells, long dsRNA duplexes of approximately 500 
bp have been shown to act as Dicer precursors for the production of a pool of siRNAs which are 
subsequently able to inhibit target gene expression specifically (Hamilton and Baulcombe 1999; 
Zamore et al. 2000; Elbashir et al. 2001b).  It was then shown that recombinant human Dicer was also 
capable of processing long dsRNA in vitro, and generated ~22 bp siRNA fragments following 
incubation with a 130 bp dsRNA duplex (Zhang et al. 2002).  Synthetic long dsRNA of ~500 bp have 
been shown to effect silencing of HIV-1 genes and to suppress viral replication in targeted mammalian 
cells (Park et al. 2002; Yamamoto et al. 2002).  While these studies demonstrate the efficiency of Dicer 
and the RNAi pathway in mammalian cells, the use of synthetic long dsRNA remains a controversial 
issue since longer dsRNA duplexes >30 bp have been shown to induce non-specific silencing (Caplen 
et al. 2001; Elbashir et al. 2001a) by activating cytoplasmic PKR and causing an eventual repression of 
global protein translation (Clemens 1997).   
Nonetheless, the use of expressed long dsRNA soon followed and the endogenous transcription 
of long dsRNA up to 1000 bp resulted in highly efficient, target specific silencing in mammalian cells 
(Paddison et al. 2002; Diallo et al. 2003; Yi et al. 2003a; Tran et al. 2004) which is supported by a later 
study which shows that endogenously expressed RNAi activators are not recognised by cytoplasmic 
sensors of dsRNA (Robbins et al. 2006).  Tran et al. co-expressed long complementary single stranded 
RNAs from separate plasmids with the potential to form dsRNA and showed that when both RNA 
strands were expressed, siRNAs were produced from the annealed dsRNA which were capable of 
specific silencing of both endogenous and exogenous genes without activating PKR (Tran et al. 2004).  
The remaining studies utilized long dsRNA expressed as stem-loop, hairpin-like structures from the 
RNA Pol II cytomegalovirus (CMV) promoter.  Hairpin stem duplexes were generally long and ranged 
from 500 to 1000 bp with loop/linker sequences of 6 to 700 nt and in all cases resulted in effective and 
specific gene silencing, again suggesting the absence of immune stimulation (Paddison et al. 2002; 
Diallo et al. 2003; Yi et al. 2003a).  Diallo et al. used hairpin structures with a dsRNA stem region 800 
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bp in length, to completely inhibit the expression of specific endogenous genes.  Furthermore, they 
showed the presence of 21 nt RNA species complementary to the silenced gene in targeted cells 
(Diallo et al. 2003).  The constructs described above represented the first long hairpin RNAs (lhRNAs).  
Their ability to generate a pool of multiple siRNAs capable of gene specific silencing without prior 
identification of susceptible target sites, offers enormous potential for their development as 
combinatorial RNAi strategies.  In a study by Konstantinova et al., a series of Pol II-expressed lhRNAs 
with stem lengths of 300 bp were constructed to target the HIV-1 tat and nef genes in an attempt to 
inhibit viral replication.  However EFIα, 7tetO and HIV-1 LTR driven lhRNAs showed marginal anti-HIV-
1 activity when compared to a Pol III-expressed shRNA targeting a corresponding sequence 
(Konstantinova et al. 2006).  The use of expressed lhRNAs as novel treatment modality therefore 
requires further characterisation of the structural design of lhRNAs and the promoters that will drive 
their expression.  In addition, validation of the reported sequence-specific gene silencing is necessary 
to eliminate possible non-specific knockdown effects.   
Long hairpin RNAs driven by RNA Pol III promoters such as U6 and H1 were therefore developed 
soon thereafter as novel Dicer substrate precursors (Akashi et al. 2005; Nishitsuji et al. 2006; 
Watanabe et al. 2006; Weinberg et al. 2007).  Pol III-expressed transcripts result in shorter defined 
transcripts with 2-3 nt 3‟ uridine overhangs akin to natural pre-miRNA 3‟ overhangs, and are therefore 
likelier Dicer substrates.  Like shRNAs, lhRNAs mimic the structure of endogenous precursor 
microRNAs (pre-miRNAs).  In contrast, the hairpin stem of Pol III-expressed lhRNAs is longer than that 
of shRNAs yet much shorter than those of the Pol II-expressed lhRNAs described above, and have 
typically ranged from 50-197 bp.  RNA Pol III lhRNA transcripts have been used to inhibit the gene 
expression of both HIV-1 and HCV which are both rapidly evolving viruses.  A noteworthy benefit 
afforded by the lhRNAs used against these viruses was their ability to maintain target gene 
suppression in the presence of emerging mutations which abrogated the effects of single shRNAs 
(Akashi et al. 2005; Nishitsuji et al. 2006).  Akashi et al. showed the production of two discrete siRNA 
species from a 50 bp hairpin stem.  The production of more than one unique siRNA enables a greater 
region to be targeted and thus provides a likely reason for the inhibition of HCV irrespective of 
genotypic variations, again highlighting the advantages of lhRNAs as a combinatorial RNA approach.   
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Prior to the initiation of the research described in this thesis, lhRNAs had been designed to target 
only long contiguous sequences and little research had sought to characterise the mechanism by 
which lhRNAs are processed or the siRNA products which are generated by Dicer cleavage.  Evidence 
suggests that Dicer may generate multiple effective siRNAs from an lhRNA stem duplex, suggesting a 
possibility for incorporating the sequences of multiple siRNAs into the design of a single lhRNA.  
Processing of the hairpin stem would potentially enable the generation of a pool of siRNAs capable of 
simultaneously silencing multiple non-contiguous gene targets. 
 
1.11   Objectives of this thesis  
 
To sustain the inhibition of HIV replication effectively using RNAi-based therapeutic approaches, 
single RNAi effectors should be multimerised using one of the combinatorial RNAi strategies described 
above.  Long hairpin RNAs (lhRNAs) represent an attractive system for the simultaneous derivation of 
multiple siRNAs from a single transcript, since theoretically, Dicer cleaves the dsRNA stem region at 
regular intervals to yield multiple siRNA duplexes.  Prior to the initiation of this project however, the 
products of lhRNA cleavage had not been characterized, and this was due, in part, to the fact that 
lhRNAs had only ever been used against long contiguous sequences.  The overall aim of this project 
was to characterise the potential of lhRNAs for use as a combinatorial RNAi strategy.  This thesis 
aspired to demonstrate the possibility of incorporating the sequences of multiple unique siRNA 
sequences, targeted to non-contiguous sites, within a single lhRNA.  The investigation sought to 
characterise the processing trends of lhRNAs encoding multiple discrete siRNA sequences and thus 
the ability of Dicer to generate multiple functional siRNAs simultaneously from a single expressed 
transcript.  The final endeavor was to develop a novel lhRNA-based combinatorial RNAi strategy 
capable of effectively inhibiting highly mutable disease targets such as HIV.  
 
The abovementioned specific objectives of the project were met as follows: 
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1. Long hairpin RNAs were designed to encode up to three unique highly effective siRNA 
sequences targeted against non-contiguous, conserved regions within the HIV-1 genome.  A 
selection of candidate anti-HIV siRNA sequences were incorporated into lhRNA designs based 
on their antiviral efficacy in previously published studies.  RNA Pol III lhRNA expression 
cassettes were subsequently generated for assessment of inhibitory efficacy in vitro. 
2. The effect of sequential and spatial arrangement of putative siRNA sequences within the 
lhRNA duplex, on the RNAi activity afforded by each encoded siRNA sequence, was 
thoroughly investigated.  Putative siRNA sequences were placed in each possible position 
within the hairpin stem to determine potential positional effects.  Additionally, base pair spacing 
at siRNA encoding junctions was manipulated in lhRNAs encoding two or three siRNAs, to 
establish optimal structural features of an lhRNA stem duplex. 
3. The processing of lhRNA duplexes incorporating two or three siRNAs, by the enzyme Dicer, 
was characterised and optimised for the generation of two, equally processed and fully 
functional siRNAs from a single hairpin duplex. 
4. A novel lhRNA-based combinatorial RNAi system was designed to incorporate a combination 
of two optimally designed discrete dual-targeting lhRNAs.  The ability of this unique RNAi 
precursor structure to be processed intracellularly was explored and the inhibitory efficacy of 
processed products was determined. 
5. The ability of lhRNAs alone, or within a unique combinatorial system, to inhibit the replication 
of a primary HIV-1 subtype C isolate was assessed in vitro. 
6. Potential off-target and non-specific effects caused by exogenously introduced lhRNA 
expression cassettes into mammalian cells were assessed.  The activation of genes involved 
in the non-specific innate immune response was investigated and the potential saturation of 
the endogenous miRNA biogenesis pathway was determined by assessing derepression of 
both an endogenous and an exogenously introduced miRNA in lhRNA-transfected cells. 
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CHAPTER 2 
The efficacy of generating three independent anti-HIV-1 siRNAs 
from a single Pol III-expressed long hairpin RNA. 
 
2.1 Introduction  
 
The use of Pol III-driven lhRNAs offers an attractive combinatorial RNAi strategy.  However, 
extensive characterisation is still required to determine the mechanism as well as the efficiency by 
which these constructs are processed.  Powerful gene silencing mediated by lhRNAs has been 
reported, however the RNAi activity contributed by different regions within the lhRNA stem has yet to 
be investigated.  Preliminary evidence following further studies by others and us, characterising 
lhRNAs targeted to regions within HBV and HIV-1, suggests a possibility that lhRNA duplexes are not 
processed equally along the duplex, but rather that a bias exists for the cleavage of siRNAs at the base 
of the stem (Barichievy et al. 2007; Weinberg et al. 2007).  Long hairpin RNAs with a stem length of 62 
bp were assessed for their abilities to generate multiple siRNAs targeted against the HBx gene of HBV, 
and to silence minimal 21 nt targets spanning the duplex region.  However a maximum of two 
processed siRNAs were observed.  A third siRNA encoded by regions adjacent to the loop sequence 
was unable to be detected, which correlated with the poor RNAi inhibition from this region (Weinberg et 
al. 2007).   Similarly lhRNAs targeted against the HIV LTR effected knockdown only of target 
sequences complementary to the base of the lhRNA stem (Barichievy et al. 2007).  This phenomenon 
has not however been fully characterised and it is possible that the poor RNAi activity observed from 
siRNA sequences towards the loop of the hairpin stem was due to their ineffective guide sequences or 
inaccessibility of their target sequences, although northern blot analysis indicates a compromise not 
only of silencing efficacy but also of processing (Weinberg et al. 2007).   
Efforts to harness lhRNAs as a tool for gene silencing prior to the initiation of this study, had only 
utilized hairpin stems targeting contiguous sequences of a specific gene (Akashi et al. 2005; Nishitsuji 
et al. 2006; Watanabe et al. 2006; Barichievy et al. 2007; Weinberg et al. 2007).  This system mediates 
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silencing without prior identification of RNAi-susceptible target sites which is required for efficient 
silencing by single siRNA or shRNA guide sequences.  However, rather than contiguous lhRNAs, 
which may produce multiple, yet only moderately effective siRNAs, lhRNAs may in theory be designed 
to incorporate the sequences of multiple highly effective siRNAs.  This system would allow for the 
inclusion of previously characterised effective siRNA sequences within the hairpin stem, which once 
cleaved, yield guide strands able to target independent gene sequences, thus making lhRNAs an ideal 
tool for the development of a combinatorial RNAi strategy.   
Dicer acts as a molecular ruler, and cleaves substrate RNA at an exact length from the site 
where it binds (Macrae et al. 2006).  The products of human Dicer cleavage are generally ~22 nt, and 
in support of this, the siRNA species detected by Weinberg et al. in a mammalian cell line were ~22 nt 
in length (Weinberg et al. 2007).  Therefore a stem of 63-75 bp should theoretically provide a substrate 
for 3 successive Dicer cleavage reactions and the subsequent generation of 3 discrete siRNAs.  In this 
study, RNA Pol III-expressed lhRNAs 69 bp in length were designed to encode three 23 bp putative 
siRNA sequences targeted against three non-contiguous sites within the HIV genome previously 
shown to be highly susceptible to silencing by RNAi.  Target sequences included conserved regions 
within the tat (Lee et al. 2002a), rev (Lee et al. 2002a) and vif (Lee et al. 2005) open reading frames, 
thus providing a platform for the simultaneous suppression of both early and late phase viral transcripts 
(section 1.8.3).  A panel of lhRNAs was generated, each consisting of a different spatial arrangement 
of adjacent siRNA sequences.  This allowed for putative siRNA sequences to be placed in each 
possible sequential position within the duplex to control for any potential positional effects on inhibitory 
efficacy of individual guide sequences.   The work described in this chapter characterises the efficacy 
of expressed lhRNAs designed to generate up to three siRNAs targeted to non-contiguous sequences 
within the HIV-1 genome and highlights the advantages and current limitations of this strategy as a 
combinatorial RNAi tool. 
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2.2 Materials and Methods 
 
2.2.1 Generation of plasmids encoding U6-driven lhRNA and shRNA sequences 
 
U6-expressed lhRNA and shRNA sequences were constructed using a two-step PCR (Figure 
2.3) which was adapted from a protocol originally used by Castanotto et al. to generate Pol III-driven 
shRNAs (Castanotto et al. 2002).  In the first round of PCR, 10 ng of pTZU6+1, a plasmid containing 
the human U6 snRNA RNA Pol III promoter sequence (Bertrand et al. 1997) was used as a template.  
The universal U6 forward primer (Table 2.1) was complementary to the 5‟ end of the U6 promoter and 
was used for both rounds of PCR.  It included a SpeI restriction enzyme recognition site to facilitate 
screening of correctly inserted clones.  The reverse primer for the first round (R1) of PCR was 
complementary to 21 nt of the 3‟ end of the U6 promoter and contained a linker encoding the sense 
strand of the hairpin duplex as well as the loop sequence (Table 2.1).  PCR reactions were carried out 
on a Mastercycler® (BioRad, CA, USA) and standard thermocycling conditions were used: initial 
denaturation at 95 °C for 5 minutes (min), followed by 30 cycles of denaturing at 95 °C for 30 seconds 
(sec), annealing at 55 °C for 30 sec and extension at 72 °C for 30 sec and a final extension step at 
72°C for 10 min.  In each 50 µl reaction, 10 pmol of each primer was used with the Expand High 
Fidelity
PLUS
 Taq polymerase kit (Roche, Basel, Switzerland) reagents: 1.5 mM MgCl2; 200 µM dNTP 
mix; 2.5 U Expand HiFi
PLUS 
Taq polymerase and 1× Expand HiFi
PLUS
 Reaction Buffer (proprietary 
information). The first round of PCR generates the complementary sequence of the lhRNA sense 
strand as well as the loop sequence.  For the second round of PCR, a 1:500 dilution of the round one 
amplicon (approximately 10 pg) was used as the template.  The reverse primer sequence (R2) 
contained an 18-21 nt overlapping sequence with the loop region of the round one reverse primer and 
encodes the antisense strand of the lhRNA as well as 6 thymidine residues for Pol III transcriptional 
termination (Table 2.1).  This overlap between each pair of reverse primers enables the extension of 
the PCR product to generate a U6 expressed lhRNA cassette with a transcription termination signal.  
The conditions for the second round PCR were the same as the first.  PCR products were 
electrophoretically resolved on a 1.5% agarose gel run in Tris-Borate-EDTA (TBE) buffer (890 mM Tris 
base; 890 mM boric acid and 32 mM EDTA), and visualized on a UV transilluminator. 
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Figure 2.1:  Schematic representation of the two step PCR cloning strategy used to generate 
lhRNA and shRNA expression cassettes.  The first round of PCR generates an amplicon encoding 
the sense strand as well as the loop of the lhRNA.  The second round amplicon encodes the sense, 
loop and antisense sequences and is cloned directly into the TA cloning vector pTZ57R/T.  The 
inverted repeat sequences, once transcribed, fold back on themselves to form a hairpin duplex.
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Table 2.1:  Oligonucleotides used to generate lhRNAs encoding three putative siRNAs and corresponding shRNAs 
 
Primer 
 
Sequence (5’-3’) Length 
(nt) 
U6 forward 
 
CTAACTAGTGGCGCGCCAAGGTCGGGCAGGAAGAGGG 37 
lhRNA-tat-rev-vif R1 CTTGAAATGGAATGTATACCTCTAAACAAGGCAGCCGAAGAGACACAGACAAGCCCTTCATCACTATCCCCGCGGTG
TTTCGTCCTTTCCACAA                                  
94 
lhRNA-tat-rev-vif R2 AAAAAAGCGGAGACAGCGACGAAGAGCTTGCCTGTGCCTCTTCAGCTACCTTGTTCAGAAGTACACATCCCACTCTC
TTGAAATGGAATGTATA 
94 
lhRNA-rev-vif-tat R1 CTTGAAGCCCTTCATCACTATCCCCGCAAATGGAATGTATACCTCTAAACAAGGCAGCCGAAGAGACACAGACGGTG
TTTCGTCCTTTCCACAA                            
94 
lhRNA-rev-vif-tat R2 AAAAAAGCCTGTGCCTCTTCAGCTACCTTGTTCAGAAGTACACATCCCACTTGCGGAGACAGCGACGAAGAGCTCTC
TTGAAGCCCTTCATCAC 
94 
lhRNA-vif-tat-rev R1 CTTGAAGGCAGCCGAAGAGACACAGACAAGCCCTTCATCACTATCCCCGCAAATGGAATGTATACCTCTAAACGGTG
TTTCGTCCTTTCCACAA           
94 
lhRNA-vif-tat-rev R2 AAAAAAGTTCAGAAGTACACATCCCACTTGCGGAGACAGCGACGAAGAGCTTGCCTGTGCCTCTTCAGCTACCTCTC
TTGAAGGCAGCCGAAGA 
94 
shRNA-tat R1 CTCTTGAAGCCCTTCATCACTATCCCCGCGGTGTTTCGTCCTTTCCACAA  
 
50 
shRNA-tat R2 AAAAAAGCGGAGACAGCGACGAAGAGCTCTCTTGAAGCCCTTCATCAC 
 
48 
shRNA-rev R1 CTCTTGAAGGCAGCCGAAGAGACACAGACGGTGTTTCGTCCTTTCCACAA 
 
50 
shRNA-rev R2 AAAAAAGCCTGTGCCTCTTCAGCTACCTCTCTTGAAGGCAGCCGAAGA 
 
48 
shRNA-vif R1 CTCTTGAAATGGAATGTATACCTCTAAACGGTGTTTCGTCCTTTCCACAA 
 
50 
shRNA-vif R2 AAAAAAGTTCAGAAGTACACATCCCACTCTCTTGAAATGGAATGTATA 
 
48 
lhRNA-rev-vif-tat b R1 CTCTTGAAGCCCTTCATCACTATCCCCGCAAATGGAATGTATACCTCTAAAC*AGGCAGCCGAAGAGACACAGACGG
TGTTTCGTCCTTTCCACAA 
95 
lhRNA-rev-vif-tat b R2 AAAAAAGCCTGTGCCTCTTCAGCTACCT*GTTCAGAAGTACACATCCCACTTGCGGAGACAGCGACGAAGAGCTCTC
TTGAAGCCCTTCATC 
91 
lhRNA-rev-vif-tat c R1 CTCTTGAAGCCCTTCATCACTATCCCCGCTAAATGGAATGTATACCTCTAAAC*AGGCAGCCGAAGAGACACAGACG
GTGTTTCGTCCTTTCCACAA 
96 
53 
 
lhRNA-rev-vif-tat c R2 AAAAAAGCCTGTGCCTCTTCAGCTACCT*GTTCAGAAGTACACATCCCACTTAGCGGAGACAGCGACGAAGAGCTCT
CTTGAAGCCCTTCATCA 
93 
lhRNA-rev-vif-tat d R1 CTCTTGAAGCCCTTCATCACTATCCCCGCTTAAATGGAATGTATACCTCTAAAC*AGGCAGCCGAAGAGACACAGAC
GGTGTTTCGTCCTTTCCACAA 
97 
lhRNA-rev-vif-tat d R2 AAAAAAGCCTGTGCCTCTTCAGCTACCT*GTTCAGAAGTACACATCCCACTTAAGCGGAGACAGCGACGAAGAGCTC
TCTTGAAGCCCTTCATCA 
94 
lhRNA-rev-vif-tat e R1 CTTGAAGCCCTTCATCACTATCCCCGCAGTTAAATGGAATGTATACCTCTAAACA**GCAGCCGAAGAGACACAGAC
GGTGTTTCGTCCTTTCCACAA 
96 
lhRNA-rev-vif-tat e R2 AAAAAAGCCTGTGCCTCTTCAGCTACC**GTTCAGAAGTACACATCCCACTTAACTGCGGAGACAGCGACGAAGAGC
TCTCTTGAAGCCCTTCATCAC 
96 
lhRNA-rev-vif-tat f R1 CTTGAAGCCCTTCATCACTATCCCCGCTTAAATGGAATGTATACCTCTAAACAAGGCAGCCGAAGAGACACAGACGG
TGTTTCGTCCTTTCCACAA   
96 
lhRNA-rev-vif-tat f R2 AAAAAAGCCTGTGCCTCTTCAGCTACCTTGTTCAGAAGTACACATCCCACTTAAGCGGAGACAGCGACGAAGAGCTC
TCTTGAAGCCCTTCATCAC 
96 
lhRNA-rev-vif-tat g R1 CTTGAAGCCCTTCATCACTATCCCCGCTTAAATGGAATGTATACCTCTAAACTAAGGCAGCCGAAGAGACACAGACG
GTGTTTCGTCCTTTCCACAA   
97 
lhRNA-rev-vif-tat g R2 AAAAAAGCCTGTGCCTCTTCAGCTACCTTAGTTCAGAAGTACACATCCCACTTAAGCGGAGACAGCGACGAAGAGCT
CTCTTGAAGCCCTTCATCAC 
97 
 
Underlined sequences represent restriction endonuclease recognition sites.  The loop sequence is italicized.  Highlighted sequences indicate the overlapping regions between each 
pair of reverse primers. 
 
Bold letters indicate sites of G:U mismatch introductions in the sense strand.  Double underlined letters indicate nucleotide spacers inserted between siRNA 
encoding sequences and asterisks indicate positions where nucleotide spacers have been deleted.
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Round 2 amplicons that were visualized as a single band at the correct molecular weight on an 
agarose gel were ligated directly into the TA cloning vector pTZ57R/T using the InsTAclone
TM
 PCR 
Cloning Kit (Fermentas, WI, USA).  A 3:1 molar ratio of insert to vector (0,09 pmol insert:0.03 pmol 
vector) was ligated using 5 U T4 DNA ligase and T4 DNA ligase buffer (40 mM Tris-HCl, 10 mM MgCl2, 
10 mM DTT and 0.5 mM ATP [pH 7.8 at 25°C]) in a 20 µl volume and the reaction was incubated at 
room temperature overnight.  A 7 µl aliquot of the ligation reaction was then used to transform 100 µl of 
chemically competent DH5α E.coli (Appendix A1.1).  Transformed cells were plated on Luria Bertani 
agar plates containing ampicillin (Gibco, BRL, UK), X-Gal (5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside) (Sigma, MO, USA) and IPTG (Isopropyl-β-D-1-thiogalactopyranoside) (Roche, 
Basel, Switzerland) (Appendix A1.1) and incubated at 37°C overnight. 
Individual white colonies were cultured in 3 ml of ampicillin-containing Luria Bertani broth 
(Appendix A1.1) at 37°C overnight with shaking.  Plasmid DNA was then purified using the High Pure 
Plasmid Isolation Kit for small-scale (mini) preparations of purified plasmid DNA (Roche, Germany) 
(Appendix A1.2.1).  Plasmids were screened for the presence of inserts and their relative orientation by 
digesting plasmid DNA with EcoRI and SpeI or with HindIII and SpeI (Fermentas, WI, USA) (Figure 
2.1).  Digested plasmids were resolved on a 3% agarose gel.  Positive clones resulting in digested 
fragments of the desired molecular weight were verified by sequencing with M13 forward and reverse 
primers by automated cycle sequencing (Inqaba Biotech, South Africa), M13 forward: 5‟- 
GTAAAACGACGGCCAG -3‟, M13 reverse: 5‟- CAGGAAACAGCTATGAC -3‟.  The protocol for 
sequencing plasmids encoding lhRNAs included modifications in the cycle to reduce enzyme depletion 
and DMSO to stabilise the hairpin and lower melting temperatures.  Clones with the correct sequence 
were cultured in 200 ml ampicillin-containing LB overnight for large-scale preparation of plasmid DNA 
using the QIAGEN Plasmid Maxi Kit (QIAGEN, CA, USA) (Appendix A1.2.2). 
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2.2.2 Dual luciferase fusion reporter plasmids 
 
To determine knockdown induced by each putative siRNA encoded by the lhRNA sequences, a 
set of dual luciferase-based reporter vectors were constructed containing the individual target 
sequences of each siRNA or the target sequences of all three siRNAs in tandem.   The target vectors 
were constructed using the psiCHECK
TM
-2 (Promega, WI, USA) plasmid which comprises an HSV TK-
driven Firefly luciferase cassette as well as an SV40-driven Renilla luciferase cassette with a multiple 
cloning site situated within the 3‟ UTR.  Following insertion of a target sequence within the multiple 
cloning site, knockdown can be measured as a ratio of Renilla luciferase to Firefly luciferase 
expression.  To insert the target sequences into the 3‟ UTR of the Renilla luciferase open reading 
frame, the psiCHECK
TM
-2 (Promega, WI, USA) plasmid backbone was initially prepared by digestion 
with 15 U each of XhoI and NotI with Buffer O (50 mM Tris-HCl [pH 7.5 at 37°C]; 10 mM MgCl2; 100 
mM NaCl and 0.1 mg/ml BSA) (Fermentas, WI, USA) in a 50 µl volume for 1.5 hours at 37°C.  The 
digested plasmid was then dephosphorylated by adding 5 U of Antarctic phosphatase (AP) (NEB, MA, 
USA) to the digestion reaction together with AP buffer (50 mM bis-tris-propane-HCl, 1 mM MgCl2 and 
0.1 mM ZnCl2 pH 6.0) to a 60 µl total volume.  The reaction was incubated at 37°C for a further 10 min.  
The phosphatase reaction was heat-inactivated for 15 min at 65°C followed by resolution of the linear 
psiCHECK vector backbone DNA on a 0.8% agarose gel. The double-digested vector backbone band 
was then excised and purified using the MinElute
TM
 Gel Extraction kit (QIAGEN, CA, USA) according to 
the manufacturer‟s instruction (Appendix A1.3).  
 The individual tat, rev and vif target sequences were generated by amplifying the desired target 
sequence from the HIV-1 subtype B molecular clone pNL4-3 (Adachi et al. 1986) with gene specific 
primers in a standard PCR reaction using the same thermocycling conditions and reagents described 
in 2.2.1.  Each forward primer contained a 5‟ XhoI restriction site linker and each reverse primer 
contained a 5‟ NotI restriction site linker (Table 2.2).  PCR amplicons were individually ligated to 
pTZ57R/T as described in 2.2.1. and clones were screened for inserts by digestion with XhoI and NotI  
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(Fermentas, WI, USA).  The insert fragment was then excised from an agarose gel and purified using 
the MinElute
TM
 Gel Extraction kit (QIAGEN, CA, USA) according to the manufacturer‟s instructions 
(Appendix A1.3). 
To generate a combined target sequence containing the tat, rev and vif individual target 
sequences adjacent to one another, partially overlapping oligonucleotides (Table 2.2) (10 µM each) 
encoding the collective target sequence were treated with T4 Polynucleotide Kinase (PNK) 
(Fermentas, WI, USA) with Reaction buffer A (50 mM Tris-HCl [pH 7.6 at 25°C]; 10 mM MgCl2; 5mM 
DTT; 0.1mM spermidine and 0.01 mM EDTA) for 30 min at 37°C.  The oligonucleotides were annealed 
by slow cooling to room temperature following heating to 95°C for 5 min. The forward oligonucleotide 
contained a 5‟ XhoI restriction site linker and the reverse oligonucleotide contained a 5‟ NotI restriction 
site linker.  To ligate the vector backbone to the target sequence inserts, 60 fmol (approximately 50 ng) 
of purified psiCHECK backbone fragment was ligated with 180 fmol of each digested PCR fragment or 
annealed dsDNA fragment, both containing 5‟ XhoI and 3‟ NotI cohesive ends, in a 20 µl reaction 
volume using 10 U T4 DNA ligase (NEB, MA, USA).  A 10 µl aliquot of the ligation reaction was then 
used to transform 100 µl chemically competent DH5α E.coli as described previously.  Transformed 
cells were plated onto ampicillin-containing agar plates and incubated overnight at 37°C.  Purified 
plasmids from individually cultured colonies were screened by digestion with XhoI and NotI 
(Fermentas, WI, USA) and clones with the correct sized insert were subsequently verified by 
automated cycle sequencing (Inqaba Biotech, South Africa) using a forward primer specific to the 
Renilla luciferase ORF: 5‟ GAGGACGCTCCAGATGAAATG 3‟.  
 Reporter vectors containing the HXB2 as well as the FV5 derived vif target sequences were 
constructed using a similar strategy to that described above.  Complementary oligonucleotides (Table 
2.2) were treated with PNK (Fermentas, WI, USA), annealed and cloned directly into the XhoI-NotI 
sites of the dephosphorylated psiCHECK
TM
-2 linearised vector as previously described.  An EcoRV site 
was incorporated into the overlapping region of each oligonucleotide to facilitate screening of plasmids 
containing inserted target sequences. 
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Table 2.2:  Primers used to amplify target sequences for directional cloning into psiCHECK™-2 
 
Primer Sequence (5’ to 3’) Length 
(nt) 
tat target forward 
 
GATCTCGAGAGTGTTGCTTTCATTGCCAA 29 
tat target reverse 
 
GATCGCGGCCGCGCATTACATGTACTACTTACTGCTT 37 
rev target forward 
 
GATCTCGAGAAGGTGGAGAGAGAGACAGA 29 
rev target reverse 
 
GATCGCGGCCGCCACCAATATTTGAGGGCTTC 32 
vif target forward 
 
GATCTCGAGATTTCAAGGAAAGCTAAGGA 29 
vif target reverse 
 
GATCGCGGCCGCAATGCCAGTCTCTTTCTCCT 32 
tat-rev-vif target forward 
 
GATCTCGAGGCGGAGACAGCGACGAAGAGCTTGCCTGTGCCTCTTCAGCTACC 53 
tat-rev-vif target reverse 
 
GATCGCGGCCGCGTGGGATGTGTACTTCTGAACAAGGTAGCTGAAGAGGCACAGGC 56 
FV5 vif target forward 
 
CTCGAGATATCGTTCAGAAGTACATATTCCATGC 34 
FV5 vif target reverse 
 
GCGGCCGCATGGAATATGTACTTCTGAACGATATC 35 
HXB2 vif target forward 
 
CTCGAGATATCGTTCAGAAGTACACATCCCACGC 34 
HXB2 vif target reverse 
 
GCGGCCGCGTGGGATGTGTACTTCTGAACGATATC 35 
 
Underlined sequences represent the XhoI and NotI restriction endonuclease recognition sites in the forward and reverse primers respectively as well as the EcoRV restriction 
endonuclease recognition site within the overlapping region of forward and reverse oligonucleotides.  Highlighted sequences indicate complementary overlapping regions between the 
pair of oligonucleotides.
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2.2.3 Assessing the efficacy of expressed lhRNAs in cell culture 
 
Transfection of cultured mammalian cells 
The HEK293 cell line was maintained in Dulbecco‟s modified Eagle‟s medium (DMEM), 
(BioWhittaker, MD, USA) supplemented with 10% heat inactivated fetal calf serum (FCS), (Delta 
Bioproducts, Johannesburg, SA) at 37°C and 5% CO2 as described in Appendix A1.4.  Cells were 
seeded at 120 000 cells per well in 24-well tissue culture plates (Nunclon™ ∆ Surface, Nunc, 
Denmark) 24 hours prior to transfection in antibiotic-free medium.  Hairpin encoding plasmids (750 ng) 
together with dual luciferase target reporter plasmids (150 ng) were co-transfected in a 5:1 ratio.  One 
hundred nanograms of plasmid pCI-eGFP (Passman et al. 2000), a plasmid expressing enhanced 
green fluorescent protein (GFP) from a CMV promoter,  was also co-transfected to control for 
transfection efficiency.  Each transfection was performed in triplicate.  Transfections were carried out 
using 1 µl Lipofectamine
TM
 2000 (Invitrogen, CA, USA) per 1 µg DNA and 0.2× OptiMEM (Gibco, BRL, 
UK) (Appendix A1.5).  Twenty four hours after transfection, culture medium was replaced and 48 hours 
after transfection cells were observed by fluorescence microscopy using the Axiovert 100 M 
microscope (ZEISS, Germany) to visualize GFP to ensure equal transfection efficiency. 
 
Dual luciferase reporter assay 
Reporter assays (Figure 2.2) were carried out 48 hours post transfection using the Dual-
Luciferase
®
 Reporter Assay System (Promega, WI, USA) according to the manufacturer‟s instructions.  
Culture medium was removed and cells were lysed with 100 µl Passive Lysis Buffer for 20 min with 
gentle agitation.  Following lysis, 10 µl cell lysate was added to Costar
® 
96 well flat bottom assay plates 
(Corning Incorporated, NY, USA).  Firefly and Renilla luciferase activity were measured independently 
using 50 µl 1× Luciferase Reagent II and Stop & Glo
®
 solutions (proprietary information) respectively in 
a Veritas
TM
 Microplate Luminometer (Turner Biosystems, CA, USA).  All Renilla luciferase values were 
normalised to background Firefly luciferase values.  The average expression ratio for pTZU6+1 
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(Bertrand et al. 1997), a control plasmid containing the U6 promoter with no RNAi effector sequence 
was set to 100%, and relative expression levels of other samples were calculated accordingly. 
 
 
 
Figure 2.2:  Diagrammatic representation of the dual luciferase reporter assay.  A target 
sequence of choice is cloned into the 3‟ UTR of the human Renilla luciferase gene so that if targeted 
by a complementary shRNA or lhRNA the mRNA transcript is degraded and Renilla expression 
inhibited.  Renilla luciferase activity is normalised to Firefly luciferase which is expressed independently 
within the same vector. 
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2.2.4 Detection of processed anti-HIV-1 hairpin sequences using polyacrylamide gel 
electrophoresis (PAGE) and northern blot analysis 
 
HEK293 cells were maintained as described (Appendix A1.4).  For northern blot analysis cells 
were seeded to approximately 70% confluence in 60 cm
2
 Costar
®
 tissue culture plates (Corning Inc, 
NY, USA) in antibiotic-free medium.  Cells were transfected 24 hours later with 19 µg hairpin 
expression plasmids together with 1 µg pCI-eGFP as described in Appendix A1.5. 
Forty eight hours after transfection, total RNA was extracted using TriReagent
TM
 (Sigma, MO, 
USA) according to the manufacturer‟s instructions (Appendix A1.6).  Standard RNA handling 
procedures to avoid RNase contamination were followed.  Thirty micrograms of each RNA sample was 
resolved on a 15% polyacrylamide gel prepared at a 1:19 ratio of bis:acrylamide with 8 M urea and 
TBE buffer (890 mM Tris base; 890 mM boric acid and 32 mM EDTA).  Decade Marker
TM
 (Ambion, TX, 
USA) was used as a molecular weight marker and was prepared as per the kit‟s instructions (Appendix 
A1.7).  Once total RNA was separated the polyacrylamide gel was stained with 10 mg/ml ethidium 
bromide (Sigma, MO, USA) for 5 minutes and visualized on a UV transilluminator (Kodak Gel Logic 
200 Imaging System) to check RNA integrity and quality. 
The RNA was transferred to Hybond-N+ positively charged nylon membrane (GE Healthcare, NJ, 
USA) using the Semi-dry Electroblotting Unit Z34,050-2 (Sigma, MO, USA) at 3.3 mA/cm
2 
for one hour.  
RNA was then UV cross-linked to the membrane at 2000 × 100 µJ/cm
2
 in a Ultra-Violet Products (UVP) 
UV cross linker (UVP, Inc., CA, USA) and then the membrane was baked at 80°C for 1 hour. 
Oligonucleotide probes (20 µM) (Table 2.3) were labeled with γ-
32
P-ATP (6000 Ci/mmol) 
(PerkinElmer, MA, USA) in 20 µl total volume using 5 U Polynucleotide Kinase (PNK) and PNK buffer 
(50 mM imidazole HCl (pH 6.6); 10 mM MgCl2; 5 mM DTT; 0.1 mM spermidine and 0.1 mM EDTA) 
(Promega, WI, USA) at 37°C for 20 min.  The reaction was diluted to 50 µl and purified by 
centrifugation through a sephadex G-25 column for 2 min at 2000 rpm.   
Membranes were prehybridised in 10 ml/100 cm
2
 of pre-warmed Rapid-Hyb buffer (GE 
Healthcare, NJ, USA) at 42°C for 20 min.  Following pre-hybridisation the labelled probe was added to 
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the buffer and incubated with the membrane overnight at 42°C.  Following overnight hybridisation, 
membranes were washed once with 0.1% SDS (sodium dodecylsulphate) and 5% SSC (NaCl, Na-
citrate) (Sigma, MO, USA) in a volume of 50 ml at room temperature for 20 min and then subsequently 
washed twice with 0.1% SDS and 1% SSC in a volume of 50 ml at 42°C for 15 min each before 
exposure to Fuji x-ray film for 24-72 hours at -80°C.  Membranes were stripped with 50 ml 1% SDS for 
30 min at 80°C and then re-probed.  A probe complementary to U6 snRNA was used to verify equal 
loading of each RNA sample. 
 
Table 2.3:  Oligonucleotide probes used to detect lhRNA guide sequences 
 
Probe Sequence (5’ to 3’) Length (nt) 
rev GCCTGTGCCTCTTCAGCTACCT 23 
vif GTTCAGAAGTACACATCCCACTT 23 
tat 1 GCGGAGACAGCGACGAAGAGCTT 23 
tat 2 ACTTGCGGAGACAG 14 
tat 3 GCGCGCGGAGACAG 14 
U6 snRNA TAGTATATGTGCTGCCGAAGCGAGCA 26 
LNA nucleotides are underlined. 
 
2.2.5 HIV viral challenge assay  
 
U87.CD4.CCR5 cells were maintained in DMEM supplemented with 15% FCS, 1 µg/ml 
puromycin, 300 µg/ml G418, glutamine, penicillin and streptomycin as described in Appendix A1.4.  
Cells were seeded at 100 000 cells per well in 12-well tissue culture plates (Nunclon™ ∆ Surface, 
Nunc, Denmark) 24 hours prior to transfection in antibiotic-free medium.  Cells were then transfected 
with 900 ng hairpin expression plasmids or pTZU6+1 negative control together with 100 ng pCI-eGFP 
as described in Appendix A1.5.   
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FV5 (GenBank accession number DQ382363) is a primary HIV-1 CCR5-utilizing subtype C virus 
that was isolated from a drug-naïve HIV-positive AIDS patient admitted to the Johannesburg Hospital 
AIDS clinic, and propagated by standard PBMC co-culture techniques (HIV Pathogenesis Research 
Unit).  The co-receptor tropism of FV5 was established genotypically by automated sequencing of the 
V3 loop of the viral env gene (GenBank® accession number 05ZAFV5), and confirmed phenotypically 
by MT-2 fusion assay (HIV Pathogenesis Research Unit).  
Viral stocks were then expanded by infecting U87.CD4.CCR5 cells in 75 cm
2 
tissue culture 
flasks (Corning Incorporated, NY, USA).  Once cells reached approximately 60% confluence, culture 
medium was removed and 750 µl viral stock was suspended in 5 ml medium and added to the cells for 
overnight incubation under standard cell culturing conditions.  After 24 hours culture medium was 
removed, wells were washed three times with phosphate buffered saline (PBS) to remove residual 
virus and 20 ml fresh medium was added to the cells.  Cells were propagated for a further 72 hours 
before high titer culture supernatants were harvested and dispensed into 500 µl aliquots.  The 50% 
tissue culture infectious dose (TCID50) of the harvested supernatants was then determined as 
described in Appendix A1.9.  The TCID50 assay quantifies viable virus by measuring p24 antigen 
concentration (Appendix A1.8) following a dilution assay.   
Twenty four hours after transfection, U87.CD4.CCR5 cells were infected with FV5 at a TCID50 
1000. An aliquot of titered virus was serially diluted to a final TCID50 1000 per ml.   Culture medium was 
then removed from transfected cells and 1 ml of the viral dilution was dispensed into each transfected 
well.  Twenty four hours after infection cells were washed three times using PBS to remove residual 
virus from cultures and 1 ml fresh medium was added to each well.  At days 0 (day of washing), and 
specified time points thereafter, 100 µl of supernatant was collected from each well and analysed by 
ELISA (Murex Biotech LTD, Dartford, UK) for p24 antigen production as a marker of viral replication.   
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2.2.6 Quantitative real-time reverse transcription PCR (qRT-PCR) to detect induction 
of interferon related genes 
 
HEK293 cells were maintained as described in Appendix A1.4.  Cells were seeded at 120 000 
cells per well in 24-well tissue culture plates (Nunclon™ ∆ Surface, Nunc, Denmark) 24 hours prior to 
transfection in antibiotic-free medium.   Cells were transfected with 900 ng hairpin expression plasmids 
or poly (I:C) (Sigma, MO, USA) together with 100 ng pCI-eGFP as described in Appendix A1.5.  Poly 
(I:C) is a synthetic double-stranded RNA analogue and was used as a positive control for induction of 
IFN-β expression.  
To measure concentrations of IFN-related genes in cells transfected with lhRNA and shRNA 
expressing plasmids, total RNA was extracted from cells 48 hours after transfection using 
TriReagent
TM
 (Sigma, MO, USA) according the manufacturer‟s instructions (Appendix A1.6).  Standard 
RNA handling procedures to avoid RNase contamination were followed and RNA pellets were 
resuspended in 10 μl nuclease free water.  RNA samples were DNase treated with 2 U DNase 
(Fermentas, WI, USA) for 60 min at 37°C after which DNase was inactivated during a 5 min incubation 
at 95°C.  RNA was reverse transcribed using the Sensiscript
®
 reverse transcription kit (QIAGEN, CA, 
USA).  In a 10 µl reaction, 50 ng DNase treated RNA was incubated with 0.5 U Sensiscript RT; 1× RT 
buffer (proprietary information), 10 µM oligo-dT primer and 5 mM of each dNTP at 37°C for 60 min.  
Following reverse transcription GAPDH and IFN-β mRNA were amplified by real-time PCR using the 
SYBR
®
 Green Jumpstart Taq Ready Mix kit (Sigma. MO, USA) in a Roche Lightcycler V.2.  The 20 µl 
reaction consisted of 2 µl cDNA generated from the RT reaction described above, 10 µM of each 
primer and SYBR Green Ready Mix (0.5 U Taq DNA Polymerase; 10 mM Tris-HCl pH 8.3; 50 mM KCl; 
3.5 mM MgCl2; 0.2 mM each dNTP; stabilizers; internal reference dye and SYBR Green).  The 
following primer sets were used to amplify IFN-β and GAPDH mRNA: IFN-β Forward: 5‟- TCC AAA 
TTG CTC TCC TGT TGT GCT -3‟, IFN-β Reverse: 5‟- CCA CAG GAG CTT CTG ACA CTG AAA A -3‟, 
GAPDH Forward: 5‟- AGG GGT CAT TGA TGG CAA CAA TAT CCA -3‟ and GAPDH Reverse: 5‟- TTT 
ACC AGA GTT AAA AGC AGC CCT GGT G -3‟.  Thermal cycling parameters consisted of a hot start 
for 30 seconds at 95 
°
C followed by 50 cycles of denaturation at 95°C for 10 sec, annealing at 58°C for 
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10 sec and extension at 72°C for 10 sec.  Specificity of the PCR products was verified by melting curve 
analysis and IFN-β values were normalised against GAPDH values. 
 
2.2.7 Statistical analysis 
 
Statistical analysis was carried out using the GraphPad Prism software (GraphPad, Software, Inc., 
CA, USA).  Differences were considered significant when p<0.05 and was determined using either an 
unpaired Student‟s t-test or by ANOVA.  The results of the TCID50 assay were analysed using the 
Spearman-Karber statistical formula as described in Appendix A1.9. 
 
2.3 Results 
 
2.3.1 Design of anti-HIV-1 lhRNAs 
 
Long hairpin RNAs (lhRNAs) with stem lengths of 69 bp, a 7 nt terminal loop sequence and a 2-3 
nt terminus were designed to incorporate three independent anti-HIV siRNA sequences, such that 
three unique and non-overlapping 21-23 nt siRNAs could potentially be generated following three 
successive Dicer cleavage reactions (Figure 2.3).  Sites targeted by each putative guide strand were 
based on previously published effective shRNAs which target conserved regions in the HIV-1 genome 
shown to be highly susceptible to RNAi.  These target sites included an overlapping tat/rev site (Lee et 
al. 2002a) referred to hereafter as tat; an overlapping rev/env site (Lee et al. 2002a) referred to 
hereafter as rev; and a site within the vif ORF (Lee et al. 2005).  Each lhRNA was designed to be 
transcribed from the U6 snRNA RNA Pol III promoter.  RNA Pol III promoters naturally produce small 
transcripts which have a defined transcription start site and a termination signal consisting of ≥4 
consecutive thymidine residues thus producing a well defined transcript.  Furthermore, termination 
results in a 2 nt 3‟ overhang, which is optimal for Dicer recognition (Ma et al. 2004), nuclear export 
(Zeng and Cullen 2004) and the evasion of RIG-1 recognition (Marques et al. 2006).  RNA Pol III 
transcripts therefore serve as ideal substrates for Dicer processing. 
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Figure 2.3: Schematic representation of an lhRNA expression cassette showing the upstream 
U6 promoter and the predicted lhRNA structure post transcription.  Long hairpin RNAs were 
designed to have a 69 bp stem allowing for three predicted Dicer cleavage reactions and the 
subsequent generation of three siRNAs. 
 
Because of the incorporation of independent siRNA sequences within the hairpin duplex, plasmids 
encoding three variants of the hairpin were constructed:   lhRNA-tat-rev-vif, lhRNA-rev-vif-tat and 
lhRNA-vif-tat-rev, allowing for each unique siRNA sequence to be sequentially placed at each possible 
position within the hairpin duplex (Figure 2.4 A).  It has been shown that human Dicer may favour the 
production of siRNAs positioned at the base of the stem (Barichievy et al. 2007; Weinberg et al. 2007), 
and the assessment of three lhRNA positional variants enables the assessment of any possible 
sequence or positional effects.  G:U wobble base mismatches were introduced at regular intervals 
along the sense strand of the hairpin duplex (C is replaced by a T; A is replaced by a G in the DNA 
sequence) (Figure 2.4) to facilitate propagation of inverted repeat sequences in E.coli and sequencing 
of plasmids containing correctly cloned lhRNAs.  Individual shRNAs matching the putative siRNA 
sequences included in the lhRNAs were constructed with corresponding G:U mismatches and loop 
sequences to act as positive controls (Figure 2.4 B).   
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Figure 2.4:  Design of anti-HIV lhRNAs incorporating three putative siRNAs. (A) Anti-HIV lhRNAs 
were designed to encode three 23 bp siRNA sequences targeted to the tat, rev and vif open reading 
frames of HIV-1.  Three variants of the lhRNA were designed to allow for every possible spatial 
arrangement of putative siRNAs.  Introduced G:U wobble base pairs are indicated in bold.  (B) 
Individual shRNAs encoding corresponding siRNAs were designed to incorporate equivalent G:U 
mismatches and the same loop sequence. 
   
2.3.2 Inhibitory efficacies of lhRNAs encoding three putative siRNAs 
 
The long hairpin RNA sequences were assessed for their ability to inhibit the respective targets of 
each encoded siRNA in vitro.  A non-specific lhRNA targeted against the TAR loop of HIV (Barichievy 
et al. 2007) was used as a negative control (lhRNA control) and this target sequence was not included 
in the psiCHECK reporter vectors.  Target-specific knockdown was determined as a ratio of Renilla 
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luciferase to Firefly luciferase, and the values were normalised to pTZU6+1 (mock).  When assessing 
knockdown of the individual target sequences, all of the lhRNA expression cassettes showed 
significant, yet variable inhibition of fusion gene activity (Figure 2.5 A).  When only the tat target 
sequence was inserted downstream from the Renilla luciferase reporter gene, shRNA-tat mediated a 
90% reduction in the Renilla to Firefly luciferase ratio while shRNA-rev and shRNA-vif showed no 
effect at all.  This result was expected and confirms target specificity of control shRNAs.  lhRNA-tat-
rev-vif contains the tat siRNA sequence in the first position of the hairpin stem, distal from the loop 
sequence, and showed the greatest reduction (approximately 50%) in Renilla-tat fusion gene 
expression, whereas lhRNA-vif-tat-rev and lhRNA-rev-vif-tat were less effective.  A similar trend was 
observed when assessing the inhibitory efficacies of hairpin expression cassettes against the individual 
rev and vif target sequences.  The shRNAs showed target specific knockdown in all cases and the 
lhRNAs diminished target gene activity approximately 30-85%, with the strongest silencing effects 
consistently observed by the lhRNA containing the siRNA complementary to the target sequence 
positioned at the base of the hairpin stem.  A gradual loss of RNAi activity was observed from siRNAs 
positioned in the second and third positions of the hairpin duplex.  Inhibition of a specific target 
afforded by lhRNAs was also comparable to that of individual shRNAs only when the lhRNA contained 
the siRNA complementary to the target at the base of the hairpin stem.  The non-specific lhRNA control 
showed no effect on Renilla to Firefly luciferase ratios as expected.   
When all three target sequences were cloned in tandem downstream of the Renilla luciferase ORF to 
create a combined target, both shRNA and lhRNA constructs reduced Renilla to Firefly luciferase ratios by 
approximately 90% (Figure 2.5 B), which indicates an additive knockdown effect by the siRNAs within each 
lhRNA.  A bias in RNAi activity was thus observed which correlates with the position of siRNA sequences 
within the hairpin stem and supports previous data using lhRNAs, (Barichievy et al. 2007; Weinberg et al. 
2007), which also showed diminishing silencing efficacy from the base towards the loop of the hairpin stem.
68 
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Figure 2.5:  Inhibitory efficacy of lhRNAs encoding three putative siRNAs.  Dual luciferase 
reporter assays were used to measure target knockdown following co-transfection of HEK293 cells 
with lhRNA expression plasmids together with psiCHECK reporter plasmids containing the tat, rev or 
vif specific target sequences (A), or a combination of all of the target sequences in tandem (B), 
inserted downstream of the Renilla luciferase open reading frame.  Values represented are mean 
ratios of Renilla to Firefly luciferase (±SEM) and are normalised to cells transfected with pTZU6+1 
(mock) (*, p<0.05, t-test relative to mock transfected control). 
 
2.3.3 Detection of processed siRNAs from lhRNA precursors 
 
To analyse processing of anti-viral sequences generated from hairpin expression cassettes, 
PAGE northern blot analysis was carried out on total RNA extracted from HEK293 cells transfected 
with lhRNA or control shRNA expressing plasmids or with pTZU6+1 (mock).  Figure 2.6 shows the 
signals obtained following hybridisation of a membrane containing immobilised RNA with three probes 
complementary to each of the guide strands of processed siRNAs, and exposure to X-ray film.  Each 
probe was able to detect mature guide strands processed from shRNA controls and the guide strands 
generated from shRNA precursors were detected at a higher concentration than those produced from 
lhRNA transcripts.  This indicates that Dicer processes shRNA substrates more efficiently than lhRNA 
substrates.  In the context of lhRNAs, the tat and vif probes only detected siRNAs generated from the 
base position of the hairpin stem.  The rev probe detected siRNAs that were processed from all three 
positions within the three lhRNAs, however, processing occurred in a gradient with most siRNA being 
generated from the base of the stem and decreasing quantities of siRNA generated from the loopside 
of the hairpin duplex.  This observation provides an explanation for the gradient in knockdown 
efficiency seen in Figure 2.5.  The processing of lhRNA duplexes by Dicer appears to yield minimal or 
undetectable quantities of siRNA from the second and third positions of the stem and minimal RNA 
activity is thus observed from these regions of the hairpin.  This phenomenon is not due to inefficient 
transcription of long hairpin transcripts or their relative instability since all probes are able to detect full 
length lhRNA precursor RNA, but is likely to be a result of inefficient Dicer turnover for multiple 
cleavage reactions.  As expected, no signal was obtained from RNA extracted from mock transfected 
cells and signals obtained following hybridisation with a probe complementary to U6 snRNA showed 
equal loading of each RNA sample (Figure 2.6).   
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Figure 2.6:  PAGE northern blot analysis of total RNA extracted from cells transfected with 
lhRNAs encoding three siRNAs.  A single blot was hybridised with γ-
32
P-ATP-labeled probes 
complementary to the mature guide strands of tat, rev and vif and exposed to x-ray film.  lhRNA and 
shRNA precursor RNA as well as processed siRNAs are indicated.  Decade Marker
TM
 was used as a 
molecular weight marker (MW) and a probe complementary to U6 small nuclear RNA was used as a 
control to verify equal loading of each RNA sample.  
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Dicer is known to cleave its substrates inconsistently every 21-25 nt resulting in slightly varied 
RNA products (Macrae et al. 2006).  To eliminate the possibility that mature siRNA products are not 
detected from the second and third position of the hairpin due to misalignment of the probe, two 
variables of the original tat probe (tat probe 1) were designed to span alternative possible mature tat 
guide sequences.  These two probes, termed tat probe 2 and 3 were 14 nt in length and contained 
LNA (locked nucleic acid) nucleotides for higher affinity binding.   
 
          
Figure 2.7:  PAGE northern blot analysis of putative anti-tat guide sequences. (A) Three different 
probes were designed to span different regions of the putative tat siRNA guide strand.  (B) Signals 
obtained from processed siRNAs approximately 22 nt in size are indicated. 
 
 Figure 2.7 shows that regardless of the sequence of the tat probe, siRNA products were only 
observed from shRNA-tat and lhRNA-tat-rev-vif but were still not detected from the second and third 
position of lhRNAs.  Therefore although Dicer products may vary slightly, there were no unpredicted tat 
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guide sequences generated from the second and third positions of the hairpin duplex.   This result 
confirms the hypothesis that Dicer processing decreases in efficiency along the hairpin duplex yielding 
minimal siRNA products from regions adjacent to the loop sequence. 
 
2.3.4 Effect of spacing between siRNA encoding sequences 
 
It is clear from the data described above that Dicer does not process a long hairpin stem duplex 
with equal efficiency.  Guide strand sequences of siRNAs positioned at the base of the stem are 
produced at higher concentrations than those positioned toward the loop sequence.  It is also known 
however that Dicer does not consistently cleave its substrate at exactly the same position but instead 
cleaves its substrate every 21-25 nt (Macrae et al. 2006), thus generating processed products of 
slightly variable lengths.  It was therefore hypothesized that modifications made to the nucleotide 
spacing between siRNA encoding sequences may affect the position of Dicer cleavage and potentially 
augment processing of siRNAs proximal to the loop sequence.   
Six variables of the original lhRNA-rev-vif-tat (lhRNA-rev-vif-tat a) were therefore generated 
which contained 0-4 bp inserted or deleted at each siRNA encoding junction (between the rev and vif 
siRNAs or between the vif and tat siRNAs) and were termed lhRNA-rev-vif-tat b-g (Figure 2.8 A).  This 
resulted in a series of lhRNAs with varied stem lengths of 68-72 bp and varied bp spacing between 
each siRNA encoding sequence.  More specifically lhRNA-rev-vif-tat b contained a 1 bp deletion at the 
rev/vif junction; lhRNA-rev-vif-tat c contained a 1 bp deletion at the rev/vif junction and a 1 bp insertion 
at the vif/tat junction; lhRNA-rev-vif-tat d contained a 1 bp deletion at the rev/vif junction and a 2 bp 
insertion at the vif/tat junction; lhRNA-rev-vif-tat e contained a 2 bp deletion at the rev/vif junction and a 
4 bp insertion at the vif/tat junction; lhRNA-rev-vif-tat f contained 2 bp insertion at the vif/tat junction; 
and lhRNA-rev-vif-tat g contained a 1 bp insertion at the rev/vif junction and a 2 bp insertion at the 
vif/tat junction (Figure 2.8 A). 
73 
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Figure 2.8:  The effects of altered nucleotide spacing at the junctions of siRNA encoding 
sequences on knockdown efficacy of lhRNAs.  Six variants of the lhRNA-rev-vif-tat hairpin 
containing up to 4 bp (the numbers and the sequence of the inserted bp with respect to the sense 
strand are indicated in brackets) inserted or deleted at each siRNA junction (A) were tested for their 
ability to inhibit psiCHECK reporter plasmids containing a combination of all of the target sequences in 
tandem (B) or each specific target sequence (C), downstream of the Renilla luciferase (hRLuc) open 
reading frame.  Values represented are mean ratios of Renilla to Firefly luciferase (±SEM) and are 
normalised to cells transfected with pTZU6+1 (mock) (*, p<0.05, t-test relative to mock transfected 
control). 
 
These hairpin expression plasmids were transiently co-transfected with a psiCHECK dual 
luciferase target reporter plasmid containing the tat, rev or vif target sequence or a combination of all 
three target sequences downstream from the Renilla luciferase open reading frame and knockdown 
was determined as a ratio of Renilla luciferase: Firefly luciferase with values were normalised to 
pTZU6+1 (mock).  When targeted against the psiCHECK rev target, all variants were able to decrease 
the Renilla to Firefly luciferase ratio approximately 90% with the exception of variant „e‟ which was only 
capable of a 60% reduction suggesting that the 2 bp deleted at the rev-vif junction may be detrimental 
to Dicer processing of the first siRNA.  Guide sequences targeted to the vif sequence were present in 
the second position of the hairpin variants, and inhibition of the vif target was significant yet variable.  
In certain variants such as „e‟ and to a lesser extent „d‟, knockdown from siRNAs in the second position 
was increased; however in „c‟, „f‟ and „g‟ knockdown was weaker than that of the parent lhRNA.  
Modification of bp spacing did not appear to affect knockdown afforded by siRNAs in the third position 
and knockdown from these siRNAs was consistently poor (Figure 2.8 C).  When the inhibitory efficacy 
of lhRNA-rev-vif-tat variants was tested against the combined target, an additive effect was again 
evident in all of the hairpins which inhibited Renilla luciferase expression more than 90%.  The only 
variant whose knockdown was slightly less effective was „e‟, a likely consequence of the decreased 
RNAi activity of the first position siRNA (Figure 2.8 B).  These results suggest a possibility for 
improving RNAi activity from the first and second position siRNAs by optimising the spatial 
arrangement of these sequences along an lhRNA duplex.  RNAi activity from the third position siRNA 
is unlikely however to be significantly improved. 
 C
H
A
P
T
E
R
 2
 
75 
 
Northern blot analysis was carried out on total RNA extracted from HEK293 cells transfected with 
the lhRNA-rev-vif-tat variants to determine the effect of nucleotide spacing on Dicer processing efficacy 
and the subsequent generation of mature guide sequences (Figure 2.9).  Processed siRNAs from the 
first position of all the variant hairpins were detected at relatively similar quantities, albeit less than that 
processed from shRNA-rev and again with the exception of variant „e‟ where negligible siRNA was 
detected.  This provides an explanation for the decreased knockdown of the rev target by this construct 
and suggests that the modified spacing of this hairpin caused a decrease in Dicer processing of the 
first position of this construct.  The possibility also remains that the 2 bp deletion in the „e‟ variant alters 
the thermodynamic stability of the putative siRNA, possibly resulting in the incorporation of the sense 
strand into RISC and the elimination of the guide strand.  One should also note that siRNA quantity is 
not necessarily always correlated with potency.  While the „a‟ variant shows considerably better 
inhibition of the rev target (Figure 2.8 C), elevated levels of siRNA are not detected when compared to 
the other variants (Figure 2.9).  It is possible that the position of Dicer cleavage within the (0/0) 
configuration results in a guide strand with a more potent seed region or a 5‟ end which is more 
favourable for RISC incorporation, ultimately leading to increased levels of knockdown.  A probe 
complementary to U6 snRNA showed equal loading of each RNA sample (Figure 2.9). 
  
Figure 2.9:  PAGE northern blot analysis of total RNA extracted from HEK293 cells transfected 
with lhRNA-rev-vif-tat and its spacing variants.  Signals obtained following hybridisation of 
immobilised RNA to a γ-
32
P-ATP-labeled probe complementary to the mature guide strand of the rev 
siRNA are shown.  Processed siRNA products from the first position of all lhRNA variants as well as 
from shRNA-rev are indicated.  A probe complementary to U6 small nuclear RNA was used as a 
control to verify equal loading of each RNA sample.  
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2.3.5 Inhibition of HIV-1 replication in infected cells in culture 
 
Although lhRNAs were assessed for their inhibitory efficacies against reporter gene targets, and 
were shown to be capable of significant inhibition of reporter gene expression, this system is somewhat 
artificial in that only a single transcript bearing perfect complementarity to each siRNA sequence within 
the lhRNA is expressed from each reporter plasmid.  In contrast, in the context of an HIV-infected cell 
population, a pool of viral variants is likely to exist.  Therefore to determine the ability of lhRNAs to 
inhibit gene expression and replication of an infectious HIV-1 primary isolate in vitro, the HIV 
permissive cell line U87.CD4.CCR5 was transfected with lhRNA or shRNA expressing plasmids and 
subsequently challenged with the HIV-1 subtype C viral isolate FV5.   
Concentration of p24 antigen present in supernatants was measured longitudinally on days 0, 3 
and 5 following infection (Figure 2.10 B) and on day 6 both p24 antigen levels and viral RNA copies 
were determined (Figure 2.10 A).  It is evident from Figure 2.10 A and B that shRNA-tat was the most 
effective inhibitor of viral replication followed closely by shRNA-rev, but shRNA-vif showed little to no 
inhibition of the virus.  Since we have deduced that siRNAs positioned at the base of the stem 
contribute the majority of RNAi activity of the entire lhRNA, it was not unexpected in the case of the 
tested lhRNAs that lhRNA-tat-rev-vif showed the strongest knockdown of the virus followed by lhRNA-
rev-vif-tat, and that lhRNA-vif-tat-rev demonstrated no inhibition of the virus which is likely to be a result 
of the ineffective shRNA-vif sequence positioned at the base of the hairpin.  The fact that viral 
replication was not inhibited at all by lhRNA-vif-tat-rev again proves that the inhibitory activity of 
lhRNAs is primarily due to the RNAi activity of the guide sequence positioned at the base of the stem 
and that the second and third siRNA within a long hairpin stem do not compensate for an ineffective 
first position siRNA.   
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Figure 2.10:  Inhibition of the HIV-1 subtype C FV5 viral isolate by lhRNAs encoding three siRNAs.  U87.CD4.CCR5
 
cells were transfected 
with the indicated hairpin constructs and subsequently infected with the HIV-1 FV5 viral isolate at a TCID50 1000. Concentration of p24 antigen as 
well as viral RNA copies present in supernatants were measured 6 days post infection (*, p<0.05, t-test relative to mock transfected control) (A) 
and p24 levels were also measured longitudinally at specified time points (B).
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To determine whether imperfect sequence complementarity was the causative factor of the 
ineffective vif siRNA, the guide sequence was aligned with the vif sequence of the subtype B HXB2 
virus and the subtype C FV5 virus.  Although the guide sequence was perfectly complementary to the 
subtype B isolate, three G:U wobble base pairs were present between the guide strand sequence and 
the subtype C isolate.  Furthermore all three of these misaligned bases were present within the seed 
region at the 5‟ end of the guide strand (Figure 2.11 A). 
 
 
Figure 2.11:  The conservation of the shRNA-vif-derived target site between FV5 and HXB2.  (A) 
Sequence alignments of lhRNA- and shRNA-derived tat, rev and vif guide sequences with the 
complementary regions within FV5 and HXB2 HIV-1 isolates.  Sequence numbering is based on isolate 
HXB2, accession K03455. (B) Inhibition of FV5 and HXB2 vif target reporter expression by shRNA-vif 
and the indicated lhRNAs.  Values represented are mean ratios of Renilla to Firefly luciferase (±SEM) 
and are normalised to cells transfected with pTZU6+1 (mock). 
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To confirm whether these mismatches are the cause of the inefficiency of shRNA-vif and 
lhRNA-vif-tat-rev, the FV5 vif target and the HXB2 vif target sequences were cloned downstream of the 
Renilla luciferase ORF in a psiCHECK dual luciferase reporter plasmid.  Plasmids expressing lhRNAs 
as well as shRNA-vif were transiently co-transfected together with the HXB2 or FV5 vif psiCHECK dual 
luciferase target reporter plasmids described above.  Knockdown was determined as a ratio of Renilla 
luciferase: Firefly luciferase and values were normalised to pTZU6+1 (mock).  Neither shRNA-vif or 
any of the lhRNAs were able to mediate knockdown of the FV5 vif target sequence however when 
tested against the HXB2 vif sequence, shRNA-vif was highly effective and the lhRNAs showed the 
expected knockdown trend with lhRNA-vif-tat-rev being the most effective followed by lhRNA-rev-vif-tat 
and lhRNA-tat-rev-vif showing negligible knockdown (Figure 2.11 B).  This confirms that the presence 
of mismatched nucleotides between the vif guide strand and the target sequence rendered this siRNA 
ineffective against the FV5 viral isolate.  This data also supports the results of the reporter gene 
knockdown assays showing that RNAi activity induced by lhRNAs is primarily mediated by siRNAs 
located at the base of the hairpin stem. 
 
2.3.6 lhRNAs do not induce a non-specific immune response 
 
The introduction of exogenous long dsRNA (>30 bp) into the cytoplasm of mammalian cells has 
been shown to elicit an interferon response by activating PKR and 2‟,5‟ OAS resulting non-specific 
gene silencing (section 1.7.1).  It has since been shown that expressed RNAi effector sequences can 
evade cytoplasmic activators of the interferon pathway (Marques et al. 2006; Robbins et al. 2006).  
However the use of lhRNAs in a gene therapy context remains a controversial issue because of the 
potential of long dsRNA to elicit an immune response.  To exclude the possibility of non-specific gene 
knockdown effects or toxicities caused by the induction of a non-specific interferon response following 
introduction of lhRNAs into the cellular environment, IFN-β mRNA concentrations were measured in 
cells transfected with lhRNAs, shRNA controls or the dsRNA analogue poly (I:C) which served as a 
positive control.  None of the shRNA or lhRNA expression cassettes induced expression of IFN-β  
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relative to mock transfected cells as measured by qRT-PCR with samples normalised to GAPDH 
(Figure 2.12).  Although further investigation into the activity of interferon pathway-related genes is 
required in immune cells such as monocytes and dendritic cells as well as in vivo, the use of expressed 
long hairpin RNAs does not appear to stimulate a type-1 interferon response in the HEK293 cell line, a 
result which is similar to previous reports using Pol III-expressed lhRNAs (Akashi et al. 2005; 
Barichievy et al. 2007).  
 
 
 
Figure 2.12:  The potential induction of the IFN response in cells transfection with lhRNA 
expression cassettes.  IFN induction was assessed by measuring IFN-β mRNA concentration in total 
RNA extracted from cells transfected with the indicated hairpin expression cassettes or with poly I:C 
which served as a positive control.  Mean normalised ratios of IFN-β : GAPDH (±SEM) (n=3) are 
indicated as determined by qRT-PCR (*, p<0.05, t-test relative to poly (I:C) transfected control). 
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2.4 Discussion  
 
The lhRNAs described in this Chapter were designed to encode three highly effective siRNA 
sequences within the dsRNA duplex, for the simultaneous targeting of three conserved non-contiguous 
sites within the HIV genome.  It is worthy to note that the nomenclature of long hairpin RNAs is 
currently under debate because of the structural differences between the Pol III-expressed lhRNA 
constructs described here, and the much longer Pol II-driven lhRNAs originally described.  The 
Berkhout laboratory refers to structures similar to those described in this thesis as extended-shRNAs 
(Liu et al. 2007; Liu et al. 2009), while in a recent review such structures were termed tandem hairpin 
RNAs (Sibley et al. 2010).  These constructs have been defined here as Pol III-expressed long hairpin 
RNAs because it is felt that this term accurately describes, and correctly defines this class of hairpins. 
Initially, lhRNAs expressed from Pol III promoters were only used against single contiguous 
sequences and the RNAi activity contributed by each processed siRNA was not characterised (Akashi 
et al. 2005; Nishitsuji et al. 2006; Watanabe et al. 2006).  The incorporation of three discrete siRNA 
sequences within the hairpins used here allows for comparison of relative RNAi activity with that of 
individual shRNAs with corresponding guide sequences.  The differential spatial arrangement of 
siRNAs within the hairpin duplex also enables the determination of potential positional effects on the 
inhibitory efficacies of individual siRNAs.  Dual luciferase reporter assays to test the transient inhibitory 
efficacy of lhRNAs encoding three unique siRNAs showed that lhRNAs were capable of significantly 
inhibiting all target sequences but that the most effective knockdown was consistently observed from 
siRNAs generated from the base of the stem of the lhRNA.  These lhRNA-generated siRNAs showed a 
decrease in target gene expression of up to 98%, comparable to that achieved by individual shRNAs 
targeting the same region (Figure 2.5).  However guide sequences generated from the second and 
third positions of the duplex showed a gradual loss of RNAi activity.  To corroborate this data, inhibition 
of FV5 viral replication was proven to be mediated primarily by the inhibitory activity of guide 
sequences positioned at the base of the stem (Figure 2.10).  Northern blot analysis also detected an 
abundance of siRNA that was generated from the base of the hairpin stem but little to negligible 
quantities generated from the second or third positions of the duplex (Figure 2.6).   
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These results support previous studies which showed diminishing RNAi activity from the base 
towards the loop of contiguous lhRNAs with stems of 62 and 63 bp (Barichievy et al. 2007; Weinberg et 
al. 2007), and it is evident that this decrease in inhibitory activity is due to the decline in processing as 
Dicer proceeds along the duplex structure.  A recent study by Sano et al. investigated the silencing 
efficacies as well as the processing trends of 50, 53 and 80 bp lhRNAs targeted to contiguous 
sequences within the tat and rev genes of HIV-1.  They too observed a reduction in both knockdown 
efficacy and siRNA concentration for siRNAs in the third position, proximal to the loop sequence (Sano 
et al. 2008).  In contrast to the observation of diminishing siRNA generation from lhRNAs in previous 
work studying contiguous hairpins (Barichievy et al. 2007; Weinberg et al. 2007; Sano et al. 2008), the 
lhRNAs used in this Chapter comprise unique siRNAs variably positioned within the duplex, and it was 
thus possible to also show that the consistently observed gradient effect is largely independent of the 
siRNA sequence.  
A fundamental follow up study to that of Sano et al. investigated the role of the N terminal helicase 
domain of human Dicer in dsRNA processing.  Dicer helicase mutants showed defective processing of 
thermodynamically unstable pre-miRNA substrates yet enhanced processing of thermodynamically 
stable lhRNA substrates (Soifer et al. 2008).  Interestingly, when the processing of 50 bp and 80 bp 
lhRNAs was examined, Dicer helicase mutants generated a slight increase in the first siRNA, 
positioned at the base of the hairpin, and a 3-5 fold increase in the second and third siRNA.  This 
suggests that the helicase domain of human Dicer has evolved to allow for the processing of 
thermodynamically unstable miRNA precursors and may represent the limiting factor for the cleavage 
of lhRNA substrates.  In addition, Ma et al. also showed a substantial increase in the catalytic efficiency 
in helicase mutants, further implicating this domain in Dicer turnover (Ma et al. 2008).  To further 
support these observations, Giardia Dicer, which lacks a helicase domain, is capable of multiple 
turnover kinetics (Zhang et al. 2002).  The helicase domain is therefore thought to mediate the 
conformational changes in the Dicer enzyme following cleavage reactions for the release of mature 
miRNAs, thus restricting the multiple turnover kinetics of the enzyme.  Therefore in the absence of a 
functional helicase domain, conformational changes are inhibited thus allowing for subsequent multiple 
cleavage reactions (Ma et al. 2008; Soifer et al. 2008). 
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Concurrent with this work, Liu et al. attempted to establish an optimal design for extended short 
hairpin RNAs (e-shRNAs), which are structurally similar to the Pol III-expressed lhRNAs described 
here.  These e-shRNAs encoded two non-contiguous siRNAs targeted against the pol and nef genes of 
HIV-1 (Liu et al. 2007).  It was also shown that e-shRNAs are processed from the base towards the 
loop of the hairpin and that there is a correlation between siRNA production and activity.  Liu et al. then 
investigated the effect of spacing between each siRNA encoding sequence to potentially improve the 
inhibitory activity of the second siRNA.  A 43 bp length was established as the minimal length of e-
shRNAs for the production of two siRNAs, and 19 bp siRNA sequences separated by 4 bp and with a 2 
bp terminal extension, was determined as the optimal hairpin design for the production of two effective 
siRNAs (Liu et al. 2007).  Such spacing arrangements did not however prove optimal in the lhRNAs 
described in this Chapter suggesting that the siRNA sequence or specific sequence elements may play 
a role in optimal Dicer processing (Vermeulen et al. 2005).  Nonetheless, minor modifications to the bp 
spacing at the junctions between siRNA encoding regions were investigated and it was shown that 
knockdown by siRNAs generated from the second position of the hairpin could be improved (Figure 
2.8).  Although it is difficult as yet to make gross generalizations regarding the optimal spatial 
arrangement of siRNA sequences within a long hairpin context, augmented knockdown from the first 
two siRNAs of the lhRNA duplex promises to be a feasible goal following further characterisation of 
lhRNAs, however this is unlikely to be the case for a third siRNA (Liu et al. 2007; Sano et al. 2008).  
This was again confirmed in a later study attempting to stack up to four siRNA sequences in an e-
shRNA. Although a third siRNA was detected, it was present in reduced quantities, and hairpins 
encoding only two siRNAs again proved to be the most efficacious (Liu et al. 2009). 
  The potential of Pol III-driven lhRNAs to produce up to three unique siRNAs capable of inducing 
significant inhibition of non-contiguous sites within the HIV-genome has been clearly demonstrated.  
However an upper size limitation clearly exists which is associated with the inability of Dicer to act as a 
rapid turnover enzyme in mammalian cells.  Mature RNAi products were consistently generated in a 
gradient from the base towards the loop of the hairpin stem, however minor spacing modifications were 
able to augment or hinder RNAi activity from siRNAs positioned further along the stem.  It is therefore 
hypothesized that further manipulation and optimisation of the lhRNA design may result in efficient 
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Dicer cleavage of two functional siRNAs for effective multiple targeting.  The concept explored in this 
study, of multiple unique siRNA production from a single expressed construct, is potentially an 
invaluable tool for the development of combinatorial RNAi strategies.  
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CHAPTER 3 
Deriving two functional siRNAs from dual-targeting long hairpin 
RNAs. 
 
3.1 Introduction  
 
The ability of lhRNA duplexes to incorporate the sequences of multiple independent siRNAs 
capable of silencing more than one non-contiguous site has been clearly demonstrated.  However, in 
support of previous studies (Barichievy et al. 2007; Weinberg et al. 2007; Sano et al. 2008), siRNAs 
positioned at the base of the hairpin duplex were cleaved with the greatest efficiency and were capable 
of inducing the strongest inhibitory activity of their cognate targets (>80%), while siRNAs in the second 
and third sequential positions within the hairpin duplex were poorly processed and in some cases 
contributed only minimal RNAi activity to the overall efficacy of the lhRNA (30-70%).  The gradual 
decline in Dicer processing from the 3‟ overhang towards the terminal loop results in efficacious levels 
of a maximum of two siRNAs and therefore clearly suggests an upper size limit for expressed lhRNAs.  
Deriving more than two predicted functional siRNAs from an lhRNA scaffold remains difficult and 
requires a better understanding of the in situ processivity of human Dicer for such substrates.   
Soifer et al. proposed that the helicase domain of human Dicer induces a conformational change 
in the enzyme following an initial cleavage reaction, thereby restricting subsequent processing of long 
dsRNA substrates (Soifer et al. 2008).  Yet it was clearly observed here that by modifying the base pair 
spacing at siRNA junctions, the production of a second siRNA may be significantly augmented 
(Saayman et al. 2008).  Furthermore, Liu et al. designed extended shRNAs (e-shRNAs) incorporating 
the sequences of two functional non-contiguous siRNAs, and a number of parameters pertaining to the 
optimal design of hairpins encoding two siRNAs were subsequently proposed (Liu et al. 2007).  In 
support of the results described in section 2.3.4, the spacing at the junctions between siRNA encoding 
regions played an imperative role in the processing and thus RNAi activity induced by the second 
siRNA (Liu et al. 2007).  A hairpin duplex length of 43 bp was observed to be the minimum length, 
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while a hairpin duplex of 44 bp was determined as the optimal length, for the production of two efficient 
guide strands.  It is therefore possible to manipulate long dsRNA Dicer substrates for two subsequent 
cleavage reactions; however a general framework outlining the design of such substrates remains to 
be established.  Although Liu et al. described optimal design principles for e-shRNAs encoding two 
siRNAs, these principles were based on the sequences of only two siRNAs utilized in their study.  The 
PAZ domain of Dicer has exhibited a binding preference for specific sequences resulting in the 
preferred cleavage of certain substrates over others (Vermeulen et al. 2005).  One cannot thus assume 
that the established parameters are universally applicable to all siRNA sequences.  Moreover, the 
sustained generation of efficacious levels of a second siRNA when the lhRNA dose is reduced, has yet 
to be demonstrated. 
To determine an optimal configuration for an efficacious lhRNA design, a series of hairpins 
encoding two putative siRNAs (dual-targeting lhRNAs) were designed and generated.  Hairpins were 
designed to incorporate the sequences of two siRNAs targeted against independent sites within the 
HIV-1 genome.  A total of four unique siRNA sequences were inserted at both positions of a hairpin 
duplex and their ability to be processed efficiently as well as their inhibitory activity in each position was 
investigated.  The effects of base pair spacing between siRNA encoding regions, as well as before the 
loop sequence, on siRNA production and activity was explored.  A maximum stem length for 
generating efficient lhRNAs capable of producing two highly-functional siRNAs from a single pol III-
expressed lhRNA construct, regardless of the siRNA sequence was determined.  Additionally, insight 
into the preferred length and structure of Dicer substrates was gained.  Finally, two optimised and 
highly effective dual-targeting lhRNAs were identified and the possibility of integrating both hairpins into 
a single vector for combinatorial RNAi purposes was explored.   
 
 
 
 C
H
A
P
T
E
R
 3
 
87 
 
3.2 Materials and Methods 
 
3.2.1 Generation of plasmids containing Pol-III expressed lhRNA and shRNA 
sequences 
 
The procedure for generating dual targeting lhRNAs was similar to the method used to generate 
lhRNAs encoding three putative siRNA sequences described in 2.2.1.  A panel of U6-driven lhRNA 
sequences encoding two putative siRNA sequences targeted to the tat and nef or int and LTR ORFs 
were constructed by a two-step PCR.  In the first round of PCR, 10 ng pTZU6+1 was used as a 
template.  The universal U6 forward primer described in 2.2.1 was used for both rounds of PCR.  The 
reverse primers for the first round of PCR were complementary to 18-21 nt of the 3‟ end of the U6 
promoter and contained a linker encoding the complementary sequence of the sense strand of the 
lhRNA as well as the loop sequence (Table 3.1).   For the second round of PCR a 1:500 dilution of the 
R1 amplicon was used as the template for the reaction.  The round two reverse primer sequences 
were designed to overlap the loop region of the round one reverse primer by 18-21 nt and contained a 
linker encoding the complementary sequence of the antisense strand of the lhRNA as well as 6 
deoxyadenosines (Table 3.1).  This overlap between each pair of reverse primers enabled the 
extension of the PCR product to generate a U6 expressed lhRNA cassette with a transcription 
termination signal.  Control U6-driven shRNAs corresponding to the sequences included in the lhRNA 
expression constructs were generated by a single round of PCR using pTZU6+1 a template, and 
amplified with the universal U6 forward primer and specific reverse primers encoding the shRNA 
sequence (Table 3.1).   
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Table 3.1:  Oligonucleotides used to generate dual-targeting lhRNAs and corresponding shRNAs 
 
Primer 
 
Sequence (5’-3’) Length 
(nt) 
U6 forward 
 
CTAACTAGTGGCGCGCCAAGGTCGGGCAGGAAGAGGG 37 
H1 forward  
 
GGATCCTCGAGCGGCCGCTAGCAACGCTGACGTCATCAACCCG 43 
7SK forward  
 
GGATCCTCGAGCGGCCGCTAGCAGTATTTAGCATGCCCCACC 42 
lhRNA-tat-nef +1 R1 
 
CTGGGTCAGGGACATATTGTACTTCCAGCCAGACACTGCTCTTCATCACTATCCCCGCGGTGTTTCGTCCTTTCCAC
AA 
79 
lhRNA-tat-nef +1 R2 
  
AAAAAAGCGGAGACAGCGACGAAGAGCGGTGCCTGGCTAGAAGCACAAGACGTCTGGGTCAGGGACATATT 71 
lhRNA-tat-nef +2 R1 
 
CTGGGTCAGGGACATATTGTACTTCCAGCCAGACACCTGCTCTTCATCACTATCCCCGCGGTGTTTCGTCCTTTCCA
CAA 
80 
lhRNA-tat-nef +2 R2 
 
AAAAAAGCGGAGACAGCGACGAAGAGCGTGTGCCTGGCTAGAAGCACAAGACGTCTGGGTCAGGGACATATT 72 
lhRNA-tat-nef-+3 R1 
 
CTGGGTCAGGGACATATTGTACTTCCAGCCAGACACACTGCTCTTCATCACTATCCCCGCGGTGTTTCGTCCTTTCC
ACAA 
81 
lhRNA-tat-nef +3 R2 
 
AAAAAAGCGGAGACAGCGACGAAGAGCGTGGTGCCTGGCTAGAAGCACAAGACGTCTGGGTCAGGGACATATT 73 
lhRNA-nef-tat +1 R1 
 
CTGGGTCAGGGACATGCTCTTCATCACTATCCCCGCTATTGTACTTCCAGCCAGACACGGTGTTTCGTCCTTTCCAC
AA 
79 
lhRNA-nef-tat +1 R2 
 
AAAAAAGTGCCTGGCTAGAAGCACAAGGGCGGAGACAGCGACGAAGAGCACGTCTGGGTCAGGGACATGCT 71 
lhRNA-nef-tat +2 R1 
 
CTGGGTCAGGGACATGCTCTTCATCACTATCCCCGCCTATTGTACTTCCAGCCAGACACGGTGTTTCGTCCTTTCCA
CAA 
80 
lhRNA-nef-tat +2 R2 
 
AAAAAAGTGCCTGGCTAGAAGCACAAGGTGCGGAGACAGCGACGAAGAGCACGTCTGGGTCAGGGACATGCT 72 
lhRNA-nef-tat +3 R1 
 
CTGGGTCAGGGACATGCTCTTCATCACTATCCCCGCACTATTGTACTTCCAGCCAGACACGGTGTTTCGTCCTTTCC
ACAA 
81 
lhRNA-nef-tat +3 R2 
 
AAAAAAGTGCCTGGCTAGAAGCACAAGGTGGCGGAGACAGCGACGAAGAGCACGTCTGGGTCAGGGACATGCT 73 
lhRNA-LTR-int +1 R1 CTGGGTCAGGGACATAACTAACCATTGCCCTCCGGCTGTCCGAGAGATCTCTAATTACGGTGTTTCGTCCTTTCCAC
AA 
79 
lhRNA-LTR-int +1 R2 
 
AAAAAAGTAACTAGAGACCTCTCAGACGGCCGGAGAGCAATGGCTAGTCACGTCTGGGTCAGGGACATAAC 71 
89 
 
lhRNA-LTR-int +2 R1 CTGGGTCAGGGACATAACTAACCATTGCCCTCCGGCCTGTCCGAGAGATCTCTAATTACGGTGTTTCGTCCTTTCCA
CAA 
80 
lhRNA-LTR-int +2 R2 
 
AAAAAAGTAACTAGAGACCTCTCAGACGTGCCGGAGAGCAATGGCTAGTCACGTCTGGGTCAGGGACATAAC 72 
lhRNA-LTR-int +3 R1 CTGGGTCAGGGACATAACTAACCATTGCCCTCCGGCACTGTCCGAGAGATCTCTAATTACGGTGTTTCGTCCTTTCC
ACAA 
81 
lhRNA-LTR-int +3 R2 AAAAAAGTAACTAGAGACCTCTCAGACGTGGCCGGAGAGCAATGGCTAGTCACGTCTGGGTCAGGGACATAAC 
 
73 
lhRNA-int-LTR +1 R1 
 
CTGGGTCAGGGACATGTCCGAGAGATCTCTAATTACTAACTAACCATTGCCCTCCGGCGGTGTTTCGTCCTTTCCAC
AA 
79 
lhRNA-int-LTR +1 R2 
 
AAAAAAGCCGGAGAGCAATGGCTAGTCGGTAACTAGAGACCTCTCAGACACGTCTGGGTCAGGGACATGTC 71 
lhRNA-int-LTR +2 R1 
 
CTGGGTCAGGGACATGTCCGAGAGATCTCTAATTACCTAACTAACCATTGCCCTCCGGCGGTGTTTCGTCCTTTCCA
CAA 
80 
lhRNA-int-LTR +2 R2 
 
AAAAAAGCCGGAGAGCAATGGCTAGTCGTGTAACTAGAGACCTCTCAGACACGTCTGGGTCAGGGACATGTC 72 
lhRNA-int-LTR +3 R1 
 
CTGGGTCAGGGACATGTCCGAGAGATCTCTAATTACACTAACTAACCATTGCCCTCCGGCGGTGTTTCGTCCTTTCC
ACAA 
81 
lhRNA-int-LTR +3 R2 
 
AAAAAAGCCGGAGAGCAATGGCTAGTCGTGGTAACTAGAGACCTCTCAGACACGTCTGGGTCAGGGACATGTC 73 
H1-lhRNA-tat-nef +1 R1 CTGGGTCAGGGACATATTGTACTTCCAGCCAGACACTGCTCTTCATCACTATCCCCGCGGGTCCGAGTGGTCTCATA
C 
79 
H1-lhRNA-tat-nef +1 R3 GGAGATCTACTAGTAAAAAAGCGGAGACAGCGACG 35 
 
7SK-lhRNA-LTR-int +1 R1 CTGGGTCAGGGACATAACTAACCATTGCCCTCCGGCTGTCCGAGAGATCTCTAATTACGAGGTACCCAGGCGGCGCA
CA 
79 
7SK-lhRNA-LTR-int +1 R3 GGAGATCTACTAGTAAAAAAGTAACTAGAGACCTC 35 
 
shRNA-tat R1 AAAAAAGCGGAGACAGCGACGAAGAGCTGGGTCAGGGCTCTTCATCACTATCCCCGCGGTGTTTCGTCCTTTCCACA
A 
78 
shRNA-nef R1 AAAAAAGTGCCTGGCTAGAAGCACAAGTGGGTCAGGATTGTACTTCTAGCCAGGCACGGTGTTTCGTCCTTTCCACA
A 
78 
shRNA-LTR R1 AAAAAAGTAACTAGAGATCCCTCAGACTGGGTCAGGGTCTGAGAGATCTCTAGTTACGGTGTTTCGTCCTTTCCACA
A 
78 
shRNA-int R1 AAAAAAGCCGGAGAGCAATGGCTAGTGATTGGGTCAGGTAACTAACCATTGCTCTCCGGCGGTGTTTCGTCCTTTCC
ACAA 
81 
Underlined sequences signify restriction endonuclease recognition sites.  Highlighted sequences indicate the overlapping regions between each pair of reverse primers.  Italics 
represent the 5 nt terminal extension before the loop sequence indicated in red.  Bold letters show sites of G:U mismatch introductions in the sense strand.  Double underlined 
letters designate mismatched nucleotide spacing between siRNA encoding sequences.
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To determine the effects of using alternative Pol III promoters to drive the expression of dual-
targeting lhRNAs, lhtat-nef +1 and lhLTR-int +1 were regenerated to be driven off the RNA Pol III H1 
and 7SK promoters respectively.  H1-driven lhtat-nef +1 and 7SK-driven lhLTR-int +1 sequences were 
generated in a similar manner but using a three-step PCR (Figure 3.1).  Either a plasmid expressing 
the human H1 promoter, or genomic DNA was used as respective templates.  Forward primers 
complementary to the 5‟ end of the human H1 or 7SK RNA Pol III promoters were used for all three 
rounds of PCR, and both forward primers included BamHI; XhoI; NotI and NheI restriction 
endonuclease recognition sites to facilitate cloning into alternate vectors in the future (Table 3.1).   
Round one reverse primers were unique in that they overlapped the 5‟ end of the H1 or 7SK promoter 
sequence, and round two reverse primers were the same as those used for the generation of the 
respective U6-driven lhRNAs (Table 3.1).  Round three reverse primers overlapped the 3‟ end and the 
termination signal of the respective lhRNAs and contained a linker with the SpeI (BcuI) and BglII 
restriction endonuclease recognition sites (Table 3.1).  Reagents and thermocycling conditions were 
the same as those described in 2.2.1.  All the final PCR products were ligated directly into the TA 
cloning vector pTZ57R/T (Fermentas, WI, USA), and sequences were confirmed by standard 
procedures as described in 2.2.1.   
To clone H1-lhRNA-tat-nef +1 and 7SK-lhRNA-LTR-int +1 head to tail into a single vector 
(pTZ57R/T) (Figure 3.2), correctly sequenced individual clones were first screened for orientation by 
digestion with EcoRI and NotI or EcoRI and BglII.  The pTZ57R/T plasmid containing 7SK-lhRNA-LTR-
int +1 in the reverse orientation was linearised by digesting 1 µg of the plasmid with 20 U SpeI and 
Tango
TM 
Buffer (33 mM Tris-acetate [pH7.5 at 37°C]; 10 mM Mg-acetate; 66 mM K-acetate and 0.1 
mg/ml BSA) (Fermentas, WI, USA), in a 20 µl reaction at 37°C for two hours.  Five units of Antarctic 
phosphatase (AP) (NEB, MA, USA) were then added to the digestion reaction together with AP buffer 
(50 mM bis-tris-propane-HCl, 1 mM MgCl2 and 0.1 mM ZnCl2 pH 6.0) in a 30 µl total volume. The 
reaction was incubated at 37°C for a further 30 min.  The phosphatase reaction was heat-inactivated 
for at 65°C for 15 min. 
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Figure 3.1:  Schematic representation of the three step PCR cloning strategy used to generate 
H1-driven lhtat-nef +1 and 7SK-driven lhLTR-int +1 expression cassettes.  The first two rounds of 
PCR proceed as described in 2.2.1.  The third round of PCR produces inverted repeat sequences with 
a terminal linker containing SpeI and BglII restriction sites. 
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Figure 3.2:  Schematic diagram illustrating the cloning strategy used to incorporate the H1-
driven lhtat-nef +1 and 7SK-driven lhLTR-int +1 dual-targeting lhRNAs within a single pTZ57R/T 
plasmid vector.  The pTZ-7SK-lhRNA-LTR-int +1 plasmid was linearised by digestion with SpeI and 
the H1-lhRNA-tat-nef +1 cassette was excised from the pTZ-H1-lhRNA-tat-nef +1 plasmid by digestion 
with NheI and SpeI.  The H1-lhRNA-tat-nef +1-containing fragment was ligated into the linearised pTZ-
7SK-lhRNA-LTR-int +1 plasmid backbone to generate a single plasmid containing the 7SK-lhRNA-
LTR-int +1 and H1-lhRNA-tat-nef +1 expression cassettes. 
 
The H1-lhRNA-tat-nef +1 insert in the forward orientation was excised by digesting 1 µg of the 
pTZ57R/T plasmid containing the insert with 10 U of each SpeI and NheI and Tango
TM 
Buffer (33 mM 
Tris-acetate [pH7.5 at 37°C]; 10 mM Mg-acetate; 66 mM K-acetate and 0.1 mg/ml BSA) (Fermentas, 
WI, USA), in a 20 µl reaction at 37°C for 1 hour.  Digested DNA was resolved on a 1% agarose gel and 
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the pTZ-7SK-lhRNA-LTR-int +1 linearised backbone fragment as well as the H1-lhRNA-tat-nef +1 
insert fragment were excised from the gel and purified using the MinElute
TM
 Gel Extraction kit 
(QIAGEN, CA, USA) according to the manufacturer‟s instructions (Appendix A1.3).  The two purified 
fragments were ligated in a 1:1 ratio (approximately 50 ng of each) in a 20 µl reaction volume using 10 
U of T4 DNA ligase (NEB, MA, USA).  The ligation reaction was incubated at room temperature for 1 
hour before transformation of chemically competent DH5α E.coli (Appendix A1.1).  DNA isolated from 
individual clones was screened by digestion with XhoI and SpeI. 
 
3.2.2 Dual luciferase fusion reporter plasmids 
 
Individual target sequences complementary to the antisense strand of each putative siRNA were 
prepared by treating partially complementary oligonucleotides (Table 3.2) with polynucleotide kinase 
(Promega, WI, USA) and annealing them as described in 2.2.2.  Each pair of overlapping 
oligonucleotides had an XhoI site at the 5‟ end of the forward oligonucleotide and a SpeI site at the 5‟ 
end of the reverse oligonucleotide.  In addition, an EcoRV restriction site was incorporated into both 
the forward and reverse oligonucleotides within the overlapping region to facilitate screening of 
plasmids containing the inserted target sequence.  A combined target sequence containing the LTR, 
int, tat and nef antisense target sequences in tandem, was prepared by a similar procedure using two 
sets of partially complementary oligonucleotides (Table 3.2) that contained a short overlapping region 
to facilitate the generation of a full length combined target sequence for insertion into psiCHECK. 
The psiCHECK
TM
-2 (Promega, WI, USA) plasmid backbone was prepared as described in 2.2.2.  
Dual luciferase psiCHECK target reporter plasmids were constructed by directly cloning the target 
sequences into the XhoI-NotI sites of the plasmid backbone such that the cloned sequences were 
within the 3‟ UTR of Renilla luciferase.  The oligonucleotide sequences used to generate such target 
sequences are listed in Table 3.2.
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Table 3.2:  Oligonucleotides used to generate gene specific target sequences 
 
Oligonucleotide Sequence (5’-3’) Length 
(nt) 
tat antisense target forward TCGAGATATCGCTCTTCGTCGCTGTCTCCGCA 32 
tat antisense target reverse CTAGTGCGGAGACAGCGACGAAGAGCGATATC 32 
nef antisense target forward TCGAGATATCCTTGTGCTTCTAGCCAGGCACA 32 
nef antisense target reverse CTAGTGTGCCTGGCTAGAAGCACAAGGATATC 32 
LTR antisense target forward TCGAGATATCGTCTGAGAGGTCTCTAGTTACA 32 
LTR antisense target reverse CTAGTGTAACTAGAGACCTCTCAGACGATATC 32 
int antisense target forward TCGAGATATCGACTAGCCATTGCTCTCCGGCA 32 
int antisense target reverse CTAGTGCCGGAGAGCAATGGCTAGTCGATATC 32 
LTR-int-tat-nef antisense target forward 1 TCGAGATATCAGTAACTAGAGATCCCTCAGACGAAGAGCCGGAGAGCAATGGCTAGTAGGCAGC 64 
LTR-int-tat-nef antisense target reverse  1 TCTCCGCTGCCTACTAGCCATTGCTCTCCGGCTCTTCGTCTGAGGGATCTCTAGTTACTGATATC 65 
LTR-int-tat-nef antisense target forward 2  GGAGACAGCGACGAAGATGACGGTGCCTGGCTAGAAGCACAAGA 44 
LTR-int-tat-nef antisense target reverse 2 CTAGTCTTGTGCTTCTAGCCAGGCACCGTCATCTTCGTCGCTG 43 
 
Underlined sequences represent the XhoI and SpeI restriction endonuclease recognition sites in the forward and reverse primers respectively as well as EcoRV restriction 
endonuclease recognition sites within the overlapping region of forward and reverse oligonucleotides.  Highlighted sequences indicate complementary regions between the pair of 
oligonucleotides and sequences in green represent overlapping regions.
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3.2.3 Assessing the inhibitory efficacy of expressed lhRNAs in cell culture 
 
Procedures for assessing the knockdown efficacy of dual-targeting lhRNAs against individual or 
combined psiCHECK target reporter plasmids were similar to those described in 2.2.3.  HEK293 cells 
were cultured and transfected as previously described.   Inhibition was initially assessed in cells 
transfected with 750 ng hairpin expression plasmid, 150 ng psiCHECK target reporter plasmid and 100 
ng pCI-eGFP.  For dose dependent inhibition assays, hairpin expression plasmids were transfected in 
diminishing quantities together with 150 ng psiCHECK target reporter plasmid and 100 ng pCI-e-GFP.  
The total amount of transfected DNA was kept constant at 1 µg and was made up with pUC19 (NEB, 
MA, USA) when hairpin expression plasmids were transfected at lower concentrations.  
 
3.2.4 Detection of processed anti-HIV-1 hairpin sequences 
 
Guide strands of siRNAs generated from dual targeting lhRNAs were detected according to the 
procedures described above (2.2.4).  Membranes were however exposed to a phosphor plate which 
was scanned 3-7 days later using a Fujifilm FLA-7000 phosphorimager.  Sequences of the probes 
complementary to the guide strands of tat, nef, LTR and int are as follows: tat probe 5‟- GCG GAG 
ACA GCG ACG AAG AGC -3‟; nef probe 5‟– GTG CCT GGC TAG AAG CAC AAG –3‟; LTR probe 5‟– 
GTA ACT AGA GAC CTC TCA GAC –3‟ and int probe 5‟– GCC GGA GAG CAA TGG CTA GTC –3‟.  
The intensities of guide strands derived from dual-targeting lhRNA precursors were quantified relative 
to guide strands generated from shRNA controls using the Fuji ImageQuant software. 
 
3.2.5 Statistical Analysis 
 
Statistical analysis was carried out using the GraphPad Prism software (GraphPad, Software, Inc., 
CA, USA).  Differences were considered significant when p<0.05 and was determined using one-way 
ANOVA followed by a Dunnett‟s Multiple Comparison post-test. 
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3.3 Results 
 
3.3.1 Optimal design of dual-targeting lhRNAs 
 
To establish a set of universally applicable guidelines for the optimal design of lhRNAs for the 
efficient production of two functional guide sequences, a series of anti-HIV-1 dual-targeting lhRNAs 
were designed to incorporate the sequences of four unique siRNA sequences complementary to 
conserved regions within the HIV-1 genome (Figure 3.3).  These regions were selected because they 
have previously been shown to be highly susceptible to RNAi-mediated gene silencing.  They include 
sequences within the tat (Lee et al. 2002a), nef (Westerhout et al. 2006b), LTR (Barichievy et al. 2007) 
and int (Nishitsuji et al. 2006) open reading frames.  To assess the effect of siRNA sequence as well 
as siRNA position within the duplex, on Dicer processing, two panels of lhRNAs were generated 
(Figure 3.4).  One panel of lhRNAs incorporated siRNA sequences against tat and nef while the 
remaining panel comprised siRNA sequences target to int and the LTR.  Two sets of hairpins were 
present within each panel, allowing for each siRNA encoding sequence to be situated in both 
sequential positions of the hairpin duplex.   
Human Dicer does not process siRNAs positioned at the loopside of stem duplexes with the 
same efficiency as it does siRNAs at the base of the stem duplex (Barichievy et al. 2007; Liu et al. 
2007; Weinberg et al. 2007; Saayman et al. 2008; Sano et al. 2008).  However, optimal spatial 
arrangement of the putative siRNA sequences within the duplex may result in augmented cleavage, 
and thus RNAi activity of a second siRNA sequence.   Although gross generalizations regarding the 
most favourable siRNA spacing cannot yet be made, the insertion or deletion of bp at the siRNA 
junctions appears to enhance or reduce the efficiency of a second cleavage reaction.  Liu et al. 
reported that 4 bp inserted between two 19 bp siRNAs sequences resulted in the production of two 
functional siRNA species (Liu et al. 2007).  The effects of spacing between siRNA-encoding sequences 
within the dual-targeting lhRNAs studied in this Chapter, was thus investigated to ensure silencing 
efficacy from both siRNAs.  Each set of hairpins therefore consisted of three lhRNAs with 1, 2 or 3 
random mismatched bp inserted at the junction between siRNA encoding sequences of 21 bp.  In 
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addition, another 5 bp were inserted adjacent to the loop sequence to eliminate the possibility of the 
second Dicer cleavage reaction occurring within the loop sequence thus yielding an ineffective second 
siRNA product.  The lhRNA design approach described above resulted in four sets of hairpin duplexes 
each containing three dual-targeting lhRNAs with stem duplexes 48, 49 or 50 bp in length and with a 9 
nt terminal loop (Figure 3.4).  All lhRNAs were designed to be transcribed from the U6 snRNA Pol III 
promoter.  G:U and U:G pairings were introduced at regular intervals along the sense strand of the 
duplex to facilitate enhanced propagation of inverted repeat sequences in E.coli as well as to assist 
with accurate sequencing of the lhRNAs.  
 
 
 
Figure 3.3:  Schematic representation of a dual-targeting lhRNA expression cassette showing 
the upstream U6 promoter and the predicted lhRNA structure post transcription.  Dual targeting 
lhRNAs were designed to incorporate two 21 bp siRNA sequences with variable spacing (1, 2 or 3 bp) 
at the junction and a 5 bp terminal extension. The resulting duplexes of 48, 49 or 50 bp allow for two 
predicted Dicer cleavage reactions and the subsequent generation of two siRNAs containing unique 
guide strands (indicated in colour).
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Figure 3.4: Design of anti-HIV dual-targeting lhRNAs.  Panels of anti-HIV lhRNAs were designed to encode two 19 bp + 2 nt siRNAs targeted to 
the tat and nef genes (A) and (B) or the LTR and int genes (C) and (D).  siRNA sequences were positioned in both sequential positions of the 
hairpin duplex and within each set of lhRNAs, up to  three random mismatched bp were inserted at the junction of siRNA encoding sequences.  A 
terminal extension of 5 bp was inserted adjacent to the 9 nt loop sequence.
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3.3.2 Inhibitory effects of expressed lhRNAs in cell culture 
 
To assess the ability of variable length dual-targeting lhRNAs to inhibit the cognate targets of the 
respective incorporated siRNA sequences in vitro, HEK293 cells were transfected with dual-targeting 
lhRNAs from each panel in Figure 3.4 or with individual relevant shRNA expression plasmids serving 
as positive controls.  These hairpin constructs were transiently co-transfected with a psiCHECK dual 
luciferase target reporter plasmid containing either the tat, nef, LTR or int target sequence or a 
combination of all four target sequences downstream from the Renilla luciferase open reading frame 
(Figure 3.3 A).  A non-specific lhRNA targeted against the HBx gene of HBV (Weinberg et al. 2007) 
was used as a negative control (lhRNA control).  Knockdown was determined as a ratio of Renilla 
luciferase: Firefly luciferase and values were normalised to pTZU6+1 (mock).  Regardless of whether 
1, 2 or 3 bp were inserted at the siRNA junction, or the relative orientation of siRNA sequences within 
the duplex, siRNAs at the base of the hairpin were consistently capable of suppressing their respective 
targets approximately 80-95%. This knockdown was comparable to the inhibition achieved by 
individual control shRNAs which, as expected, showed target specific knockdown (Figure 3.5 A).  
Interestingly however, silencing abilities of siRNAs in the second position of the hairpin duplex showed 
efficient knockdown when only one mismatched bp was present between siRNA encoding regions, 
while a gradual decrease in efficacy was seen with increasing spacing at the siRNA junction.  The 
increased spacing did not however appear to affect inhibitory activity of siRNAs at the base of the 
duplex (Figure 3.5 A).  This result was consistent among all four target sequences and suggests that 
putative siRNA sequences of 19 bp + 2 nt with one mismatched base pair inserted between them 
provides an optimal lhRNA design ensuring maximum RNA activity from both positions of the hairpin 
duplex.  This also implies that 19 bp + 3 nt is the maximum length of an siRNA present within a long 
dsRNA duplex.  Attention should be drawn to lhtat-nef +1 and lhLTR-int +1, both of which show >80% 
target inhibition by siRNAs generated from both positions of the hairpin.  When tested against a 
psiCHECK reporter plasmid containing a combination of all four target sequences inserted in the 3‟ 
UTR of Renilla luciferase, lhtat-nef +1 and lhLTR-int +1 again showed potent inhibition of the combined 
target at levels comparable to those afforded by individual shRNAs (Figure 3.5 B).
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Figure 3.5:  Inhibitory efficacy of dual-targeting lhRNAs.  Dual luciferase reporter assays were used to measure target knockdown following 
co-transfection of HEK293 cells with dual-targeting lhRNA expression plasmids together with psiCHECK reporter plasmids containing each 
specific target sequence (A) or a combination of all of the target sequences in tandem (B), inserted downstream of the Renilla luciferase 
(hRLuc) open reading frame.  Values represented are mean ratios of Renilla to Firefly luciferase (±SEM) and are normalised to cells transfected 
with pTZU6+1 (mock) (*, p<0.05, one-way ANOVA relative to mock transfected control). 
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3.3.3 Detection of mature siRNAs generated from dual-targeting lhRNAs  
 
To analyse processed anti-viral sequences from transfected hairpin expression cassettes, PAGE 
northern blot analysis was carried out on total RNA extracted from HEK293 cells transfected with dual-
targeting lhRNA or control shRNA expression plasmids or with pTZU6+1 (mock).  Figure 3.6 shows the 
signals obtained following hybridisation of membranes with four probes complementary to each of the 
guide strands of processed siRNAs.  Confirming the results in Figure 3.5, northern blots showed a 
detectable signal from all dual-targeting lhRNAs when probed for the guide sequences of siRNAs 
positioned at the base of the stem.  However, siRNAs at the base of the stem were only detected at 
comparable levels to shRNAs from lhRNAs when one or two bp were inserted at the junction.  In the 
case of the LTR and int probes, minimal signals were detected from first position siRNAs where 3 bp 
were inserted at the siRNA junction.  This contradicts the knockdown data (Figure 3.5) where spacing 
did not appear to affect RNAi activity from the base of the hairpin, and suggests that increased spacing 
may have a negative effect on the first Dicer cleavage reaction.   
When probing for processed products from the second position of the hairpin, siRNAs were 
generally detected at lower concentrations.  This decrease in siRNA production from the second 
position was observed in a gradient fashion with an inverse relationship to the bp spacing present at 
the junction between siRNA encoding sequences.  When only one mismatched base pair was inserted 
at the junction, siRNAs in the second position were detected at similar levels to those of siRNAs at the 
base of the stem and the least signal reduction was observed.  However when three mismatched base 
pairs were inserted at the siRNA junction, siRNAs in the second position were hardly detected, despite 
extended exposure of the blot.  Where no signal was detected for siRNAs produced from the base of 
the stem (lhint-LTR +3), it was not unexpected that no signal was obtained for siRNAs at the top of the 
stem, since problems associated with the first Dicer cleavage reaction will invariably affect the second 
Dicer cleavage step.   
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Figure 3.6: PAGE northern blot analysis of total RNA extracted from cells transfected with the indicated dual targeting lhRNAs or 
shRNA controls.  (A) and (B) represent two blots hybridised with labeled probes complementary to the guide strands of tat and nef (A) or LTR 
and int (B) and exposed to a phosporimaging plate.  lhRNA and shRNA precursor RNA as well as processed siRNAs are indicated.  Decade 
Marker
TM
 was used as a molecular weight marker (MW) and a probe complementary to U6 small nuclear RNA was used as a control to verify 
equal loading of each RNA sample.  The approximate band intensities (%) of generated guide sequences relative to the guide sequence 
derived from the relevant shRNA are indicated.
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It should be noted that 2-3 bands differing in size by only 1 nt are often visible for a single 
siRNA which indicates that Dicer does not consistently cleave the duplex at the same position but 
rather generates siRNAs ranging in size from 19-22 nt.  lhtat-nef +1 and lhLTR-int +1 were the most 
effective lhRNAs in producing siRNAs from the first position as well as from the second position in 
similar quantities.  Signals obtained following hybridisation with a probe complementary to U6 snRNA 
show equal loading of each RNA sample (Figure 3.6). 
 
3.3.4 Dose response inhibition of individual target sequences by lhtat-nef +1 and 
lhLTR-int +1  
 
A structural lhRNA design has been identified which enables the efficient cleavage of dual-
targeting lhRNAs into two distinctive siRNAs, both capable of highly significant inhibition of their 
cognate targets in vitro.  The knockdown described in 3.3.2 however, was a result of lhRNAs 
transfected in a ratio of 5:1 (lhRNA expression cassette:target reporter plasmid), and  although potent 
RNAi activity was observed throughout the hairpin duplex of both lhtat-nef +1 and lhLTR-int +1, it 
remained to be determined whether or not this potency was able to be sustained at lower 
concentrations.  To determine the effective dose of the dual-targeting lhRNAs, as well as to investigate 
whether or not the RNAi activity from the second position of the hairpin duplex is decreased when 
lhRNAs are present at low concentrations, a dose response inhibition assay was carried out.  Cells 
were transfected with decreasing concentrations of lhRNA expression plasmids, together with a fixed 
quantity of target reporter plasmid, and the inhibitory efficacies of decreased quantities of siRNAs from 
both positions of the hairpin duplex were determined.   
It was found that both siRNAs generated from lhtat-nef +1 and lhLTR-int +1 were capable of 
maintaining effective target knockdown >60% from both positions of the hairpin duplex at concentration 
ratios as low as 0.005:1 (less than 1 ng) and 0.05:1 (7.5 ng) in the cases of lhtat-nef +1 and lhLTR-int 
+1 respectively (Figure 3.7).  Therefore even when lhRNAs were present at very low concentrations, 
RNAi activity throughout the hairpin duplex remained highly effective.  This is suggestive of a strong 
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dual siRNA response and also suggests that the design of the above mentioned lhRNAs allows for 
efficient Dicer processing along the entire duplex. 
 
 
Figure 3.7:  Dose response inhibition of individual targets by effective dual-targeting lhRNAs.  
Dual luciferase reporter assays were carried out to determine knockdown of the tat and nef targets (A) 
and LTR and int targets (B) following transfection with decreasing quantities of lhtat-nef +1 and lhLTR-
int +1 respectively.  Values represented are mean ratios of Renilla to Firefly luciferase (±SEM) and are 
normalised to mock transfected cells (0 ng).  
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Important to note however, is that although the four siRNA sequences selected for incorporation 
into the dual-targeting lhRNAs of this study showed equal inhibitory efficacies at high concentrations 
(Figure 3.5 and 3.7), when present at low concentrations it became evident that the RNAi activity 
afforded by each siRNA sequence was not equal (Figure 3.7).  Within lhtat-nef +1, both the tat and nef 
siRNAs are highly potent, and at very low concentrations siRNA-nef is only slightly less effective than 
siRNA-tat and this is likely to be a result of siRNA-nef being located in the second position of the 
hairpin.  Interestingly, the lhtat-nef +1 lhRNA is substantially more potent than lhLTR-int +1 and is able 
to maintain powerful knockdown at concentrations ten fold lower than lhLTR-int +1.   
In the context of lhLTR-int +1, siRNA-int is situated in the second position of the hairpin duplex, 
yet displays stronger inhibition than siRNA-LTR when the hairpin is present at low quantities.  However 
even though siRNA-int is stronger than siRNA-LTR, siRNA-int is capable of 50% target inhibition at a 
concentration five times that required by siRNA-tat for 50% target knockdown.  This assay clearly 
reveals the strength of the tat and nef siRNAs and the relative weakness of the LTR siRNA in the 
context of dual-targeting lhRNAs, and indicates that at low concentrations, the inhibitory activity, even 
of highly effective siRNA sequences, is not uniform. 
 
3.3.5 The use of alternative Pol-III promoters to drive expression of lhRNAs  
 
Cellular toxicities may arise as a result of over-expression of RNAi effector molecules (An et al. 
2006; Grimm et al. 2006) (section 1.7).  The lhRNA and shRNA expression cassettes generated in this 
study have all been designed to be expressed from the human U6 snRNA Pol III promoter.  As 
previously described, RNA Pol III transcripts act as ideal substrates for nuclear export as well as for 
Dicer processing.  However because the U6 promoter is known to express transcripts at very high 
levels (Good et al. 1997), the activity of alternative RNA Pol III promoters was investigated.  The 
simultaneous expression of multiple hairpins from a lentiviral vector requires the use of different 
promoters (ter Brake et al. 2008).  Therefore for future combinatorial strategies harnessing the effective 
dual-targeting lhRNAs described in this Chapter,  lhtat-nef +1 and lhLTR-int +1 sequences were 
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regenerated to be expressed from the human H1 or 7SK promoters respectively in individual 
expression plasmids as well as within a single vector.  Both H1 and 7SK are RNA Pol III promoters 
which have previously been used to effectively drive the expression of hairpin RNAs (Brummelkamp et 
al. 2002; Czauderna et al. 2003b), albeit it at potentially lower levels than U6 (Makinen et al. 2006). 
The effect of using alternate Pol III promoters H1 or 7SK to drive expression of lhtat-nef +1 and 
lhLTR-int +1 was assessed by a dual luciferase reporter assay following transfection of HEK293 cells 
with the various hairpin constructs.  Very similar inhibition of each target was obtained when comparing 
the U6 driven transcripts to H1 or 7SK driven transcripts.  When combining the two hairpin expression 
cassettes in a single vector, knockdown of the tat and nef targets remained highly potent and 
knockdown of the LTR and int targets was only minimally reduced (Figure 3.8).  lhRNA-mediated 
inhibition therefore remained effective regardless of the Pol III promoter used.   
Northern blot analysis was carried out on RNA extracted from cells transfected with the U6, H1 
or 7SK expressed lhRNAs to determine expression levels from each promoter.  When expressed from 
alternate Pol III promoters, similar siRNA concentrations were generated from the differently expressed 
lhRNAs except H1-lhtat-nef +1 which generated slightly more siRNA than U6-lhtat-nef +1.  Slightly less 
siRNA was also generated from the lhRNAs when combined in a single vector (Figure 3.9).  Important 
to note was the difference in hairpin precursor RNA concentration.  H1 generated the least precursor 
RNA followed by U6 and then 7SK (Figure 3.9).  The human H1 promoter thus appears to be the most 
effective in producing maximum siRNA with the least accumulation of precursor RNA.  The use of the 
dual-targeting lhRNAs described in this Chapter could therefore be improved by using alternative, more 
efficient promoters.  Furthermore, because these lhRNAs are effective at such low doses, the 
precursor accumulation seen in Figure 3.4 may also be decreased by using a lower concentration of 
these constructs.  Moreover the strength of H1-lhtat-nef +1 and 7SK-lhLTR-int +1 was also maintained 
when expressed from within a single vector.  This suggests that if used in combination, these two dual-
targeting lhRNAs may potentially offer a basis for a combinatorial system effectively targeting four 
independent genes. 
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Figure 3.8:  Effect of different RNA Pol III promoters on the inhibitory efficacy of lhRNAs.  Dual luciferase reporter assays showing 
knockdown of each individual target by lhtat-nef+1 driven by the U6 or H1 promoter and lhLTR-int+1 driven by the U6 or 7SK promoter.  H1-
lhtat-nef-7SK-lhLTR-int represents a single vector consisting of two lhRNA expression cassettes.  Individual U6 driven shRNAs were used as 
controls.  Values represented are mean ratios of Renilla to Firefly luciferase (±SEM) and are normalised to cells transfected pTZU6+1 (mock) (*, 
p<0.05, one-way ANOVA relative to mock transfected control).   
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Figure 3.9:  Effect of different RNA Pol III promoters on the intracellular processing of lhRNAs.  PAGE northern blot analysis was carried 
out on total RNA extracted from cells transfected with the indicated transcripts.  Labeled probes complementary to the guide strand of putative 
siRNAs targeting tat, nef, LTR and int were hybridised to immobilised RNA and exposed to a phosphorimaging plate.  lhRNA and shRNA 
precursor RNA as well as processed siRNAs are indicated.  Decade MarkerTM indicates fragment size and a probe complementary to U6 
snRNA was used as a loading control.
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3.4 Discussion 
 
The catalytic activity of human Dicer is restricted to two efficient cleavage reactions, after which 
processivity rapidly declines (Barichievy et al. 2007; Liu et al. 2007; Weinberg et al. 2007; Saayman et 
al. 2008; Sano et al. 2008).  Despite these repeated observations, little is known about the exact 
mechanism of action of human Dicer or the sequence and structure of an ideal Dicer substrate.  Liu et 
al. recently attempted to optimise the design of hairpins encoding three and four siRNA sequences (Liu 
et al. 2009).  Hairpins of 88 and 92 bp encoding four unique siRNAs had a decreased overall efficacy 
along the entire stem and suggest that the production of four siRNAs from a hairpin duplex is not 
feasible.  Slightly shorter hairpins of 63 and 66 bp encoding three siRNAs were able to effectively 
inhibit all three target sites; however, mature siRNAs were yet again observed to be generated with 
greater efficacy from the base of the stem, thus yielding unequal quantities of siRNA products.   
Interestingly hairpins encoding three siRNAs containing a slightly longer terminal extension (5 bp vs. 2 
bp) showed slightly enhanced activity from the second and third siRNAs.  Once again hairpins of 43 bp 
encoding only two siRNAs were capable of consistently potent silencing from both positions of the 
hairpin duplex and exhibited the strongest inhibition of HIV-1 viral replication (Liu et al. 2009), once 
more implicating dual acting hairpins as ideal combinatorial hairpin substrates.  This work therefore 
sought to characterise the inhibitory efficacy and processing trends of hairpin duplexes encoding two 
siRNAs.  In addition, the effects on Dicer processing of siRNA sequence as well as of bp spacing at 
siRNA junctions and prior to the loop sequence were thoroughly investigated.  A set of parameters 
have thus been proposed for the design of dual-targeting lhRNAs capable of producing two highly 
active siRNAs produced at similar quantities and effective at low doses. 
Four effective siRNA sequences identified from previously published studies (Lee et al. 2002a; 
Nishitsuji et al. 2006; Westerhout et al. 2006b; Barichievy et al. 2007) were exploited in the design of 
the dual-targeting lhRNAs described here in order to identify an optimal sequence-independent design 
for dual-targeting hairpins . These lhRNAs were designed to incorporate the sequences of two of the 
above mentioned siRNAs in both positions of the duplex and with 1-3 mismatched bp inserted at the 
siRNA junction.  A small terminal extension preceding the loop sequence has been shown to enhance 
 C
H
A
P
T
E
R
 3
 
110 
 
the RNAi activity of the second and third siRNA in 66 bp hairpins encoding three siRNAs (Liu et al. 
2009).  Each lhRNA had a 5 bp terminal extension inserted prior to the loop sequence to augment 
processing of the entire hairpin stem.  The bp spacing inserted at the siRNA junctions proved to have a 
marked effect on the generation of siRNAs from the hairpin duplex and thus the knockdown efficacy of 
the lhRNAs.  When only 1 mismatched bp was inserted at the junction between siRNA encoding 
sequences, the strongest inhibitory activity was induced from both positions of the hairpin duplex 
regardless of siRNA sequence or position.  In the case of lhtat-nef +1 and lhLTR-int +1, PAGE northern 
blots indicated that siRNAs were also generated from both positions of the duplex in equal quantities.  
Furthermore RNAi activity from both positions of the duplex was maintained even when these lhRNAs 
were present at very low concentrations or when expressed from weaker RNA Pol III promoters.  
These results suggest that 19 bp + 2 nt siRNA sequences with 1 bp inserted at the junction in the 
context of a dual-targeting lhRNA constitutes an effective structure for optimal processing by Dicer.  
When 3 bp were inserted at the siRNA junction the knockdown afforded by siRNAs in the second 
position was markedly reduced, and northern blot analysis showed a decrease in siRNA production 
from both positions of the hairpin.  The decrease in siRNA production from the second position was 
marked, to the point that no siRNA was detected at all.  However this is not surprising if the first 
cleavage reaction is also being negatively affected, since Dicer processing begins at the open end of 
the duplex and proceeds towards the loop.  Therefore if the first siRNA is not cleaved, the second 
siRNA will not be cleaved either.  These results provide a guideline for the maximum length of a hairpin 
stem as well as a maximum length for each individual siRNA encoding sequence, for efficient Dicer 
processing.  In the case of lhLTR-int +3, slightly less hairpin precursor RNA was detected by northern 
blot analysis which indicates that slightly longer transcripts may not be transcribed as efficiently by a 
Pol III promoter or that an lhRNA with a 3 bp insert is less stable.  The fact that the 3 inserted bp are 
mismatched, thus creating a small bulge in the centre of the duplex may also play a role in the 
observed decline in Dicer processing.  It has been shown that the N-terminal helicase domain of 
human Dicer plays a role in the preferred processing of thermodynamically unstable duplexes such as 
pre-miRNAs (Ma et al. 2008; Soifer et al. 2008), but that when this domain is mutated, cleavage of 
thermostable duplexes such as lhRNAs is enhanced (Soifer et al. 2008).  However, shRNAs designed 
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to incorporate mismatches or small bulges within the stem, thus causing a reduction in thermodynamic 
stability, showed a marked reduction in processing regardless of the presence or absence of a mutated 
helicase domain (Soifer et al. 2008).  The resulting bulge in dual-targeting lhRNAs with 3 bp inserted at 
the siRNA encoding junction may therefore be the limiting factor for efficient Dicer processing, and in 
support of previous studies, may affect not only the second but the first cleavage reaction too.  It is 
therefore possible that the dramatic decrease observed in intracellular processing of lhRNAs with 3 bp 
inserted at the siRNA junction may be less pronounced if the inserted bp were flanking bp of the siRNA 
sequence. 
In conclusion a general framework for the design of effective dual-targeting lhRNAs has been 
provided.  It should be noted that both the sequence and spatial arrangement of siRNAs within a 
duplex affect the efficiency of Dicer processing, and that adjustments in the length of the duplex stem 
and the insertion of base pairs between each siRNA encoding sequence as well as prior to the loop 
sequence, may serve to augment RNAi activity throughout the stem.  Two highly effective dual-
targeting lhRNAs have been identified, namely lhtat-nef +1 and lhLTR-int +1 which together may 
generate four different siRNAs.  These lhRNAs may be combined with other anti-HIV RNAi activators, 
or with conventional antiretroviral drugs to formulate a unique combination therapy for the treatment of 
HIV.  Alternatively, the intrinsic combinatorial properties of these dual-targeting lhRNAs can be 
exploited in future endeavors to develop novel multiplexed RNAi modalities.  
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CHAPTER 4 
Combining two effective dual-targeting lhRNAs within a single 
expression cassette as a novel combinatorial RNAi structure. 
 
4.1 Introduction  
 
The capacity for lhRNAs to encode multiple siRNA sequences has been exploited in the 
development of potential combinatorial RNAi strategies.  However following extensive characterisation 
of lhRNAs, the limitations of such constructs have been clearly demonstrated.  Efficacious quantities of 
only two siRNAs can be derived from a single lhRNA stem.  However, a computational algorithm has 
predicted and experiments have confirmed that to prevent the emergence of HIV-1 viral escape 
mutants, four independent gene sequences should be simultaneously suppressed (Leonard and 
Schaffer 2005; ter Brake et al. 2008).   Although optimised to produce two siRNAs efficiently, dual-
targeting lhRNAs do not therefore represent a sufficient combinatorial approach for the prevention of 
resistance.  However instead of using hairpins encoding three siRNAs, with only moderately efficacious 
levels of the third siRNA being produced, a combination of dual-targeting lhRNAs may offer a more 
efficient strategy for the simultaneous targeting of more than two gene sequences.  It was shown in 
Chapter 3 that two effective dual-targeting lhRNAs can be expressed from a single vector for the 
suppression of four independent gene targets, however this strategy is analogous to the use of multiple 
expressed shRNAs and the same associated problems and limitations exist (section 1.10.1).  Avenues 
need to be explored which investigate the feasibility of developing novel lhRNA-based combinatorial 
RNAi systems.   
The combination of effective dual-targeting lhRNAs in tandem within a single expression cassette 
represents an attractive possibility, however the configuration of such a structure requires further 
exploration.  During the initial quest to generate RNAi effector mimics following the demonstration that 
synthetic siRNAs could cause gene specific silencing in mammalian cells (Elbashir et al. 2001a), Leiral 
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and Sioud identified a bispecific siRNA structure configured with two shRNA structures separated by 8 
nucleotides which essentially acted as a linker between the two shRNAs (Leirdal and Sioud 2002).  
This structure was transcribed in vitro by a T7 RNA polymerase and was shown to be processed 
intracellularly to yield RNA species correlating to the size of the individually incorporated shRNAs.  It 
was hypothesized that an endoribonuclease was responsible for cleaving the single stranded RNA 
linker sequence to yield two functional shRNAs which were shown to effectively silence their cognate 
targets.  This bispecific shRNA design was expanded upon soon thereafter by Anderson et al. who 
investigated the combinatorial properties of this unique structure to suppress two HIV-1 host cell 
receptors simultaneously (Anderson et al. 2003).  Anderson et al. also showed that intracellular 
processing of this structure resulted in two discrete shRNA species capable of significant inhibition of 
complementary host cell receptor genes.  Three different linker sequences were analysed for their role 
in the efficacy of these bispecific hairpin structures.  Of the three sequences examined, only one 
resulted in optimal processing and gene silencing, indicating that the RNA sequence separating the 
two hairpin moieties plays an important role in the efficacy of such constructs.  Although the bispecific 
shRNA structure as well as the mechanism by which it is processed, was not sufficiently characterised, 
these two studies suggest an interesting new approach to combining previously characterised lhRNAs.  
Chapter three identified two unique highly effective lhRNAs, lhtat-nef +1 and lhLTR-int +1, each 
optimised for the generation of two potent siRNAs, for future incorporation into a multiplexed RNAi-
based therapy.  In this chapter a novel combinatorial RNAi structure is described that demonstrates the 
effects of tethering these two highly effective dual-targeting lhRNAs, adjacent to one another in a 
double-lhRNA expression cassette driven from a single RNA Pol III promoter.  In addition, the ability of 
this novel structure to generate four independent functional siRNAs is revealed.  These constructs did 
not induce an interferon response nor did they cause saturation of the endogenous miRNA biogenesis 
pathway and therefore represent a promising new strategy for the simultaneous suppression of 
multiple viral genes.   
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4.2 Materials and Methods 
 
4.2.1 Generation of U6-driven double-lhRNA expression cassettes 
 
Double-lhRNA expression cassettes were generated by the 2-step PCR method described in 
2.2.1, using the existing dual-targeting lhRNAs (lhtat-nef +1 and lhLTR-int +1) as templates.  A total of 
four rounds of PCR were therefore required for the production of a double-lhRNA sequence.  Round 
one reverse primers were complementary to the last 18 nt and two thymine residues at the 3‟ terminal 
end of the dual-targeting lhRNA template.  To generate the double-lhRNA: lhLTR-int-lhtat-nef, lhRNA-
LTR-int +1 was used as a template and was amplified with the universal U6 forward primer and unique 
LITN R1 reverse primer: 5‟- CTG GGT CAG GGA CAT ATT GTA CTT CCA GCC AGA CAC TGC TCT 
TCA TCA CTA TCC CCG CAA GTA ACT AGA GAC CTC TCA -3‟ (78 nt).  The lhRNA-tat-nef +1 R2 
primer (Table 3.1) was used as the reverse primer for the second round of PCR.  To generate the 
double-lhRNA: lhtat-nef-lhLTR-int, lhRNA-tat-nef +1 was used as a template and amplified with the 
universal U6 forward primer and unique TNLI R1 reverse primer: 5‟- CTG GGT CAG GGA CAT AAC 
TAA CCA TTG CCC TCC GGC TGT CCG AGA GAT CTC TAA TTA CAA GCG GAG ACA GCG ACG 
A -3‟ (76 nt).  The lhRNA-LTR-int +1 R2 primer was used as the reverse primer for the second round of 
PCR.  Individual shRNAs and dual-targeting lhRNAs described in Chapter 3 were used as positive 
controls. 
 
4.2.2 Dual luciferase fusion reporter plasmids 
 
Dual luciferase fusion reporter plasmids encoding the sequence targeted by the antisense strand 
of each putative siRNA were described in 3.2.2.  To determine strand biasing, dual luciferase fusion 
reporter plasmids encoding the sequence targeted by the sense strand of each putative siRNA were 
also generated.  These reporter plasmids were constructed using the same method described in 3.2.2 
with partially complementary oligonucleotides (Table 4.1). 
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Table 4.1:  Oligonucleotide sequences used to generate gene specific target sequences 
 
Oligonucleotide Sequence (5’-3’) Length 
(nt) 
tat sense target forward TCGAGATATCGCTCTTCGTCGCTGTCTCCGCA 32 
tat sense target reverse CTAGTGCGGAGACAGCGACGAAGAGCGATATC 32 
nef sense target forward TCGAGATATCCTTGTGCTTCTAGCCAGGCACA 32 
nef sense target reverse CTAGTGTGCCTGGCTAGAAGCACAAGGATATC 32 
LTR sense target forward TCGAGATATCGTCTGAGAGGTCTCTAGTTACA 32 
LTR sense target reverse CTAGTGTAACTAGAGACCTCTCAGACGATATC 32 
int sense target forward TCGAGATATCGACTAGCCATTGCTCTCCGGCA 32 
int sense target reverse CTAGTGCCGGAGAGCAATGGCTAGTCGATATC 32 
 
Underlined sequences represent the XhoI and SpeI restriction endonuclease recognition sites in the forward and reverse primers 
respectively as well as EcoRV restriction endonuclease recognition sites within the overlapping region of forward and reverse 
oligonucleotides.  Highlighted sequences indicate complementary overlapping regions between the pair of oligonucleotides. 
 
4.2.3  Assessing the inhibitory efficacy of expressed lhRNA and dlhRNA constructs 
against sense and antisense targets in cell culture 
 
Double-lhRNA expression cassettes were assessed for their ability to knockdown four individual 
target sites simultaneously in cell culture according to previously described procedures (section 2.2.3).  
Individual shRNAs as well as individual dual-targeting lhRNAs were used as positive controls.  In 
addition to determining the knockdown of each individual target complementary to the antisense strand 
of each putative siRNA, inhibition of sequences complementary to the sense strand of each putative 
siRNA was also determined using the procedure described in 2.2.3 and the dual luciferase reporter 
plasmids described in 4.2.2.  
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4.2.4 Detection of processed anti-HIV-1 hairpin sequences from dlhRNAs 
 
Guide strands of siRNAs generated from expressed double-lhRNAs were detecting using PAGE 
northern blot analysis according to the procedure described in 3.2.4.  The antisense strand of each 
siRNA was detected using the oligonucleotide probes listed in 3.2.4.  The passenger strands of 
putative siRNAs were detected using the following oligonucleotides complementary to the sense strand 
of each siRNA: tat sense probe 5‟- GCT CTT CAT CAC TAT CCC CGC -3‟; nef sense probe 5‟– ATT 
GTA CTT CCA GCC AGA CAC –3‟; LTR sense probe 5‟– GTC CGA GAG ATC TCT AAT TAC –3‟ and 
int sense probe 5‟– AAC TAA CCA TTG CCC TCC GGC –3‟.  The intensities of guide strands derived 
from dual-targeting lhRNA precursors were quantified relative to guide strands generated from shRNA 
controls using the Fuji ImageQuant software. 
 
4.2.5 Suppression of  HIV-1 subtype B and subtype C gene targets 
 
HIV-1 FV5 challenge assay 
To determine the extent of inhibition of HIV-1 subtype C primary isolate FV5, U87.CD4.CCR5 
cells were seeded and transfected as described in 2.2.5.  In this challenge assay however, the relative 
strength of the various hairpin constructs was determined by transfecting cells with two different 
concentrations of hairpin expressing plasmids.  One set of cells was transfected with1 µg of each 
construct and the other set was transfected with only 100 ng of each construct.  The challenge assay 
proceeded as described in 2.2.5.  
 
Inhibition of gene targets in the pNL4-3.Luc.R-E- molecular clone 
Hairpin expression cassettes were assessed for inhibitory efficacy of an HIV-1 subtype B target by 
determining knockdown of the pNL4-3 molecular clone.  HEK293 cells were maintained and seeded for 
transfection as described in 2.2.3.  Cells were co-transfected with each hairpin expression plasmid 
together with the molecular clone pNL4-3.Luc.R-E- (Connor et al. 1995; He et al. 1995).  This 
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molecular clone has a Firefly luciferase gene inserted into the nef gene and is competent for only a 
single round of replication.  Suppression of viral gene expression was therefore measured by levels of 
Firefly luciferase activity.  Cells were transfected with one of three concentration ratios of hairpin 
expression plasmid to molecular clone:  5:1 (750 ng : 150 ng), 1:1 (150 ng : 150 ng), and 0.1:1 (15 ng 
:150 ng).  Approximately 50 ng of phRL-CMV (Promega, WI, USA) was also transfected as a 
background luciferase control and 100 ng pCI-eGFP was co-transfected to control for transfection 
efficiency.   At the lower hairpin concentrations, total DNA was made up with pTZU6+1.  Dual 
luciferase reporter assays were carried out as described in 2.2.3 but Firefly luciferase values were 
normalised against background Renilla luciferase values. 
 
4.2.6 Assessing the off target effects of lhRNA and double-lhRNA expression 
cassettes in vitro 
 
Assay for derepression of an exogenously introduced miRNA 
HEK293 cells were seeded at 120 000 cells per well in 24-well tissue culture plates (Nunclon™ 
∆ Surface, Nunc, Denmark) 24 hours prior to transfection in antibiotic-free medium as described in 
6.1.5.  To determine the effects of transfected hairpin constructs on the functioning of an exogenously 
introduced miRNA, cells were cotransfected with 100 ng pCMV miR-31 HBx (Ely et al. 2008), and 100 
ng of psiCHECK HBx, together with the indicated quantity of hairpin construct.  miR-31 HBx is a CMV-
driven pri-miRNA shuttle vector based on the endogenous pri-miRNA-31.  The guide sequence of this 
natural miRNA is substituted with an effective anti-HBV guide sequence targeted against the HBx 
ORF.  The psiCHECK HBx plasmid expresses the cognate target of the guide strand downstream of 
the Renilla ORF.  Transfections were carried out as described in 6.1.5 and 48 hours after transfection, 
a dual luciferase reporter assay was performed (2.2.3) to determine the ability of miR-31 HBx to inhibit 
its target in the presence of transfected hairpin expression cassettes. 
 
 
 
 C
H
A
P
T
E
R
 4
 
118 
 
Assay for derepression of an endogenous miRNA 
To assess potential saturation of the endogenous miRNA pathway caused by transfected hairpin 
constructs, Huh7 cells were cotransfected with 80 ng psiCHECK-miR-16T×7 (Ely et al. 2009): a 
psiCHECK
TM
-2 plasmid containing 7 miR-16 target sites downstream of the Renilla luciferase ORF; 
750 ng hairpin expression plasmid or pTZ-U6-miR-16S×7 sponge plasmid (Ely et al. 2009): a plasmid 
containing 7 imperfectly complementary copies of a miR-16 target site; and 150 ng pCI-eGFP.  
Transfections and reporter assays were performed as described above to determine the ability of 
endogenous miR-16 to knock down psiCHECK-miR-16T×7 in the presence of the sponge plasmid or 
transfected hairpin expression cassettes. 
 
Detection of non-specific immune response 
To determine the induction of IFN response-related genes, HEK293 cells were maintained and 
seeded as described in 2.2.6.  Cells were transfected with 900 ng of each hairpin expression plasmid 
or equivalent quantities of the dsRNA analogue poly (I:C) together with 100 ng pCI-eGFP per well.  
IFN-β mRNA was then quantified by reverse transcription of total RNA extracted from transfected cells 
and real-time PCR as described in 2.2.6. 
 
4.2.7 Statistical analysis 
 
Statistical analysis was carried out using the GraphPad Prism software (GraphPad, Software, Inc., 
CA, USA).  Statistical difference was considered significant when p<0.05 and was determined using 
one-way ANOVA followed by a Dunnett‟s Multiple Comparison post-test. 
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4.3 Results 
 
4.3.1 Design of U6-driven double-lhRNA (dlhRNA) expression cassettes 
 
In order for the combinatorial capacity of lhRNAs to be realised, novel lhRNA-based RNAi 
strategies need to be explored.  Two studies successfully used a bispecific shRNA structure for the 
generation of two independent shRNAs able to enter into the RNAi pathway (Leirdal and Sioud 2002; 
Anderson et al. 2003).  Although it was suggested that this structure is likely to be cleaved by a single 
stranded ribonuclease at the site of the linker sequence, the mechanism by which these structures was 
processed was never fully characterised.  However, the possibility of incorporating effective lhRNAs 
into a dual specific structure is highly attractive and offers enormous potential as a novel combinatorial 
RNAi approach.  A similar structure was therefore adopted, modified, and investigated for its capacity 
to incorporate the dual-targeting lhRNAs already extensively described in Chapter 3. 
Novel RNAi effector precursors were designed, which consisted of a combination of two 
previously identified highly effective dual-targeting lhRNAs, under the control of a single RNA Pol III 
promoter for the potential generation of multiple unique siRNAs from a single expressed transcript.  
Double-lhRNA (dlhRNA) cassettes were designed to be driven off a U6 promoter, yielding a double 
lhRNA structure comprising two optimised dual-targeting lhRNAs adjacent to one another.  In contrast 
to previously described bispecific shRNAs which were separated by linker sequences of 8 nt, the two 
hairpin structures were separated by only two uridine residues; akin to a natural 2 nt 3‟ overhang ideal 
for Dicer recognition.  Should this construct be recognised as an RNAi substrate precursor, the 
structure ought to allow for five Dicer cleavage reactions, yielding four independent effective siRNAs 
(Figure 4.1 A).  Two dlhRNA cassettes were constructed based on the two most effective dual-
targeting lhRNAs described in Chapter 3: lhtat-nef +1 and lhLTR-int +1, with each construct allowing 
each lhRNA to be in both the first and second position of the expression cassette (Figure 4.1 B). 
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Figure 4.1: Schematic representation of a double-lhRNA expression cassette and the predicted 
double long hairpin structure post transcription.  (A) Double-lhRNAs were designed to incorporate 
two effective dual-targeting lhRNAs adjacent to one another. The resulting structure allows for five 
predicted cleavage reactions and the subsequent generation of four siRNAs.  (B) Two dlhRNAs: 
lhLTR-int-lhtat-nef and lhtat-nef-lhLTR-int were designed to incorporate a combination of two dual-
targeting lhRNAs (lhtat-nef +1 and lhLTR-int +1) arranged in both possible sequential positions. 
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4.3.2 Detection of multiple siRNAs derived from a U6-driven double-lhRNA 
expression cassette  
 
Double-long hairpin RNAs (dlhRNAs) represent a unique RNA structure and although each 
discrete hairpin entity contained a short 3‟ overhang, the capacity of these structures to act as RNAi 
precursors and thus Dicer substrates was unknown.  Each dlhRNA has the potential to be processed 
to yield up to four unique siRNAs.  Following generation of the two dlhRNAs expression cassettes, 
PAGE northern blot analysis was carried out on total RNA extracted from HEK293 cells transfected 
with plasmids expressing dlhRNA cassettes, to determine whether or not these novel structures were 
processed intracellularly, and to detect the potential generation of mature siRNAs.  
Figure 4.2 shows the signals obtained following hybridisation with the same probes listed in 3.2.4.  
These probes were complementary to the antisense strand of each putative siRNA incorporated in the 
dlhRNA structure.  All probes were able to detect dlhRNA precursor RNA from both dlhRNA constructs 
(lhLTR-int-lhtat-nef and lhtat-nef-lhLTR-int), which indicates that the dlhRNA sequences were 
effectively transcribed.  All probes were also able to detect individual lhRNA precursor RNA of the 
same molecular weight as precursors detected in Figure 3.6, from the lhLTR-int-lhtat-nef dlhRNA 
cassette, indicating that both lhRNAs (lhLTR-int and lhtat-nef) are being processed from this particular 
dlhRNA and are present in the cell.  The lhRNA in the second position of the dlhRNA cassette (lhtat-
nef) was however detected at a much lower intensity than that in the first position (lhLTR-int).  This 
suggests that either this lhRNA is not effectively cleaved and is thus present at a lower concentrations 
in the cell, or more likely that Dicer recognises the 3‟ overhang of the construct and thus processes the 
lhRNA in the second position first.  This would initially result in two siRNAs derived from lhtat-nef, and 
an lhLTR-int lhRNA precursor which may then serve as a secondary Dicer substrate for the generation 
of two more siRNAs.  All four mature siRNAs were detected from lhLTR-int-lhtat-nef and this is the first 
demonstration that four siRNAs can be successfully generated from a single U6-expressed lhRNA-
based construct.   
In the case of the dlhRNA lhtat-nef-lhLTR-int, a single lhRNA precursor was only detected by the 
tat and nef probes again indicating that the hairpin in the first position (lhtat-nef) is a bi-product of initial 
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Dicer cleavage reactions and therefore abundantly present in cells.  However not only was the lhLTR-
int precursor absent, mature siRNAs were also not detected with the LTR and int probes.  Only the tat 
and nef probes were able to detect mature siRNAs from this construct.  This was an unexpected 
observation which indicates that mature guide strands are not produced from the second hairpin of 
lhtat-nef-lhLTR-int.  This may imply that siRNA cleavage products, or indeed the entire lhRNA 
precursor is unstable and perhaps degraded intracellularly following transcription.  A second possibility 
to explain these observations is the phenomenon of strand biasing, whereby the sense (passenger) 
strand is functionally active and the antisense guide strand is degraded.  Results observed in Figure 
3.6 clearly show that the exact position of Dicer cleavage is variable.  Although the concept of strand 
biasing is not yet well studied, it seems obvious that a slight shift in the position of Dicer cleavage may 
modify the thermodynamic stability of the siRNA duplex resulting in the unintended incorporation of the 
sense strand into RISC and the subsequent degradation of the antiviral antisense strand. 
To eliminate the possibility of active passenger strands, oligonucleotide probes complementary to 
the passenger strand of each putative siRNA within the dlhRNA were used for northern blot analysis 
(Figure 4.3).  As expected, precursor RNA of dlhRNAs, lhRNAs and shRNAs were detected, however 
no mature sense strands were detected from any of the hairpin constructs, indicating that siRNA 
passenger strands had indeed been degraded.  Consistent with the signals detected with the antisense 
probes, no lhLTR-int precursor RNA was detected from the lhtat-nef-lhLTR-int dlhRNA with the sense 
probes confirming that this hairpin and products thereof were not present within the cell.
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Figure 4.2:  PAGE northern blot analysis to detect processed guide strands derived from dlhRNA precursors.  PAGE northern blot 
analysis was carried out on total RNA extracted from cells transfected with double-lhRNA expression cassettes or with individual shRNA 
expression cassettes used as positive controls.  Labeled probes complementary to the guide strand of LTR, int, tat and nef were hybridised to 
immobilised RNA and exposed to a phosphorimaging plate.  Precursor hairpin RNA as well as processed siRNAs are indicated.  Decade 
Marker
TM
 indicates fragment size and a probe complementary to small nuclear U6 RNA was used as a loading control.  The approximate band 
intensities (%) of generated guide sequences relative to the guide sequence derived from the relevant shRNA are indicated.
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Figure 4.3:  PAGE northern blot analysis to detect processed passenger strands derived from dlhRNA precursors.  PAGE northern blot 
analysis was carried out on total RNA extracted from cells transfected with double -lhRNA expression cassettes or with individual shRNA 
expression cassettes used as positive controls.  Labeled probes complementary to the passenger (sense) strand of LTR, int, tat and nef were 
hybridised to immobilised RNA and exposed to a phosphorimaging plate.  Precursor hairpin RNA is indicated.  Decade Marker
TM
 indicates 
fragment size and a probe complementary to small nuclear U6 RNA was used as a loading control. 
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4.3.3 Inhibitory efficacy of processed guide sequences derived from double-lhRNA 
expression cassettes  
 
The results in 4.3.2 show that up to four mature siRNAs may be generated from a single dlhRNA 
construct.  The ability of these siRNAs derived from dlhRNA expression cassettes to knock down their 
cognate targets was subsequently investigated.  RNAi activity was tested in a dual luciferase reporter 
assay using the psiCHECK reporter plasmids described in 3.2.2.  The dlhRNA lhLTR-int-lhtat-nef was 
successfully able to elicit a 70-80% decrease in the Renilla to Firefly luciferase ratio of all four gene 
targets, comparable to the knockdown achieved by single dual-targeting lhRNAs (Figure 4.4).  The 
observed RNAi activity implies that all four of the siRNAs derived from this construct were highly 
effective and active at similar levels.  The production of siRNAs from dlhRNA precursors capable of 
similar RNAi activity to those generated from dual-targeting lhRNAs, also suggests that each of the 
precursors are processed by a similar mechanism.  Only two mature siRNAs were derived from the 
dlhRNA lhtat-nef-lhLTR-int (Figure 4.2).  Consistent with these findings, significant inhibition was 
observed only of the tat and nef targets (Figure 4.4), confirming that the second lhRNA of this construct 
and its encoded siRNAs are indeed inactive.   
To determine whether the sense strand of each putative siRNA encoded by the dlhRNA 
constructs was actively being incorporated into RISC for target specific knockdown, target sequences 
complementary to each individual sense strand (sense targets) were inserted downstream of the 
Renilla ORF in dual luciferase reporter vectors and target knockdown was measured in a dual 
luciferase reporter assay.  Consistent with the results in Figure 4.3 where no sense strands were 
detected by northern blot analysis,  no inhibition >40% of the sense targets was observed by any of the 
siRNAs generated from the dlhRNA expression cassettes or from individual shRNA and lhRNA 
expression cassettes (Figure 4.5), suggesting that the sense strands of processed siRNAs were 
promptly degraded.
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Figure 4.4:  Dual luciferase reporter assays to measure inhibitory efficacies of guide strands derived from lhRNAs.  Knockdown of 
target sequences complementary to the antisense strand of LTR, int, tat and nef when the target sequence was inserted downstream of the 
Renilla luciferase open reading frame are shown.  Values represented are mean ratios of Renilla to Firefly luciferase (±SEM) and are 
normalised to cells transfected with a plasmid containing a U6 promoter only with no RNAi effector sequence (mock) (*, p<0.05, one-way 
ANOVA relative to mock transfected control). 
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Figure 4.5:  Dual luciferase reporter assays to measure inhibitory efficacies of passenger strands derived from lhRNAs.  Knockdown of 
target sequences complementary to the sense strand (passenger strand) of LTR, int, tat and nef when the target sequence was inserted 
downstream of the Renilla luciferase open reading frame is shown.  Values represented are mean ratios of Renilla to Firefly luciferase (±SEM) 
and are normalised to cells transfected with a plasmid containing a U6 promoter only with no RNAi effector sequence (mock) (*, p<0.05, one-
way ANOVA relative to mock transfected control). 
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4.3.4 The efficacy of expressed lhRNAs and double-lhRNAs to protect cells against 
HIV-1 viral infection  
 
The ability of the lhRNA and dlhRNA constructs described above, to inhibit the gene expression 
and thus replication of an HIV-1 viral isolate, was determined by challenging U87.CD4.CCR5 cells 
transfected with each of the hairpin constructs, with FV5, a primary subtype C HIV-1 viral isolate.  The 
viral titer present in a natural infection is difficult to replicate in a challenge assay, therefore antiviral 
activity was quantified at two different concentrations of the various hairpin constructs to deduce their 
relative efficacies.  The individual shRNAs targeted to the LTR, tat and nef sequences showed potent 
inhibition (>90%) of FV5 replication when present at both a high (1000 ng) and a low (100 ng) 
concentration.  Unexpectedly however, the shRNA targeted to the int gene only inhibited viral 
replication approximately 60 % even when present at a high concentration (Figure 4.6 A).  Since 
alignments showed that the siRNA sequence is perfectly complementary to the viral sequence, this 
lack of activity may be a result of inaccessibility of the target sequence.  The emergence of mutations 
within the target site or the emergence of mutations in regions outside of the target site which affect 
viral replication as a compensatory mechanism (Leonard et al. 2008) may also potentially abrogate the 
effects of the siRNA-int.   
When examining the inhibitory activity of single dual-targeting lhRNAs, lhtat-nef, comprising two 
highly effective siRNA sequences, suppressed viral replication almost completely.  The viral inhibition 
achieved by this lhRNA was stronger than that of either individual shRNA suggesting an additive effect 
of the anti-tat and anti-nef siRNAs.  The lhLTR-int dual-targeting lhRNA, comprising only one effective 
siRNA sequence, inhibited FV5 replication by approximately 50% when using a high concentration of 
hairpin.  However, no viral inhibition was observed when the hairpin was present at a lower dose 
(Figure 4.6 A).  A single effective siRNA within a lhRNA was therefore not sufficient to compensate for 
the ineffective siRNA, thus reducing the efficacy of the entire lhRNA.  
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Figure 4.6:  Inhibition of replication of an HIV-1 subtype C isolate.  (A) U87.CD4.CCR5
 
cells were 
transfected with 100 ng or 1000 ng of the indicated hairpin constructs and subsequently infected with 
the HIV-1 FV5 viral isolate at a TCID50 1000. Concentration of p24 antigen present in supernatants was 
measured 72 hours post infection.  Viral knockdown is expressed as a mean percentage p24 antigen 
of mock transfected cells ±SEM (*, p<0.05, one-way ANOVA relative to mock transfected control).  (B) 
Cell morphology of infected U87 CD4
+ 
CCR5
+ 
cells indicating degrees of protection against viral 
infection by the indicated hairpin constructs. 
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We previously showed that the second lhRNA, lhLTR-int and its encoded siRNAs are not present 
in cells transfected with the dlhRNA lhtat-nef-lhLTR-int.  However the potent lhtat-nef, placed in the first 
position of the dlhRNA was able to compensate for the inactive lhLTR-int and thus maintain silencing 
by the dlhRNA, not only at high concentrations but at low concentrations too (Figure 4.6 A).  In cells 
transfected with the dlhRNA lhLTR-int-lhtat-nef, all four siRNAs were generated in similar quantities 
and were all active as seen in Figures 4.3 and 4.5 respectively.  However lhLTR-int present in the first 
position, showed minimal RNAi activity and the inhibition observed by the dlhRNA is therefore likely to 
be a result of compensatory knockdown afforded by the effective lhtat-nef present in the second 
position of the dlhRNA.  Of interest however, is that the compensatory effect contributed by lhtat-nef 
was much stronger when this lhRNA was placed in the first position of the dlhRNA indicating that the 
lhRNA placed in the first position of this novel structure is cleaved more efficiently and thus exhibits 
stronger RNAi activity that that of the lhRNA placed in the second position of the dlhRNA.  
 The cellular protection offered by the tested hairpin constructs was also determined visually by 
observing cell morphology using standard microscopy.  Cell morphologies clearly correlated with the 
inhibitory efficacy of each of the hairpins.  Cells transfected with effective hairpin constructs displayed a 
healthy phenotype whereas where in cells where minimal RNAi activity was observed, massive cell 
destruction and pathology was clearly visible (Figure 4.6 B). 
In the event that mutations arose within the int region of the FV5 replicating strain, thus 
rendering this siRNA sequence ineffective, the protective ability of the hairpin constructs was also 
tested against the subtype B molecular clone, pNL4-3.Luc.R-E-.  Additionally, inhibition was measured 
from three different concentrations of hairpin expression cassettes to further investigate the strength of 
the compensatory effects offered by the lhtat-nef hairpin.  Knockdown of pNL4-3.Luc.R-E- was 
determined by a standard dual luciferase assay measuring Firefly luciferase values and normalizing 
them against background Renilla luciferase values.  The efficacy trend of each of the hairpin constructs 
very closely mirrored that obtained against the FV5 viral isolate (Figure 4.7).  Again shint was 
ineffective against the pNL4-3.Luc.R-E- clone as was lhLTR-int.  The potent lhtat-nef was effectively 
able to rescue the overall efficacy of the dlhRNA lhtat-nef-LTR-int, however in the context of the 
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dlhRNA lhLTR-int-tat-nef, this lhRNA could only rescue the overall efficacy of the dlhRNA when the 
dlhRNA was present at high concentrations, but this effect was clearly diminished at very low 
concentrations when we can assume negligible quantities of the second lhRNA are being processed. 
 
 
 
 
Figure 4.7:  Inhibition of an HIV-1 subtype B molecular clone.  HEK293
 
cells were transfected with 
150 ng pNL4-3.Luc.R-E- together with 750 ng (5:1 ratio); 150 ng (1:1 ratio) or 15 ng (0.1:1 ratio) of the 
indicated hairpin constructs.   Values represented are mean ratios of Firefly to Renilla luciferase 
(±SEM) expressed as a percentage of mock transfected cells (*, p<0.05, one-way ANOVA relative to 
mock transfected control). 
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4.3.5 Assessment of potential off target effects caused by exogenously introduced 
lhRNA and double-lhRNA expression cassettes in vitro  
 
Saturation of the endogenous RNAi pathway 
An important safety concern is the disruptive effect that lhRNA-based constructs may have on the 
endogenous cellular miRNA pathway (section 1.7).  Expressed lhRNA constructs require the 
endogenous RNAi machinery for their biogenesis, and competition with natural miRNA precursors for 
certain components of the pathway may occur, leading to saturation of the miRNA biogenesis pathway 
and a subsequent disruption of natural miRNA function.  To assess any such effects, two assays were 
carried out to determine saturation and the consequent derepression of both an endogenous and an 
exogenous miRNA, potentially caused by exogenously introduced RNAi sequences.  In the first assay 
potential off target effects leading to the disruption in function of the natural endogenous miR-16 were 
investigated.   The experiment was optimised for the Huh-7 cell line and these cells were co-
transfected with hairpin expression plasmids together with a psiCHECK target reporter plasmid 
containing seven copies of a miR-16 target site cloned downstream from the Renilla luciferase open 
reading frame using a method previously described (Ebert et al. 2007; Ely et al. 2009).  Endogenous 
miR-16 should be capable of inhibiting its cognate target thus causing a reduction in the Renilla:Firefly 
luciferase ratio.  Potential saturation effects caused by the co-transfected hairpin constructs will result 
in disrupted miR-16 function and reduced silencing of the reporter gene.  At a concentration of 5:1 
(lhRNA expression cassette:target reporter plasmid), none of the lhRNAs showed any saturation 
effects on the natural endogenous miRNA pathway as seen by the ability of endogenous miR-16 to 
knock down its cognate psiCHECK target in the presence of transfected hairpins.  However when the 
designed sponge, (a cassette expressing seven copies of an imperfectly matched miR-16 target) was 
co-transfected with the psiCHECK target, a disruption in miR-16 functioning, analogous to the effects 
of saturation, was clearly evident by the inability of endogenous miR-16  to no longer suppress its 
target (Figure 4.8 A).
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Figure 4.8:  Assessment of potential saturation effects of exogenously introduced hairpin 
expression cassettes on the endogenous miRNA biogenesis pathway.  (A) The effect of 
exogenously introduced hairpin expression cassettes on the function of endogenous miR-16 was 
analysed following co-transfection of a dual luciferase reporter plasmid containing 7 copies of the miR-
16 target downstream of the Renilla luciferase ORF together with the indicated hairpin expressing 
plasmids or miR-16 sponge plasmid expressing 7 copies of an imperfectly matched miR-16 target.  
Mean ratios (±SEM) of Renilla to Firefly luciferase were used to determine derepression of miR-16 (*, 
p<0.05, one-way ANOVA relative to pTZ-U6-miR16 sponge control).  (B) The effect of transfected 
hairpin expression cassettes on the function of an exogenously introduced miRNA was assessed by 
co-transfection of a plasmid expressing highly effective miR-31 HBx together with a dual luciferase 
reporter plasmid with the HBx target cloned downstream of the Renilla luciferase ORF, and increasing 
quantities of representative shRNA, lhRNA and multi-lhRNA expression cassettes.  Mean ratios 
(±SEM) of Renilla to Firefly luciferase were used to determine derepression of miR-31 HBx (*, p<0.05, 
one-way ANOVA relative to mock transfected control). 
 
Potential saturation effects were also eliminated using a second, more sensitive assay, to 
determine possible disruption in the functioning of an exogenously introduced miRNA.  HEK293 cells 
were co-transfected with an exogenous pri-miRNA expression cassette containing an effective guide 
sequence targeted to a site within the HBV genome: pCMV miR-31 HBx and its cognate target 
plasmid: psiCHECK HBx in a 1:1 ratio.  Co-transfection of these two plasmids at this ratio results in 
potent inhibition of the target as measured by the reduction in the ratio of Renilla:Firefly luciferase.  The 
pCMV miR-31 HBx pri-miRNA expression cassette was introduced at its lowest functional 
concentration, and is thus present intracellularly at lower levels than endogenous miR-16 allowing for a 
more sensitive detection of derepression.  Together with these plasmids, a representative shRNA, 
lhRNA or double-lhRNA expression plasmid was also transfected in diminishing quantities to determine 
any potential derepression as a result of exogenously introduced hairpin constructs.  U6-driven shLTR 
showed interference with miR-31 HBx mediated inhibition of its target when present at higher 
concentrations, however U6-driven lhLTR-int or U6-driven lhLTR-int-lhtat-nef showed no disruptive 
effects on the functioning of miR-31 HBx (Figure 4.8 B). 
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Induction of the type 1 interferon response 
To exclude the possibility of non-specific effects caused by the induction of a non-specific type 
1 interferon response, IFN-β mRNA concentrations were measured in transfected cells as described in 
section 2.3.6.  None of the hairpin cassettes induced expression of IFN-β as measured by quantitative 
qRT-PCR with samples normalised to GAPDH (Figure 4.9).  These results are very promising and 
suggest that expressed lhRNAs and dlhRNAs do not interfere with the natural gene regulation pathway 
nor stimulate the induction of the innate immune response in the above mentioned cell lines.   
 
 
Figure 4.9:  The potential induction of the IFN response in cells transfected with hairpin 
expression cassettes.  IFN induction was assessed by measuring IFN-β mRNA concentration in total 
RNA extracted from cells transfected with the indicated representative shRNA, lhRNA and double-
lhRNA expression cassettes or with poly I:C which served as a positive control.  Mean normalised 
ratios of IFN-β : GAPDH (±SEM) are indicated as determined by quantitative RT-PCR (*, p<0.05, one-
way ANOVA relative to poly I:C control). 
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4.4 Discussion  
 
Certain limitations exist for most combinatorial RNAi strategies used to date and long hairpin 
RNAs are no exception.  Advances in the development of a safe and efficient combinatorial RNAi 
strategy are therefore fundamentally important for the use of the RNAi pathway to inhibit rapidly 
evolving viruses such as HIV-1.  To improve on the findings described in Chapter 2 and 3, a novel 
lhRNA-based approach was designed for the simultaneous production of four siRNAs from a single 
expressed transcript.  The two highly effective and optimised dual-targeting lhRNAs: lhtat-nef +1 and 
lhLTR-int +1 (referred to as lhtat-nef and lhLTR-int respectively in this Chapter), identified in Chapter 3, 
were cloned adjacent to one another in both sequential positions to yield two double-long hairpin RNA 
(dlhRNA) structures: lhtat-nef-lhLTR-int and lhLTR-int-lhtat-nef, each driven by a single U6 snRNA 
RNA Pol III promoter.  Four unique siRNAs were easily detected following processing of the dlhRNA 
lhLTR-int-lhtat-nef, and all four siRNAs sequences were capable of highly effective knockdown of their 
cognate targets, a very encouraging result in the quest for a combinatorial system able to suppress a 
minimum of four target sites simultaneously.  Some variation was however evident in the quantities of 
the siRNAs products.   
The mechanism of processing of these dlhRNA structures is unclear.  If the PAZ domain of Dicer 
recognises the terminal 3‟ overhang (Ma et al. 2004), the lhRNA in the second position should be 
processed first, resulting in two siRNAs and a single dual-targeting lhRNA following the initial two Dicer 
cleavage reactions.  The lhRNA bi-product would then serve as a Dicer substrate for the secondary 
cleavage reactions resulting finally in four unique siRNAs.  This model is supported by the abundance 
of precursor RNA from the first position lhRNA present in the cell (Figure 4.2).  However siRNAs 
produced from the lhRNA in the first position were present at greater concentrations suggesting that 
this hairpin was processed more efficiently.  This may be a result of the lhRNA bi-product serving as a 
more favourable Dicer substrate than the dlhRNA precursor.  However this represents only one model 
for the mechanism by which these novel structures are processed.  It has been previously shown that 
efficient expression of siRNA sequences from the CMV Pol II promoter, required modification of the 
promoter such that the hairpin was positioned adjacent to the transcription initiation site (Xia et al. 
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2002).  Giering et al. also showed that the position of the hairpin relative to the transcription initiation 
site plays an important role in the RNAi activity induced by such hairpin sequences (Giering et al. 
2008).  The 5‟ end of these Pol II-expressed transcripts had a greater effect on the efficacy of the 
hairpin than the 3‟ end, which consisted of either a minimal poly (A) tail or a U1 3‟ termination box (Xia 
et al. 2002; Denti et al. 2004; Giering et al. 2008).  This suggests that the 5‟ end of hairpin sequences 
may play a stronger role in the docking of Dicer than the 3‟ 2 nt overhang present in Pol III transcribed 
hairpins, in which case the lhRNA sequence in the first position of the dlhRNA structures described in 
this Chapter should theoretically be processed first.   
The sequence of the 3‟ ends of siRNAs has been shown previously to affect the binding affinity of 
Dicer for its substrate (Vermeulen et al. 2005).  The siRNA sequence also appeared to play a role in 
the mechanism and efficiency by which these dlhRNA structures are processed.  In the case of the 
dlhRNA lhtat-nef-lhLTR-int no siRNA products or lhRNA precursor RNA was detected from the hairpin 
in the second position (lhLTR-int) suggesting a problem with processing of this specific lhRNA from 
within a dlhRNA configuration.  Since no precursor RNA was detected at all, it implies that the entire 
second lhRNA was degraded following cleavage from the first lhRNA.  Intriguing structural elements 
within dlhRNAs allow for the possibility of processing by other RNase enzymes rather than Dicer, 
which may lead to unpredictable cleavage within the hairpin stem.  However, these possibilities remain 
to be verified and further investigation into the mechanism by which dlhRNAs are processed is required 
before any such speculation can be confirmed.  
The system described in this Chapter offers a potential lhRNA-based combinatorial RNAi strategy 
for the simultaneous silencing of four gene targets without inducing any obvious cellular toxicities.  The 
unique dlhRNA structure does not appear to elicit an immune response and furthermore, the 
intracellular expression of dlhRNAs does not effect any derepression of endogenous or exogenously 
introduced miRNAs, indicative of no saturating effects on the endogenous miRNA biogenesis pathway.  
The inhibitory efficacy of this innovative construct coupled with its apparent safety suggests that it may 
be a good combinatorial RNAi candidate with which to pursue further work.  The dlhRNAs used in this 
Chapter to test such a system incorporated shRNAs sequences with variable efficacy against HIV-1.  
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Although both dlhRNA constructs mediated significant inhibition of a primary isolate, the system may 
be improved upon by incorporating only highly effective sequences.  The recent identification of a large 
panel of highly effective anti-HIV shRNAs should provide an ideal source from which to select potent 
candidates for incorporation into future dlhRNAs (McIntyre et al. 2009a).  That being said, the 
incorporation of sub-optimal RNAi effector sequences in the current dlhRNAs provided a unique 
opportunity to gain fundamental insights into the mode of action of such constructs.  It became evident 
that highly effective siRNAs within a dlhRNA are able to compensate for ineffective siRNA sequences 
and maintain inhibition of HIV replication in the short term.  This is a convenient analogy to emerging 
mutations which render single siRNA sequences ineffective.  Moreover, it suggests a possibility that 
should a mutation arise in a single target site, the emergence of viral escape mutants will be prevented 
as a result of the silencing abilities of the remaining siRNAs, a vital factor in successful combinatorial 
systems.  Although further characterisation of the processing trends of such structures is required, the 
ability of these novel double-lhRNA constructs to produce four effective siRNAs will be of significant 
value for future combinatorial antiviral therapeutic applications. 
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CHAPTER 5 
Discussion and Conclusions 
 
5.1   General Discussion  
 
The RNAi pathway has been extensively exploited for the development of therapeutic modalities.  
A wide variety of RNAi effector mimics has been designed for the successful inhibition of an array of 
disease causing genetic elements.  However, the limitation of single RNAi effectors has been clearly 
shown when these have been used against rapidly evolving targets such as HIV.  Under the selective 
pressure of a single siRNA sequence, HIV quickly develops mutations, usually within the targeted 
sequence, thus abrogating the effects of the RNAi-based therapeutic effector (section 1.9.2).  The 
rapid evolution of resistant viral strains is a major problem when using a sequence specific therapeutic 
platform such as RNAi and a combination of RNAi effector sequences is therefore required to sustain 
inhibition of viral replication in much the same way as HAART.  Successful multimerisation of single 
RNAi effector sequences into long hairpin RNA structures was described here as a possible RNAi-
based combination therapy.   
The possibility of simultaneously deriving multiple independent siRNAs from lhRNA stem duplexes 
of varying length and design was extensively investigated.  The observed trends by which hairpin 
stems were processed allowed us to gain insight into the intrinsic functionality of human Dicer.  The 
processing trends clearly implicated this enzyme as the limiting factor in multiple siRNA generation as 
a result of its inability to act efficiently as a multiple turnover enzyme in vivo.  However, thorough 
characterisation of the spatial and sequential arrangement of guide sequences within the hairpin stem 
led to the identification of an optimal design for dual-targeting lhRNAs, ensuring the efficient generation 
of two highly functional guide sequences from each hairpin stem.  The observations and conclusions 
drawn from Chapters 2 and 3 have greatly expanded upon the limited body of knowledge surrounding 
the capacity of lhRNAs to act as effective combinatorial RNAi precursors.  Furthermore, the powerful 
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dual-targeting lhRNAs that were identified formed the foundation upon which the novel combinatorial 
double long hairpin structure was built.  
To facilitate the development of a combinatorial RNAi strategy incorporating the structurally and 
sequentially optimised dual-targeting lhRNA species described in Chapter 3, a novel multiplexed 
double long hairpin RNA (dlhRNA) structure was described.  The dlhRNA structure amalgamates the 
insight gained in Chapters 2 and 3 surrounding the properties of lhRNAs, into a unique lhRNA-based 
construct, which meets all the demands of a combinatorial RNAi-based therapy.  Two effective dual-
targeting lhRNAs were successfully tethered together under the control of a single Pol III promoter.  
The design of dlhRNAs is akin to that of engineered polycistronic transcripts (Chung et al. 2006) in that 
two hairpin structures are arranged in tandem within a single transcript.  However, dlhRNA constructs 
contain no specific flanking regions, and furthermore, each hairpin incorporates the sequences of two 
effective guide strands instead of only one.  Although further work is required to deduce the exact 
mechanism by which this novel RNA structure is processed, the PAGE northern blot data in Figure 4.2, 
when compared to that in Figure 3.6, suggest that this combinatorial RNAi precursor is processed by 
the endogenous RNAi machinery.  Optimised dlhRNAs not only encompass the properties of 
previously described combinatorial RNAi platforms, but in addition include added features not yet 
described in multiplexed RNAi approaches.  This unique configuration allows for the generation of four 
highly active RNAi guide sequences, which in turn are able to target four independent sites within the 
HIV-1 genome for specific inhibition.  This strategically correlates with the number of targeted genes 
predicted to prevent the emergence of viral escape mutants (Leonard and Schaffer 2005; ter Brake et 
al. 2008).  In addition, when dlhRNAs are efficiently processed, the active guide strands derived from 
dlhRNAs are generated in similar quantities unlike the unpredictable quantities of guide strands 
generated from polycistronic miRNA shuttles; or the variable quantities derived from multiple shRNAs 
expressed from different promoters.  The incorporation of four powerful siRNA sequences into a 
dlhRNA will thus enable equal and potent knockdown of all four targeted genes.  However since the 
siRNA sequence appears to play a role in dlhRNA processing, ongoing work aims to determine a set of 
parameters which will ensure consistent processing of these structures.  Finally dlhRNA precursors are 
expressed from a single RNA Pol III promoter, thus reducing the risk of cellular toxicities and saturation 
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effects potentially caused by multiple Pol III expression cassettes, and eliminating the possibility of 
promoter occlusion. 
The dlhRNA design therefore shows promise as a novel combinatorial RNAi strategy and further 
work which will characterise and optimise this unique system is worth pursuing.  It now remains to be 
tested whether dlhRNAs will be able, as suggested, to suppress viral replication in the long term, 
without the emergence of viral escape mutants.  Encouraging results in Figures 4.6 and 4.7 do 
however imply that in the event of arising mutations in one or even two target sequences, 
compensatory effects will ensure the maintenance of viral inhibition.  To determine the ability of 
dlhRNA constructs to counteract the emergence of viral escape mutants, future work will include 
cloning dlhRNA expression cassettes into a suitable lentiviral delivery vector (discussed in section 5.2), 
which will be used to transduce an appropriate cell line for the stable expression of these antiviral 
constructs.  Transduced cells will be infected with HIV-1 and monitored for viral breakthrough for 6-8 
weeks by measuring viral RNA production or CA-p24 levels, in a similar procedure to those used to 
determine viral escape from single lhRNAs/e-shRNAs (Sano et al. 2008; Liu et al. 2009). In the event 
of viral breakthough, proviral DNA will be isolated from infected cells and the target sequences will be 
amplified, cloned into a suitable plasmid and sequenced to determine the genotypic variations of 
escape mutants.  Hairpins encoding two and three siRNAs have been shown to suppress viral 
replication for 48 and 49 days respectively, demonstrating their distinct advantage over single shRNAs, 
to which the virus quickly became resistant (Sano et al. 2008; Liu et al. 2009).  Although hairpins 
encoding two siRNAs have been observed to inhibit HIV-1 replication more potently than hairpins 
encoding three siRNAs (Liu et al. 2009), the latter hairpins provide an advantage against viral escape 
since they target a third site, thus making escape more difficult.  However, when challenged with a 
higher viral dose, replication was detected even in cells containing a hairpin encoding three unique 
siRNAs (Liu et al. 2009), thus highlighting the importance of a combinatorial RNAi system able to target 
four unique sites.  An intriguing point to note is that although viral breakthrough was eventually 
detected, viral escape mutations were scattered and did not emerge as the dominant genotype (Liu et 
al. 2009).  Although this observation highlights the fact that HIV is able to escape by multiple routes, it 
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also suggests that in the event of emerging escape mutants; the fitness of these variants may be 
compromised. 
Further measures to prevent the emergence of drug resistant viral strains may require the 
investigation of novel combination therapies.  Given the success of HAART, the combination of lhRNA-
based therapeutic effectors together with antiretroviral drugs may be an option worth exploring.  
Alternatively, the combination of dlhRNAs with alternative anti-HIV gene therapy modalities such as 
ribozymes, RNA decoys, transdominant rev proteins or U1 adaptors (Rossi et al. 2007; Reyes-Darias 
et al. 2008) remains a viable option.  Nonetheless, for the potential of lhRNA-based combinatorial RNAi 
strategies, alone or as a component of a novel combination therapy, to be eventually realised in a 
clinical setting, two main focus areas still require a substantial amount of characterisation, namely the 
optimisation of in vivo delivery and ensuring the safety of such constructs. 
 
5.2   Potential delivery vectors for lhRNA constructs 
 
RNAi-based therapeutic applications require effective delivery platforms so that effector 
sequences may reach their target cells or tissues.  An array of delivery strategies has been extensively 
investigated and include both viral and non-viral delivery vectors.  Non-viral strategies have largely 
been used for the delivery of synthetic siRNA molecules and include but are not limited to cholesterol 
conjugates; polycation nanoparticles; positively charged antibodies and RNA aptamers [reviewed in 
(Castanotto and Rossi 2009; Whitehead et al. 2009)].  Expressed RNAi sequences are typically 
delivered within the backbone of viral vectors which are based on RNA viruses such as retroviruses 
and lentiviruses; or DNA viruses which include Herpes Simplex Virus, Adenovirus and 
Adenoassociated virus [reviewed in (Gonzalez-Rojas et al. 2010)].  HIV causes a chronic infection and 
thus requires long term treatment regimens to control viral loads.  The lhRNA-based constructs 
described in this thesis need to be stably expressed to achieve effective viral suppression.  Viral 
vectors, more specifically retrovirus based vectors, have therefore become the delivery vehicles of 
choice to deliver anti-HIV therapeutic effectors because of their inherent capabilities of integrating into 
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the host genome for the stable expression of transgenes.  Lentiviral vectors are largely based on HIV, 
and this class of vectors has been widely used for the delivery of RNAi effector precursors as a result 
of their low immunogenicity; their ability to infect both dividing and non-dividing cells; and their efficient 
integration into host chromosomes which results in the stable long term expression of the delivered 
transgene [reviewed in (Vigna and Naldini 2000)].   
Several major safety concerns exist for the use of HIV based delivery vectors and include the 
emergence of replication competent recombinants, recombination events with wild type HIV and the 
oncogenic potential of integrating vectors.  These concerns have led to a number of advances in the 
biosafety features of these vectors (Dull et al. 1998; Kim et al. 1998; Zufferey et al. 1998), resulting in a 
safe and efficient HIV-1 based lentiviral vector strategy.  However the incorporation of anti-HIV RNAi 
effector sequences leads to additional complications since viral sequences within the vector may 
become targets for the encoded siRNA sequences, leading to impaired vector production (ter Brake 
and Berkhout 2007).  Encoded shRNAs have been shown to reduce transduction titers by targeting 
sequence elements within the HIV-1 vector backbone and more commonly sequences within the Gal-
Pol transcript.  The use of human codon-optimised Gag-Pol sequences is however able to largely 
abrogate interference of vector production caused by siRNA sequences targeted to sites within this 
transcript (Kotsopoulou et al. 2000; ter Brake and Berkhout 2007).  The inhibition of Dicer using anti-
Dicer siRNAs (Poluri and Sutton 2008) or the saturation of the RNAi machinery with an excess of 
random shRNAs (Liu et al. 2009) in the packaging cell line have also effectively overcome titer-related 
issues.  Another approach to prevent vector targeting is to use non-primate lentiviral vectors such as 
feline immunodeficiency virus (FIV) (Poeschla et al. 1998) which are prepared by a similar method to 
HIV-based vectors, but bear little sequence homology with HIV and thus are resistant to the effects of 
anti-HIV RNAi sequences.  It is also possible to use heterologous packaging to circumvent the 
restriction of antiviral targets, whereby HIV-1 vectors are efficiently packaged by FIV (Morris et al. 
2004b). 
Not only do lentiviral vectors serve as delivery vehicles for RNAi-based therapies, but it has been 
speculated that they may also provide a secondary means of protection against HIV infection.  These 
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HIV-derived vectors have been termed conditionally replicating HIV lentiviral vectors and are capable 
of competing with wild type HIV in infected cells for both regulatory proteins such as Tat and Rev as 
well as for encapsidation (Dropulic et al. 1996; Bukovsky et al. 1999).  These vectors are thus targeted 
to cells naturally infected with the virus and, in addition, this process reduces viral infection and spread, 
and results in vector mobilization enabling the spread of the vector to surrounding cells (Morris and 
Looney 2005).  Although this may seem like an attractive strategy, the phenomenon does not occur 
with self-inactivating (SIN) vectors and therefore raises the initial safety concerns of lentiviral vectors. 
Significant advances in the efficiency and safety of lentiviral vectors have in recent years been 
made, and in addition, strategies to overcome the inhibition of HIV-1-based lentiviral vectors by anti-
HIV siRNA sequences have been successfully developed.  Single anti-HIV long hairpin RNAs/e-
shRNAs have been effectively packaged into lentiviral vectors to mediate long-term gene silencing in 
transduced cell lines (Sano et al. 2008; Liu et al. 2009). Nevertheless, optimised vectors for the 
delivery of complex combinatorial RNAi systems, such as those described in Chapter 4, will 
necessitate further exploration. 
 
5.3   Future safety endeavors for lhRNA expression cassettes 
 
The use of RNA Pol III promoters to drive the expression of RNAi effector mimics offers many 
advantages, and they are thus the promoters of choice (section 1.6.2).  Nevertheless, several major 
drawbacks have been associated with the strong ubiquitous expression of Pol III transcripts and have 
been previously discussed (section 1.7.3).  Although the lhRNA constructs described in this work 
showed no evidence of saturating the endogenous miRNA biogenesis pathway, every endeavor to 
minimize the effective dose of expressed RNAi effectors should be undertaken.  A further safety 
concern related to RNAi-based therapeutics is the potential sequence specific off target effects 
mediated by partial complementarity of therapeutic effectors or their passenger strands, and cellular 
hexanucleotide mRNA sequences (Lewis et al. 2005; Birmingham et al. 2006; Jackson et al. 2006) 
(section 1.7.2).  Off target effects are further complicated by combinatorial RNAi systems where the 
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generation of multiple guide sequences increases the risk of non-specific gene silencing.  Furthermore, 
the inconsistency of the exact position of Dicer cleavage may result in slightly shifted guide sequences 
which serve to further increase the pool of guide strands, thus making the prediction of potential off 
target effects an almost impossible task.   
A major advantage of the multimeric pri-miRNA shuttle combinatorial RNAi system, is its 
expression from RNA Pol II promoters, which enables inducible and tissue-specific expression.  
However, the use of alternative Pol III promoters, such as tRNA promoters, to drive lhRNA expression 
may also possibly alleviate certain non-specific effects.  The tRNA family of promoters has been 
successfully used to drive expression of modified tRNA transcripts containing shRNA encoding 
sequences at their 3‟ termini (Boden et al. 2003b; Kawasaki and Taira 2003; Scherer et al. 2007).  
tRNA promoter-driven shRNAs are efficiently exported form the nucleus and effect target inhibition at 
similar or in some cases even enhanced levels to that of U6 or H1-expresed shRNAs (Boden et al. 
2003b).  tRNA transcripts are processed within the nucleus prior to export and it remains uncertain 
whether attached shRNAs are removed from the chimeric transcript by tRNAseZ
L 
within the nucleus as 
suggested by recent evidence (Bogerd et al. 2010), or whether Dicer is responsible for processing the 
shRNA from the transcript in the cytoplasm.   A distinct advantage of tRNA-shRNA systems is that the 
nuclear karyopherin exportin-t is responsible for exporting tRNA products from the nucleus to the 
cytoplasm (Arts et al. 1998; Kutay et al. 1998).  The potential export of shRNAs still attached to tRNAs 
by an alternative karyopherin to exportin-5 may circumvent the risk of saturating the natural miRNA 
nuclear export factor.  Alternatively, the strong and ubiquitous Pol II U1 snRNA promoter has been 
used to effectively drive the expression of shRNAs (Denti et al. 2004).  Furthermore, U snRNAs are 
exported from the nucleus by CRM1 (Fornerod et al. 1997) and this system therefore offers another 
approach to overcome saturation of the RNAi pathway at the point of nuclear export. 
It is also possible to make use of inducible RNA Pol III promoters which have enabled the 
development of conditional RNAi systems, thus allowing for the spatial and temporal regulation of gene 
silencing.  The development of an inducible Pol III promoter was initially demonstrated by Ohkawa and 
Taira who constructed an inducible derivative of the RNA Pol III U6 snRNA promoter to drive the 
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expression of an antisense RNA (Ohkawa and Taira 2000).  The tet operator-repressor system which 
was well characterised in Pol II systems was adopted for the development of an inducible Pol III 
system.  The tetracycline operator sequence (tetO) was inserted within the U6 promoter at different 
positions but was found to function effectively only when positioned between the TATA box and the 
transcription start site.  This construct was then introduced into Hela cells expressing the Tet repressor 
(tetR) which, binds to tetO and blocks transcription in the absence of tetracycline.  The addition of 
tetracycline thus results in the dissociation of tetR and the consequent transcription of the downstream 
sequence.  This system represents a straight forward, rapid and reversible mechanism for the 
regulation of gene silencing afforded by Pol III-expressed RNAi effector sequences and was first 
employed for the expression of shRNAs by van der Wetering et al. to silence β-catenin in a colorectal 
cancer line cell (van de Wetering et al. 2003).  The tetO sequence was inserted downstream of the 
TATA box of the H1 Pol III promoter and shRNA expression was derepressed by the addition of 
doxycycline.  This method has since also been used to drive a number of siRNA sequences under the 
control of the U6 (Czauderna et al. 2003b; Matsukura et al. 2003) as well as the 7SK Pol III promoters 
(Czauderna et al. 2003b).  This simple design has also been expanded upon and one such example 
was the construction of a lentiviral vector containing Tet-inducible U6 or H1 driven siRNA sequences 
targeted against Drosha or PKR, as well as CMV-driven tetR within the same all in one vector 
(Aagaard et al. 2007).  Although this strategy offers a convenient approach for inducible RNAi, 
sustained basal promoter activity results in a “leaky” system and furthermore, this strategy offers no 
capacity for cell or tissue specific expression.   
Fritsch et al. first reported the use of the CRE-lox-based approach for the inducible expression of 
H1-siRNA precursors (Fritsch et al. 2004).  To prevent any alteration of the promoter sequence a 
neomycin cassette flanked by two lox sites was inserted between the sense and antisense strands of 
the siRNA.  The neomycin sequence contained a termination signal preventing the transcription of full 
transcript.  Upon addition of CRE recombinase, the neomycin cassette is eliminated and the remaining 
lox site acts as a loop sequence between the sense and antisense strands.  The CRE-lox approach for 
conditional RNAi has been used for both the U6 and H1 Pol III promoters and the neomycin sequence 
may be replaced with any stuffer sequence (Kasim et al. 2004; Tiscornia et al. 2004; Ventura et al. 
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2004).  Furthermore it has been shown that the lox-flanked cassette may also be inserted within the 
promoter between the distal and proximal site enhancers, thereby disrupting promoter activity 
(Coumoul et al. 2004).  This strategy enables tight regulation of shRNA expression and tissue specific 
regulation has been shown in mice stably expressing CRE recombinase in certain cell populations 
(Coumoul et al. 2005), thus providing a platform for simultaneous regulation of gene silencing, both 
temporally and spatially.  The drawback of this strategy however, is that the effects are largely 
irreversible, and in a therapeutic setting, the delivery of CRE recombinase to human cell populations 
for stable expression is not feasible. 
The inducible expression systems described above have largely been used to investigate loss of 
function phenotypes in controlled cell populations.  The potential of these systems to be manipulated 
for the controlled expression of RNAi-based therapeutic modalities in diseased cell populations 
remains an attractive possibility but which requires further characterisation.  A clinically relevant 
inducible expression system has been described which makes use of a chimeric promoter comprising 
the RNA Pol II HIV LTR promoter fused to a minimal hsp70 promoter (Unwalla et al. 2004; Unwalla et 
al. 2006).  The chimeric promoter is induced by Tat in HIV-infected cells, which binds to the TAR loop 
within the LTR promoter thereby recruiting PTEF-b to the promoter for the activation of transcription 
from the hsp70 promoter.  The use of this system to drive expression of anti-HIV shRNAs results in an 
inducible therapeutic modality which is naturally activated only in HIV-infected cells.  The incorporation 
of lhRNA-based combinatorial RNAi expression cassettes into a relevant and effective inducible 
expression system, coupled with an efficient delivery platform, may ultimately lead to a clinically 
relevant gene therapy. 
 
5.4   Pre-clinical and clinical gene therapy  
 
Given the associated safety concerns with RNAi-based therapies related to potential induction of 
an interferon response, the saturation of components of the endogenous miRNA biogenesis pathway, 
possible sequence-related off target effects, and delivery vector biosafety, a thorough pre-clinical 
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assessment of the efficacy and safety of combinatorial RNAi systems is absolutely essential.  
Experiments to exclude such non-specific effects in cell culture models in vitro are relatively straight 
forward and were described in section 4.3.5.  The problem lies in the lack of a physiologically relevant 
animal model in which to perform pre-clinical evaluation studies of anti-HIV therapeutics.  However in 
recent years, several mouse models have been developed which are appropriate for in vivo testing.  
Anti-HIV gene therapies may be administered through adoptive T cell immunotherapy, whereby T cells 
are isolated from a patient and subsequently transduced ex vivo with a viral vector carrying the 
therapeutic effector.  Transduced T cells are then expanded before re-infusion into the patient.  
However the use of this technology against HIV has achieved variable success [reviewed in (Varela-
Rohena et al. 2008)].   
A more popular approach has been the ex vivo transduction of enriched populations of CD34+ 
haematopoietic stem cells for a protective immunotherapy.  The first such study initially investigated 
whether haematopoietic stem cells (HSC) transduced with a lentiviral vector carrying a Pol III-
expressed anti-rev siRNA, were able to retain their ability to differentiate into mature T lymphocytes 
and macrophages which are the primary targets of HIV infection (Banerjea et al. 2003).  Not only were 
the transduced stem cells able to mature into both T cells and macrophages, but the macrophages 
derived from the transduced stem cells were resistant to HIV infection in vitro.  Furthermore, 
transduced CD34+ cells were engrafted into severe combined immunodeficiency (SCID-hu) mice in 
order to reconstitute the thymocyte population absent in this mouse model.  Normal maturation 
patterns of thymocytes were observed and when this cell population was challenged ex vivo with HIV, 
T cells showed protection against the virus.  This fundamental study therefore showed that the 
reconstitution of a functional and protected immune system in vivo is possible, and suggests that a 
similar strategy could be adopted in humans.  More recently, new and improved humanized mouse 
models have been developed and studied (Legrand et al. 2006).  The human immune system (HIS) 
BALB/c RAG-2
-/-
γc
-/-
 mouse model which is a recombination activating gene (RAG) deficient mouse 
strain that also lacks the cytokine receptor gamma chain, efficiently sustains the development and 
maturation of all lymphoid cellular compartments and thus enables the experimentation with human T 
cells.  Recently this model was used to engraft CD34+ HSC transduced with a lentiviral vector carrying 
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an shRNA targeted against nef (ter Brake et al. 2009).  Following differentiation, mature CD4+ T cells 
were infected with HIV-1 ex vivo, and potent viral inhibition was observed, suggesting the successful 
reconstitution of HIV-1 resistant T cells.   Although further experiments to challenge mice with HIV in 
vivo are still required, the use of murine models of HIV infection has led to significant progress in the 
development of clinically relevant RNAi-based therapeutics. 
A little over ten years since the discovery of the RNAi pathway, clinical trials harnessing RNAi 
effector mimics for the treatment of a wide range of diseases are already well underway (Castanotto 
and Rossi 2009).  The first RNAi-based clinical trial for the treatment of HIV is currently in progress. 
This Phase I trial is being conducted at The City of Hope National Medical Center in Duarte, California.  
A lentiviral vector containing three therapeutic modalities, one being a Pol III-expressed shRNA 
targeting the tat/rev common exon of HIV, was used for the efficient transduction of haematopoietic 
stem cells.  Transduced cells were capable of differentiating into mature lymphocyte lineages upon 
engraftment into SCID-hu murine models, and furthermore, showed long-term resistance to HIV 
infection (Li et al. 2005; Li et al. 2006; Anderson et al. 2007).  During the clinical trial, transduced stem 
cells were infused into four HIV positive individuals by autologous bone marrow transplantation for the 
treatment of AIDS related-lymphoma.  This trial, of which the outcome is eagerly awaited, is a 
fundamental step forward in the race to deliver RNAi-based anti-HIV therapies in the clinic. 
 
5.5 The complex interplay between HIV infection and the RNAi pathway 
 
Expanding evidence suggests that an intricate relationship naturally exists between viral 
infection and the RNAi pathway.  Intriguing data have shown that a number of viruses may either 
exploit the RNAi pathway to their advantage or alternatively activate mechanisms which repress the 
pathway.  Furthermore, the expression levels of both viral and host derived miRNAs may be modulated 
during viral infection for host or viral gene regulation (Berkhout and Haasnoot 2006) and these factors 
should be considered when developing RNAi-based antiviral strategies. 
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Infection by HIV is not exempt from these observations and has been shown to interfere with 
components of the RNAi machinery for its own advantage.  It may therefore be important to determine 
the effect of anti-HIV lhRNA-based therapeutic modalities on this natural interplay.  The HIV Tat protein 
is able to directly interact with the helicase domain of Dicer and thus reduce processing of siRNA 
precursors in vitro (Bennasser and Jeang 2006).  TRBP is an essential co-factor of Dicer 
(Chendrimada et al. 2005; Haase et al. 2005), yet this protein also binds to the TAR loop within the 
viral LTR to mediate transcriptional activation (Gatignol et al. 1991; Christensen et al. 2007).  It was 
shown that ectopic expression of viral TAR RNA is able to sequester TRPB thus inhibiting RNAi 
(Bennasser et al. 2006).  However since the RNAi pathway is still functional in cells infected with HIV, it 
is unlikely that the competition for TRBP represents a critical inhibitory factor.  Moreover the TAR loop 
itself may act as a DICER substrate, although the role of this putative miRNA-like structure remains 
unknown (Klase et al. 2007; Ouellet et al. 2008).  Besides the TAR loop acting as an alleged miRNA, 
HIV has been proposed to encode a miRNA precursor within its nef gene.  The encoded miR-N367 
targets a site at the 3‟ end of nef which overlaps the U3 region of the viral LTR and is thought to play a 
role in transcriptional regulation of the virus (Omoto et al. 2004; Omoto and Fujii 2005). 
Cellular miRNAs have also been implicated in the HIV-RNAi interaction.  The polycistronic 
miRNA cluster miR-17/92 is seen to be downregulated in HIV-infected cells.  The histone 
acetyltransferase P300/CBP-associated factor (PCAF) is a co-factor for Tat and plays a role in 
processive viral transcription.  Intriguingly, PCAF is a target for miR-17-5p and miR-20a, which are two 
miRNA components of the miR-17/92 cluster, suggesting an intricate interplay between HIV replication 
and miRNA-mediated gene regulation of host factors (Triboulet et al. 2007).  Two more cellular 
miRNAs, miR-29a and miR-29b, are also involved in the regulation of viral replication (Ahluwalia et al. 
2008; Nathans et al. 2009).  These two miRNAs target a conserved site within the viral nef gene 
(Ahluwalia et al. 2008) and miR-29a has been shown to suppress HIV replication through accumulation 
of viral mRNA in P-bodies (Nathans et al. 2009). 
Finally, it has been proposed that the interaction between HIV and the RNAi pathway may also 
contribute to the multifaceted mechanism underlying viral latency (discussed in section 1.8.5).  In 
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resting CD+ T cells harbouring latent HIV, a cluster of five cellular miRNAs have been shown to be 
upregulated (Huang et al. 2007).  These enriched cellular miRNAs inhibit HIV-1 protein translation 
through interactions with the 3‟ end of viral mRNA transcripts and therefore appear to play a pivotal 
role in HIV latency.  The use of a panel of miRNA inhibitors effectively facilitated viral production in 
resting T cells and may potentially be used to aid in the purging of latent reservoirs (Han and Siliciano 
2007; Huang et al. 2007).  It is obvious from the studies described above that an RNAi-based HIV-host 
relationship exists, yet a better understanding of this interplay at the molecular level is imperative for 
the development of enhanced RNAi-based antiviral therapeutics. 
 
5.6   Concluding remarks   
The field of RNAi has grown substantially in recent years.  This pathway has not only had a 
profound effect on functional genomics studies but moreover, has provided scientists with an exciting 
new tool with which to develop novel therapeutics.  It is therefore no surprise that the discoverers of 
this fundamental gene regulation pathway, Andrew Fire and Craig Mello, were awarded the 2006 
Nobel Prize in Physiology or Medicine.  Interest in this field has continued to grow and so has the 
number of strategies used to exploit the effector molecules of this pathway.  Mimics of intermediate 
RNAi effectors have diversified over the years and have recently included structures which enable the 
silencing of multiple targets simultaneously.  Analogous to the combination therapy which constitutes 
HAART, combinatorial RNAi strategies have also been manipulated for the treatment of HIV.  This 
thesis has focused on one such strategy, namely that of Pol III-expressed long hairpin RNAs, for the 
simultaneous derivation of multiple non-contiguous RNAi effector sequences.  These constructs were 
extensively characterised and subsequently incorporated into a novel double long hairpin RNA 
structure, ideally suited for the long term inhibition of HIV gene expression and replication.  The 
development of dlhRNAs has aimed to resolve many issues and limitations associated with current 
combinatorial RNAi approaches and although further improvement of the this novel approach is 
imminent, the foundation has been laid for the development of dlhRNA-based therapeutic modalities 
for the treatment not only of HIV, but of other viruses, particularly those with high rates of mutation 
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such as HCV.  The work described in this thesis has substantially contributed to the ultimate 
achievement of an RNAi-based combinatorial therapy for the sustained inhibition of HIV.  
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APPENDIX 
 
A1 Laboratory Procedures 
 
A1.1 E.coli Transformation of competent DH5α E.coli 
 
A1.1.1 Competent DH5α 
DH5α E.coli cells were grown to mid log phase in Luria Bertani broth (LB) [10 g/l Bacto-Tryptone 
(Oxoid, Hampshire, UK); 5 g/l Bacto Yeast extract (Oxoid, Hampshire, UK); 10 g/l sodium chloride 
(NaCl) (Merck, Darmstadt, Germany) dissolved in dH2O and autoclaved at 121°C for 25 min at 1 
kg/cm
2
].  Cells were collected by centrifugation at 3 000×g for 15 min, resuspended in 5 ml PIPES 
transformation buffer (100 mM CaCl2, 10 mM PIPES-Cl and 15% glycerol, pH 7.0, autoclaved and 
stored at -20°C), and incubated on ice for 20 min.  Cells were collected by centrifugation at 1 000×g for 
10 min, resuspended in 2 ml PIPES transformation and dispensed into 100 µl aliquots for storage at -
70°C. 
 
A1.1.2 Transformation 
A 100 µl aliquot of competent DH5α was thawed on ice and approximately 0.5 µg plasmid DNA or 
7 µl ligation reaction was added, gently mixed and incubated on ice for 30 min.  Samples were then 
heat shocked at 42°C for 90 sec and returned to ice for a further 5 min.  Positive transformants were 
selected by overnight growth at 37°C, on LB agar plates containing 100 µg/ml ampicillin. 
For blue-white screening, ampicillin positive LB agar plates were spread with a volume of 40 µl of 
5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal) (20 mg/ml stock in dimethyl formamide; 
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Sigma, MO, USA), and a volume of 8µl of Isopropyl-β-D-1-thiogalactopyranoside (IPTG) (100 mg/ml 
aqueous solution; Roche, Germany).  Plates were air-dried at 37°C for 20 min and stored at 4°C. 
 
A1.2 Plasmid purification 
A1.2.1 Small-scale preparations of purified plasmid 
Small-scale purification of plasmid DNA was carried out using the High Pure Plasmid Isolation Kit 
for small-scale (mini) preparations of purified plasmid DNA (Roche, Germany).  LB broth (3 ml) 
containing 100 µg/ml ampicillin was inoculated with a single transformed colony and incubated 
overnight at 37°C with shaking.  Cultures were centrifuged at 3 000×g for 10 min, the supernatant was 
discarded and pellets were resuspended in 250 µl Suspension Buffer (50 mM Tris-HCl, 10 mM EDTA, 
pH 8.5 at 25°C) containing 2.5 mg RNase A.  Once resuspended, 250 µl Lysis Buffer (0.2 M NaOH and 
1% SDS) was added to the bacterial cells, incubated for 5 min at room temperature and then 350 µl 
chilled Binding Buffer (4 M guanidine hydrochloride, 0.5 M potassium acetate, pH 4.2) was added, 
incubated on ice for 5 min and centrifuged at maximum speed for 10 min.  The supernatant was 
transferred to a High Pure filter tube and centrifuged at maximum speed for 1 min.  The flowthrough 
was discarded and 700 µl Wash Buffer II (20 mM NaCl, 2 mM Tris-HCl, pH 7.5 at 25°C) was added 
and again centrifuged at maximum speed for 1 min.  An additional 1 min centrifugation step was 
carried out following discarding of flowthrough and then 100 µl Elution Buffer (10 mM HCl, pH 8.5 at 
25°C) was added to the filter tube, which was centrifuged at maximum speed for 1 min to elute the 
purified plasmid DNA into a nuclease-free tube. 
 
A1.2.2 Large-scale preparations of purified plasmid 
Large-scale preparation of plasmid DNA was carried out using the QIAGEN Plasmid Maxi Kit 
(QIAGEN, CA, USA).  Approximately 200 ml LB broth was inoculated with a single transformed colony 
and incubated overnight at 37°C with shaking.  Cultures were centrifuged at 3 000×g for 30 min and 
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bacterial pellets were resuspended in 10 ml Buffer P1 (50 mM Tris-HCl, pH 8.0; 10 mM EDTA) 
containing 100 µg/ml RNase A at a concentration of 100 µg/ml.  Ten milliliters of Buffer P2 (200 mM 
NaOH; 1% SDS) was added to bacterial suspensions, mixed thoroughly and incubated at room 
temperature for 5 min.  Ten milliliters of Buffer P3 (3 M Potassium acetate, pH 5.5) was then added to 
the lysate mixed thoroughly and transferred to a QIAfilter Cartridge and incubated for 10 min at room 
temperature.  A QIAGEN-tip 500 was equilibrated by adding 10 ml Buffer QBT (750 mM NaCl; 50 mM 
MOPS, pH 7.0; 15% Isopropanol; 0.15% Triton® X-100) to the column and allowing it to drain through 
the column by gravity flow.  The lysate from the QIA filter cartridge was then passed through the 
equilibrated column.  The column was washed twice with 30 ml Buffer QC (1 M NaCl; 50 mM MOPS, 
pH 7.0; 15% Isopropanol) and then the DNA was eluted with 15 ml Buffer QF (1.6 M NaCl; 50 mM 
MOPS, pH 7.0; 15% Isopropanol).  The DNA was precipitated by adding 10.5 ml isopropanol and 
centrifugation at 5 000×g for 60 min at 4°C.  The pellet was air dried for 5-10 min and then 
resuspended in 100-200 µl nuclease-free water. 
 
A1.3 DNA purification from agarose gels 
DNA was extracted from agarose gels using the MinElute
TM
 Gel Extraction kit (QIAGEN, CA, 
USA).  DNA bands were excised from agarose gels and 3× volume of Buffer QG (composition not 
provided) was added to the gel fragment which was subsequently dissolved at 50°C.  One volume of 
isopropanol (Merck, Darmstadt, Germany) was then added and the solution was transferred to a 
QIAquick spin column and centrifuged for 1 min at maximum speed.  The flow through was discarded 
and 500 µl Buffer QG was added to the column and centrifuged again at maximum speed for 1 min.  
The flow through was again discarded and 750 µl Buffer PE (wash buffer, composition not provided) 
was then spun through the column.  The column was then transferred to a clean tube and 10 µl Buffer 
EB (elution buffer, 10 mM Tris-HCl pH 8.5) was added to the column which was then centrifuged for 1 
min at maximum speed to elute the purified DNA.  
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A1.4 Cell culture 
The HEK293 and Huh7 cell lines were maintained in Dulbecco‟s modified Eagle‟s medium (DMEM), 
(BioWhittaker, MD, USA) supplemented with 10% heat inactivated fetal calf serum (FCS), (Delta 
Bioproducts, Johannesburg, SA) at 37°C and 5% CO2.  U87.CD4.CCR5 cells were maintained in 
DMEM supplemented with 15% FCS; 1 µg/ml puromycin; 300 µg/ml G418; 100 U/ml penicillin; 100 
µg/ml streptomycin; and glutamine at 37°C and 5% CO2. 
Cells were cultured in 75 cm
2
 tissue culture flasks and were passaged every 3-4 days upon 
reaching 80-90% confluency.  HEK293 cells were subcultured using phosphate buffered saline (PBS) 
(Gibco, BRL, UK) containing 0.01% EDTA.  Culture medium was aspirated from the tissue culture 
vessel and 2-3ml saline was used to gently detach and suspend the cells.  Huh7 and U87.CD4.CCR5 
cells were passaged with 0.5× trypsin-EDTA solution (Gibco, BRL, UK).  Culture medium was 
aspirated from the tissue culture vessel and cells were washed once with 3ml PBS before adding 1 ml 
trypsin-EDTA to the cells.  Cells were then incubated at 37°C for approximately 5 minutes or until cells 
started to lift.  Cells were gently suspended and an equal volume of medium was added to inactivate 
the trypsin.  Cells were split to 20-30% confluency and 15 ml fresh medium was added to each 75 cm
2
 
flask. 
 
A1.5 Transfections 
Cells were seeded 24 hours prior to transfection by counting cells using the dye-exclusion 
haemocytometer method.  A representative sample of the cells to be seeded was stained with trypan 
blue and counted on a haemocytometer.  The number of viable cells in the sample was then calculated 
and seeded accordingly.  In a 24-well tissue culture plate, HEK293 cells were seeded at 120 000 cells 
per well, Huh7 cells were seeded at 100 000 cells per well and U87.CD4.CCR5 cells were seeded at 
50 000 cells per well in a volume of 500 µl of antibiotic-free medium.  
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Cells were transfected using Lipofectamine
TM
 2000 (Invitrogen, CA, USA) and OptiMEM (Gibco, 
BRL, UK).  One microlitre of Lipofectamine
TM
 2000 was used per µg of DNA transfected and the total 
volume of DNA/ Lipofectamine
TM
 2000/OptiMEM was equal to one fifth of the total volume of plating 
medium.  For a single well in a 24-well tissue culture dish, 1µg of DNA was added to 50 µl of OptiMEM 
in a microfuge tube.  In a separate tube 1 µl Lipofectamine
TM
 2000 was added to 50 µl OptiMEM.  Each 
solution was incubated at room temperature for 10 min and then the Lipofectamine
TM
 2000/OptiMEM 
mixture was added to the DNA/OptiMEM mixture and incubated at room temperature for a further 20 
min.  The DNA/ Lipofectamine
TM
 2000/OptiMEM mixture was then added to the cells.  Total volumes 
were calculated and master mixes were prepared for each triplicate transfection.  The number of cells 
plated, the volume of plating medium, the quantity of DNA transfected and the amount of 
Lipofectamine
TM
 2000/OptiMEM used was adjusted according to the surface area of the tissue culture 
vessel that cells were seeded in. 
 
A1.6 RNA extraction from mammalian cells 
Culture medium was aspirated off cell cultures and 1 ml TriReagent
TM 
(Sigma, MO, USA) was 
added to each 60 cm
2
 dish and incubated for 5 min at room temperature.  Cell lysates were added to 
1.7 ml eppendorf tubes containing 200 µl chloroform (Merck, Darmstadt, Germany), vortexed and 
centrifuged at 13 000 rpm for 30 min at 4°C.  The clear top layer of the supernatant was removed and 
an equal volume of isopropanol (Merck, Darmstadt, Germany) was added, vortexed briefly and 
centrifuged again at 13 000 rpm for 30 min at 4°C.  The supernatant was discarded and the pellet was 
air dried briefly before resuspension in ± 100 µl nuclease-free water.  Volumes of TriReagent
TM 
and 
chloroform used were adjusted accordingly for RNA extraction from smaller surface areas. 
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A1.7 DecadeTM Marker System 
In a nuclease-free tube, 1 µl Decade Marker RNA (100 ng); 6 µl nuclease-free water; 1 µl 10× 
kinase reaction buffer; 1 µl [γ-
32
P]ATP and 1 µl T4 polynucleotide kinase were mixed and incubated at 
37°C for 1 hr.  Following incubation 8 µl nuclease-free water and 2 µl 10× cleavage reagent were 
added to the reaction which was then incubated at room temperature for 5 min before adding 20 µl Gel 
Loading Buffer II.  The mixture was heated at 95° for 5 min prior to loading. 
 
A1.8 p24 antigen ELISA 
HIV p24 antigen was measured by Murex HIV Antigen mAB (Murex Biotech LTD, Dartford, UK).  
One hundred µl Conjugate Working Solution I (biotinylated murine anti-p24 monoclonal antibodies, 
Proclin® preservative, bovine albumin, heat inactivated mouse serum and aggregated human IgG in 
phosphate buffer) was added to each pre-coated ELISA well together with 100 µl viral supernatant 
(diluted as necessary in culture medium).  The samples were mixed by aspiration and incubated at 
37°C for one hour.  ELISA strips were washed five times with Wash Buffer (phosphate buffer and 
Proclin® preservative) using an automated plate washer (BioRad, CA, USA).  Two hundred µl of 
Conjugate Working Solution II (peroxidase conjugate streptavidin, phosphate buffer, Proclin® 
preservative, bovine casein and bovine aprotinin) was then added to each well and incubated at 37°C 
for 30 min.  ELISA strips were washed for a second time as described above and 200 µl Substrate 
Solution (tetramethylbenzidine, dimethyl sulphoxide, Thiomersal preservative, phosphate citrate buffer 
and hydrogen peroxide) was then added to each well followed by incubation at room temperature for 
20 min.  The reaction was then stopped by adding 50 µl 2 M H2SO4 (Merck, Darmstadt, Germany) to 
each well.  Fluorescence was analysed at 450 nm using an automated plate reader (BioRad, CA, 
USA). 
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A1.9 TCID50 
U87.CD4.CCR5 cells were seeded at 10 000 cells per well in a 96-well flat-bottomed tissue 
culture plate 24 hours prior to infection.  Cells were seeded only in the centre 24 wells as seen in the 
plate format in Table A1.  The rest of the wells on the periphery of the plate were each filled with 200 µl 
PBS.  On the day of infection, culture medium was aspirated off the cells and 50 µl fresh medium was 
added to each well containing cells.  In a separate 96-well plate, eight serial four-fold dilutions of virus 
stock were carried out in triplicate ranging from 4
-2
 to 4
-9
 and then 150 µl of each dilution was added to 
the relevant wells bring the total volume of each well to 200 µl.  The day following infection each well 
was washed three times with PBS and 200 µl fresh medium was added to each well.  On day 7 
following infection, supernatants were harvested and tested for p24 antigen as described in A1.8.  A 
well was scored as positive if the absorbance at 450 nm was greater than the absorbance of the 
negative control + 0.050.  The TCID50 is calculated by the Spearman-Karber method, a statistical 
calculation where M = xk + d [0.5 - (1/n) (r)].  In the Spearman-Karber formula, xk = dose of the highest 
dilution; r = sum of the number of “-“ responses; d = spacing between dilutions and n = number of wells 
per dilution.  
 
Table A1:  Plate format of a dilution assay used to calculate the TCID50 of HIV viral isolates. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS 
B PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS 
C PBS PBS 4
-2 
4
-3
 4
-4
 4
-5
 4
-6
 4
-7
 4
-8
 4
-9
 PBS PBS 
D PBS PBS 4
-2
 4
-3
 4
-4
 4
-5
 4
-6
 4
-7
 4
-8
 4
-9
 PBS PBS 
E PBS PBS 4
-2
 4
-3
 4
-4
 4
-5
 4
-6
 4
-7
 4
-8
 4
-9
 PBS PBS 
F PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS 
G PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS 
H PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS 
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ABSTRACT
Several different approaches exist to generate ex-
pressed RNA interference (RNAi) precursors for
multiple target inhibition, a strategy referred to as
combinatorial (co)RNAi. One such approach makes
use of RNA Pol III-expressed long hairpin RNAs
(lhRNAs), which are processed by Dicer to
generate multiple unique short interfering siRNA ef-
fectors. However, because of inefficient intracellular
Dicer processing, lhRNA duplexes have been limited
to generating two independent effective siRNA
species. In this study, we describe a novel strategy
whereby four separate anti-HIV siRNAs were
generated from a single RNA Pol III-expressed tran-
script. Two optimized lhRNAs, each comprising two
active anti-HIV siRNAs, were placed in tandem to
form a double long hairpin (dlhRNA) expression
cassette, which encodes four unique and effective
siRNA sequences. Processing of the 30 position
lhRNA was more variable but effective multiple pro-
cessing was possible by manipulating the order of
the siRNA-encoding sequences. Importantly, unlike
shRNAs, Pol III-expressed dlhRNAs did not compete
with endogenous and exogenous microRNAs to
disrupt the RNAi pathway. The versatility of ex-
pressed lhRNAs is greatly expanded and we
provide a mechanism for generating transcripts
with modular lhRNAs motifs that contribute to
improved coRNAi.
INTRODUCTION
Exogenous RNA intermediates of the RNA interference
(RNAi) pathway have become powerful tools for the de-
velopment of reverse genetics approaches and novel thera-
peutics against a wide variety of diseases (1). Specifically,
expressed short hairpin RNAs (shRNAs), which mimic
precursor microRNA (pre-miRNA), are Dicer substrates
of the mammalian miRNA pathway and have been exten-
sively exploited for the production of effectors of the
RNAi pathway (2). However, to prevent emergence of
resistant viral mutants from highly mutable targets, such
as those of human immunodeficiency virus (HIV) and
hepatitis C virus (HCV), a combination of multiple
short interfering RNA (siRNA) effectors is required
(3,4). Therefore, an effective combinatorial RNAi
(coRNAi) system aimed at generating active siRNA
products, and which is capable of targeting multiple sites
simultaneously, remains an important objective.
Harnessing the RNAi pathway to suppress multiple
gene targets concurrently has been attempted using
several different coRNAi strategies with varying success.
The most common approach is to place shRNA expres-
sion cassettes adjacent to each other to achieve combined
expression of multiple shRNAs (5–9). However, there are
several limitations to combining multiple shRNA cas-
settes. Typically shRNAs are expressed from powerful
constitutively active promoters (e.g. U6, H1 and U1 pro-
moters). A coRNAi approach, with several shRNA ex-
pression cassettes in tandem, risks overwhelming the
endogenous RNAi pathway. High levels of specific
shRNAs may have serious and potentially fatal conse-
quences, which are important for application to gene
therapy (10). Another concern relates to the use of
lentiviral vectors, which are often employed to deliver
therapeutic anti-HIV RNAi sequences to T cells. These
vectors are prone to recombining or deleting repeat se-
quences (11,12). Although this problem may be alleviated
by simultaneous use of different promoters (8), such an
arrangement of expressed silencing sequences would
require careful empirical assessment to optimize expres-
sion of each shRNA. Other coRNAi approaches have
made use of a combination of primary microRNA
(pri-miRNA) shuttles, where siRNA guide sequences are
placed within mimics of endogenous polycistronic
pri-miRNAs (13–18). Although polycistronic pri-miRNA
shuttles represent a promising coRNAi approach, efficient
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processing of multiple siRNAs from these pri-miRNA
precursors is variable (13,15,18) and development of new
methods of achieving coRNAi remains important.
Exploiting the action of endogenous Dicer to process
long dsRNA templates and form multiple siRNA species
is potentially a useful approach for achieving coRNAi.
The most well-studied method is to employ Pol III pro-
moters to generate transcripts with defined 50- and
30-termini that fold into long hairpins with duplex
regions of between 30 and 100 bp (19–27). These
lhRNAs, which have 2 nt 30-OH overhangs have been
shown to be intracellular Dicer substrates and produce
multiple siRNA species (19–23). We and others have
shown that siRNAs are processed by Dicer in a gradient
of decreasing efficiency, which starts from the base of the
dsRNA hairpin duplex and moves towards the apical loop
(19,20,22,26).
Here we describe a novel lhRNA-based strategy
whereby four independent siRNAs were produced in ef-
fective doses from a single RNA Pol III-expressed tran-
script. Two optimized dual-targeting lhRNAs were placed
in tandem within a single transcript to form a double long
hairpin RNA (dlhRNA) template. We show that the
dlhRNA is processed into two lhRNAs, which in turn
produce four active anti-HIV siRNAs. Moreover, there
was no evidence of disruption of the endogenous
miRNA pathway by dlhRNAs. This work describes a
novel and safe dlhRNA approach to coRNAi and
expands the versatility of expressed lhRNAs for applica-
tions requiring simultaneous silencing of multiple targets.
MATERIALS AND METHODS
Hairpin expression plasmids
The procedure for generating hairpin RNAs is a modifi-
cation of the PCR-based method described by Castanotto
et al. (28) and later adapted by ourselves to generate
lhRNAs (20). A panel of twelve U6-driven lhRNAs
encoding two putative siRNA sequences targeted to the
HIV-1 tat and nef or int and LTR sequences was con-
structed using two rounds of PCR. Selection of target
sites was based on previously reported effective
knockdown of HIV-1 tat (29), nef (23), int (30) and LTR
(20) sequences by shRNAs. Oligonucleotide sequences
used in each of the amplification reactions are provided
in Supplementary Table 1. During the first round of PCR
a U6 promoter-containing plasmid DNA, pTZ-U6+1, was
used as template (31). A universal U6 forward primer
complementary to the 50-end of the U6 promoter was
used for both rounds of PCR. The reverse primers for
the first round of PCR were complementary to 18–21 nt
of the 30-end of the U6 promoter and included sequences
encoding the sense strand and loop of the lhRNA. The
first round of PCR product was used as template for the
second round of PCR. The round two reverse primer se-
quences were designed to hybridize to the loop-encoding
region at the 30 extremity of the first round PCR amplicon.
These primers included the sequence encoding the anti-
sense strand of the lhRNA as well as a RNA Pol III ter-
mination signal. Double-lhRNA expression cassettes were
similarly generated using the two-round PCR method
described above, but previously generated lhRNAs were
used as templates. For dlhRNAs, round one reverse
primers were complementary to the last 18 nt of the
lhRNA template that would be positioned at the 50-side.
These primers included a spacer of two adenosine residues
and a sequence encoding the sense strand of the
30-lhRNA. To complete synthesis of the dlhRNA cas-
settes, round two reverse primers were employed that
were the same as those used during the second round of
PCR to generate lhRNA cassettes. To propagate the ex-
pression cassettes, the final PCR products were ligated
directly to the TA cloning vector pTZ57R/T (Fermentas,
WI, USA), and sequences were confirmed using standard
procedures. Twelve lhRNA plasmids were generated:
plhLTR-int +1, plhLTR-int +2, plhLTR-int +3,
plhint-LTR+1, plhint-LTR+2, plhint-LTR+3, plhtat-nef
+1, plhtat-nef+2, plhtat-nef+3, plhnef-tat+1, plhnef-tat
+2 and plhnef-tat +3. Two dlhRNA plasmids were
propagated: plhLI-TN and plhTN-LI. U6-driven
shRNAs encoding siRNAs corresponding to those
included in the lhRNA expression constructs were
generated using a single round of PCR. The U6
promoter-containing plasmid DNA was used as
template. Amplification with the universal U6 forward
primer and specific reverse primers enabled formation of
the shRNA-encoding sequences and these were inserted
into pTZ57R/T (Fermentas) to generate: pshLTR,
pshint, pshtat and pshnef. pH1-lhtat-nef +1 and
p7SK-lhLTR-int +1 are plasmids expressing two
lhRNAs from H1 and 7SK promoters, respectively.
These transcriptional regulatory elements were
incorporated using a similar procedure to that described
above, but genomic DNA from HEK293 cells was used as
a template. Forward and reverse primers used during the
first round of PCR are listed in Supplementary Table 1.
Second round reverse primers were the same as those used
to generate U6-driven lhRNAs.
Target plasmids
Dual luciferase sense and antisense target plasmids were
constructed by inserting annealed oligonucleotides
encoding the HIV-1 targets into the 30-UTR of the
Renilla Luciferase cassette of the psiCheck-2 plasmid
(Promega, WI, USA). After treatment with polynucleotide
kinase (Promega) sticky end-containing duplex oligo-
nucleotides were ligated to XhoI–NotI sites (sense
targets) or XhoI–SpeI sites (antisense targets). Sequences
of these oligonucleotides are provided in Supplementary
Table 2. Identification of correct clones was facilitated by
the introduction of an EcoRV site within each insert.
Cell culture and transfections
HEK293 and Huh7 cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM; BioWhittaker, MD,
USA) supplemented with 10% heat inactivated fetal calf
serum (FCS; Delta Bioproducts, Johannesburg, South
Africa) at 37C and 5% CO2. U87.CD4.CCR5 cells were
maintained in DMEM supplemented with 15% FCS,
1 mg/ml puromycin, 300 mg/ml G418, glutamine, penicillin
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and streptomycin. Transfections were carried out using a
ratio of 1 ml Lipofectamine2000 (Invitrogen, CA, USA) to
1 mg total DNA according to the manufacturer’s instruc-
tions. Medium was changed 24 h after transfection and
analyses were carried out a further 24 h thereafter.
Co-transfecting a plasmid that constitutively produces
enhanced green fluorescent protein (pCI-eGFP) followed
by fluorescence microscopy was used to verify equivalent
transfection efficiencies (32).
To evaluate the effects of the lhRNA- and shRNA-
encoding plasmids on a reporter target, 120 000
HEK293 cells were seeded 24 h prior to transfection in
each well of a 24-well culture dish. Cells were transfected
with 150 ng target plasmid, 750 ng of lhRNA or shRNA
encoding plasmid and 100 ng of pCI-eGFP, unless other-
wise stated. For northern blot analysis HEK293 cells were
seeded at 80% confluency in 10-cm culture dishes 24 h
prior to transfection. Cells were transfected with 18 mg of
hairpin-encoding plasmid and 1 mg pCI-eGFP. To deter-
mine the induction of interferon (IFN) response-related
genes, HEK293 cells were seeded as described above and
transfected with 900 ng of lhRNA or shRNA encoding
plasmid and 100 ng pCI-eGFP per well. Control
double-stranded RNA, Poly (I:C; Sigma, MO, USA),
was transfected at equivalent amounts to the hairpin
encoding plasmids. Measurement of IFN response
gene mRNA concentrations were then determined using
quantitative PCR according to previously described
methods (33).
To assess saturation of the endogenous miRNA
pathway caused by the lhRNA constructs, Huh7 cells
were co-transfected with 80 ng psiCheck-miR-16T 7
(18), 750 ng hairpin expression plasmid or
pTZ-U6-miR-16S 7 sponge and 150 ng pCI-eGFP.
psiCheck-miR-16T 7 is a psiCheck plasmid-containing
7 miR-16 target sites downstream of the Renilla luciferase
ORF and pTZ-U6-miR-16S 7 sponge includes a Pol III
expression cassette that transcribes RNA containing seven
copies of a miR-16 target site. To determine the effects of
the lhRNA constructs on the silencing efficacy of an ex-
ogenous miRNA, HEK293 cells were cotransfected with
100 ng pCMV miR-31 HBx, 100 ng of psiCheck-HBx
together with the hairpin constructs (18,34). pCMV
miR-31 HBx encodes a miRNA shuttle that has a guide
cognate in the X gene (HBx) of hepatitis B virus, and
psiCheck-HBx is the reporter target vector.
Dual luciferase reporter assay
Firefly and Renilla luciferase activity was determined
using a Veritas dual-injection luminometer (Turner
Biosystems, C A, USA) according to the instructions of
the manufacturer of the Dual-Luciferase Reporter kit
(Promega). Target-specific Renilla luciferase expression
was normalized to background Firefly luciferase expres-
sion. Average expression ratios for a control plasmid were
set to 100%, and relative expression for other samples was
calculated accordingly. Two independent experiments in
triplicate were performed and the data were expressed as
the mean± SD.
Inhibition of gene targets in the full-length HIV luciferase
reporter molecular clone
Hairpin expression cassettes were assessed for efficacy
against a full-length HIV-1 target by determining
knockdown in a HIV-1 molecular reporter
pNL4-3.Luc.R-E-, as has been previously described
(35,36). This molecular clone has a Firefly luciferase
gene inserted into the nef gene and is capable of only a
single round of replication. Suppression of viral gene ex-
pression was measured by determining Firefly luciferase
activity. HEK293 cells (120 000) were co-transfected
with 1:1 (150 ng:150 ng) ratio of hairpin expression
plasmid to pNL4-3.Luc.R-E-. Approximately 50 ng of
phRL-CMV (Promega), which encodes Renila luciferase,
was used to control for transfection efficiency. Dual
luciferase reporter assays were carried out as described
above.
Northern blot analysis
Total RNA, extracted from HEK293 cells 48 h after
transfection, was prepared using TriReagentTM (Sigma)
according the manufacturer’s instructions. Thirty micro-
grams of RNA was resolved on urea denaturing 15%
polyacrylamide gels and blotted onto nylon membranes.
DecadeTM Marker (Ambion, TX, USA) was prepared ac-
cording the manufacturer’s instructions and run alongside
the cellular RNA. Blots were hybridized to DNA oligo-
nucleotides to detect products of hairpin processing. These
probes were complementary to regions spanning the target
sense or antisense sequences of the hairpins. Probes were
labelled at their 50-ends using [-32P] ATP with T4
Polynucleotide kinase then purified using standard pro-
cedures. Northern blot hybridization and washing were
carried out according to previously described methods
(26). After analysis using a FLA-7000 phosphorimager
(Fujifilm, Japan), blots were stripped and reprobed. An
oligonucleotide probe that was complementary to U6
small nuclear RNA was used as a control to verify equal
loading of cellular RNA. Sense probe oligonucleotide se-
quences were the following: tat(S) probe: 50-GCG GAG
ACA GCG ACG AAG AGC-30, nef(S) probe: 50-GTG
CCT GGC TAG AAG CAC AAG -30, LTR(S) probe: 50-
GTA ACT AGA GAC CTC TCA GAC-30, int(S) probe:
50-GCC GGA GAG CAA TGG CTA GTC-30. Antisense
probe oligonucleotide sequences were: tat (AS) probe:
50-GCT CTT CGT CGC TGT CTC CGC-30; nef (AS)
probe: 50-CTT GTG CTT CTA GCC AGG CAC-30;
LTR (AS) probe: 50-GTC TGA GAG GTC TCT AGT
TAC-30; and int (AS) probe: 50-GAC TAG CCA TTG
CTC TCC GGC-30.
RESULTS
Optimal design of Pol III-driven single lhRNA cassettes
encoding two unique siRNA sequences
We and others have previously established that Pol
III-expressed lhRNA sequences, which include a 2–3 nt
uridine 30-end overhang, can generate independent
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effective siRNAs in cells (19,21). However, Dicer cleavage
is initiated at the base of the hairpin duplex, and
proceeds towards the loop with decreasing cleavage effi-
ciency. Previously, Liu et al. (21) have shown that
two rounds of Dicer cleavage can yield two effective
siRNAs when lhRNAs are generated from a H1 Pol III
promoter. The arrangement of each siRNA along a
hairpin duplex was optimal for 44 and 45 bp stems (21),
where siRNA precursors of 19 bp are separated by 3–4 bp.
To avoid second Dicer cleavage occurring within the ter-
minal loop, we generated lhRNAs with a longer
48–50 bp complementary duplex sequence and a 9 nt
loop (Figure 1A). We designed several sets of U6
lhRNA expression plasmids that each encode two
siRNA sequences. The intended siRNAs targeted
four unique HIV-1 sites within tat (29), nef (23), LTR
(20) and int (30), which have previously been shown to
be susceptible to RNAi-mediated silencing (Figure 1A
and B). In total, four different series of lhRNAs were
generated: two sets of lhRNAs targeted against tat and
nef and two sets targeted against int and the LTR,
allowing for each siRNA-encoding sequence to be
situated in the stem base or loop side positions of the
hairpin duplex (Figure 1B). The position of these
putative 19 bp+2nt siRNAs were adjusted within each
of the four lhRNA series by inserting 1, 2 or 3 symmetrical
paired mismatched bases at the junction between first and
second siRNAs (Figure 1B). In addition, four
U6-expressing shRNA controls were generated for each
target. All lhRNAs and shRNAs included G:U pairings
that were introduced at regular intervals along the
sense strand of the duplex. The antisense sequence was
retained to ensure complete hybridization to each
intended target RNA. The addition of G:U wobbles
facilitated propagation of lhRNA expressing plasmids in
Escherichia coli (24,25).
The processing and silencing efficacy of two siRNAs
derived from a single U6-driven lhRNA in cell culture
To assess the ability of variable length dual targeting
lhRNAs to inhibit their targets in cultured cells,
HEK293 cells were transfected with lhRNAs (Figure 1B)
or with individual shRNA expression plasmids. These
hairpin constructs were transiently co-transfected with a
psiCheck dual luciferase target reporter plasmid contain-
ing the tat, nef, LTR or int target sequence within the
30-UTR of the human Renilla luciferase (hRLuc) tran-
script (top panel Figure 2A and B). A lhRNA targeted
against the HBx gene of HBV (26) was used as a
negative lhRNA control. Knockdown was determined ac-
cording to the ratios of Renilla to Firefly luciferase
activities and values were normalized relative to that
obtained after co-transfection with the empty U6 vector
pTZU6+1 (Mock). Regardless of the spacing at the
siRNA junctions, or the relative arrangement of the
siRNA sequence, siRNAs in the first position of the hair-
pin (at the base of the duplex) were consistently capable of
suppressing their respective targets by 80%, which is
comparable to the knockdown achieved by individual
control shRNAs. Target inhibition from the siRNA
derived from the loopside position of the hairpin duplex
was most efficient when only one mismatched base pair
was present between siRNA encoding regions (+1 config-
uration). A gradual decrease in efficacy was observed with
increased spacing at the junction of the first and second
siRNAs (Figure 2A and B).
siRNA and hairpin-intermediates derived from long
processed hairpin precursors were analysed by using
small RNA northern blot hybridization carried out on
total RNA extracted from transfected HEK293 cells.
Figure 2C and D show representative blots using four
probes complementary to each of the intended siRNA
guide strands. The signal for siRNAs derived from the
Figure 1. Design of dual targeting lhRNAs. (A) Schematic representation of an lhRNA expression cassette showing upstream U6 promoter and
the predicted structures of the transcribed lhRNAs. Dual targeting lhRNAs encode two 19 bp +2nt siRNAs and have a 5 bp +2nt spacer before
the loop sequence. (B) Four different series of 48–50 bp lhRNAs were generated that target tat and nef as well as int and LTR. Each 19 bp
+2nt siRNA-encoding sequence is positioned either in the stem or loopside of the lhRNA duplex and separated by 1, 2 or 3 mismatched paired
bases.
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Figure 2. Knockdown efficacy and processing of dual targeting lhRNAs. Dual luciferase reporter assays showing knockdown of the LTR and int
targets (A) and tat and nef targets (B) when the target sequence was inserted downstream of the Renilla luciferase (hRLuc) open reading frame.
Values represented are mean ratios of Renilla to Firefly luciferase (n =3, SEM) and are normalized to cells transfected with a plasmid containing a
U6 promoter only with no RNAi effector sequence (mock). Small RNA (PAGE) northern blot analysis was carried out on total RNA extracted from
cells transfected with the indicated transcripts. Labelled probes complementary to the guide strand of LTR and int (C) or tat and nef (D) were
hybridized to immobilized RNA and exposed to a phosphorimaging plate. lhRNA and shRNA precursor RNA as well as processed siRNAs are
indicated. The amount of processed guide strand is shown and normalized for each blot relative to the shRNA (set at 100). Decade MarkerTM
indicates fragment size and a probe complementary to small nuclear U6 RNA was used to detect U6 snRNA as a loading control.
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first position of the lhRNAs with a+1 configuration was
similar to that of the corresponding shRNA cassette. With
the exception of the lhtat-nef series, the guide signal of the
first position siRNA decreased with an increase in the
mismatched paired bases inserted between the putative
siRNAs of the hairpin duplex. For example, in the case
of the LTR and int probes, very weak guide hybridization
signals were detected when three mismatched bases were
inserted between the siRNA-encoding regions. With the
exception of lhnef-tat, processed products from the
second position of the hairpin were easily detected after
transfection of plasmids encoding lhRNAs with a+1 con-
figuration. The tat siRNA from the lhnef-tat set was not
detected for all spacing arrangements and correlates with
poor knockdown that was observed with tat reporter
targets (Figure 2A and B). The decrease in siRNA pro-
duction from the second position was observed in a
gradient fashion; an increase in mismatched paired bases
at the junction between siRNA encoding sequences
resulted in a decreased detection of processed second-
position guide strand. This result is in accordance with
the gradient in inhibition observed for the psiCheck
reporter gene targets (Figure 2A and B) and previously
reported for longer hairpins (19). When only one pair of
mismatched bases was inserted at the junction, siRNAs in
the second position were detected at similar levels to those
of siRNAs at the base of the stem. It should be noted that
2–3 bands, differing in size by 1 nt, are often visible for
single siRNA guide strands. This indicates that Dicer does
not consistently cleave the duplex at the same position and
therefore generates guide strands ranging in size from
19–22 nt. While the potency of individual shRNAs differ
(in the order: shtat > shnef >> shint > shLTR), reporter
gene inhibition was effective for both siRNAs along the
duplex, even when transfecting with decreasing concentra-
tions of hairpin-expressing plasmid (Supplementary
Figure 1), using different Pol III promoters (H1 and
7SK), and when combining two different hairpin expres-
sion cassettes in a single vector (Supplementary
Figure 2A). Thus lhRNAs lhtat-nef +1 and lhLTR-int
+1 are optimally designed to allow for efficient processing
along the entire hairpin duplex to produce a strong dual
siRNA response.
The generation of four independent and effective siRNAs
from a single U6-driven double lhRNA (dlhRNA)
expression cassette
Placement of two shRNAs together within the same tran-
script has been shown to produce siRNAs targeted to two
independent sites (37,38). Although Pol III-expressed
shRNAs and lhRNAs consist of defined 50- and
30-termini that facilitate Dicer recognition and cleavage,
shRNAs expressed from Pol II promoters produce longer
50-leader and 30-trailer sequences which often results in
variable production of active siRNAs (39–41). To
develop a system for generating four separate siRNAs
from a single transcript, we combined the two most effect-
ive lhRNAs described here. lhtat-nef+1 and lhLTR-int+1
were placed in tandem to generate two dlhRNA expres-
sion constructs (Figure 3A). A 2-nt UU bridge was
included between each lhRNA to mimic the 30-overhang
generated for a single Pol III-generated lhRNA. dlhLI-TN
and dlhTN-LI included lhRNAs lhLTR-int +1 and
lhtat-nef+1 in either the 50-position or 30-position of the
dlhRNA transcripts, respectively (Figure 3B).
To characterize the processing of dlhRNAs, small RNA
northern blot analysis was performed as before. Figure 3C
shows the signals obtained following hybridization with
antisense (AS) and sense (S) probes to detect siRNA
guide and passenger strands. All probes detected the
full-length dlhRNA transcripts from both dlhRNA con-
structs. However, only dlhLI-TN generated detectable
processed precursors representing both lhRNAs. For
dlhTN-LI, strong signals were detected for the
50-position lhRNA precursor, lhtat-nef +1, with S and
AS probes to tat and nef. No hybridization signal was
detected by either S or AS probes to LTR and int for
the 30-position lhLTR-int +1, suggesting that this
lhRNA precursor is rapidly degraded following initial
Dicer cleavage of the dlhRNA transcript. For dlhLI-TN,
the 50-position lhRNA, lhLTR-int +1, was detected by
S and AS probes targeted to LTR and int. The lhRNA
in the 30-position (lhtat-nef+1) was detected by S and AS
tat and nef probes, but at a lower concentration than that
of the 50-position lhRNA precursor. Again this suggests
that processing of the dlhRNA renders lhRNA at the
30-position less stable. Nevertheless, all four siRNAs
guide sequences were detected from dlhLI-TN
demonstrating that a single dlhRNA construct is capable
of successfully generating four independent siRNA guide
strands.
To determine whether the guide strands were capable of
effecting knockdown of defined HIV targets, a
dual-luciferase reporter gene assay was performed as
before. Double long hairpin RNA dlhLI-TN inhibited
all four targets by 70–80% (Figure 3D), indicating that
four effective siRNAs were generated from this dlhRNA
and that a decreased amount of tat and nef guide strand
derived from the second lhRNA did not affect knockdown
under these conditions of transient transfection. As
expected, dlhTN-LI, only inhibited tat and nef reporter
targets, confirming that compromised processing of the
second position lhRNA affects downstream guide strand
production and subsequent target knockdown. To deter-
mine whether the passenger strand of each putative pro-
cessed siRNA was active, dual-luciferase reporter
constructs were generated that included AS targets. The
passenger strands were largely ineffective, and guide
strand formation was according to the intended bias.
Ability of the dlhRNAs to inhibit cognate targets within
the context of a full-length HIV-1 sequence was also
determined (Figure 4A and B). To quantify the anti-viral
effects of these hairpins, we co-transfected the shRNA-,
lhRNA- and dlhRNA-expressing plasmids with the HIV-1
molecular clone pNL4-3.Luc.E-R-. This reporter plasmid
lacks functional env and the nef reading frame is
substituted with a Firefly luciferase ORF (Figure 4A).
Knockdown was measured by determining Firefly
luciferase activity, which was normalized to activity of
Renilla luciferase that was consitutively expressed from a
co-transfected plasmid. Luciferase ratios were determined
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Figure 3. Generation of four effective individual siRNAs from a single dlhRNA transcript containing two adjacent lhRNAs. (A) Schematic repre-
sentation of a dlhRNA expression cassette driven by a single promoter showing the predicted structure and derivation of four siRNAs. (B) Effective
dual targeting long hairpin RNAs lhtat-nef+1 and lhLTR-int+1 were both combined in 50 or 30 positions within the dlhRNA transcript to generate
lhLI-TN and lhTN-LI. (C) Low molecular weight northern blot analysis was carried out on total RNA extracted from cells transfected with the
dlhRNA expression cassettes with individual targeting shRNAs used as positive controls. Labelled probes complementary to the guide and antisense
strand of LTR, int, tat and nef were hybridized to immobilized RNA and exposed to a phosphorimaging plate. Precursor hairpin RNAs as well as
processed siRNAs are indicated. The amount of processed guide strand is shown and normalized for each blot relative to the shRNA (set at 100).
Decade MarkerTM indicates fragment size and a probe complementary to small nuclear U6 RNA was used to detect U6 snRNA as a loading control.
(D) Dual luciferase reporter assays showing knockdown of the sense (S) and antisense (AS) targets of LTR, int, tat and nef when the target sequence
was inserted downstream of the Renilla luciferase open reading frame. Values represented are mean ratios of Renilla to Firefly luciferase
(n=3,±SEM) and are normalized to cells transfected with a plasmid containing a U6 promoter only with no RNAi effector sequence (mock).
Nucleic Acids Research, 2010 7
 at University of W
itwatersrand on June 9, 2010 
http://nar.oxfordjournals.org
D
ow
nloaded from
 
relative to that of a mock control vector (Figure 4B). The
individual shRNAs targeted to the tat and nef sequences
showed potent luciferase inhibition (>80%), whilst
shRNAs targeted to LTR and int were less effective
(70% and 40% knockdown, respectively). This may
reflect a lower potency of individual LTR and int
siRNAs (Supplementary Figure 1). As expected, inhibition
of the HIV-1 reporter by lhRNAtat-nef was similar to that
achieved by each of the tat or nef shRNAs. However, the
dual targeting hairpin lhLTR-int was only capable of in-
hibiting the HIV-1 reporter by 20%. This confirms
previous observations that LTR and int targets were
silenced less effectively when produced from lhLTR-int.
Importantly, both double lhRNA expression cassettes
achieved good silencing of the reporter gene. However,
dlhTN-LI achieved slightly better silencing than
dlhLI-TN. This may be a result of better knockdown
achieved by the more efficiently processed nef- and tat-
targeting guides (Figure 3C). Collectively these data
indicate that although there may be variability in the
silencing efficacy of individual siRNAs, compensatory
effects may result in good overall silencing which is a de-
sirable property of coRNAi applications.
lhRNA cassettes do not disrupt independent
RNAi-mediated gene silencing or stimulate
the innate IFN response
An important safety concern of potentially therapeutic
lhRNAs is the possible disruptive effect that they may
have on the endogenous cellular miRNA pathway. Both
exogenous siRNAs and shRNAs can compete with each
other or with endogenous miRNAs for access to compo-
nents of the RNAi machinery (42,43). However, RNAi
activators that are present in lower concentrations, are
less likely to saturate the RNAi pathway (34,43,44). To
assess effects of lhRNA cassettes on independent RNAi,
two assays were performed to determine whether lhRNA
expression cassettes have any derepression effect on
silencing caused by an endogenous or an exogenous
miRNA. In the first assay, HEK293 cells were
co-transfected in a 1:1 ratio with an exogenous miRNA
shuttle, pCMV miR-31 HBx (targeted to a unique site
within the HBV genome), and its cognate dual-luciferase
reporter target plasmid, psiCheck HBx (34). Diminishing
amounts of plasmids expressing shRNA, lhRNA or
dlhRNAs relative to pCMV miR-31 HBx were
co-transfected in ratios of 5:1, 1:1 and 0.1:1, respectively.
U6 promoter-driven shLTR showed significant derepres-
sion of miR-31 HBx mediated knockdown at ratios of 5:1
and 1:1 but not at a ratio of 0.1:1. However, equivalent
ratios of U6 promoter-driven lhLTR-int or dlhLI-TN had
no effect on miR-31 HBx knockdown efficacy (Figure 5A).
In the second assay, Huh-7 cells were co-transfected with a
panel of hairpin-expressing plasmids together with a
dual-luciferase reporter plasmid containing seven copies
of a natural miR-16 target site (18). A miRNA ‘sponge’
construct expressing seven copies of an imperfectly
matched miR-16 target, pU6 miR16Tx7, significantly
derepressed miR-16 silencing of its reporter cognate
(Figure 5B). However, at a concentration of 5:1 (sh/
lhRNA expression cassette:target reporter plasmid),
none of the hairpin RNAs had any detectable disruptive
effect on endogenous miR-16 silencing of its reporter
cognate. Together, these results suggest that lhRNAs
and dlhRNAs, although expressed from a potent U6
promoter, are less likely than shRNAs to compete with
RNAi pathway components necessary for either exogen-
ous or endogenous miRNA function. Although lhRNA
and shRNA expression cassettes are expressed from U6
Pol III promoters, intracellular precursors and siRNA
guide strands from lhRNA cassettes are present at lower
concentrations than those derived from shRNA expres-
sion cassettes (Figure 3C). Lastly, to exclude the possibil-
ity of non-specific effects caused by the induction of an
interferon response, IFN- mRNA concentrations were
measured in transfected cells. As previously shown for
other Pol-III generated lhRNAs (21,22,26), quantitative
qRT–PCR demonstrated that none of the hairpin cas-
settes induced expression of IFN- (Figure 5C).
DISCUSSION
Despite extensive optimization of hairpin stem length,
siRNA sequence, and the spatial arrangement of unique
siRNAs along a lhRNA duplex, it seemed unlikely that
expressed lhRNAs can be designed to produce more than
two, possibly three, separate effective siRNAs (19,21,27).
Deriving high concentrations of more than two independ-
ent functional siRNAs from an lhRNA scaffold remains
Figure 4. Inhibition of full-length HIV-1 molecular clone
pNL4-3.Luc.R-E-. (A) The separate regions of the NL4-3.Luc
sequence targeted by the four generated siRNAs are shown schematic-
ally. (B) HEK293 cells were transfected in a 1:1 ratio of
pNL4-3.Luc.R-E- together with indicated hairpin constructs and trace
amounts of Renilla luciferase plasmid phRL-CMV. The four
siRNA-targeted regions are indicated above in the modified HIV
genome of pNL4-3.Luc.R-E-. Values represented are mean ratios of
Firefly luciferase normalized to Renilla luciferase (n=3,±SEM) and
expressed as a percentage of mock (pU6+1) transfected cells (set at
100%).
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difficult and requires new ways of exploiting the process-
ing of dsRNA substrates by Dicer. To develop effective
Pol III-driven lhRNAs expressing two functional siRNAs,
we tested the effects of combining two 19 bp+2nt siRNAs
within a single 48–50 bp lhRNA duplex, and included up
to three mismatched paired bases between each
siRNA-encoding sequence. Liu et al. (21) showed that a
single mismatched paired base between two effective
siRNAs at the centre of the lhRNA stem is well tolerated
and results in the same level of processing or siRNA
activity within the context of a 43 bp lhRNA. In total,
we established a panel of four unique anti-HIV siRNAs
was used to generate 12 dual-targeting lhRNA structures.
When tested against respective HIV targets, we observed
an inverse correlation between siRNA silencing potency
and increased spacing between each siRNA along the
duplex. Optimal siRNA processing from lhRNAs
occurred when only one mismatched paired base was
placed between each 19 bp + 2nt siRNA, and this was
irrespective of siRNA position or sequence. These data
are in accordance with previously published data report-
ing on dual-targeting lhRNAs (21), and is in accordance
with predicted Dicer cleavage intervals of 22 nt (20 bp
+2nt) in human cells (45). With some dual-acting
lhRNAs, processing of the siRNA at the first position di-
minished when more mismatches were inserted in the
lhRNA duplex at the junction of each the siRNAs. This
is likely to be caused by an inhibitory effect on processing
which is caused by bulges occurring at the Dicer cleavage
sites (46). However, the +1 configuration did not affect
Dicer processing through the lhRNA duplex.
Importantly, we were able to identify two effective and
optimized dual-targeting anti-HIV lhRNAs, lhtat-nef+1
and lhLTR-int+1, which together produce high levels of
four siRNAs that inhibit their cognate targets. These
lhRNAs were ideally optimized for inclusion into a
single combinatorial dlhRNA expression cassette.
Based on HIV reverse-transcriptase error rates, it has
been determined that a minimum of four separate HIV
target sites should be targeted simultaneously to prevent
the emergence of RNAi-resistant viral species (47,48).
Therefore, it was encouraging that the dlhRNA design,
with two highly effective lhRNAs joined together within
a single expressed transcript, enabled accurate processing
into four active anti-HIV siRNAs. Apart from
polycistronic miRNA mimics (13–17), this is the first
example of four active guide strands being derived from
a single Pol III expression cassette, and provides a useful
framework for generating effective coRNAi strategies
against highly evolving viruses or multiple rogue genetic
elements. Nevertheless, the mechanism by which these
dlhRNA structures are processed is unclear. Although
previous attempts to generate binary or dual shRNA-
containing transcripts suggest that these duplexes can be
processed into siRNA-sized products, the mechanism for
their intracellular cleavage remains unexplained (37,38).
Although we do not exclude involvement of other
RNases in the processing of dlhRNA precursors,
Figure 5. Assessment of non-specific effects mediated by long hairpin RNAs. (A) Analysis of effects of a shRNA, lhRNA and dlhRNA expression
cassette on the repression of HBx target reporter sequence by an exogenously introduced miR-31 HBx shuttle using a dual luciferase assay.
Co-transfection of reporter plasmid, containing an HBx target sequence downstream of the Renilla luciferase ORF, was carried out together with
three different concentrations of RNAi expression cassettes and empty backbone plasmid (mock). Mean ratios of Renilla to Firefly luciferase (as a
percentage of psiCheck2 empty backbone vector) were used to determine derepression of miR-31 HBx. Statistical significance was determined using a
one-way ANOVA relative to mock transfected control (pU6+1, *P< 0.05 and **P < 0.001). (B) The effect of hairpin expression cassettes on the
function of endogenous miR-16 was analysed following co-transfection of a dual luciferase reporter plasmid containing seven copies of the miR-16
target downstream of the hRluc ORF together with the indicated hairpin-expressing plasmids or miR-16 sponge plasmid expressing seven copies of
an imperfectly matched miR-16 target. Mean ratios of Renilla to Firefly luciferase were used to determine derepression of miR-16. (C) The induction
of the IFN response was assessed by measuring IFN- mRNA concentration in total RNA extracted from cells transfected with the indicated
shRNA, lhRNA and multi-lhRNA expression cassettes. Poly I:C served as a positive control. Mean normalized ratios of IFN-:GAPDH
(n=3,±SEM) determined by using quantitative RT–PCR are indicated. Statistical significance was determined using a one-way ANOVA
relative to mock transfected control (pU6 +1, *P< 0.001).
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it seems likely that Dicer is responsible for the initial
cleavage to form lhRNA species. This is supported by
evidence that Dicer is capable of cleaving hairpins with
either 50- and 30-extensions, albeit less efficiently (39–41).
The fact that the 30-position lhRNA is present in reduced
amounts (or degraded completely) suggests that, once
cleaved, the 50-position lhRNAs is initially protected by
Dicer before being processed into shorter hairpin
products. Since the intrinsic stability of the two lhRNAs
is the same within the dlhRNA system, it remains odd that
the 30-position lhRNA in dlhLI-TN is processed but
is degraded in the context of dlhTN-LI. The only
difference appears to be the sequence presented for
second round Dicer cleavage. Moreover, the 50-terminus
of the lhLTR-int within dlhLI-TN has a triphosphate
moiety generated by Pol III transcription, a feature
which is lacking for lhLTR-int in the context of
dlhTN-LI, and which may add to the stability of
lhLTR-int. However a clearer picture is likely to emerge
with the study of more dlhRNA combinations comprising
different lhRNAs.
Although coRNAi aims to induce strong silencing from
multiple guide strands, high levels of shRNA produced
from Pol III promoters are known to be associated with
unwanted cellular toxicities. High levels of expressed
shRNAs in the liver may cause fatality in mice as a
result of saturation of the endogenous RNAi machinery
(10). In addition, McBride and colleagues have observed
toxicities caused by shRNA-based vectors in brain, which
may have been caused by a buildup of guide strand RNA
(49,50). Replacement of shRNAs with miRNA shuttles
reduced neurotoxicities, suggesting that natural RNAi
pathway precursors are less likely to interfere with en-
dogenous miRNA functions. Although not fully under-
stood, it is likely that highly expressed shRNAs abrogate
the function of natural and exogenous miRNAs
(10,34,43,44,51,52). Here, we have shown that both
lhRNAs and dlhRNAs do not induce the same disruptive
effects on endogenous miRNA that were observed after
transfection of a U6-generated shRNA. This augurs well
for the safety and potential therapeutic application of
these constructs. Moreover, although there have been
concerns about induction of the IFN response by
long (>30 bp) duplex RNA, we did not detect any
IFN-b mRNA activation for any of the hairpins tested.
This confirms previously reported results from analysis of
expressed lhRNAs (24,25,53), and suggests that intracel-
lular transcription of dsRNA hairpins is less likely than
exogenous synthetic RNA to activate the type 1 IFN
response. This is explained by the fact that expressed
lhRNAs, unlike transfected synthetic duplex RNA, do
not traverse the endosome which contain Toll-like recep-
tors that are typically activated by introduced siRNAs
(54,55).
In conclusion, we show that RNA Pol III-expressed
dlhRNA transcripts may be processed to generate four
independent siRNAs that can effect significant
knockdown of non-contiguous siRNA-susceptible
regions of HIV-1. Although there is some variation in
the processing efficiency of the 30-lhRNA, effective
coRNAi can be achieved. Importantly, the dlhRNA
constructs described here do not appear to disrupt the
natural miRNA pathway, which represents an important
objective for their implementation as potential therapeutic
agents. This design of dlhRNA cassettes improves on the
limited versatility of expressed lhRNAs and provides a
useful approach for generating transcripts with modular
lhRNAs motifs that achieve effective coRNAi in mamma-
lian cells.
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Chapter 11
Effective Pol III-Expressed Long Hairpin RNAs Targeted
to Multiple Unique Sites of HIV-1
Sheena M. Saayman, Patrick Arbuthnot, and Marc S. Weinberg
Abstract
The RNA interference (RNAi) pathway has in recent years been exploited for the development of novel
antiviral therapies. The emergence of viral escape mutants, however, is a major impediment to the use
of RNAi effectors to treat highly mutable viruses such as HIV-1. A combinatorial approach is therefore
required for long-term inhibition of gene expression. RNA Pol III-driven long hairpin RNA (lhRNA)
duplexes can be cleaved several times by Dicer, yielding multiple functional siRNAs from a single con-
struct. Here we describe a method for the generation of ectopically expressed U6-lhRNAs encoding
three separate siRNA sequences targeting unique sites in HIV-1. This methodological overview will
explain some crucial aspects of lhRNA design and cloning as well as facile experiments to determine their
efficacy in cell culture.
Key words: Long hairpin RNA, lhRNA, RNA interference, Dicer, HIV-1, therapeutics.
1. Introduction
RNA interference (RNAi) is an evolutionary conserved pathway
in eukaryotes whereby double-stranded RNA acts as an intracel-
lular trigger to regulate gene expression (1). The RNAi path-
way has been popularly used as a tool to silence genes and holds
much promise as novel therapeutic approach aimed at suppressing
specific cellular and viral genes at the post-transcriptional level.
The therapeutic development of RNAi has been made possible
by usurping elements of the endogenous mammalian microRNA
(miRNA) biogenesis pathway (see Chapter 14) through exoge-
nously introduced synthetic short interfering RNAs (siRNAs) (2)
M. Sioud (ed.), RNA Therapeutics, Methods in Molecular Biology 629,
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or through gene expression constructs which produce 21–29 bp
short hairpin RNAs (shRNAs) (3, 4). These shRNA mimics of
precursor miRNA are cleaved by the RNase III endonuclease
Dicer to form effective siRNAs which unwind to load single-
stranded RNA guide strands into an Argonaute-containing RNA-
induced silencing complex (RISC). Loaded RISC complexes
target cognate complementary mRNA sequences to mediate post-
transcriptional gene silencing by Argonaute-2-mediated cleavage
or translational suppression of targeted mRNAs (5).
A significant hurdle for the use of RNAi-based therapeu-
tics has been the targeting of highly mutable sequences, such as
genomic and sub-genomic RNAs from the human immunodefi-
ciency virus type 1 (HIV-1). HIV replicates using an error-prone
reverse transcriptase and has been shown to escape the silencing
effects of expressed shRNAs by rapidly developing resistant viral
variants (6–8). The emergence of such viral escape mutants is not
unexpected since single-base mismatches between guide strand
and target is enough to prevent silencing (6, 9). To circumvent
this problem, efforts are underway to generate expressed RNAi
effectors, which simultaneously target multiple sites within the
viral genome (10–13). While a number of approaches are available
to induce combinatorial silencing of viral sequences [reviewed
in (14–16)], we have made use of RNA Pol III-expressed long
hairpin RNAs (lhRNAs) with duplex stems encoding more than
one putative siRNA sequence (17). In mammalian cells, introduc-AQ1
tion of synthetic dsRNA of greater than 30 bp leads to a strong
innate immunostimulatory response (18). Although certain syn-
thetic siRNA sequences were found to activate innate immunity
(see Chapter 3), studies using expressed sequences have shown
that safe and effective gene-specific silencing can be achieved and
that these duplexes evade cytoplasmic activators of the type 1
interferon response (19, 20).
Long hairpin RNAs generated from Pol III promoters include
2–3 nt 3′-terminal uridine overhangs, which are produced by
transcriptional termination. These 3′-overhangs facilitate export
to the cytoplasm and allow binding of the Paz domain of human
Dicer (hDicer) (21, 22). Processive cleavage of the lhRNA by
hDicer then occurs from the open-ended stem to the loop of
the hairpin duplex (23). Multiple successive siRNAs are pro-
duced by the intracellular processivity of hDicer in decreasing
order of efficiency along the lhRNA duplex, resulting in the pro-
duction of at least three non-overlapping functional siRNAs per
lhRNA (17, 23–26). Long hairpin RNAs can be designed to
target one contiguous sequence within the genome or, alterna-
tively, can be made to incorporate multiple independent target
sequences. The advantage of the latter is that separate mRNAs
can be silenced simultaneously and previously characterized
effective shRNA/siRNA sequences can be incorporated into a
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single lhRNA. The optimal positioning of different 19 bp siRNA
within an lhRNA duplex for efficient processing of successive siR-
NAs often requires empirically testing different sequence spacing
arrangements at the junction of each siRNA. However, while no
clear rules exist, we provide some design guidelines for optimally
spacing effective 19 bp siRNA sequences along the length of an
lhRNA duplex.
Here we present a method for cloning and generating
69 bp long hairpin RNAs expressed from the U6 snRNA pro-
moter which encodes three separate anti-HIV siRNA duplexes
(Fig. 11.1a). This method can be generally adapted for appli-
cations where multiple siRNAs are required for the simultaneous
targeting of up to three separate and unique RNA sites. A number
of different methodologies are available for producing shorter Pol
III-expressed hairpin duplexes such as shRNAs. However, many
of these are not easily adapted for generating lhRNAs. Owing to
the increased length of the dsRNA duplex for lhRNAs and associ-
ated problems with subsequent PCR, cloning and sequencing of
long inverted repeat sequences, we have relied on a modification
of the two-round PCR protocol originally used by Castanotto
et al. (27) to generate Pol III-expressed shRNAs. In addition
Fig. 11.1. Design of U6-expressed lhRNAs and shRNA controls targeting three sites of HIV-1. (a) Schematic illustration
of lhRNAs and shRNAs comprising 69 and 23 bp duplexes, respectively. G:U pairings are indicated as a corrugated sense
strand. A sequence of two terminal 3′-U residues is derived from the Pol III (U6) transcriptional termination signal. The
intended mechanism of transcription and processing by Dicer of the lhRNAs to form three anti-HIV siRNAs is illustrated.
(b) The sequence and predictive structure of the lhRNA, lhRNA tat-rev-vif, and each shRNA are shown. The order and
special arrangement of the siRNA-encoded sequences within the lhRNA is indicated along the extent of the duplex. G:U
and U:G pairings are indicated with an arrowhead. The putative guide strandsare shaded in red, blue and green for tat,
rev and vif siRNAs, respectively.AQ2
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to describing the design, PCR and cloning of U6-lhRNA cas-
settes, we describe a simple luciferase-based reporter gene assay
for detecting the efficacy of each siRNA generated from the
parental lhRNA duplex. Moreover, we provide a standard poly-
acrylamide gel electrophoresis (PAGE) northern blot protocol,
which allows convenient quantitative detection of each siRNA
and associated precursors generated from an lhRNA expression
cassette.
2. Materials
2.1. PCR of
lhRNA-Encoding DNA
Templates
1. Expand High FidelityPLUS PCR kit (Roche) (see Note 1).
2. pTZU6+1 template plasmid (28) containing the human
U6 snRNA RNA Pol III promoter.
3. PAGE-purified, synthesized oligodeoxynucleotide primers
for PCR.
4. 1X Tris-acetate-EDTA (TAE) electrophoresis running
buffer: 40 mM Tris, 1 mM ethylenediaminetetraacetic acid
(EDTA), 20 mM glacial acetic acid. Store at room temper-
ature.
5. InsTAcloneTM PCR Cloning Kit (Fermentas, WI, USA)
which includes the plasmid pTZ57R/T. Store all kit com-
ponents at –20◦C.
6. Competent Escherichia coli DH5α bacterial cells. Aliquot
and store at –70◦C.
7. 5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-
Gal). X-Gal should be dissolved in dimethylformamide at
a concentration of 20 mg/mL and stored in the dark at
–20◦C.
8. Isopropyl-β-D-1-thiogalactopyranoside (IPTG). IPTG is
dissolved in ddH2O at a concentration of 100 mg/mL,
filter sterilized and stored at –20◦C.
9. Luria Bertani broth (LB): 10 g/L Bacto-Tryptone, 5 g/L
bacto yeast extract, 10 g/L sodium chloride (NaCl) con-
taining 1 μg/mL ampicillin. Autoclave prior to the addi-
tion of antibiotic and store at 4◦C.
10. Agar plates containing 1 μg/mL ampicillin. Store inverted
at 4◦C.
11. High Pure Plasmid Isolation Kit for small-scale (mini)
preparations of purified plasmid DNA.
12. SpeI, NotI, EcoRI and HindIII restriction enzymes
(10 U/μL), supplied with recommended 10X buffers.
Store at –20◦C.
13. QIAGEN Plasmid Maxi Kit (for transfections).
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14. Common restriction enzymes, each 5–10 U/μL, supplied
with recommended 10X buffers. Store at –20◦C.
2.2. Generation of
Target Reporter
Plasmids
1. psiCHECKTM-2 vector.
2. Complementary forward and reverse oligodeoxynucleotides
for annealing and directional cloning.
3. XhoI and NotI restriction enzymes (10 U/μL) supplied with
recommended 10X buffers. Store at –20◦C.
4. MinEluteTM Gel Extraction Kit.
5. Antarctic phosphatase.
2.3. Cell Culture and
Determination of
Knockdown
Efficiency by Dual
Luciferase Reporter
Assays
1. Human embryonic kidney 293 (HEK293) cell line.
2. Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% heat-inactivated fetal calf serum (FCS).
Store at 4◦C.
3. Phosphate-buffered saline containing 0.01% EDTA.
4. LipofectamineTM 2000 transfection reagent.
5. OptiMEM.
6. Plasmid pCI-eGFP (29), a GFP-expression plasmid under
control of the CMV promoter.
7. Dual-Luciferase R© Reporter Assay System (Promega, WI,
USA). Store the kit at –20◦C, and once the luciferase assay
substrate has been reconstituted, aliquot and store in the
dark at –70◦C.
8. Costar R© 96 well flat bottom assay plates.
9. VeritasTM Microplate Luminometer.
2.4. Detection of
lhRNA Processing by
PAGE Northern Blots
1. TriReagentTM (Sigma, MO, USA). Store at 4◦C.
TriReagentTM should only be used in a fume hood.
2. A 15% polyacrylamide gel with 8 M urea (20 × 20 ×
0.8 cm): 40% acrylamide solution (19:1 acrylamide:bis-
acrylamide) 18.5 mL; 10X TBE 5 mL; urea 24.03 g;
ammonium persulphate 20 mg; N,N,N,N′-tetramethyl-
ethylenediamine (TEMED) 15 μL (see Note 2).
3. Loading buffer: 95% formamide, 0.025% xylene cyanol,
0.025% bromophenol blue, 0.025% sodium dodecyl sul-
phate (SDS), 18 mM EDTA.
4. 10X Tris-borate-EDTA buffer (TBE): 890 mM Tris–HCl,
890 mM boric acid and 20 mM EDTA, pH 8.0. Store
at room temperature and discard if a precipitate begins to
form.
5. DecadeTM Marker kit (Ambion, TX, USA). Components
include Decade Marker RNA (100 ng/μL in 10 mM
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Tris–HCl, pH 7.0), T4 polynucleotide kinase (10 U/μL),
10X kinase reaction buffer, 10X cleavage reagent, gel
loading buffer and nuclease-free water. Store the Decade
Marker RNA at –70◦C, the cleavage reagent at room tem-
perature and all the other reagents at –20◦C.
6. Semi-dry blotter.
7. Hybond-N+ nylon membrane.
8. Ultra-Violet Products (UVP) UV cross-linker.
9. Rapid-hybridization buffer.
10. γ32P-ATP (6,000 Ci/mmol).
11. T4 polynucleotide kinase (PNK), supplied with 10X PNK
buffer.
12. DNA oligonucleotides (approximately 18–21 nt) comple-
mentary to the antisense strand of each siRNA sequence
(see Note 3).
13. Sephadex columns. These can be prepared using 5 g
Sephadex R© G-25 in 50 mL TE buffer. Insert 0.5 cm
nylon fibre into a 1 mL syringe and then add 1 mL
of sephadex/TE solution. Spin at 2,000g for 2 min (see
Note 4).
14. Hybridization incubator with a rotisserie.
15. Sodium dodecyl sulphate, 1% solution in water. Store at
room temperature. However if a precipitate begins to form,
the solution may be heated to re-dissolve precipitate.
16. 20X Sodium chloride sodium citrate (SSC) buffer: 3 M
NaCl, 0.3 M sodium Citrate dehydrate, pH 7.0.
17. Medical x-ray film.
18. Phosphorimaging plates.
19. Phosphorscanner.
3. Methods
3.1. Generating
U6-Driven lhRNA
Vectors Targeting
Three Unique
Sequences Within
HIV-1
3.1.1. The Design of
U6-Driven lhRNA
Cassettes
Here we provide some design guidelines for optimally spac-
ing three effective anti-HIV 19 bp siRNA sequences along the
length of a U6-driven lhRNA duplex. We also describe impor-
tant design features which need to be considered for construct-AQ3
ing and cloning a plasmid containing an lhRNA expression cas-
sette ex. The lhRNA comprises a stem of 69 bp and a loop of
seven nucleotides. The lhRNA is designed to be transcribed from
a U6 RNA Pol III promoter such that three 21–23 bp siRNAs
can potentially be generated by hDicer cleavage (Fig. 11.1a, b).
We chose to incorporate the sequences of three unique anti-HIV-
1 shRNAs targeting Tat/Rev (referred to as tat) (30), Rev/Env
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(rev) (30) and Vif (vif) open reading frames (31) (Fig. 11.1b).
Some of the design criteria are described below:
1. A single 69 bp lhRNA duplex encodes three separate
19 bp siRNAs (for tat, rev and vif, respectively). However,
since intracellular Dicer cleavage occurs approximately every
22–23 nucleotides along the dsRNA duplex, for optimal
Dicer cleavage, each 19 bp siRNAs with two 3′-terminal
nucleotides is spaced every 23 nt from the base of the stem
(see Fig. 11.1b) (see Note 5).
2. The guide strands for each siRNA are placed sequentially
in the 3′-arm of the lhRNA duplex. To avoid confusion,
the sense strand always represents the 5′-arm such that
transcription occurs in the following direction: sense–loop–
antisense.
3. Wobble base mismatches (G:U or U:G bp) are introduced
into the sense strand of the lhRNA duplex (C is replaced
by a T; A is replaced by a G in the DNA sequence) at
regular intervals (every 4–8 bp) (Fig. 11.1b). These mis-
matches greatly facilitate PCR of the lhRNA expression cas-
sette, cloning of inverted repeat sequences in E. coli and later
sequencing of clones (see Note 6).
4. Individual short hairpin RNAs (shRNAs) with correspond-
ing G:U mismatches serve as positive controls for each
siRNA generated from the lhRNA duplex (Fig. 11.1b).
5. We chose a random 7 nt loop sequence: 5′-UCAAGAG-3′.
A longer loop provides a unique anchor for two rounds of
PCR (Fig. 11.1b and Section 3.1.2b) (see Note 7).AQ4
3.1.2. Generation of
Expressed lhRNAs by a
Two-Step PCR
1. U6-expressing lhRNAs are constructed using a two-step
PCR which was adapted from Castanotto et al. (27)
(Fig. 11.2). In the first round of PCR, 10 pg of pTZU6+1
is used as a template.
2. The universal U6 forward primer, 5′-CTA ACT AGT GGC
GCG CCA AGG TCG GGC AGG AAG AGG G-3′, is com-
plementary to the 5′-end of the U6 promoter and is used for
both rounds of PCR. It includes SpeI and NotI sites to facil-
itate later screening of correctly inserted clones (see Section
3.2).
3. The reverse primer for the first round (R1) of PCR for the
lhRNA (tat-rev-vif) is complementary to 18–21 nt of the
3′-end of the U6 promoter and contains a linker encoding
the tat-rev-vif siRNA sequences: lhRNA tat-rev-vif (R1) 5′-
CTT GAA ATGGAA TGT ATA CCT CTA AAC AAG GCA
GCC GAA GAG ACA CAG ACA AGC CCT TCA TCA
CTA TCC CCG CGG TGT TTC GTC CTT TCC ACA
A-3′.
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Fig. 11.2. A two-step PCR strategy for producing a U6-driven lhRNA cassette for cloning
in the TA vector pTZ57R/T.
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4. We use standard thermocycling conditions: 95◦C for 5 min,
followed by 30 cycles of denaturing at 95◦C for 30 s, anneal-
ing at 55◦C for 30 s, extension at 72◦C for 30 s. With the
Expand High Fidelity Taq polymerase kit, 10 pmol of each
primer is used in a 50 μL reaction. The first round of PCR
produces the complementary sequence of the lhRNA sense
strand as well as of the loop sequence.
5. For the second round of PCR, a 1:500 dilution of the round
one PCR product (approximately 10 pg) is used as the tem-
plate. The U6 forward primer is used again and the reverse
primer sequence (R2) is designed to have 18 nt of over-
lapping sequence with the loop region of the round one
reverse primer. The R2 primer encodes the complementary
sequence of the antisense strand of the lhRNA as well as six
thymidine (uridine) residues for Pol III-transcriptional ter-
mination (Fig. 11.2). The primer for round two is lhRNAAQ5
tat-rev-vif (R2) lhRNA tat-rev-vif R2 5′-AAA AAA GCG
GAG ACA GCG ACG AAG AGC TTG CCT GTG CCT
CTT CAG CTA CCT TGT TCA GAA GTA CAC ATC
CCA CTC TCT TGA AAT GGA ATG TAT A-3′. This
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overlap between each pair of reverse primers enables
the extension of the PCR product to generate a U6-
expressed lhRNA cassette with a transcription termination
signal.
6. The conditions for the second round PCR are the same as
the first, except for the additional 10 min extension step at
completion of thermal cycling. This facilitates cloning into
the TA vector, pTZ57R/T.
7. Load 5 μL of each PCR product on a 1.5% agarose gel in
1X TAE buffer, resolve electrophoretically and visualize on a
UV transilluminator.
3.1.3. Plasmid
Propagation of lhRNA
Expression Cassettes
1. If a single band is visualized representing the expected size
of the round two PCR product on the agarose gel (see Sec-
tion 3.1.2), it can be ligated directly into the TA cloning
vector pTZ57R/T (see Note 8). The ligation reaction is set
up by adding together: 4 μL round two PCR product, 1 μL
pTZ57R/T, 4 μL 5X ligation buffer and 1 μL (5 U) T4
DNA ligase. The volume is made up to 20 μL with water.
The reaction can be left at room temperature overnight.
2. The ligation reaction (7 μL) is used to transform
100 μL competent DH5α cells before plating on ampicillin-
containing agar plates.
3. Agar plates contain 40 μL of X-Gal stock and 8 μL of
IPTG stock for blue-white screening. Plates containing
transformed bacteria are left at 37◦C overnight.
4. Pick white colonies and grow in 3 mL of ampicillin-
containing LB at 37◦C overnight for mini-preparation of
plasmid DNA using the Roche high-pure miniprep kit.
5. Screen plasmids for presence of inserts and orientation by
digesting plasmid DNA with EcoRI and SpeI, and HindIII
and SpeI, respectively (Fig. 11.2). Run digested plasmids on
a 3% agarose gel (see Note 9).
6. Sequence positive clones with M13 forward and reverse
primers. Since errors are commonly incorporated in the syn-
thesis of long oligonucleotides, a number of clones may need
to be sequenced.
3.2. Generation of
Target Reporter
Plasmids
1. A standard PCR reaction is used to amplify approximately
200 bp of the gene containing the desired target sequences
for tat, rev and vif using 10 pmol each of gene-specific
primers and 10 pg of HIV-1 subtype B plasmid, pNL4-3, as
the template. The forward primer contains a 5′-XhoI restric-
tion site linker, while the reverse primer contains a 5′-NotI
restriction site linker.
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2. PCR products for tat, rev and vif are individually ligated
into pTZ57R/T as described above (Section 3.2). Plasmid
pTZ57R/T, containing the target sequence, is screened by
digestion with XhoI and NotI and the insert is then excised
from an agarose gel and purified using the MinElute Gel
Extraction kit according to the manufacturer’s instructions.
Fragments are eluted from the column in 20 μL of TE
buffer.
3. To insert target sequences in the 3′-UTR of the Renilla
luciferase open reading frame, the psiCHECK plasmid back-
bone is prepared by digestion with 15 units (1.5 μL) each
of XhoI and NotI for 1.5 h at 37◦C in a 50 μL volume.
One microlitre (5 U) of Antarctic phosphatase (AP) is added
to the digestion reaction together with 10X AP buffer and
water to 60 μL total volume. The reaction is incubated
at 37◦C for a further 10 min. The phosphatase reaction
is heat-inactivated for 15 min at 65◦C followed by resolv-
ing the linear psiCHECK vector backbone DNA on a 0.8%
agarose gel. The double-digested vector backbone band is
excised and purified using the MinElute Gel Extraction kit.
Fragments are eluted from the column in 20 μL of TE
buffer.
4. To ligate vector backbone to digested PCR fragments,
60 fmol (approximately 50 ng) of purified psiCHECK back-
bone fragment is ligated with 180 fmol of each tat, rev and
vif fragment in a 20 μL reaction volume containing 1 μL
(10 U) of T4 DNA ligase and 1X ligase buffer.
5. The ligase reaction is used to transform bacteria as described
previously: 10 μL of ligation reaction is used to transform
100 μL of chemically competent E. coli; the reaction is
plated onto ampicillin-containing agar plates and incubated
overnight at 37◦C.
6. Colonies are screened by digestion with XhoI and NotI
and clones with the correct sized insert are subsequently
sequenced using a forward primer specific to the Renilla
luciferase ORF: 5′-GAG GAC GCT CCA GAT GAA
ATG-3′.
3.3. Cell Culture and
Knockdown Assays
1. The HEK293 cell line is maintained with DMEM supple-
mented with 10% heat-inactivated FCS at 37◦C and 5%
CO2. Cells are passaged using PBS containing EDTA.
2. Seeding of 120,000 cells per well in 24 well plates is car-
ried out 24 h prior to transfection. lhRNA-encoding plasmid
(750 ng) together with target reporter plasmid (150 ng)
are co-transfected in a 5:1 ratio (see Note 10). A 100 ng
of plasmid pCI-eGFP is also co-transfected to control for
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transfection efficiency. Each transfection should be per-
formed in triplicate. Transfections are carried out using 1
μL lipofectamine 2000 per 1 μg DNA and 0.2X optiMEM.
3. Twenty-four hours post-transfection media should be
replaced and the dual luciferase reporter assay is carried out
a further 24 h later according to the manufacturer’s instruc-
tions. All Renilla luciferase values are normalized against
background firefly luciferase values. The average expression
ratio for a control plasmid containing the U6 promoter with
no hairpins is set to 100%, and relative expression levels of
other samples are calculated accordingly (Fig. 11.3a).
3.4. PAGE Northern
Blot Hybridization
1. Cells are cultured and transfected as previously described.
For northern blot analysis cells are seeded to approxi-
mately 70% confluence in 10 cm culture plates and trans-
fected 24 h later with 18 μg hairpin construct. Forty-
eight hours post-transfection, total RNA is extracted using
TriReagent according to the manufacturer’s instructions.
Standard RNA-handling procedures to avoid RNase con-
tamination should be followed.
2. Prepare a 15% polyacrylamide gel with a 1:19 ratio of
bis:acrylamide with 8 M urea and 1X TBE.
3. Ambion Decade Marker should be prepared as per the kit’s
instructions.
4. Add an equal volume of loading dye to 30 μg of each RNA
sample, heat at 80◦C for 5 min and then return sample to
ice before loading.
5. To warm the apparatus prior to the loading of RNA sam-
ples, the gel should be pre-electrophoresed in 0.5X TBE
buffer at 200 V for 30 min.
6. Resolve RNA samples and labelled markers at constant
voltage (200–300 V) and run the gel until the bromophe-
nol blue band migrates to within 1 cm from the bottom of
the gel.
7. Transfer to a positively charged membrane (Hybond-N+)
using a semi-dry blotter. For the transfer, the gel and mem-
brane are tightly placed between six layers of 0.5X TBE-
soaked chromatography paper and the current applied for
1 h.
8. UV cross-link the RNA to the membrane at 2,000 ×
100 μJ/cm2.
9. Bake the membrane at 80◦C for 1 h.
10. Prehybridize the membrane in 10 mL of pre-warmed rapid-
hyb buffer at 42◦C for 20 min.
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Fig. 11.3. Knockdown of individual reporter gene targets and intracellular processing of lhRNA and shRNA-expressing
plasmids in transfected HEK293 cells. (a) Average normalized Renilla:firefly luciferase activity determined 48 h after
transfecting HEK293 cells with the psiCHECK tat-rev-vif target together with each individual shRNA control and an irrel-
evant lhRNA control (lhRNA TAR) (∗p < 0.5, for experiments conducted in triplicate). (b) Northern blot analysis of RNA
extracted from HEK293 cells that had been transfected with lhRNA tat-rev-vif and shRNA-expressing plasmids. The blot
was probed with an oligonucleotide that was complementary to putative tat, rev and vif guide sequence. The blot was
stripped and re-probed with an oligonucleotide complementary to U6 snRNA to control for equal RNA loading.
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11. Label 2 μL oligo probe (20 μM) with fresh γ-32P-ATP
in a 20 μL total volume using 1 μL PNK (5 U) and
2 μL 10X PNK buffer. Dilute to 50 μL and spin through a
freshly prepared sephadex G-25 column. Add the labelled
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probe to the hybridization buffer and leave rotating at
42◦C overnight.
12. Wash membrane once with 0.1% SDS and 5X SSC in a
volume of 50 mL at room temperature for 20 min. Wash
membrane twice with 0.1% SDS and 1X SSC in a volume
of 50 mL at 42◦C for 15 min each (see Note 11).
13. Place membrane in cling wrap and expose membrane to
x-ray film for 24–72 h before developing film. The mem-
brane can also be exposed to a phosphor plate and scanned
using a phosphor-imager (e.g. Fuji FLA-7000).
14. Strip membrane in 50 mL 1% SDS at 80◦C for 30 min. The
membrane can then be re-probed as described above.
15. Once stripped, the membrane is re-probed using a 20-mer
oligonucleotide antisense to the U6 snRNA. This serves as
an ideal loading control.
4. Notes
1. We also find standard Taq polymerase easily amplifies
long hairpins but does introduce mismatches which need
to be screened by sequencing. The use of high-fidelity
thermostable polymerases may improve sequence fidelity
but often hampers the generation PCR products useful
for subsequent cloning. Nevertheless, we have used the
Expand High FidelityPLUS PCR System (Roche) to pro-
duce lhRNA-encoded PCR fragments.
2. Ammonium persulphate should be made up fresh each
time. Therefore make up small quantities at a time. Alter-
natively, small 500 μL aliquots can be frozen for up to
3 months.
3. Locked nucleic acid (LNA) oligonucleotide probes may be
used for increased specificity.
4. The sephadex G-25 should be hydrated by overnight agi-
tation in 50 mL TE buffer. Briefly centrifuge the solution
at 4,000 rpm for 2 min, discard the supernatant and add
another 50 mL TE buffer. Repeat this two to three times
before adding a final volume of TE buffer.
5. If the lhRNA is designed to encode more than two siR-
NAs, the third siRNA may not be processed efficiently or
may be present at too low a concentration to be an effec-
tive inhibitor. Although efficient production of all siRNAs
is not always guaranteed, there are modifications that may
be employed to improve the yield of the third siRNA. The
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processing of multiple siRNAs in a single duplex may be
augmented by empirically testing different spatial arrange-
ment of siRNAs along the hairpin stem. Although gross
generalizations regarding the most favourable siRNA spac-
ing cannot yet be made, improvements can be achieved by
inserting or deleting random base pairs at each siRNA junc-
tion as well as before the loop sequence.
6. Wobble mismatches can be strategically used to improve
the thermodynamic asymmetry of each siRNA, thereby
facilitating correct guide strand incorporation into RISC.
Moreover, there is some anecdotal evidence to suggest that
wobble base pairs help prevention of the induction of the
IFN response by masking protein kinase R (PKR) recogni-
tion (32).
7. There is some evidence to suggest that increasing the
duplex length at the loop side of the duplex (by 5 bp
or more) may improve cleavage of the third siRNA (26).
However, this has not been tested by us.
8. If non-specific bands are visible on the agarose gel, purify
the desired PCR fragment from the gel and then ligate
10 μL gel-purified DNA into the TA cloning vector.
9. Resolve bands properly on a high percentage agarose gel
(e.g. 3% gel). Clones with minor deletions and insertions
can be detected on the gel and screened out.
10. Lower ratios of hairpin to target can be used without sig-
nificantly affecting efficient target knockdown.
11. If high levels of background are present on the film, wash
steps can be repeated.
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Abstract: The naturally-occurring RNA interference (RNAi) pathway represents a powerful tool for the sequence-specific 
post-transcriptional silencing of gene expression. By exploiting the endogenous mammalian RNAi pathway, several 
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replication. This approach potentially has utility as a protective ‘therapeutic vaccine’ of virus-susceptible lymphocytes. In 
this review we discuss new developments aimed at improving efficacy and delivery of novel RNAi-based gene expression 
antiviral strategies. Particular attention is given to advances in combinatorial gene expression systems that prevent the 
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host factors that are required for viral replication is also discussed. These approaches form the basis for a number of 
promising ongoing and future clinical trials aimed at providing an effective, safe and prolonged single-intervention 
therapy for HIV/AIDS. 
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1. INTRODUCTION 
 Recent estimates indicate that globally there are over 33 
million people infected with human immunodeficiency virus 
type 1 (HIV-1) [1]. The epidemic is particularly severe in 
sub-Saharan Africa which accounted for 67% of all infected 
individuals and 72% of AIDS deaths in 2007 [1]. Current 
therapies aimed at inhibiting HIV replication include the use 
of drugs that target viral reverse transcriptase and protease. 
More recently, viral entry inhibitors and drugs that counter 
integrase have been introduced. These agents, particularly in 
combination as a cocktail of highly active antiretroviral 
therapy (HAART), have had an important positive impact on 
the morbidity and mortality of HIV-related illness [2]. 
However, current treatment regimens have significant limi-
tations. These include toxicities, resistance and the inability 
to eradicate a latent infection. In addition, most therapeutic 
agents have been developed to target HIV-1 subtype B, 
which affects individuals predominantly in Western Europe 
and North America, and therefore these drugs are not neces-
sarily tailored to meet the therapeutic burden of HIV in sub-
Saharan Africa, where subtype C infection is common. 
These concerns, along with ensuring patient compliance with 
treatment and the high cost of improved treatment regimes, 
have prompted the search for innovative and globally-
effective therapies to counter HIV infection.  
 The discovery by Fire, Mello and colleagues that double-
stranded RNA can effect powerful inhibition of gene expres-
sion has spawned many important biotechnological advances 
[3]. Harnessing this highly-conserved biological pathway, 
known as RNA interference (RNAi), is potentially very  
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useful for advancing antiviral gene therapy [3, 4]. Impor-
tantly, earlier development of nucleic acid-based technolo-
gies, such as antisense and ribozymes, established a foun-
dation for accelerated progression of RNAi research from the 
laboratory bench to the clinic. Indeed, today there is a flurry 
of activity in testing the antiviral potential of RNAi-based 
approaches. This review will focus on recent advances in 
RNAi-based HIV therapy, with particular emphasis on the 
mechanism of action of novel gene expression-based 
strategies that are intended for long-term single-intervention 
clinical applications. Anti-HIV gene therapy approaches 
have unique hurdles to overcome before they are ready for 
clinical use. Eliminating latent infection, efficient delivery of 
antiviral effectors and RNAi-induced viral escape are some 
of the important considerations. Drug resistance may be 
solved by inhibiting multiple targets and new strategies 
aimed at usurping natural RNAi structures to generate safe 
combinatorial RNAi modalities will be highlighted. Recently 
published genome-wide screens have identified many host 
factors that are required for viral replication. Advances in the 
silencing of these cellular genes as a treatment approach and 
means of preventing viral escape, will also be discussed. 
Recent and ongoing preclinical and clinical developments in 
the field are evaluated before concluding with a discussion of 
the future prospects of RNAi-based antiviral therapies. 
2. THE MAMMALIAN RNAI PATHWAY 
 In mammals, RNAi is triggered by double-stranded RNA 
(dsRNA), which is processed into short RNAs of ~20-30 
nucleotides in length. These short RNAs associate with 
members of the Argonaute (Ago) family of proteins to 
regulate gene expression at the transcriptional and post-
transcriptional level. RNAi plays an important role in many 
fundamental cellular functions and has increased our 
appreciation for the major role of small non-coding RNAs in 
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biology. However, it is activation of RNAi with exogenous 
regulators of gene expression, which makes their discovery 
particularly important for therapeutic application.  
 RNAi-based therapeutic approaches have been made 
possible by appropriating elements of the endogenous 
mammalian microRNA (miRNA) biogenesis pathway to 
achieve post-transcriptional gene silencing (PTGS) (Fig. 1). 
MiRNAs represent a class of short ~22 nucleotide (nt) RNAs 
derived from longer hairpin RNA-containing precursors that 
are found in single or polycistronic clusters and in exonic or 
intronic regions of coding and non-coding mRNA [reviewed 
in [5, 6]]. RNA Pol II transcripts containing short stem-loop 
structures called primary microRNAs (pri-miRNAs) are 
processed in two successive steps. The first occurs in the 
nucleus where the hairpin-like structure of the pri-miRNA is 
recognised and cleaved by the microprocessor complex, 
which comprises the RNAse III enzyme Drosha and its 
partner, DiGeorge critical region 8 protein (DGCR8). A 
shorter 70-80 nt hairpin duplex known as a precursor-
microRNA (pre-miRNA) is produced by the microprocessor 
complex [7, 8]. In rare cases, short intronic sequences may 
be processed by the spliceosome to form pre-miRNA 
hairpins or “mirtrons” without requiring Drosha cleavage [9-
12]. Once formed, pre-miRNAs containing a 2 nt 3 hydroxyl 
overhang are exported from the nucleus to the cytoplasm by 
the nuclear karyopherin exportin-5 [13, 14]. The second 
processing step occurs in the cytoplasm where the pre-
miRNA is cleaved by the RNase III enzyme Dicer to 
produce a ~22 base pair, staggered miRNA/anti-miRNA 
duplex [15, 16]. Dicer and its binding partner, TAR RNA-
binding protein (TRBP) [17], loads one of the strands, 
referred to as the mature miRNA or “guide strand”, into the 
RNA-induced silencing complex (RISC). In its simplest 
form RISC comprises Argonaute 2 (Ago2) and Dicer/TRBP 
[18, 19]. The other strand of the RNA duplex, known as the 
“passenger strand”, may be cleaved within RISC by the 
RNase H-like Piwi domain of Ago2 [20-22]; or simply 
released from the complex. Selection of the guide strand is 
based on asymmetric thermodynamic stability of the RNA 
duplex ends [23]. The strand with the weaker paired bases at 
the 5 end of the duplex is preferentially incorporated into 
RISC as a guide [reviewed in [24, 25]]. 
 The mature miRNA guide strand associates with Ago2-
containing RISC and acts as a guide by targeting 2-7 
nucleotide “seed regions” of the 3 untranslated regions (3 
UTRs) of mRNAs [26]. Complementary matches of the 
guides with 3 UTRs induce translation suppression by 
several known mechanisms: transcriptional cleavage, 
blocking of ribosomal function, deadenylation or shunting of 
mRNAs to transcriptionally inactive cytoplasmic P bodies 
[reviewed in [27, 28]]. Guide strands with near-perfect 
sequence complementarity to their cognate targets, which is 
a feature of short interfering RNAs (siRNAs), effect gene 
silencing by Ago2-mediated post-transcriptional cleavage of 
targeted RNAs. Mammalian miRNAs rarely bind their 
targets completely and hybridization of the seed region alone 
is sufficient for translational suppression [29]. RNAi guide 
sequences may additionally associate with Ago1 in a RNA-
induced transcriptional silencing complex (RITS) to induce 
transcriptional gene silencing (TGS). This is characterized 
by the targeting of siRNAs or short antisense RNAs to 
promoter elements and resultant transcriptional inhibition is 
caused by induction of silent-state epigenetic modifications 
of DNA and associated nucleosomes (Fig. 1) [30-33]. As 
siRNA-directed TGS elicits more permanent epigenetic 
modifications, TGS may offer a more sustained inhibition of 
gene expression than PTGS. This represents an exciting and 
important new approach to therapeutic HIV gene silencing.  
 Recently, other RNAi-based pathways have been 
uncovered, which make use of specific dsRNA substrates. It 
is premature to speculate on what role these newer RNAi 
pathways may have in generating novel therapeutics. In the 
germline, a number of short 24-31 nt RNAs are associated 
with Piwi-family proteins or Piwi-interacting RNAs 
(piRNAs) (Fig. 1) [reviewed in [34]] and originate from 
repeat-rich regions of the genome. piRNAs are processed 
through a distinct Dicer-independent mechanism [35] and 
cause transcriptional silencing of transposons by establishing 
de novo DNA methylation in murine fetal testes [36-38]. In 
recent studies of mouse oocytes and embryonic stem (ES) 
cells, an abundant class of endogenous siRNAs or endo-
siRNAs was discovered. These RNAs are thought to be 
derived from transcripts with long inverted repeats or from 
convergent and divergent transcripts of pseudogenes or 
transposons (Fig. 1) [12, 39, 40]. Apart from blocking retro-
transposition, little is known about the function of endo-
siRNAs. However, the ubiquity of overlapping transcripts 
suggests that there are more endo-siRNAs with their putative 
RNA targets that are present within the genome. 
3.EXOGENOUS ACTIVATORS OF RNAI 
 There is a myriad of exogenous dsRNA triggers of the 
RNAi pathway that have been introduced into cells to effect 
post-transcriptional degradation of mRNAs. The most 
common form of silencing is typically achieved by adminis-
tering chemically synthesized siRNAs. While synthetic 
siRNAs are not the focus of this review, it is worth pointing 
out that these species do have some advantages over expres-
sed RNAi effectors. siRNAs can be chemically modified to 
improve their efficacy in vivo. This may be achieved by 
increasing resistance to serum nucleases, enhanced guide 
strand function, attenuation of innate immunostimulation, 
improved pharmacokinetic properties and the addition of 
targeting ligands for uptake by specific cells in vivo 
[reviewed elsewhere in [4, 41]]. Expressed RNAi activators 
however have other advantages which are discussed below. 
 Most RNAi expression approaches generate hairpin 
duplexes that mimic natural miRNA precursors, such as pri-
miRNAs and pre-miRNAs (Fig. 2). Expressed effectors 
differ from their synthetic counterparts by providing a more 
sustained suppression of the target RNA through the 
continued renewal of RNAi precursors. RNAi expression 
cassettes are also compatible with highly efficient viral 
vectors, which may allow exploitation of the cell-specific 
targeting, integration and expression characteristics of the 
recombinant viruses. Short hairpin RNA (shRNA)-encoding 
sequences typically mimic pre-miRNAs and are widely used 
in gene-based silencing platforms. These are usually inserted 
downstream of a RNA Pol III promoter, such as H1 and U6, 
to generate transcripts with defined 5 and 3 termini. This 
allows for efficient nuclear export and processing by Dicer in 
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Fig. (1). Mammalian RNAi regulatory pathways. Pri-miRNAs of approximately 100 nt are microRNAs precursors and are transcribed by Pol 
II. Processing in the nucleus by Drosha/DGCR8 produces shorter hairpin duplexes known as a 70-80 nt pre-miRNAs. Some short intronic 
sequences, or “mirtrons”, can be directly processed by the spliceosome to form pre-miRNA-like hairpins without requiring Drosha cleavage. 
Pre-miRNAs are exported from the nucleus to the cytoplasm by the exportin-5 following which recognition and cleavage by Dicer/TRBP 
produces a ~22 base pair, staggered miRNA duplex with 2 nt 3 overhangs. Dicer/TRBP loads one of the strands, the “guide strand”, into 
RISC and directs cleavage or translational suppression of cognate RNA targets. RNA-induced trancriptional gene silencing (TGS) in 
mammals is effected by a short guide antisense RNA guide strand in the RITS complex, which is directed to promoter sequences in the 
nucleus. TGS may require the presence of low-copy promoter-derived transcripts to direct silent heterochromatin marks (H3K9 and/or H3K27 
methylation) and DNA methylation at the targeted locus [149, 150]. Endogenous siRNAs (endo-siRNAs) are derived from long hairpin 
sequences and complementary transcripts which are processed by Dicer into siRNAs. Piwi-interacting RNAs (piRNAs) are 24-31 nt short 
RNAs derived from single-stranded precursors that are expressed from transposons or genomic repeat elements in the germline. In the “ping-
pong model”, primary piRNAs interact with the Piwi protein Mili to cleave a transcript that generates a piRNA for incorporation into Miwi2, 
which in turn cycles back to produce new Mili-interacting piRNAs [151]. 
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Fig. (2). Exogenous RNAi-mediated gene silencing. RNA Pol II-derived transcripts introduce hairpin duplexes which structurally mimic 
mono or polycistronic pri-miRNAs which are recognised and processed by Drosha/DGCR8 to form pre-miRNA-like hairpins. These hairpins 
are cleaved by Dicer/TRBP following export via exportin-5. The Pol II-generated U1 short hairpin RNA (shRNA) transcripts, which contain a 
3 terminal B-box, structurally mimic pre-miRNAs but are likely to be exported by the CRM1 and exportin-5 pathways prior to Dicer/TRBP 
cleavage [152]. RNA Pol III promoters express shRNAs with defined 5 and 3 termini. U6 or H1-derived shRNAs, like pre-miRNAs, have 2 
nucleotide 3 overhangs and exit the nucleus via exportin-5. tRNALys3 and tRNAVal Pol III promoters may also be used to produced tRNA-
shRNAs for processing in the nucleus by 5 and 3 tRNA processing enzymes prior to export [43, 153]. If unprocessed by RNase ZL, tRNA-
shRNAs may exit the nucleus via exportin-t [154]. Synthetic siRNAs can be introduced for direct loading into Ago2-RISC. 
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the cytoplasm. Other transcriptional regulatory elements, 
such as U1 Pol II and tRNA Pol III promoters, have also 
been used (Fig. 2). Transcripts derived from these cassettes 
have the advantage of utilising a different nuclear export 
pathway to that of endogenous miRNAs. This is important to 
minimise disruption of the function of the naturally 
occurring RNAi activators [42-44]. Most Pol III promoters 
have the drawback of being constitutively active and not 
being amenable to tight transcriptional regulation. Pol II 
promoters, which can be regulated more easily by cell-
specific environmental factors, have recently become more 
popular for the expression of pri-miRNA mimics (discussed 
later). 
4. RNAI-MEDIATED TARGETING OF HIV RNAS 
4.1. Incoming Viral Genomic RNA as a Target 
 Incoming, uncoated HIV RNA is an enticing target for 
RNAi-mediated inhibition. Blocking viral replication at this 
stage would prevent proviral integration and subsequent viral 
gene expression and replication. There is still some debate as 
to whether incoming RNA is accessible to RNAi-mediated 
attack. Several early studies suggested that incoming RNA 
could be targeted using siRNAs [45-47]. Incoming viral 
RNA, represented by two viral RNA genomes, is continually 
bound by proteins such as p17 matrix, integrase and reverse 
transcriptase [48]. This association may limit access of the 
RNAi machinery to the target HIV genomic RNA. Also, 
following membrane fusion between the host cell and virion, 
the viral core particle is only partially dissolved while the 
RNA genome is reverse transcribed and transported towards 
the nucleus. Furthermore, reverse transcription usually 
occurs within 6 hours of viral entry into lymphocytes [49], 
providing a very short window of opportunity for RNAi-
mediated inhibition of incoming viral RNA. Indeed two 
thorough investigations using synthetic siRNAs and shRNAs 
against a wide range of targets indicate that the newly-
released viral genome remains encapsidated or partially-
encapsidated during reverse transcription, thus blocking 
access to guide strand-loaded RISC [50, 51]. These studies 
indicate that targeting of viral mRNAs is a better approach to 
achieving RNAi-mediated HIV inhibition. 
4.2. Post-Transcriptional Inhibition of HIV mRNAs and 
Viral Escape  
 Targeting of viral mRNA species transcribed from 
integrated provirus has been more successful and RNAi 
strategies have been used against every coding and non-
coding genomic sequence to inhibit viral replication. The rev 
open reading frame (ORF) was one of the first viral genes to 
be targeted using siRNAs and shRNAs [46, 52]. These initial 
investigations showed that viral transcripts generated early 
during the life cycle were accessible to RNAi-mediated 
inhibition, but not all sites were susceptible to silencing. 
Additional information on HIV target site accessibility was 
gathered using siRNAs/shRNA against the Tat-responsive 
(TAR) stem-loop RNA structure of the 5 long terminal 
repeat (LTR). The TAR target was found to be refractory to 
RNAi knockdown and emphasizes the importance of 
potential inhibition of gene silencing by secondary-structure 
RNA folding [47, 53, 54]. 
 Single nucleotide substitutions within target mRNA, 
especially in the seed region, are sufficient for viral protec-
tion from RNAi effectors [55]. In one example, a shRNA 
targeted to tat mRNA became ineffective after 25 days and 
viral genome analysis showed that a single base substitution 
within tat was responsible for the resistance [56]. Similarly, 
escape mutants appeared following several weeks of 
exposure to a shRNA targeting the nef mRNA. Further 
analysis revealed that base substitutions or deletions within 
nef modified the shRNA target [57]. These two examples 
involve targeting of non-essential viral genes but designing 
siRNAs against essential genes may also result in emergence 
of resistance [58, 59]. Even though env and rev ORFs 
overlap, viral breakthrough does occur. Inhibition of 
infection with three different HIV primary isolates in the 
presence of a single siRNA targeted to overlapping env/rev 
mRNA was not absolute. Escape mutants bearing two point 
mutations in the target sequence evolved readily [58]. The 
use of shRNAs targeted to essential viral sequences did not 
arrest all viral escape, although there was restriction of 
escape possibilities. Mutations were limited to non-silent 
changes that presumably allowed RNAi resistance while 
maintaining viral fitness [59]. Viral escape from RNAi does 
not always involve target sequence mutations. Sequencing of 
two viral mutants replicating in the presence of shRNAs 
targeted to nef mRNA revealed substitution mutations 
upstream of the siRNA target. Resistance was caused by 
alterations in viral mRNA secondary structures which 
probably prevented access of activated RISC complex to its 
cognate [60]. Even more unexpected is the emergence of 
escape through the modulation of transcription, Mutations in 
non-targeted LTR promoter sequences have been shown to 
compensate for RNAi-mediated inhibition by upregulating 
viral gene transcription [61]. Notwithstanding these addi-
tional factors associated with resistance, much of the focus 
has shifted to targeting conserved vital sequences within the 
HIV genome, since HIV is less able to mutate these sites 
without loss of fitness [59, 62-66]. Further evidence of the 
extent of RNAi tolerance to sequence polymorphisms 
emerged from a study using expressed shRNAs against three 
targets: a highly variable rev sequence, a gag site conserved 
across subtype B strains only, and a vif sequence conserved 
across all subtypes [64]. Rev-specific shRNAs inhibited the 
least number of isolates, regardless of subtype. The gag-
specific shRNAs protected against subtype B virus alone and 
the anti-vif shRNAs were effective against all isolates [64]. 
These results suggest that many separate strains of HIV may 
be silenced by targeting conserved sequences. It appears that 
the sequence space for the virus to find resistance is limited 
and many of the sequence changes in conserved target sites 
are found within natural variants of the viral population [59]. 
It will be interesting to determine the fitness costs in vivo 
that are associated with escaping the effects of RNAi. 
 Experiments by Nishitsuji et al also revealed that HIV 
dosage plays a key role in determining whether RNAi-
mediated inhibition is effective. Specifically, shRNAs 
designed to target HIV integrase showed some inhibition of 
HIV replication when shRNA-expressing CD4+ T cells were 
challenged with virus at a low dose of infection [53]. This 
effect was abrogated during long-term (22 days) culture or 
following a high-dose infection [53]. By increasing the 
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dosing regimen of virus infection on T-cells stably expres-
sing anti-HIV shRNAs, von Eije et al were able to identify 
robust shRNA-mediated inhibition by comparing the 
sustained inhibitory effects of each shRNA on its respective 
cognate target [67]. This suggests that although highly 
conserved viral sequences allow for the discovery of many 
effective anti-HIV siRNAs/shRNAs [66, 68, 69], there 
remains a need to validate observations with analysis of the 
long-term inhibitory effects against actively evolving HIV 
infection [59].  
5. HOST CELL TARGETS OF HIV  
 Although using RNAi to target viral sequences is 
important, it is clear that targeting viral sequences alone may 
not be sufficient to ensure long-term viral suppression. 
Since, HIV requires a large number of cellular host factors 
for successful replication, these are potential therapeutic 
targets for RNAi-mediated inhibition. A significant advan-
tage of targeting host genes is that these are not under selec-
tive pressure, and therefore to gain resistance, HIV would 
need to evolve an entirely new set of cellular associations to 
bypass the requirement for an important host factor.  
 The major CD4 receptor required for HIV docking was 
one of the first host cell sequences targeted using siRNAs 
[70]. While these results were promising, there has been a 
shift away from targeting CD4. This is a result of the 
ubiquitous presence of the receptor on various host cells and 
its function in normal immune pathways. The chemokine co-
receptors required for HIV entry are more attractive 
alternatives and there have been numerous studies describing 
RNAi-mediated suppression of chemokine (c-c motif) 
receptor 5 (CCR5) [71-73] and CXC chemokine receptor 4 
(CXCR4/Fusin) [71, 74]. CCR5 was particularly enticing as 
a deletion mutant allele was found to be present at a 
frequency of 0.092 in Caucasian populations, and individuals 
homozygous for the deletion are highly resistant to M-tropic 
HIV infection [75]. Unfortunately this strategy is inadequate 
for complete protection against HIV-1 as T-tropic and dual 
tropic strains can still gain access to cells. One study using 
HIV-2 showed CXCR4 to be sufficient for entry even in the 
absence of CD4 [76] and furthermore, although less 
common, there exist primary HIV isolates that utilize CCR3 
and CCR2b as co-receptors to gain access to CD4+ cells [77, 
78]. RNAi-mediated inhibition of expression of other 
proteins involved in HIV transcription, such as NF, cyclin 
T1 and CDK9, have also been shown to down-regulate viral 
replication [79, 80]. Differences in the viral life cycle in T 
cells and in macrophages may present a challenge to 
development of RNAi-based HIV therapy. Specifically, in T 
cells, nascent viral mRNAs transcribed from the provirus are 
the most attractive targets for RNAi as they are shuttled to 
the cytoplasm by Rev. However, in macrophages new 
virions do not assemble and bud at the plasma membrane. 
Instead viruses may bud into endocytic organelles and 
accumulate in these vacuoles before being released as an 
exosome. The advantage for HIV is that exosomes escape 
immune surveillance but importantly these organelles are 
also inaccessible to antiviral therapies and RNAi-based gene 
silencing [81]. Thus the identification of host factors that are 
required for HIV infection, and which are common to all 
cells infectable by the virus, has become more important for 
the development of gene expression-based antiviral silencing 
approaches.  
 Advances in high-throughput screens using robotic 
instrumentation and genome-wide siRNA libraries have 
resulted in novel reverse genetics applications to monitor 
host-pathogen interactions. Last year alone, three influential 
papers were published describing the use of large-scale 
RNAi screens to uncover host dependency factors (HDFs) 
required for HIV replication (Brass, Dykxhoorn et al. 2008; 
Konig, Zhou et al. 2008; Zhou, Xu et al. 2008). All three 
studies examined approximately 20 000 cellular genes, and 
used between three and six siRNAs to target each gene. 
König et al focused exclusively on those genes involved 
during the initial phases of viral infection and subjected the 
data to thorough, integrative and robust analysis (Konig, 
Zhou et al. 2008). In this study, a genome-wide siRNA array 
with related cellular toxicities was used to generate a 
foundation dataset, which was compared to functional, 
transcriptional and biochemical data collected from protein 
interaction and gene expression databases. Compiling 
relevant information required an ontogeny-based pattern 
algorithm to create a ‘decision matrix’ to prioritize HDFs 
involved in early replication steps of HIV (Konig, Zhou et 
al. 2008). Brass et al identified HDFs associated with the 
nuclear pore complex, various transcription factors, Golgi-
associated proteins, trans-membrane transporters, glycosy-
lation enzymes and autophagy components (Brass, 
Dykxhoorn et al. 2008). König et al identified over forty 
HDFs that regulate uncoating of the viral capsid, as well as 
fifteen factors involved in nuclear entry of the viral pre-
integration complex (PIC) (Konig, Zhou et al. 2008). Zhou 
et al catalogued genes with well characterized roles in HIV 
replication (CD4, CXCR4, Rev-mediated transport inter-
actions) as well as previously unlinked HDFs, including 
factors associated with oxidative phosphorylation and 
adipokine pathways (Zhou, Xu et al. 2008). Surprisingly 
little concordance existed in the 200-300 HDFs identified for 
each of the three studies, with no single gene in common 
between all three datasets. Importantly the results were 
generated using different HIV vectors, siRNA design 
algorithms, separate array formats, and unequal culturing 
efficacies and culture periods. Despite these limitations, the 
genes identified in all three studies have established novel 
potentially druggable targets. However, further investigation 
will be required to verify a genuine role of HDFs in a 
physiological context (e.g. HIV infection of primary T cells) 
before they may be classified as good targets. Of course 
another important consideration in developing this approach 
is making sure that silencing of cellular genes does not have 
unintended toxic effects. 
6. COMBINATORIAL RNAI AGAINST HIV 
 The rapid emergence of viral resistance to single gene 
silencing sequences has prompted development of multiple 
or combinatorial RNAi-based approaches which are akin to 
HAART. Multitarget gene silencing has an advantage over 
traditional HAART in that there are many conserved RNAi-
susceptible sequences within the HIV-1 genome. At this 
stage it is premature to predict the long-term efficacy of 
multiple targeting methods, however it has been proposed 
that assuming equal and effective inhibition, the simul-
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taneous targeting of at least four RNAi-susceptible 
sequences may be sufficient to prevent or, at the very least, 
severely delay the emergence of RNAi-resistant variants [82-
84]. There are several strategies for inhibiting multiple target 
sites on HIV-1 using RNA-based effector sequences. 
Highlighted below are some of the promising combinatorial 
approaches based on use of expressed RNAi activators. 
6.1.Multiple shRNA Expression 
 Short hairpin RNA expression cassettes using RNA Pol 
III promoters (eg. U6, H1, tRNA and VA1) can be placed 
adjacent to each other within a single delivery vector for the 
combined expression of multiple shRNAs or effector RNAs 
(Fig. 3A). Early studies showed that the simultaneous 
targeting of both wild-type HIV and RNAi-escape mutant 
variants by two or more shRNAs in tandem has limited 
usefulness, serving only to reduce the efficacy of the anti-
wild-type shRNA through diminished access to the targeted 
site [53]. Strategies which have targeted up to three separate 
conserved sites have yielded more promising results [85-87]. 
However, most show the emergence of viral escape in 
culture, although at a delayed rate when compared to single 
shRNAs alone. In a seminal study, ter Brake and colleagues 
used a single lentiviral vector to produce stably transduced T 
cells containing four tandem anti-HIV shRNA expression 
cassettes [69]. This multi-shRNA approach prevented emer-
gence of escape mutants over an 80-day period in culture. 
However it was noted that some degree of background viral 
replication occurred in the presence of the inhibiting multi-
RNAi effectors, which was attributed to the lack of silencing 
of incoming RNA and incomplete viral RNA suppression. 
This study assessed efficacy against a single molecular clone 
of HIV. It remains to be determined whether sustained 
repression of a more diverse viral population, such as 
primary virus from an infected individual, is possible. 
Additionally, ter Brake et al made use of different promoters 
to produce each shRNA, since multiple copies of the U6 
promoter were subject to deletion during lentiviral 
recombination [69]. It has been noted that the additive effect 
of using multiple promoters in tandem results in an overall 
decrease in guide strand production [69, 87]. Also, a 
combinatorial system with heterogenous promoters produces 
different amounts of each RNAi hairpin precursor and 
derived effector sequences. Theoretical computational 
analyses of escape kinetics highlight the importance of 
ensuring efficient delivery to HIV-1 susceptible cells and 
potent silencing by each individual RNAi effector of a 
multitargeting system [82].  
6.2. Long Hairpin-Based RNAs 
 An alternative approach to using multiple expression 
cassettes is to exploit the endogenous action of Dicer to 
process long dsRNA templates into multiple siRNA species. 
This has been a controversial application as the main concern 
of working with longer (> 30 bp) dsRNAs in mammalian 
cells is the potential activation of innate immune response 
[88, 89]. However, several studies have now shown that 
expressed dsRNAs, including long hairpin RNA (lhRNA), 
are unlikely to induce unwanted immunotoxicities [90-94]. 
Importantly, unlike with transfection of synthetic RNAi 
activators, expressed lhRNAs do not traverse the endosome, 
and therefore avoid activation of toll-like receptors (TLRs) 
located in this subcellular compartment. The most well-
studied approach to generating expressed lhRNAs is the use 
Pol-III promoters to generate duplexes of between 30 and 
100 bp with the 2 nt 3 overhangs that are required for 
nuclear export by the exportin-5 complex (Fig. 3B). These 
lhRNAs have been shown to be intracellular Dicer substrates 
and produce multiple siRNA species that are capable of 
simultaneously inhibiting different HIV targets [53, 90, 95-
97]. To date, two studies have investigated the potential of 
lhRNAs to prevent RNAi-resistance [53, 97]. However, only 
the study by Sano et al, show sustained antiviral activity of 
lhRNAs when targeted to the overlapping tat/rev region of 
HIV. Importantly, both Sano et al and Nishitsuji et al used 
lhRNAs targeted to a single continuous sequence, making it 
very difficult to identify the relative inhibitory contributions 
of each siRNA generated from the lhRNA. We and others 
have shown that siRNAs are processed by Dicer in a gradient 
of decreasing efficiency, starting from the base of the 
dsRNA hairpin duplex and moving towards the apical loop 
[90, 94, 95, 97]. This phenomenon also occurs when the 
arrangement of separate unique functional siRNAs along the 
lhRNA duplex is opitmized [95]. It thus seems unlikely that 
expressed lhRNAs can be made to produce more than two 
siRNAs at effective functional doses [95, 96], suggesting 
that two or more lhRNA-expression cassettes may be needed 
to induce sustained viral suppression and prevent viral 
escape.  
6.3. Polycistronic miRNA Precursor Mimics 
 The main drawback associated with use of Pol III-
mediated expression of shRNAs and lhRNAs is the powerful 
and constitutive production of RNAi effectors. This is 
especially a concern when using multiple shRNA expression 
cassettes, where many tandem Pol-III promoters are typically 
used. In vivo experiments in mice show that U6 shRNAs are 
capable of inducing severe toxicities by blocking the 
endogenous RNAi pathway [98-100]. In the most extreme 
case, high doses of shRNAs produced in the liver after 
expression from adeno-associated virus vectors induced 
acute liver toxicity and mortality in mice [98]. The toxic 
effect resulted from saturation of the exportin-5 karyopherin, 
which is responsible for transporting pre-miRNA from the 
nucleus to the cytoplasm. These observations have subse-
quently been confirmed by experiments which examined the 
long-term effects of U6 and H1-expressed shRNAs in 
lentiviral-transduced human primary peripheral blood-
derived T lymphocytes (PBLs) that were transplanted into 
immune-deficient mice [100]. Observations suggest that the 
transcriptionally stronger U6 promoter, and not the H1 
promoter, is responsible for causing unwanted toxicities. 
Further systematic experiments in cell culture show that the 
introduction of multiple shRNAs from combinatorial 
expression cassettes blocks RISC loading of individual 
siRNAs [101]. To prevent these saturating effects on the 
endogenous RNAi pathway, much of the recent attention in 
combinatorial RNAi has focused on exploiting the properties 
of natural microRNA precursor biogenesis (Fig. 3C). At 
present there is no evidence that pri-miRNA shuttles, even if  
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Fig. (3). Combinatorial RNAi-based expression approaches. A. 
Multiple shRNA expression cassettes, expressed from Pol III 
promoters (or off the U1 Pol II promoter) each produce shRNAs 
with defined 3 and 5 termini for export and processing by Dicer 
into independent siRNAs. B. lhRNAs, are processed sequentially by 
Dicer to produce up to 3 siRNAs. C. Polycistronic pri-miRNA 
mimics rely on processing by Drosha/DGCR8 to produce multiple 
pre-miRNAs that are independent Dicer substrates.  
highly expressed, can saturate the endogenous RNAi 
pathway [102-105]. MiRNAs also have other advantages for 
developing combinatorial RNAi approaches. Since pri-
miRNAs are expressed from Pol II promoters, tissue-specific 
or inducible gene regulation is possible, allowing for greater 
control of dosage and cell-specific expression. Most 
importantly, many natural pri-miRNAs are found in 
polycistronic configurations which is a feature exploited for 
the generation of multiple RNAi effectors against HIV [106-
108]. Lui et al was the first to show that a lymphocyte-
specific polycistronic miRNA cluster (miR-17-92 cluster) 
could be used to generate five anti-HIV targeting miRNA 
mimics [108]. Not all combinations of polycistronic 
miRNAs were effectively processed from their precursors, 
however strong short-term inhibition of HIV was observed in 
stably-transduced T cells challenged with HIV [108]. In a 
similar study, Aagaard et al showed that three anti-HIV 
miRNA mimics could be independently expressed within the 
framework of a natural polycistonic cluster of three pri-
miRNAs (miR106b-miR-93-miR-25 cluster) [106]. When 
the polycistronic miRNA cassette was expressed in T-
lymphocyte cell lines and challenged with two different 
strains of HIV, each processed miRNA mimic effectively 
suppressed the replication of the subtype B molecular clone 
HIV-LAI, but suppressed the more pathogenic subtype B lab 
strain HIV-IIIB less effectively [106]. It remains to be shown 
whether combinatorial approaches based on polycistronic 
miRNA mimics can prevent viral escape in the long term. 
Moreover, at this stage, further investigation is needed to 
address important questions relating optimization in genera-
ting miRNA mimics from their endogenous polycistronic 
scaffolds. For example, which endogenous pri-miRNA 
backbone structure represents the best scaffold for guide 
sequence substitution? Does the choice of backbone affect 
the guide strand efficacy, and does each backbone function 
equally well when placed adjacent to each other in a 
polycistronic fashion? Is the choice of backbone affected by 
cell-specific factors for proper processing, and if so, can this 
be exploited for therapeutic use?  
7. POTENTIAL UNWANTED TOXICITIES 
 An important consideration in advancing use of RNA-
based gene therapy approaches is the potential to induce 
unwanted off target effects (OTEs). These may result from 
innate immunostimulation and non specific interaction of 
RNAi effectors with host cellular sequences. The intra-
cellular presence of duplexed RNA may activate the innate 
immune system. Specifically the cytoplasmic receptors 
dsRNA dependent protein kinase (PKR) and retinoic-acid-
inducible gene-I (RIG-I), leading to a type 1 Interferon (IFN) 
response [reviewed in [109]]. Over 300 interferon-stimulated 
genes (ISGs) are activated by increased circulating levels of 
cytokines IFN- and  [110]. In particular, the activation of 
2’-5-oligoadenylate synthetases (2-5-OAS) leads to general 
translational arrest, resulting in apoptosis via the non-
specific degradation of cellular mRNA by activated RNase L 
[reviewed in [109, 111]]. Exogenously introduced RNAs 
(ssRNAs and dsRNAs) are also capable of interacting with 
different endosomal Toll-like receptors (TLRs), leading to a 
signaling cascade that activates the IFN pathway. However, 
it is important to note that expressed duplexed RNA can 
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evade detection by TLRs when expressed in CD34+ 
progenitor hematopoietic stem cells [93]. The therapeutic use 
of RNAi may also be complicated by induction of sequence-
specific OTEs. Unintended binding of the guide strand seed 
regions to complementary cellular sequences may lead to 
translational inhibition [112, 113]. Cellular hexanucleotide 
mRNA sequences that may interact with potentially 
therapeutic guides are widespread, which makes it difficult 
to predict true OTEs using computational algorithms. In the 
future, it is likely that transcriptional and proteomic array 
data will be necessary to exclude off-target toxicities 
associated with a particular siRNA guide sequence. Ideally, 
to limit the non specific silencing therapeutic sequences 
should be expressed in specific target tissues, potent and 
effective at a low concentration. Analyses of the global 
effects on gene expression become even more important 
when using multiple targeting approaches. This is especially 
the case for long duplex RNAs where it is often difficult to 
predict the variety of guide sequences generated from RNAi 
effectors.  
8. HIV MODULATES THE RNAI PATHWAY (OR 
VICE VERSA) 
 There is a number of intriguing studies which suggest a 
delicate interplay between the endogenous RNAi pathway 
and HIV replication. Specifically, the viral transactivator Tat 
appears to directly inhibit Dicer processing of siRNA 
precursors in vitro [114]. Moreover, there is possibly a direct 
association between viral transcriptional activation and the 
RNAi processing pathway since Dicer requires its binding 
partner, TRBP, for functional RNAi [17]. TRBP, like Tat, 
also binds the HIV-1 TAR loop to ensure viral trans-
criptional activation [115-117]. Sequestration of TRBP by 
the HIV-1 TAR loop may thus inhibit Dicer activity, thereby 
reducing the overall effectiveness of RNAi [118]. Never-
theless, the role of both Tat and TRBP as RNAi inhibitory 
factors remains controversial. A global decrease in cellular 
microRNAs upon HIV infection should be expected but this 
has not been widely observed using large-scale genomic 
screens [119, 120]. Nevertheless, in a thorough study, 
Triboulet et al have reported that HIV infection downregu-
lates members of the miR-17-92 polycistronic miRNA 
cluster. This affects the Tat co-factor, P300/CBP-associated 
factor (PCAF), which is responsible for RNA Pol II 
elongation and processive viral transcription [120]. Although 
these results suggest a direct link between cellular miRNAs 
and increased HIV activation, at this stage it remains unclear 
as to what causes a decrease in miR-17-19 levels upon 
infection.  
 There is the possibility that HIV encodes its own 
miRNAs or siRNAs [121-123]. However with only frag-
mentary data available and without a clear understanding of 
the mechanism by which these miRNAs/siRNAs might 
function, little can be inferred about the role of these putative 
effector sequences. Nevertheless, Omoto et al have shown 
that HIV nef encodes a miRNA (miR-N367) that appears to 
affect transcription of viral mRNAs through interactions with 
the negative response element (NRE) of the U3 LTR region 
[122, 123]. Also, two human miRNAs, miR-29a and miR-
29b, detected in infected peripheral lymphocytes were shown 
to inhibit nef expression and HIV replication in vitro [124] 
and in vivo [125]. The TAR stem-loop region has been 
shown to be a substrate for Dicer cleavage but a function of 
this putative viral miRNA remains inconclusive [126, 127]. 
Lastly, a cluster of host miRNAs are activated in latently-
infected CD4+ T cells [128]. These miRNAs appear to 
contribute to viral latency by targeting sequences within the 
3 UTRs of most HIV mRNA species. Interestingly, one 
suggested mode of therapy is to inhibit latency-associated 
miRNAs with antisense inhibitors. This may activate dor-
mant virus and allow conventional therapies to eradicate the 
reservoir of latently-infected cells [128, 129].  
9. THE THERAPEUTIC APPLICATION OF ANTI-HIV 
RNAI 
9.1. Pre-Clinical Studies 
 Current gene therapy protocols have focused mainly on 
achieving long term suppression of HIV by using retroviral 
or lentiviral vectors that generate stably expressed RNAi 
transgenes. More recently, HIV-based lentiviral vectors have 
been used for delivery and stable integration of transgenes in 
hematopoietic cells, such as CD4+ T cells or CD34+ 
haematopoietic progenitor stem cells (HSCs). The aim of this 
approach has been to provide a protective and reconstituted 
immune system in vivo (reviewed in [130]). In a seminal 
paper, primary CD34+ HSCs transduced with anti-rev 
shRNAs underwent successful differentiation to form mature 
macrophages or T cells [131]. These in vitro data were 
further assessed using a humanised mouse model of HIV 
infection. In this model lentiviral vector-transduced human 
haematopoetic stem cells were used to reconstitute the T-
lymphoid compartment of SCID (severe combined 
immunodeficiency) mice that do not produce these immune 
cells [131, 132]. Engraftment of RNAi-transduced HSCs into 
the mice (SCID-hu mice) resulted in reconstitution of 
thymocytes that matured and responded to mitogenic 
stimulation as expected for normal T cells. Significant viral 
resistance was observed following ex vivo HIV challenge of 
differentiated, transduced macrophages and T cells [131]. 
While useful, the SCID-hu mouse model has low 
engraftment levels with limited systemic spread of HIV 
following infection, and this has prompted research aimed at 
further modifying SCID mice. One model is the non-obese 
diabetic/SCID (NOD/SCID) mouse which harbours a 
complete null mutation in the common cytokine receptor  
chain that abrogates interleukin 2 binding (NOD/ 
SCID/IL2r-) [133]. In these mice T and B cell development 
is disrupted as the  chain receptor is required for innate 
immunity [134]. In a recent elegant study, a single-chain 
antibody specific for the T-cell specific CD7 receptor was 
conjugated to several anti-HIV siRNAs via an arginine tag 
[135]. Impressively, anti-vif and anti-tat siRNA-antibody 
conjugates were introduced into NOD/SCID/IL2r- and 
SCID-hu mice and prevented HIV infection and CD4+ T cell 
loss without any observed toxicities. Using a mouse model 
derived from a recombination activating gene (RAG)–
deficient strain that also lacks a  chain receptor (BALB-
Rag2
-l-), HSCs tranduced with a lentivector encoding an 
anti-HIV nef shRNA showed significant inhibition of HIV 
replication [136]. All of the mouse models described above 
have demonstrated their utility for ex vivo engraftment and 
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immune reconstitution of T cells that are protected from the 
cytopathic effects of HIV, providing a foundation for similar 
approaches in human patients. Using a non-human primate 
model, An et al were able to report successful stable T-cell 
expression of shRNAs directed to CCR5 in rhesus macaques 
[137]. Following transplantation of rhesus HSCs, consistent 
downregulation of CCR5 expression was observed in mature 
T cells for up to 14 months. These cells were less susceptible 
to simian immunodeficiency virus (SIV) infection when 
assessed ex vivo [137]. Although physiologically-relevant 
models of HIV are lacking, success with murine models of 
HIV infection has led to progress towards clinical trial 
assessment of RNAi-based anti HIV therapy. Advances of 
these investigations are briefly described below.  
9.2. Clinical Studies 
 A number of anti-HIV RNAi effectors have all been 
tested in human phase 1 or 2 clinical trials with varying 
efficacies depending on the transfer vector used and whether 
T cells or haematopoetic progenitor cells were transduced 
[138-141]. The first example of RNAi in a stem cell setting 
is currently being conducted by John Rossi and collaborators 
at the City of Hope Medical Center in Duarte, California. 
This trial involves a pilot study of transduced HSCs in AIDS 
lymphoma patients to assess the safety and therapeutic 
feasibility of using a lentiviral vector encoding three anti-
HIV modalities, including a U6-expressed shRNA targeted 
to the tat/rev overlapping region [4, 142]. This clinical trial 
was initiated when a lentiviral construct expressing the anti-
HIV transgene was shown to successfully transduce primary 
HSCs and induce long-term inhibition of HIV replication in 
these cells [143]. Transduced cells were additionally able to 
differentiate normally into different lymphocyte lineages 
without evidence of untoward effects. Protected HSCs gave 
rise to phenotypically normal T cells that were HIV resistant 
when engrafted into SCID-hu mice [144]. For the human 
trial, bone marrow lymphocytes were removed from four 
patients and cultured ex vivo to enrich progenitor cells. 
Following enrichment, the haematopoietic precursors were 
transduced with the lentiviral vector before autologous 
reintroduction into patients who had undergone bone marrow 
ablation [142]. Outcomes from these studies are keenly 
awaited and will be of importance for refinement of this 
exciting new technology.  
10. CONCLUSIONS AND FUTURE PROSPECTS  
 Just over 10 years have passed since RNAi was disco-
vered and already RNAi-based gene expression strategies are 
being tested in a clinical setting. Although much has been 
achieved, a complete understanding of the mammalian RNAi 
pathway, and its influences on cellular biology, remains an 
important focus of research. RNAi belongs to a paradigm 
where cellular function and gene activity are integrally 
linked to short (and long) non-coding RNAs. These newly-
discovered RNAs are found throughout the genome and we 
are only now beginning to understand their roles in the cell. 
The influence of the intricate network of small RNAs on 
gene expression is complex, and the effects of exogenous 
therapeutic sequences on normal gene function will require 
rigorous characterisation. Careful regulation of RNAi 
effector dose and targeted delivery of therapeutic sequences 
will be important to avoid unintended disruption of 
endogenous RNAi pathways. 
 Some RNAi-related pathways such as TGS are being 
considered seriously as potential antiviral modalities. Using 
synthetic and expressed antisense RNAs, we and others have 
previously reported that HIV transcription can be blocked 
when targeting the LTR promoter of the integrated provirus, 
resulting in permanent inhibition of gene expression [33, 
145-147]. This approach was recently shown to be feasible 
in T cells transduced with replication-competent lentiviruses 
expressing the anti-HIV TGS-inducing transgene [148]. If 
specific viral or cellular genes can be permanently silenced, 
this may alleviate the need for continuous expression of the 
therapeutic RNA inhibitor and has enormous potential for 
therapeutic application. However, as with other emerging 
RNA-based therapies, the safety and sustained inhibitory 
potential of TGS-based RNAi will need to be evaluated 
comprehensively. 
 The rapid progress of RNAi -based HIV therapy has been 
stimulated by important improvements in the efficacy and 
safety of modern lentiviral vectors, as well as better animal 
models of HIV infection. This has enabled rigorous pre-
clinical testing and proof-of-concept studies. In human trials 
conducted thus far, we know that transduction of HSCs can 
be accomplished safely and therefore the outcome of phase 2 
efficacy studies is eagerly anticipated. Future clinical trial 
results will soon determine whether introduction into CD34+ 
HSCs of expressed RNAi activators results in a) protection 
and possibly immune reconstitution of all derived haemato-
poietic lineage cells; and b) effectively achieves long-term 
viral suppression in HIV/AIDS patients. Although it is 
currently unclear how AIDS may be cured by harnessing 
RNAi, the potential of gene therapy for countering HIV 
infection is exciting. The technology has the potential to 
improve the quality of life and lifespan of infected indivi-
duals and to relegate HIV to an easily-managed chronic 
infection. Momentum in the field is now considerable and 
this is likely to overcome existing hurdles. Prospects for 
advancing RNAi-based therapy for HIV infection are 
exciting and important developments in the field will no 
doubt be realised during the coming years.  
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Abstract
RNA Interference (RNAi) effectors have been used to inhibit rogue RNAs in mammalian cells. However, rapidly evolving
sequences such as the human immunodeficiency virus type 1 (HIV-1) require multiple targeting approaches to prevent the
emergence of escape variants. Expressed long hairpin RNAs (lhRNAs) have recently been used as a strategy to produce
multiple short interfering RNAs (siRNAs) targeted to highly variant sequences. We aimed to characterize the ability of
expressed lhRNAs to generate independent siRNAs that silence three non-contiguous HIV-1 sites by designing lhRNAs
comprising different combinations of siRNA-encoding sequences. All lhRNAs were capable of silencing individual target
sequences. However, silencing efficiency together with concentrations of individual lhRNA-derived siRNAs diminished from
the stem base (first position) towards the loop side of the hairpin. Silencing efficacy against HIV-1 was primarily mediated by
siRNA sequences located at the base of the stem. Improvements could be made to first and second position siRNAs by
adjusting spacing arrangements at their junction, but silencing of third position siRNAs remained largely ineffective.
Although lhRNAs offer advantages for combinatorial RNAi, we show that good silencing efficacy across the span of the
lhRNA duplex is difficult to achieve with sequences that encode more than two adjacent independent siRNAs.
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Introduction
RNA Interference (RNAi) is a highly conserved biological
pathway in eukaryotes where gene silencing is mediated by a
double-stranded RNA (dsRNA) trigger [1]. Exploitation of the
RNAi pathway has lead to fundamental new tools for genetics
research and for sequence-specific therapeutic approaches aimed
at suppressing rogue cellular genes or viral-associated RNAs.
RNAi has traditionally been induced in mammalian cells through
the exogenous introduction of synthetic short interfering RNAs
(siRNAs) [2], or through the use of RNA Pol III or Pol II gene
constructs which express 21–29 bp short hairpin RNAs (shRNAs)
[3–6]. Expressed short hairpins resemble pre-microRNAs (pre-
miRNAs), which are part of the endogenous microRNA (miRNA)
pathway [7,8]. The targeting of highly mutable sequences, such as
genomic and sub-genomic RNAs from infectious agents, remains a
significant hurdle for the use of RNAi-based therapeutics. In
particular, the human immunodeficiency virus type 1 (HIV-1),
which replicates using an error-prone reverse transcriptase, has
been shown to escape the silencing effects of shRNAs. Resistant
viral variants emerge easily in cell culture experiments, even when
targeting highly conserved sequences [9–11]. Effective targeting of
rapidly evolving targets requires a combinatorial approach, which
is analogous to Highly Active Antiretroviral Therapy (HAART)
[reviewed by [12,13]].
The targeting of many sites simultaneously using RNAi has
been attempted with multiple shRNA expression units, where each
unit is expressed from a RNA Pol III promoter [14–16] or RNA
Pol II promoter [17]. Similarly, concatenated miRNA mimics
expressed from a single RNA Pol II promoter have been shown to
suppress simultaneously up to three separate target sequences
[6,18,19]. Although RNAi-mediated silencing in lower eukaryotes
can be achieved efficiently by introducing precursor dsRNAs
comprising more than 150 base pairs (bp), intracellular presence of
dsRNA of greater than 30 bp leads to a strong innate
immunostimulatory response, which is mediated by dsRNA-
activating protein kinase (PKR) and 29–59 oligoadenylate synthe-
tase [20]. A re-evaluation of long dsRNA greater than 30 bp in
mammalian cells has shown that safe and effective gene-specific
silencing can be achieved when dsRNA is expressed from DNA-
based expression cassettes [21–26]. Although a complete charac-
terization of how intracellular dsRNAs are discriminated remains
to be established, intracellularly expressed dsRNA seem capable of
evading cytoplasmic activators of the type 1 interferon response
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[27,28]. A natural potential advantage of longer dsRNAs is that
processing by the RNAse III endonuclease Dicer theoretically
allows for the generation of multiple siRNAs, providing a
mechanism of combinatorial targeting of rapidly-evolving RNAs.
The silencing caused by lhRNAs may also be more effective than
that resulting from a single unique siRNA derived from an
individual shorter (,30 bp) expressed shRNA.
Akashi et al. showed that (,50 bp) long hairpin RNAs (lhRNAs)
expressed from tRNAVal and U6 RNA Pol III promoters
generated multiple siRNAs [24]. We and other have shown that
similar constructs were capable of suppressing Hepatitis B Virus
(HBV) [26], Hepatitis C Virus (HCV) [29] and HIV-1 [30–33]
targets. To date, lhRNAs capable of producing more than two
independent siRNAs have only been used against contiguous
target sequences. Since ,60 bp hairpin RNAs should be capable
of providing a substrate for at least three catalytic reactions
involving Dicer, we have examined the possibility of introducing
three distinct non-contiguous target sequences that, if processed by
Dicer, are capable of generating highly-effective independent
siRNA species. To determine the ability of targeting disparate
regions in the HIV-1 genome, we generated a panel of ,69 bp
U6-lhRNA expression cassettes, each consisting of a different
arrangement of three adjacent 21-mer putative siRNA sequences.
The siRNA sequences chosen were previously characterized as
highly effective anti-HIV-1 shRNAs targeted to Tat/Env, Tat/
Rev and Vif open reading frames [4,34]. We show that all
combinations of lhRNAs were capable of significant knockdown
against individual target sequences. However, silencing efficiency
together with individual siRNA concentrations diminished from
stem base to loop side along the length of the duplex. We present
here a thorough characterisation of the efficacy of expressed
lhRNAs designed to generate multiple siRNAs targeted to non-
contiguous siRNA-susceptible regions of HIV-1.
Results
Design of anti HIV-1 lhRNA-expressing plasmids
Three sites that have been previously shown to be effective for
RNAi-mediated inhibition of HIV-1 were selected. These include
shRNAs targeted to sites within two separate overlapping reading
frames of the HIV-1 genome: Tat/Rev (tat) and Rev/Env (rev) [4].
The third site includes a sequence within the Vif open reading
frame (vif) [34] (Fig. 1A). Long hairpin RNAs of approximately
69 bp (with a 5 nt terminal loop) were designed to be transcribed
from a U6 RNA Pol III promoter such that three 21–23 bp
siRNAs could potentially be generated by Dicer cleavage (Fig. 1B).
LhRNA and shRNA expression cassettes were designed to encode
siRNA precursors targeted to each of these 3 HIV-1 sites (Fig. 1C).
G:U wobble base pairs were included at regular intervals by
adjusting sequences in the sense strand to facilitate propagation of
the lhRNA-encoding cassettes in E. coli. To control for changes in
strand bias, similar G:U mismatches were made to each shRNA
(Fig. 1C). These changes have previously been shown to have no
impact on RNAi knockdown efficacy [24,26] and may help in
suppressing the innate immune response to dsRNA [24]. The
lhRNAs were therefore intended to be capable of serving as
substrates to form siRNAs against each of the tat, rev and vif HIV-1
targets. By targeting three viral sites simultaneously, the lhRNAs
have a possible therapeutic benefit of limiting viral escape.
Although this is an important theoretical advantage, there is
some evidence to suggest that Dicer processing of lhRNAs may not
be equal across the span of the duplex [26,33] and that Dicer
favours the production of siRNAs generated from the hairpin stem
base. Thus, to assess the importance of the position of the tat, rev
and vif siRNA-encoding sequences within the anti HIV-1 lhRNAs,
their efficacy when ordered as first, second or third within the stem
duplex was assessed.
Assessing anti HIV-1 efficacy of expressed lhRNA
sequences in cell culture
Initially, to assess efficacy against HIV-1 in vitro, HEK293 cells
were cotransfected with lhRNA-or shRNA-expressing vectors
together with the dual luciferase psiCheck vector encoding a
reporter/HIV-1 fusion gene (Fig. 2A). Four target vectors were
generated, which each included tat, rev, vif or a combination of tat-
rev-vif HIV-1 21-mer targets downstream of the Renilla luciferase
open reading frame (ORF). Measurement of Renilla:Firefly
luciferase allowed convenient and accurate measurement of the
in situ efficacy of the hairpin sequences. When using the luciferase
reporter that includes all three HIV-1 targets (psiCheck tat-rev-vif),
highly effective knockdown of approximately 90% was achieved
for each of the lhRNA- and shRNA-encoding plasmids (Fig. 2B).
When the tat sequence alone was inserted downstream of the
Renilla luciferase reporter gene, the shRNA tat vector was capable
of 90% inhibition of reporter gene expression, and as expected, the
shRNA rev and shRNA vif vectors caused no decrease in reporter
fusion gene activity (Fig. 2C). lhRNA expression cassettes
diminished Renilla-tat gene activity by approximately 30–50%
and lhRNA tat-rev-vif was the most efficient. When similar
assessment was carried out on the psiCheck rev and psiCheck vif
targets, the shRNAs induced specific silencing and lhRNAs with
the siRNA-encoding sequences located at the base of the stem
duplex were most efficient. A 63 bp lhRNA targeted to the HIV-1
TAR loop, showed no inhibitory activity against any of the targets.
These data support our previous observations using lhRNAs to
inhibit HBV [26] and HIV [31,33] replication and indicate that
there is a bias of silencing efficiency that diminishes from the base
of the stem to loop side of the duplex RNA.
Detection of processed antiviral hairpin sequences
The spacing arrangement of each individual siRNAs within the
long hairpin duplex is such that 4 ‘‘neutral’’ bases were placed
between each 21-mer sequence. This arrangement was recently
determined as optimal for two siRNAs placed within an extended
shRNA [32]. To analyse primary transcripts and processed
products of the anti HIV-1 hairpin expression cassettes a northern
blot hybridisation was carried out. RNA was extracted from
transfected HEK293 cells and Figure 3A shows the signals
obtained after hybridisation to probes that were complementary
to the putative mature processed tat, rev or vif siRNA guide strands.
Mature products of each of the shRNA expression cassettes were
detectable as bands of approximately 22–23 nt in size. Processing
of the shRNA primary transcripts to produce siRNA appeared to
occur more effectively than that of lhRNA expression cassettes for
guide strands at the base of the duplex, which may be due to better
recognition by Dicer for the shRNA than the lhRNA (Fig. 3A).
The band representing precursors for construct lhRNA vif-tat-rev
was larger than the precursor bands of the other two lhRNAs,
suggesting that read-through transcription is occurring beyond the
polyT termination signal. Detection with the vif probe suggests
that the production of siRNAs were not impaired for lhRNA vif-
tat-rev (at least in the first position). For the lhRNAs, guide strands
derived from the duplex stem base region of the lhRNA expression
cassettes were present in highest concentration, while those that
originated from the second and third positions of the lhRNA stem
were only detected for the lhRNA rev-vif-tat construct, in
decreasing order of concentration. It is possible that the probes
are not detecting the second or third siRNA because of
Long Hairpin RNA Processing
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misalignment due to differential Dicer processing. To investigate
this further, we used two 14-mer locked-nucleic acid (LNA)
probes, LNA-tat-1 and LNA-tat-2, which were partially or fully
complementary to the tat siRNA respectively (Fig. 3B). LNA-tat-2
was designed to fully complement any siRNAs generated by three
Dicer processing reactions that are 21-bases apart. The results
show that only the tat siRNA guide derived from the shRNA tat or
lhRNA tat-rev-vif could be detected by both probes, which supports
the theory that there is a considerable drop in siRNA
concentration as Dicer processes along the lhRNA duplex.
Effect of spacing between siRNA-encoding sequences of
the lhRNAs on silencing efficacy
To assess the effect of the spacing between siRNA-encoding
sequences on silencing efficiency, the lhRNA rev-vif-tat encoding
cassette was modified by insertion or deletion of 1–4 bases at each
of the junctions of the siRNA-encoding sequences (Fig. 4A). When
these modified lhRNA rev-vif-tat-derived expression cassettes were
transfected into HEK293 cells together with psiCheck tat-rev-vif
target, the silencing efficacy of each of the RNAi effector
sequences was similar, and approximately 95% silencing was
achieved (Fig. 4B). Slightly diminished efficacy was observed for
lhRNA rev-vif-tat e. This sequence had a deletion of 2 bp at the rev-
vif junction, which may influence processing and silencing efficacy
of the siRNA originating from the stem base. Assessment of
silencing of individual tat, rev and vif targets again showed that the
silencing was greatest for each target cognate of the siRNA derived
from the stem base of the lhRNA sequence (Fig. 4C). When using
the psiCheck rev target, knockdown of approximately 90% was
achieved by all of the hairpins except for lhRNA rev-vif-tat e, which
again showed diminished efficacy. No rev siRNA guide was
observed for lhRNA rev-vif-tat e by northern blot when probing for
rev (Fig. 4D), explaining the lack of inhibitory activity for this
lhRNA species when detecting effects at the first position (for rev,
Fig 3C). Diminished knockdown of reporter gene activity was
observed when the fused target corresponded to the second
position siRNA within the lhRNA duplex. However, the different
spacing arrangements resulted in significant variation in silencing
efficiency at this position. Interestingly, lhRNA rev-vif-tat e was
more effective than each of the other lhRNA rev-vif-tat cassettes
against the vif target. The 2 bp deletion at the rev-vif junction of
lhRNA rev-vif-tat e may be the most optimal spacing arrangement
for the vif siRNA sequence, which is in the second position.
Inhibition of the reporter-tat target (third position) was largely
ineffective for all of the lhRNA variants. The results suggest that
there exists considerable leeway in improving first and second
Figure 1. HIV-1 C subtype genome with sites targeted by lhRNA and shRNAs. A. Organization of HIV-1 subtype C genome indicating open
reading frames (ORFs) together with the 59 and 39 long terminal repeats (LTRs). Arrows show the sites targeted by each of shRNA vif, shRNA tat and
shRNA rev, as well as the lhRNAs. B. Schematic illustration of lhRNAs comprising 69 bp in the stem. G:U pairings are indicated as corrugated sense
strand. A sequence of 2 U residues that are derived from the transcription termination signal is shown. The intended mechanism of transcription and
processing of the lhRNAs to form 3 anti HIV-1 siRNAs is illustrated. C. Sequences and predicted structure of lhRNAs and shRNAs. The order of the
siRNA-encoding sequences within the lhRNAs is indicated along the extent of the duplex. G:U and U:G pairings are indicated with an arrowhead.
doi:10.1371/journal.pone.0002602.g001
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position siRNA arrangements along an lhRNA duplex but that
third position siRNAs are unlikely to be dramatically improved by
these modifications.
Inhibition of HIV-1 replication in infected cells in culture
To assess the efficacy of lhRNA sequences in a culture model of
HIV-1 infection, U87.CD4.CCR5 cells were transfected with
various lhRNA expression plasmids followed by viral challenge
with a South African R5-tropic subtype C HIV-1 isolate, FV5
(accession: 05ZAFV5). Knockdown was assessed by determining
p24 antigen levels and viral RNA genome equivalents (Fig. 5A) in
the culture supernatant at day 6 post-infection. Of the lhRNA
expression cassettes, lhRNA tat-rev-vif was most effective and
achieved inhibition of markers of viral replication by 60–70%.
shRNA tat was the most effective of the shRNA expression
cassettes and effected inhibition of approximately 60%. Both
lhRNA rev-vif-tat and shRNA rev were less effective whereas lhRNA
vif-tat-rev and shRNA vif respectively had weak or no inhibitory
effect on HIV-1 replication in this cell culture model. The efficacy
of silencing was also observed longitudinally, again indicating the
ineffective silencing by shRNA vif and lhRNA vif-tat-rev (Fig. 5B) .
Silencing by the second and third position siRNAs from lhRNA
vif-tat-rev are not contributing to the inhibition of HIV-1
replication, but the first position is the most significant for the
other 2 lhRNAs. Analysis of the sequences of the targets from the
FV5 isolate (Fig. 5C) reveals that the putative hairpin-derived vif
guide is not perfectly complementary to its viral cognate and
includes 3 G:U wobble mismatches. Although, shRNA vif was
originally chosen as it proved to be effective at inhibiting viral
progression and replication [34], it is possible that inhibiting vif
may not immediately influence p24 output. To determine if the
FV5 vif target sequence is refractory to silencing by shRNA vif and
respective vif-containing lhRNAs, a psiCheck luciferase reporter
vector was constructed containing HXB2 and FV5 vif shRNA
target sequences. When compared to the inhibition of the HXB2
vif target, shRNA vif or lhRNA vif-tat-rev was unable to inhibit the
Figure 2. Knockdown of target-reporter fusion gene expression. A. psiCheck-derived vectors that include indicated HIV-1 target sequences
inserted downstream of the Renilla luciferase ORF. The control Firefly luciferase cassette, present on the same plasmid, is also shown. Both cassettes
are under control of constitutively active transcription regulatory elements: Herpes simplex virus thymidine kinase (HSV TK) and Simian virus 40
(SV40) promoters. B. Average normalized ratios of the Renilla:Firefly luciferase activity when cells were transfected with psiCheck tat-rev-vif dual
luciferase reporter plasmid together with lhRNA- or shRNA-encoding plasmid vectors. C. Average normalized ratios of the Renilla:Firefly luciferase
activity when cells were transfected with psiCheck tat, psiCheck rev or psiCheck vif dual luciferase reporter plasmids together with lhRNA- or shRNA-
encoding plasmid vectors. The average values from three independent transfection experiments, with standard deviations, are given (*, p,0.05, t-
test, relative to mock transfected control).
doi:10.1371/journal.pone.0002602.g002
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FV5 target (Fig 5D). These data may explain why no viral
inhibition was observed for shRNA vif and lhRNA vif-tat-rev
(Figs 5A,B). The results of the challenge assay support the previous
reporter knockdown data that lhRNA knockdown efficacy is
primarily mediated by first position siRNA sequences located at
the base of the duplex stem.
Discussion
The lhRNAs designed in this study were developed specifically
to generate three separate functional siRNAs targeting known
non-adjacent siRNA-susceptible regions of HIV-1. Such an
approach is of tremendous value to efforts aimed at combinatorial
RNAi strategies, where the targeting of highly mutagenic
sequences, such as HIV-1, may help prevent the emergence of
resistant viral variants [12,13]. Combinatorial RNAi approaches
applied to date include the use of multiple RNA Pol III promoters
to express shRNAs [15,35,36]. Various combinatorial shRNA-
expression systems have been shown to delay effectively the
emergence of shRNA-resistant HIV-1 in cell culture [15,36],
proving in principle the efficacy of a multiple targeting RNAi
strategy against a rapidly evolving target. However, there are
reservations about the use of multiple RNA Pol III expression
cassettes. Firstly, little is known about the long-term stability and
efficacy of such a system: adjacent repeat sequences may
recombine when delivered by viral vectors or when stably
expressed in rapidly dividing cells [36]. Secondly, and more
importantly, the use of multiple highly active RNA Pol III
promoters can potentially flood the cell with shRNAs and abrogate
the natural microRNA biogenesis pathway, leading to unwanted
toxicities [37–39]. It is clear that the presence of several
therapeutic hairpin species will require careful dosing in order to
achieve the desired levels of silencing.
To date, lhRNAs expressed from RNA Pol III promoters have
been used against a single contiguous target sequence in
mammalian cells. Previous reports targeting HCV and HIV have
suggested that lhRNAs (.50 bp) can adequately inhibit targets
harboring mutations that abrogate the silencing efficiency of 21 bp
shRNAs [24,30,33]. Yet, the efficacy of individually processed
siRNAs generated from expressed lhRNAs has not been
Figure 3. Northern blot analysis of RNA extracted from HEK293 cells that had been transfected with the indicated lhRNA and
shRNA-expressing plasmids. A. A single blot was probed with an oligonucleotide that was complementary to putative tat, rev and vif guide
sequences. B. The blot was probed with two 14-mer LNA oligonucleotides (LNA nucleotides underlined) which were complementary to the rev siRNA
guide sequence and adjacent nucleotides as indicated in the illustration. Both blots (from A and B) were stripped and reprobed with an
oligonucleotide complementary to U6 snRNA to control for equal RNA loading.
doi:10.1371/journal.pone.0002602.g003
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adequately characterized, making it difficult for direct compari-
sons between lhRNAs and shRNA when targeted to the same
sequence. We have previously observed that ,60 bp U6-
expressed lhRNAs targeted to a contiguous sequence within
HBV generated siRNAs more efficiently from the base of the
hairpin stem, and this correlated with greater silencing efficacy
[26]. However, we could not rule-out the possibility that second or
third Dicer cleavage reactions generate siRNAs with ineffective
guide sequences. We suspect that an increased variance of the
siRNA pool and decreased siRNA concentration for second and
third position cleavage products is likely to compromise the
efficacy of siRNAs generated from lhRNAs that require more than
two Dicer reactions. By placing three known effective siRNA
sequences adjacent to each other along a 69 bp lhRNA duplex,
some general principles concerning the efficacy of expressed
lhRNAs for combinatorial RNAi have been deduced. By
comparing different combinations of adjacent siRNA sequences
within a lhRNA duplex, we show that sequences at the base of the
hairpin stem are preferentially processed into effective siRNAs,
and that the pattern of silencing appears to be independent of the
siRNA sequence within the duplex. There was an exception, as
construct lhRNA rev-vif-tat e (Fig 4) was not able to generate a
guide strand for the first position. Some sequence differences do
exist between lhRNA rev-vif-tat e and other lhRNA variants, and it
may be possible that the sequence of the 2 nt 39 overhang plays a
role in siRNA recognition within RISC. The Paz domain of Dicer
is known to have biased preference for different 39 overhang
sequences [40], and differential selection of processed siRNAs by
the analogous Argonaut 2 Paz domain may occur similarly
[41,42]. Overall, these data are in agreement with Dicer’s
preference for cleaving dsRNA duplex ends with 2-nt 39-OH
overhangs [40,43–45] but suggests that intracellular Dicer
processivity is relatively inefficient. This perhaps underscores the
function of human Dicer as a single-turnover enzyme specialized
in generating mature miRNAs from a single cleavage reaction.
Initially, the three independent siRNA-encoding sequences
were placed within the lhRNA duplex such that they were spaced
at 23 bp intervals. Recently, Liu et al [32] showed that extended
shRNAs with two independent siRNAs functioned optimally as
independent siRNAs when spaced 4 bp apart. However, in our
hands, such spacing arrangements were not necessarily optimal
and it remains difficult to make gross generalizations regarding
Dicer-processing positions along an expressed dsRNA duplex at
this stage. Nevertheless, improvements in multiple targeting can be
achieved by further investigating the addition or deletion of
nucleotides at the siRNA junctions along the duplex. For one of
the lhRNAs, lhRNA rev-vif-tat, efficient processing of the second
siRNA was observed, albeit at reduced concentrations. If arranged
correctly, augmented knockdown can be achieved for two
independent siRNAs along a duplex, but this unlikely to be
possible for three siRNAs. Thus, one can envisage that use of
lhRNAs designed to efficiently inhibit at least two independent
siRNA-susceptible regions may help to delay the onset of HIV-1
escape variants, especially when targeting only conserved
Figure 4. Effect of nucleotide spacing between tat, rev and vif siRNA-encoding sequences on silencing efficacy. A. Schematic illustration of
hairpin sequences with boundaries between tat, rev and vif duplexes indicated. The sequences and numbers of bases inserted or deleted at the junctions
of the RNAi effecter-encoding sequences are indicated for each of lhRNA rev-vif-tat a to lhRNA rev-vif-tat g. B. Average normalized Renilla:Firefly luciferase
activity determined 48 hours after transfecting HEK293 cells with the psiCheck tat-rev-vif target together with each of lhRNA rev-vif-tat a to lhRNA rev-vif-
tat g. C. Average normalized Renilla:Firefly luciferase activity determined 48 hours after transfecting HEK293 cells with the psiCheck tat, psiCheck rev or
psiCheck vif target together with each of lhRNA rev-vif-tat a to lhRNA rev-vif-tat g. Results are given as the average values with standard deviations from
three independent transfection experiments. (*, p,0.05, t-test, relative to mock transfected control). Mock transfected cells received the empty backbone
U6+1 plasmid D. Northern blot analysis of RNA extracted from HEK293 cells that had been transfected with the indicated lhRNA and shRNA-expressing
plasmids. The blot was probedwith an oligonucleotide that was complementary to putative rev guide sequence. The blot was stripped and reprobedwith
an oligonucleotide complementary to U6 snRNA to control for equal RNA loading.
doi:10.1371/journal.pone.0002602.g004
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sequences [46]. It is unlikely that a third siRNA produced by Dicer
cleavage of an lhRNA will be present in sufficient concentration to
produce three effective siRNAs. We therefore provide a note of
caution for the use of lhRNAs containing more than two adjacent
siRNA sequences aimed at effective combinatorial RNAi.
Nevertheless, lhRNAs in combination with other multiple RNAi
effector sequences, such as Pol II-expressed multiple miRNA
precursors [14,18,19], are likely to provide an effective means of
targeting rapidly evolving sequences such as HIV-1.
In conclusion, we show that RNA Pol III-expressed lhRNAs are
capable of producing independent siRNAs that induce significant
knockdown of non-contiguous siRNA-susceptible regions of HIV-
1. Importantly, the position and arrangement of the siRNA-
encoding sequences along the lhRNA duplex plays an important
role in determining the overall efficacy of the lhRNA in target
suppression. Nonetheless, by optimizing the particular arrange-
ment of siRNA-encoding sequences along the lhRNA duplex,
effective multiple targeting is possible for up to two Dicer
processing reactions. We therefore provide a useful framework
for investigating the use of RNA Pol III-expressed lhRNAs aimed
at effective combinatorial RNAi in mammalian cells.
Materials and Methods
Target plasmids
The psiCheck target plasmids were prepared by directed
insertion of the XhoI-NotI digested HIV-1 PCR fragments into
the plasmid psiCheck2 (Promega, WI, USA) such that the target
sequences were within the 39 UTR of Renilla Luciferase. The
individual shRNA target sequences were amplified by PCR from
pNL4-3 template [47] using the following primers: sh tat target F
59- GAT CTC GAG AGT GTT GCT TTC ATT GCC AA-39
(29 nt), sh tat target R 59-GAT CGC GGC CGC GCA TTA CAT
GTA CTA CTT ACT GCT T-39 (37 nt). sh rev target F 59-GAT
CTC GAG AAG GTG GAG AGA GAG ACA GA-39 (29 nt), sh
rev target R 59-GAT CGC GGC CGC CAC CAA TAT TTG
Figure 5. HIV-1 challenge assay. U87.CD4.CCR5 cells were transfected with plasmids expressing the indicated hairpins and then subjected to
infection with an equivalent of TCID50 1000 particles of the HIV-1 FV5 viral isolate. Concentrations of HIV-1 p24 in the culture supernatant and viral
particle equivalents (A) were determined 6 days after infection. Results are expressed as the means with standard deviations of three independent
experiments (*, p,0.05, t-test, relative to mock transfected control). B. Replication kinetics of a representative experiment included in (A). C.
Sequence of lhRNA- and shRNA-derived tat, rev and vif guide sequences and complementary regions targeted within FV5 and HXB2 HIV-1 isolates.
Mismatches between the putative guide and target sequences are shown. Sequence numbering is based on isolate HXB2, accession K03455. D.
Knockdown of FV5 vif and HXB2 vif target-reporter fusion gene expression by shRNA vif and representative lhRNAs in HEK293 cells. Results are
expressed as the means with standard deviations of three independent experiments (*; p,0.05, t-test, between annotated samples).
doi:10.1371/journal.pone.0002602.g005
Long Hairpin RNA Processing
PLoS ONE | www.plosone.org 7 July 2008 | Volume 3 | Issue 7 | e2602
AGG GCT TC-39 (32 nt). sh vif target F 59-GAT CTC GAG
ATT TCA AGG AAA GCT AAG GA-39 (29 nt), sh vif target R
59-GAT CGC GGC CGC AAT GCC AGT CTC TTT CTC
CT-39 (32 nt). To generate a product consisting of all three target
sites adjacent to one another, complementary oligonucleotides
were treated with polynucleotide kinase (Promega, WI, USA),
annealed, and cloned directly into the XhoI-NotI sites of
psiCheck2. To facilitate screening, an EcoRV site was inserted
within each annealed dsDNA insert. The oligonucleotides used
include: target tat-rev-vif (+) 59- GAT CTC GAG GCG GAG
ACA GCG ACG AAG AGC TTG CCT GTG CCT CTT CAG
CTA CC-39 (53 nt) and target tat-rev-vif (2) 59-GAT CGC GGC
CGC GTG GGA TGT GTA CTT CTG AAC AAG GTA GCT
GAA GAG GCA CAG GC-39 (58 nt). Similarly, psiCheck clones
were constructed for a HXB2 and FV5 vif target: target FV5-vif
(+) 59-TCG AGA TAT CGT TCA GAA GTA CAT ATT CCA
TGC -39 and target FV5-vif (2) 59-GGC CGC ATG GAA TAT
GTA CTT CTG AAC GAT ATC -39; target HXB2-vif (+) 59-
TCG AGA TAT CGT TCA GAA GTA CAC ATC CCA CGC -
39 and target HXB2-vif (2) 59-GGC CGC GTG GGA TGT
GTA CTT CTG AAC GAT ATC -39.
Long hairpin RNA and short hairpin RNA expression
plasmids
The procedure for generating Pol III U6 shRNA cassettes has
been previously described [4,48]. A similar 2 step PCR approach
was used to produce the lhRNA and shRNA vectors complemen-
tary to the HIV-1 vif, tat, and rev genes. The first amplification was
carried out with a universal U6 forward primer and first lhRNA or
shRNA reverse primer with U6 promoter plasmid DNA as
template. The amplified product was used as template for a PCR
step with a second lhRNA or shRNA reverse primer and again the
universal U6 forward primer. The sequence of the U6 universal
forward primer was 59- CTA ACT AGT GGC GCG CCA AGG
TCG GGC AGG AAG AGG G-39. Sequences of the reverse
primers for the amplifications were as follows: lhRNA tat-rev-vif R1
59- CTT GAA ATG GAA TGT ATA CCT CTA AAC AAG
GCA GCC GAA GAG ACA CAG ACA AGC CCT TCA TCA
CTA TCC CCG CGG TGT TTC GTC CTT TCC ACA A -39
(94 nt), lhRNA tat-rev-vif R2 59- AAA AAA GCG GAG ACA
GCG ACG AAG AGC TTG CCT GTG CCT CTT CAG CTA
CCT TGT TCA GAA GTA CAC ATC CCA CTC TCT TGA
AAT GGA ATG TAT A -39 (94 nt). lhRNA rev-vif-tat R1 59- CTT
GAA GCC CTT CAT CAC TAT CCC CGC AAA TGG AAT
GTA TAC CTC TAA ACA AGG CAG CCG AAG AGA CAC
AGA CGG TGT TTC GTC CTT TCC ACA A -39 (94 nt),
lhRNA rev-vif-tat R2 59- AAA AAA GCC TGT GCC TCT TCA
GCT ACC TTG TTC AGA AGT ACA CAT CCC ACT TGC
GGA GAC AGC GAC GAA GAG CTC TCT TGA AGC CCT
TCA TCA C -39 (94 nt). lhRNA vif-tat-rev R1 59- CTT GAA GGC
AGC CGA AGA GAC ACA GAC AAG CCC TTC ATC ACT
ATC CCC GCA AAT GGA ATG TAT ACC TCT AAA CGG
TGT TTC GTC CTT TCC ACA A -39 (94 nt), lhRNA vif-tat-rev
R2 59- AAA AAA GTT CAG AAG TAC ACA TCC CAC TTG
CGG AGA CAG CGA CGA AGA GCT TGC CTG TGC CTC
TTC AGC TAC CTC TCT TGA AGG CAG CCG AAG A -39
(94 nt). shRNA tat R1 59- CTC TTG AAG CCC TTC ATC ACT
ATC CCC GCG GTG TTT CGT CCT TTC CAC AA -39
(50 nt), shRNA tat R2 59- AAA AAA GCG GAG ACA GCG
ACG AAG AGC TCT CTT GAA GCC CTT CAT CAC -39
(48 nt). shRNA rev R1 59- CTC TTG AAG GCA GCC GAA
GAG ACA CAG ACG GTG TTT CGT CCT TTC CAC AA -39
(50 nt), shRNA rev R2 59- AAA AAA GCC TGT GCC TCT TCA
GCT ACC TCT CTT GAA GGC AGC CGA AGA -39 (48 nt).
shRNA vif R1 59- CTC TTG AAA TGG AAT TGT ATA CCT
CTA AAC GGT GTT TCG TCC TTT CCA CAA -39 (50 nt),
shRNA vif R2 59- AAA AAA GTT CAG AAG TAC ACA TCC
CAC TCT CTT GAA ATG GAA TGT ATA -39 (48 nt). The
sequences for variants of lhRNA rev-vif-tat were: lhRNA rev-vif-tat b
R1 59- CTC TTG AAG CCC TTC ATC ACT ATC CCC GCA
AAT GGA ATG TAT ACC TCT AAA CAG GCA GCC GAA
GAG ACA CAG ACG GTG TTT CGT CCT TTC CAC AA-39
(95 nt), lhRNA rev-vif-tat b R2 59- AAA AAA GCC TGT GCC
TCT TCA GCT ACC TGT TCA GAA GTA CAC ATC CCA
CTT GCG GAG ACA GCG ACG AAG AGC TCT CTT GAA
GCC CTT CAT C-39 (91 nt). lhRNA rev-vif-tat c R1 59- CTC
TTG AAG CCC TTC ATC ACT ATC CCC GCT AAA TGG
AAT GTA TAC CTC TAA ACA GGC AGC CGA AGA GAC
ACA GAC GGT GTT TCG TCC TTT CCA CAA -39 (96 nt),
lhRNA rev-vif-tat c R2 59- AAA AAA GCC TGT GCC TCT TCA
GCT ACC TGT TCA GAA GTA CAC ATC CCA CTT AGC
GGA GAC AGC GAC GAA GAG CTC TCT TGA AGC CCT
TCA TCA -39 (93 nt). lhRNA rev-vif-tat d R1 59- CTC TTG AAG
CCC TTC ATC ACT ATC CCC GCT TAA ATG GAA TGT
ATA CCT CTA AAC AGG CAG CCG AAG AGA CAC AGA
CGG TGT TTC GTC CTT TCC ACA A -39 (97 nt), lhRNA rev-
vif-tat d R2 59- AAA AAA GCC TGT GCC TCT TCA GCT
ACC TGT TCA GAA GTA CAC ATC CCA CTT AAG CGG
AGA CAG CGA CGA AGA GCT CTC TTG AAG CCC TTC
ATC A -39 (94 nt). lhRNA rev-vif-tat e R1 59- CTT GAA GCC
CTT CAT CAC TAT CCC CGC GCG CAA ATG GAA TGT
ATA CCT CTA AAC GGC AGC CGA AGA GAC ACA GAC
GGT GTT TCG TCC TTT CCA CAA -39 (96 nt), lhRNA rev-
vif-tat e R2 59- AAA AAA GCC TGT GCC TCT TCA GCT
ACC GTT CAG AAG TAC ACA TCC CAC TTG CGC GCG
GAG ACA GCG ACG AAG AGC TCT CTT GAA GCC CTT
CAT CAC -39 (96 nt). lhRNA rev-vif-tat f R1 59- CTT GAA GCC
CTT CAT CAC TAT CCC CGC TTA AAT GGA ATG TAT
ACC TCT AAA CAA GGC AGC CGA AGA GAC ACA GAC
GGT GTT TCG TCC TTT CCA CAA -39 (96 nt), lhRNA rev-
vif-tat f R2 59- AAA AAA GCC TGT GCC TCT TCA GCT
ACC TTG TTC AGA AGT ACA CAT CCC ACT TAA GCG
GAG ACA GCG ACG AAG AGC TCT CTT GAA GCC CTT
CAT CAC -39 (96 nt). lhRNA rev-vif-tat g R1 59- CTT GAA GCC
CTT CAT CAC TAT CCC CGC TTA AAT GGA ATG TAT
ACC TCT AAA CGA AGG CAG CCG AAG AGA CAC AGA
CGG TGT TTC GTC CTT TCC ACA A -39 (97 nt), lhRNA rev-
vif-tat g R2 59- AAA AAA GCC TGT GCC TCT TCA GCT
ACC TTC GTT CAG AAG TAC ACA TCC CAC TTA AGC
GGA GAC AGC GAC GAA GAG CTC TCT TGA AGC CCT
TCA TCA C -39 (97 nt). The 63 bp lhRNA control plasmid,
lhRNA TAR, which was designed to target an irrelevant site
which included the HIV-1 TAR stem-loop (complementary to
positions 454–512, numbering according to HIV-1 HXB2
sequence, accession K03455), has been previously described
[26]. For all lhRNA constructs, each pair of primers had an
overlapping sequence of 19 bases that enabled extension of the
PCR product to generate a U6 promoter lhRNA cassette with a
RNA Pol III transcription termination signal [48]. Amplified PCR
products were ligated to a T/A cloning vector (pTZ57R/T,
Fermentas, WI, USA) to generate pTZ-U6 lhRNA and shRNA
plasmids. Sequences were confirmed by standard procedures.
Cell culture
The human embryonic kidney cell line, HEK293, was
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM,
BioWhittaker, MD, USA) supplemented with 10% heat inactivat-
ed fetal calf serum (FCS, Delta Bioproducts, Johannesburg, SA) at
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37uC and 5% CO2. The human astrocyte glioblastoma cell line,
U87.CD4.CCR5 (NIH AIDS Research and Reference Reagent
Program), was maintained in DMEM supplemented with 15%
heat inactivated FCS, 50 IU/mL Penicillin/50 mg/mL Strepto-
mycin mix (Gibco, BRL, UK), 1 mg/mL Puromycin (Merck,
London, UK), 300 mg/mL G418 (Sigma, MO, USA) and 1% L-
glutamine (Sigma, MO, USA) at 37uC and 5% CO2.
Transfections
Transfections were carried out using a ratio of 1 mL
Lipofectamine2000 (Invitrogen, CA, USA) to 1 mg total DNA
per well according to the manufacturer’s instructions. Media was
changed 24 hours post transfection, and analysis of cells was
carried out 24 hours thereafter. Equivalent transfection efficiencies
were verified by fluorescence microscopy by cotransfecting a
plasmid that constitutively produces enhanced green fluorescent
protein (pCI-eGFP) [49].
To evaluate the effects of the lhRNA and shRNA encoding
plasmids on a reporter target, HEK293 cells were seeded 24 hours
prior to transfection at 120 000 cells per well in 24 well culture
dishes. HEK293 cells were transfected with 150 ng of target
plasmid, 750 ng of lhRNA or shRNA encoding plasmid and
100 ng of pCI-eGFP.
To determine the induction of IFN response-related genes,
HEK293 cells were seeded as described above and transfected
with 900 ng of lhRNA or shRNA encoding plasmid and 100 ng
pCI-eGFP per well. Control double stranded RNA, poly (I:C)
(Sigma, MO, USA), was transfected at equivalent amounts to the
hairpin encoding plasmids.
For Northern blot analysis HEK293 cells were seeded at 80%
confluency in 10 cm culture dishes 24 hours prior to transfection.
Cells were transfected using Lipofectamine with 16 mg of lhRNA
or shRNA encoding plasmid, 3 mg of target plasmid, and 1 mg
pCI-eGFP.
To assess the effects of the lhRNA encoding plasmids on a
subtype C HIV-1 primary isolate in an infection challenge assay,
U87.CD4.CCR5 cells (NIH HIV/AIDS Reagent and Reference
Program) were washed with 16PBS, treated for 5 minutes with
16trypsin, counted as described above and seeded 24 hours prior
to transfection at 100 000 cells per well in 12 well culture dishes
using DMEM supplemented with 15% heat inactivated FCS only.
The following day, cells were co-transfected with 900 ng of lhRNA
encoding plasmid and 100 ng of pCI-GFP per well as described
above.
Dual luciferase assay
These were carried out according to the manufacturer’s
instructions (Promega, WI, USA) using a Veritas dual-injection
luminometer (Turner Biosystems, C A, USA). Target-specific
Renilla luciferase expression was normalized to background firefly
luciferase expression. Average expression ratios for a control
plasmid containing the U6 promoter was set to 100%, and relative
expression levels for other samples calculated accordingly. Two
independent experiments in triplicate were performed and the
data are expressed as the mean6standard deviation.
Viral propagation and challenge assay
FV5 is a primary HIV-1 CCR5-utilizing subtype C virus that was
isolated from a drug-naı¨ve HIV-positive AIDS patient admitted to
the Johannesburg Hospital AIDS clinic, and propagated by standard
PBMC co-culture techniques. The co-receptor tropism of FV5 was
established genotypically by automated sequencing of the V3 loop of
the viral env gene (accession 05ZAFV5), and confirmed phenotyp-
ically by MT-2 fusion assay. Twenty four hours post-transfection,
U87.CD4.CCR5 cells were infected with FV5 using a TCID50 1000.
Twenty four hours post infection cells were washed three times using
16PBS and fresh media was added. At days 0 (day of washing), 3, 5
and 6, 100 mL of supernatant was collected per well and analysed by
ELISA (Murex Biotech LTD, Dartford, UK) for p24 antigen
production as a marker of viral replication. Viral RNA was extracted
from 300 mL of day 6 supernatant using the COBAS Ampliprep
instrument (Roche, Germany), followed by a viral load assay with the
COBAS Amplicor (Roche, Germany) according to manufacturer’s
specifications. Day 0 p24 data was completed and in all cases no viral
p24 protein or RNA was detected indicating that all residual
infecting virus had been removed from the cultures.
Northern blot analysis
Total RNA was extracted from HEK293 cells using TriRea-
gentTM (Sigma, MO, USA) according the manufacturer’s
instructions 48 hours post-transfection. Twenty-five micrograms
of RNA was resolved on urea denaturing 15% polyacrylamide gels
and blotted onto nylon membranes. RNA molecular weight
markers, which were radioactively labeled as described below,
were run alongside the cellular RNA. Blots were hybridized to
three DNA oligonucleotides (probes tat, rev and vif) to detect
products of hairpin processing. These were complimentary to
regions spanning the antisense sequence of the long hairpin.
Probes were labeled at their 59 ends with [c-32 P] ATP and T4
polynucleotide kinase. After purification using standard proce-
dures, they were hybridized to immobilized RNA, exposed to X-
ray film and then stripped and reprobed. An oligonucleotide
sequence complementary to U6 small nuclear RNA was used as a
control to verify equal loading of the cellular RNA. Probe
oligonucleotide sequences were as follows: probe tat: 59-GCG
GAG ACA GCG ACG AAG AGC TT-39; probe rev: 59-GCC
TGT GCC TCT TCA GCT ACC TT-39; probe vif: 59-GTT
CAG AAG TAC ACA TCC CAC TT-39; and U6 small nuclear
RNA probe: 59-TAG TAT ATG TGC TGC CGA AGC GAG
CA-39. The LNA probe sequences were as follows: probe LNA-tat-
1: 59-ACT TGC GGA GAC AG-39; probe LNA-tat-2: 59-GCG
CGC GGA GAC AG-39. The LNA nucleotides are underlined.
Statistics
Statistical calculations were determined using the GraphPad
Prism software package (GraphPad, Software, Inc., CA, USA).
Statistical difference was considered significant when p,0.05 and
was determined using either an unpaired Student’s t-test or by
ANOVA.
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ABSTRACT
Human immunodeficiency virus type 1 (HIV-1) is a lentivirus that causes persistent infection result-
ing in the demise of immune regulatory cells, and ensuing diseases associated with acquired immune
deficiency syndrome (AIDS). Although current therapeutic modalities have had a significant impact
on mortality rates, novel therapies are constantly needed to prevent the emergence of resistant viral
variants that escape the effects of antivirals. RNA Interference (RNAi) is a promising therapeutic
modality for the inhibition of HIV-1 RNAs. Traditionally, RNAi effector sequences include ex-
pressed short hairpin RNAs (shRNAs) or short interfering RNAs (siRNAs). Recently, expressed long
hairpin RNAs (lhRNAs) have been used with the aim of generating multiple independent siRNAs,
which simultaneously target different susceptible sites on HIV-1. Here, modified lhRNAs expressed
from U6 RNA Pol III promoters were targeted to sites within the first transcribed sequences of the
HIV-1 5 long terminal repeat (LTR) region. Both Tat-dependent and independent suppressive effi-
cacy was demonstrated against subtype B and C reporter sequences; however, lhRNAs complemen-
tary to the TAR stem–loop were refractory to silencing. None of the lhRNAs induced an unwanted
interferon response as measured by interferon beta levels. Silencing by the lhRNAs was not equal
across the extent of its cognate sequence, with the greatest efficacy observed for sequences located at
the base of the stem. Nevertheless, direct antireplicative activity was seen when targeting lhRNAs to
a subtype B HIV clone pNL4-3 Luc and a subtype C wild-type HIV-1 strain, FV5. These data high-
light distinct target loci within the 5 LTR of HIV-1 that are susceptible to lhRNA targeting, and may
prove to have an important advantage over other RNAi target sites within HIV-1. Although lhRNAs
themselves require further manipulation to improve their overall efficacy in generating multiple
functioning siRNAs, they may prove useful in any combinatorial-based approach to treating HIV-1
infection.
INTRODUCTION
INFECTION with the human immunodeficiency virustype 1 (HIV-1) causes demise of CD4 immune regu-
latory cells. When untreated, this leads inexorably to
acquired immunodeficiency syndrome (AIDS) (Barre-
Sinoussi et al., 1983; Gallo et al., 1984; UNAIDS, 2005).
Clearance of HIV-1 by the immune system is inefficient,
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as integration of proviral DNA into the genome of host
cells acts as a permanent template for the production of
replicating virus. This is compounded by high viral muta-
tion rates that lead to variants that differ significantly
from the original viral lineage (Bhattacharya et al., 2007).
Current therapies aimed at inhibiting HIV-1 replication
include drugs that target reverse transcriptase (RT), pro-
tease (PR), and more recently, viral entry or fusion inhib-
itors. These agents, particularly in combinations of two
or more, have had an important impact on the morbidity
and mortality of HIV-related illness (Palella et al., 1998).
However, serious concerns regarding drug toxicity and
drug resistance has prompted the search for novel thera-
peutic approaches. Additionally, the efficacy of current
antiretroviral therapy is seriously threatened by the per-
sistence of latent viral reservoirs (Lassen et al., 2004).
Resistance to antiviral agents can be managed by vary-
ing existing treatment strategies and by developing novel
therapeutic agents (Daar and Richman, 2005). The emer-
gence of posttranscriptional knockdown approaches that
exploit the RNA Interference (RNAi) pathway has
proven to be a consistently potent mechanism of inhibit-
ing HIV-1 infection and replication in infected cell cul-
tures. Already there are promising RNAi-based candidate
therapeutic agents that are likely to be tested in future hu-
man clinical trials (Rossi, 2006).
Initial experiments involving RNAi as an anti-HIV
strategy have successfully targeted genomic and subge-
nomic RNAs of HIV-1, thereby inhibiting both early and
late stages of the viral life cycle (Coburn and Cullen,
2002; Jacque et al., 2002; Lee et al., 2002; Novina et al.,
2002; Surabhi and Gaynor, 2002; Morris and Rossi,
2004). Effective viral suppression has also been achieved
by targeting host-derived viral accessory proteins that are
necessary for viral replication (Novina et al., 2002; Chiu
et al., 2004; Ping et al., 2004; Ye et al., 2004; Anderson
and Akkina, 2005).
RNAi-based strategies against HIV-1 mostly involve
the use of RNA Polymerase (Pol) III-derived expression
cassettes that produce short hairpin RNAs (shRNAs).
These are often targeted to HIV-1-susceptible cells by
lentiviral vector delivery (Boden et al., 2004; Nishitsuji
et al., 2004; Li and Rossi, 2005). However, one major
drawback of using shRNAs has been the emergence of
shRNA viral escape mutants (Boden, 2003; Das et al.,
2004; Westerhout et al., 2005). Consequently, it has been
proposed that an effective RNAi-based approach to treat-
ing HIV-1 infection requires simultaneous targeting of
multiple sites (Berkhout, 2004; Grimm and Kay, 2007).
A recent innovation to multiple targeting has been to
adapt long double-stranded RNAs (dsRNA) (Park et al.,
2002; Diallo et al., 2003; Tran et al., 2004) into safe
RNAi-inducing agents in mammalian cells (Akashi et al.,
2005; Konstantinova et al., 2006). These constructs pro-
vide both potent and specific gene-silencing capabilities,
and appear to be processed into multiple short interfering
RNAs (siRNAs) by the intracellular RNAi machinery in
mammalian cells (Akashi et al., 2005; Nishitsuji et al.,
2006; Strat et al., 2006; Watanabe et al., 2006; Konstanti-
nova et al., 2007; Weinberg et al., 2007). Most impor-
tantly, intracellularly expressed long dsRNAs do not
elicit the type 1 interferon (IFN) response in vitro or in
vivo (Akashi et al., 2005; Weinberg et al., 2007).
Long dsRNA has been used to suppress HIV-1 when
targeted to nef (Yamamoto et al., 2002), and various long
hairpin RNA expression constructs (lhRNAs) have been
used successfully to suppress HIV-1 replication when
targeted to wild-type integrase (int) transcripts as well as
anti-int shRNA escape mutants (Nishitsuji et al., 2006).
HIV-1 tat, rev, and nef transcripts have also been suc-
cessfully targeted without the induction of an IFN re-
sponse (Konstantinova et al., 2006, 2007).
Importantly, most RNAi approaches to date have fo-
cused on targeting laboratory strains of HIV-1 subtype B
sequences, with little attention given to inhibiting pri-
mary subtype C sequences, which constitute the majority
(56%) of HIV-1 infections worldwide (UNAIDS, 2005).
Taking into consideration the importance of a multiple
targeted approach and the issue of viral latency, the first
180 nucleotides of the subtype C genomic RNA were
chosen for targeting using three 60-base pair (bp)
lhRNAs expressed from U6 RNA Pol III cassettes. The
targeted region is present within genomic and subge-
nomic viral RNA species and includes conserved cis-reg-
ulatory sequences within the R and U5 regions of the 5
long terminal repeat (LTR) of HIV-1 (Fig. 1). Impor-
tantly, the latent HIV-1 provirus only generates nonpro-
cessive mRNA transcripts due to the absence of the tran-
scriptional transactivator protein Tat. During active
transcription involving Tat, viral transcripts are
processed into complete mRNAs. In the current study,
expressed lhRNAs were investigated for their ability to
suppress viral replication and to inhibit Tat-mediated
processive and Tat-independent nonprocessive transcrip-
tion from both subtype B and C LTR promoters as an in-
dicator of their ability to target active as well as latent
forms of the virus.
MATERIALS AND METHODS
Target plasmids
The subtype B LTR-Luc vector, pLTR-Luc, has been
described previously (Jeeninga et al., 2000) (NIH AIDS
Research and Reference Reagent Program), and contains
an LTR promoter sequence derived from the HIV-1 LAI
molecular clone (Peden et al., 1991). To generate a sub-
type C LTR–luc construct, a two-step subcloning pro-
cesses was used. First, the LTR sequence from proviral
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samples of the HIV-1 isolate Du151 (Williamson et al.,
2003) were amplified with the following primers: Du151
LTR F 5-GATCGTCGACGATATCAGATCTGGAA-
GGGTTAATTTACTCTAAG-3 containing SalI, EcoRV,
and BglIII linkers, and Du151 LTR R 5-ATC-
GAATTCAAGCTTGTTCGGGCGCCACTGCTAGA-
GATTTTCCA-3 with HindIII, EcoRI linkers. Ampli-
fied PCR products were cloned into the T/A vector,
pTZ57R/T (Fermentas, Glen Burnie, MD) to generate
pTZ–Du151–LTR. Second, the Luc–SV40poly(A) se-
quence derived from the Firefly luciferase cassette of
plasmid pGL3 (Promega, Madison, WI) was amplified
by PCR using the following primers: Luc–SV40pA F 5-
ATTAGAATTCATGGAAGACGCCAAAAA-3 
Luc–SV40pA R 5-ATTAGGGCCCACTAGTAAGCT-
TACCACATTTGTAGAGGTTTTAC-3 containing ApaI,
SpeI, and HindIII linkers. PCR products were cloned into
the T/A vector pCR2.1 (Invitrogen, Carlsbad, CA) to
generate pCR2.1–Luc–SV40pA. For both constructed
plasmids, positive orientation clones were selected and
verified by sequencing. The BamHI–PstI digested frag-
ment of pCR2.1–Luc–SV40pA was directionally cloned
into the same sites in pTZ–Du151–LTR to generate the
expression plasmid pLTRc–Luc–SV40pA. The expres-
sion plasmid pLTRc–Luc–SV40pA–puro was con-
structed by amplifying the LTRc–Luc–SV40pA region
using primers Du151 LTR F and Luc–SV40pA R and 
inserting the PCR product in the T/A vector psiLent-
Gene-puro (Invitrogen) according to the manufacturer’s
instructions. pLTRc–Luc–SV40pA–puro was used to gen-
erate a stable HEK293 cell line under Puromycin selec-
tion (refer to Transfections). The psiCheck–LTR 2 target
plasmid was prepared by directed insertion of the XhoI–
NotI digested PCR fragment into the plasmid psiCheck2
(Promega) such that the LTR sequences are within the 3
UTR of Renilla Luciferase. The lhRNA LTR 2 target se-
quence was amplified by PCR amplification using 
LTR lhRNA 2 F (5-GATCTCGAGGAACCCACT-
GCTTAAGCCTC-3) and LTR lhRNA 2 R (5-GAT-
CGCGGCCGCTTTCCACACTAACACAAAGG-3)
primer combinations. To generate multiple short tar-
gets that “tile” the entire LTR lhRNA 2 target, comple-
mentary oligonucleotides were treated with polynu-
cleotide kinase (Promega), annealed, and cloned directly
into the XhoI–NotI sites of psiCheck2. To facilitate
screening, an EcoRV site was inserted within each an-
nealed dsDNA insert. The complementary oligonucleo-
tide sequences used were: LTR 2 Target A F 5-TCGA-
GATATCGAACCCACTGCTTAAGCCTCAAGC-3
and LTR 2 Target A R 5-GGCCGCTTGAGGCTTA-
AGCAGTGGGTTCGATATC-3; LTR 2 Target B F5-
TCGAGATATCTTAAGCCTCAATAAAGCTTGC-
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FIG. 1. Diagrammatic representation of the HIV-1 proviral genome depicting all viral open reading frames flanked by 5 and 3
long terminal repeat (LTR) sequences. A more detailed map of the 5 LTR promoter is shown, highlighting the important cis and
trans regulatory elements. The 60-bp sites targeted by the expressed lhRNAs are shown. LTR 1 spans the TAR loop completely
with LTR 2 and 3 adjacent downstream. The complete lhRNA target region spans conserved sequences within the R and U5 un-
translated transcript.
CGC-3 and LTR 2 Target B R 5-GGCCGCGGC-
AAGCTTTATTGAGGCTTAAGATATC-3; LTR 2
Target C F 5-TCGAGATATCCAATAAAGCTTGC-
CTTGAGTGCGC-3 and LTR 2 Target C R 5-GGC-
CGCGCACTCAATTCAAGCTTTATTGGATATC-3;
LTR 2 Target D F 5-TCGAGATATCTGCCTTGAGT-
GCTCTAAGTAGTGC-3 and LTR 2 Target D R 5-
GGCCGCACTACTTAGAGCACTCAAGGCA-
GATATC-3; LTR 2 Target E F 5-TCGAGATA-
TCGTGCTCTAAGTAGTGTGTGCCCGC-3 and LTR
2 Target E R 5-GGCCGCGGGCACACACTACTTA-
GAGCACGATATC-3.
Long hairpin RNA expression plasmids. The genera-
tion of the Pol III U6 shRNA II cassette has been previ-
ously described (Lee et al., 2002). A similar two-step
PCR approach was used to produce the lhRNA vectors
complementary to HIV-1 coordinates 454–512 (lhRNA
LTR 1), 507–565 (HIV lhRNA 2), and 566–624 (HIV
lhRNA 3) (numbering according to HXB2 sequence, ac-
cession K03455). The first amplification was carried out
with a universal U6 forward primer and first lhRNA re-
verse primer with U6 promoter plasmid DNA as a tem-
plate. The amplified product was used as a template for a
PCR step with a second lhRNA reverse primer and again
the universal U6 forward primer. The sequence of the U6
universal forward primer was 5-CTAACTAGTG-
GCGCGCCAAGGTCGGGCAGGAAGAGGG-3. Se-
quences of the reverse primers for the amplifications
were as follows: lhRNA LTR 1-R1 5-CCTCTC-
TTGAAGAGTCCCCTAAATAACCAGAGAACCCC-
CGGACTCAGATCCGGTCCACCCAGAAAGAAC-
CGGTGTTTCGTCCTTTCCACAA-3 (91 nt), lhRNA
LTR 1-R2 5-GATCTCTAGAAAAAAGGGTCTCT-
CTAGGTAGACCAGATCTGAGCCCGGGAG-
CTCTCTGGCTATCTAGGGAACCCTCTCTTGAA-
GAGTCCCC-3 (91 nt). lhRNA LTR 2-R1
5-TGCCCTCTCTTGAAAGACACACACCACT-CA-
GAACACCCAAGACAAACTTCATTAAGGCC-
TAAACAGTAGGCTCGGTGTTTCGTCCTTTCCA-
CAA-3 (94 nt), lhRNA LTR 2-R2 5-AAAAA-
AGAACCCACTGCTTAAGCCTCAAT-AAAGCT-
TGCCTTGAGTGCTCTAAGTAGTGTGTGCC-
CTCTCTTGAAAGAC-3 (79 nt), lhRNA LTR 3-R1 5-
GGAAATCTCTTGAACTCCCACACCAACA-
CAAAGAGTCTAAGAGACCTCCAGTCACCA-
GAATCACACAACAAACGGTGTTTCGTCCTTTC-
CACAA-3 (94 nt), lhRNA LTR 3-R2 5-AAAA-
AAGTCTGTTGTATGACTCTGGTAACTAGAGATC
C C T C A G A C C C T T T G T G T T A G T G T G G A A A -
TCTCTTGAACTCC-3 (79 nt). The lhRNA control
plasmid targeted to an irrelevant site (HBV), lhRNA
HBV, was constructed according to previously described
methods (Weinberg et al., 2007). Each pair of primers
had an overlapping sequence of 19 bases that enabled ex-
tension of the PCR product to generate a U6 promoter
lhRNA cassette with a transcription termination signal
(Castanotto et al., 2002). Amplified PCR products were
ligated to a T/A cloning vector (pTZ57R/T, Fermentas)
to generate pTZ–U6 lhRNA plasmids (pU6 lhRNA LTR
1, pU6 lhRNA LTR 2, and pU6 lhRNA LTR 3). The se-
quences were confirmed by standard procedures.
Cell culture. The human embryonic kidney cell line,
HEK293, were maintained in Dulbecco’s Modified Ea-
gle’s Medium (DMEM, BioWhittaker, Walkersville,
MD) supplemented with 10% heat-inactivated fetal calf
serum (FCS, Delta Bioproducts, Johannesburg, SA) at
37°C and 5% CO2 and transfected using the same
medium. The human astrocyte glioblastoma cell line,
U87.CD4.CCR5 (NIH AIDS Research and Reference
Reagent Program), was maintained in DMEM supple-
mented with 15% heat-inactivated FCS, 50 IU/mL Peni-
cillin/50 g/mL Streptomycin mix (Gibco, BRL, UK), 1
g/mL Puromycin (Merck, London, UK), 300 g/mL
G418 (Sigma, St. Louis, MO), and 1% L-glutamine
(Sigma) at 37°C and 5% CO2.
Transfections. HEK293 cells were seeded 24 hours
prior to transfection at 120,000 cells per well in 24-well
culture dishes. Transfections were carried out using 1 L
Lipofectamine 2000 to 1 g DNA per well as per the
manufacturer’s instructions (Invitrogen) with OptiMem
(Gibco, BRL). Media was changed 24 hours posttrans-
fection, and cells were assayed 24 hours thereafter.
To generate a stable cell line that constitutively ex-
presses Firefly luciferase from a HIV-1 subtype C 5LTR
promoter, HEK293 cells were seeded 24 hours prior to
transfection at 2.5 million cells per 10-cm dish and trans-
fected with 10 g pLTRc–Luc–SV40pA–puro using
Lipofectamine 2000 as described above. Media was
changed 24 hours posttransfection and supplemented
with 1 g/mL Puromycin for selection of stable clones.
Single colonies were picked roughly 4 weeks following
transfection and maintained in DMEM supplemented
with antibiotic until a functional assay had been per-
formed. This included assessment of basal and Tat-trans-
activated Firefly luciferase expression levels as described
below. Thereafter stable cells were maintained as de-
scribed above.
To determine the effects of the lhRNA encoding plas-
mids on a reporter target, HEK293 cells were transfected
with 90 ng of target plasmid, 900 ng of lhRNA encoding
plasmid, and 10 ng of a plasmid vector that constitutively
produces enhanced green fluorescent protein (pCI–
eGFP) per well (Passman et al., 2000) . Where necessary,
90 ng of pCMV–Tat (a gift from J. van Harmelen) or 
pCI neo (Promega) control were included per well.
Equivalent transfection efficiencies were verified by flu-
orescence microscopy. Where target plasmids only con-
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tained a Firefly luciferase expression cassette, 5 ng of Pol
II CMV driven Renilla luciferase encoding plasmid
(pRSV–RLuc, a gift from J.J. Rossi) was included per
sample.
To evaluate the lhRNA constructs on targeting and
downregulation of a subtype B-based HIV-1 molecular
clone, HEK293 cells were seeded as described above and
cotransfected with 40 ng pNL4-3.Luc.ER, 20 ng
pRSV–Ren (Renilla luciferase encoding plasmid), 80 ng
pBluescript SK (Strategene, La Jolla, CA) (carrier) and
40 ng of the lhRNA construct of interest using Lipofecta-
mine 2000 as described above. pNL4-3.Luc.ER is a
luciferase reporter HIV-1 clone provided by the NIH
AIDS Research and Reference Reagent Program that
consists of pNL4-3 with the gene for the firefly luciferase
reporter fused to the 5-end of the nef coding region using
NotI and XhoI sites. Two frame shifts render this clone
Env and Vpr, and therefore competent for a single
round of replication (Connor et al., 1995; He et al.,
1995).
To assess the effects of the lhRNA encoding plasmids
on a subtype C-based WT HIV-1 strain in a challenge as-
say, U87.CD4.CCR5 cells were washed with 1  PBS,
treated for 5 minutes with 1  trypsin, counted as de-
scribed above, and seeded 24 hours prior to transfection
at 100,000 cells per well in 12-well culture dishes using
DMEM supplemented with 15% heat-inactivated FCS
only. The following day, cells were cotransfected with
900 ng of lhRNA encoding plasmid and 100 ng of
pCI–GFP per well as described above.
Dual luciferase assay. These were carried out accord-
ing to the manufacturer’s instructions (Promega). The
samples were assayed in a Veritas dual-injection lumi-
nometer (Turner Biosystems, Sunnyvale, C A). Target-
specific Firefly luciferase expression was normalized to
background Renilla luciferase expression. Average ex-
pression ratios for control lhRNA HBV was set to 100%,
and relative expression levels for other samples calcu-
lated accordingly. Two independent experiments in trip-
licate were performed, and the data are expressed as the
mean  standard error of the mean (SEM). Statistical
difference was considered significant for p  0.05. A
Dunnett’s multiple comparison was calculated with the
GraphPad Prism software package (GraphPad Software
Inc., San Diego, CA).
Quantitative real-time RT-PCR. To measure concen-
trations of IFN response-related genes, total RNA from
lhRNA or control plasmid transfected HEK293 cells was
extracted using TriReagent™ (Sigma) according to the
manufacturer’s instructions. RNA pellets were resus-
pended in 10 L of nuclease free water, DNAse treated
for 60 minutes at 37°C, and reverse transcribed using
Sensiscript (Qiagen, GmbH, Germany) and oligo-dT
primer (10 M) according to the manufacturer’s instruc-
tions. The following primer sets (IDT, Coralville, IA)
were used to amplify IFN- and GAPDH mRNA: IFN-
Forward: 5-TCC AAA TTG CTC TCC TGT TGT GCT-
3, IFN- Reverse: 5-CCA CAG GAG CTT CTG ACA
CTG AAA A-3, GAPDH Forward: 5-AGG GGT CAT
TGA TGG CAA CAA TAT CCA-3 and GAPDH Re-
verse: 5-TTT ACC AGA GTT AAA AGC AGC CCT
GGT G-3. All real-time PCRs were carried out using the
Roche Lightcycler V.2. Controls included water blanks
and RNA extracts that were not subjected to reverse tran-
scription. Taq Readymix with SYBR green (Sigma) was
used to amplify and detect DNA during the reaction.
Thermal cycling parameters consisted of a hot start for 30
seconds at 95°C followed by 50 cycles of 95°C for 10
seconds, 58°C for 10 seconds, and 72°C for 10 seconds.
Specificity of the PCR products was verified by melting
curve analysis.
Viral propagation and challenge assay. FV5 is a pri-
mary HIV-1 CCR5-utilizing subtype C virus that was
isolated from a drug-naive HIV-positive AIDS patient
admitted to the Johannesburg Hospital AIDS clinic, and
propagated by standard PBMC coculture techniques. The
coreceptor tropism of FV5 was established genotypically
by automated sequencing of the V3 loop of the viral env
gene (Accession 05ZAFV5), and confirmed phenotypi-
cally by MT-2 fusion assay. Twenty four hours posttrans-
fection, U87.CD4.CCR5 cells were infected with FV5 us-
ing a TCID50 1000. Twenty-four hours postinfection cells
were washed three times using 1  PBS and fresh media
was added. At days 0 (day of washing) and 4, 100 L of
supernatant was collected per well and analyzed by
ELISA (Murex Biotech LTD, Dartford, UK) for p24
antigen production as a marker of viral replication. Day 0
p24 data was completed, and in all cases no viral p24
protein was detected, indicating that all residual infecting
virus had been removed from the cultures (data not
shown).
RESULTS
Because lhRNAs can be processed by Dicer to gener-
ate multiple siRNAs, such constructs have the distinct
advantage of limiting the possibility for viral escape in-
duced by base changes to sites targeted by single siRNA
sequences. In this study we generated three U6 snRNA
RNA Pol III promoter-driven cassettes (LTR lhRNA
1–3) that encode lhRNAs with 60-bp stems targeted to
conserved adjacent sites within the R/U5 (untranslated
region) of the HIV-1 subtype C 5 LTR promoter (Fig.
1). The lhRNAs were designed to include G:U mis-
matches (approximately every 4–8 nt) within the sense
strand to facilitate cloning and to prevent the possible in-
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duction of the IFN response by dsRNA-dependent pro-
tein kinase R (PKR) (Akashi et al., 2005) (Fig. 2A and
C). Initially, the inhibitory effects of the three lhRNAs
were determined by transient cotransfection with subtype
B (LTRb) and subtype C (LTRc)-derived LTR-driven lucif-
erase reporter constructs. The LTRc sequence used in this
study, Du151, was derived from a local South African iso-
late (Williamson et al., 2003), while the LTRb sequence
corresponds to the LAI molecular clone (Jeeninga et al.,
2000; Peden et al., 1991) (Fig. 2B and C).
Transient cotransfections in cell culture showed that
two of the three lhRNAs efficiently reduced LTR-driven
luciferase activity in the presence or absence of exoge-
nously supplied Tat (Fig. 2D and E). However, lhRNA
LTR 1, which targets the region containing the stable
TAR loop, proved to be ineffective in the context of both
subtype B and C LTR sequences. These data are in line
with previously observed studies which have shown that
the TAR loop is refractory to siRNA-mediated inhibition
(Yoshinari et al., 2004). For lhRNA LTR 2 and 3, there
were differences in the degree of inhibition when tar-
geted to either LTRb or LTRc sequences. Interestingly,
lhRNA LTR 2 was particularly effective against LTRb
sequences, while conversely, lhRNA LTR 3 was more
effective against LTRc sequences. LhRNA LTR 2 inhib-
ited LTRb and LTRc-driven luciferase activity by 61%
and 39%, respectively, in the presence of Tat; and by
75% and 69%, respectively, in the absence of Tat. Simi-
larly, lhRNA LTR 3 inhibited LTRb and LTRc-driven lu-
ciferase activity by 42% and 78%, respectively, in the
presence of Tat; and by 53% and 86%, respectively, in
the absence of Tat. Minor sequence variations exist be-
tween LTRb and LTRc targets, and these may be respon-
sible for the differences in efficacy for both lhRNAs LTR
2 and LTR 3 (Fig. 2C). This is especially the case for
lhRNA LTR 3, where the target LTRb has a G (compared
to an A for LTRc) at position 575, 10 nucleotides from
the base of the stem (Fig. 2C). Because siRNAs have
been shown previously to be generated predominantly
from the stem region of a lhRNA duplex (Weinberg et
al., 2007), sequence changes in this regions may have a
dramatic effect on the efficacy of a given lhRNA.
Following infection of HIV-1 permissive cells, the
virus integrates into the host chromosome forming a
proviral copy of its genome and establishing a latent in-
fection. To test the efficacy of lhRNAs at suppressing
their cognate mRNAs when expressed from an integrated
(as opposed to an episomal) target, transfections where
performed in an LTRc-driven Firefly luciferase stable
cell line (Fig. 2F). The pattern of inhibition following
transient transfection of lhRNAs in the presence or ab-
sence of Tat was largely the same, with a slightly better
inhibitory effect seen in the presence of Tat. Moreover,
as shown previously, lhRNA LTR 3 proved to be the
most effective lhRNA against a stably-expressed LTRc
target. Interestingly, a nonspecific lhRNA targeted to an
unrelated hepatitis B virus sequence (lhRNA HBV) also
showed minor suppressive activity, which may be due to
some nonspecific off-target effects (Fig. 2F). Neverthe-
less, these data suggest that minor sequence variations
may be tolerated by lhRNAs, suggesting that these se-
quences may provide important advantages for their use
against multiple HIV-1 strains, viral escape mutants, and
possibly latently infected virus. This is further demon-
strated by the ability of the lhRNAs to inhibit both non-
processive (Tat-dependent) and processive (Tat-indepen-
dent) transcripts, in principle showing inhibition of early
and late events in the life-cycle of HIV-1.
Although efficient RNAi can be induced by lhRNAs
expressed from intracellular gene vectors, differentiated
mammalian cells can react to these constructs by activat-
ing a global IFN response. At worst, this results in non-
specific mRNA degradation, translational suppression,
and cell death via apoptosis. The IFN response mediates
antiviral or antigrowth activities, and is elicited by inter-
action of dsRNA with cellular proteins such as PKR,
myxovirus A (MxA), and 2,5-oligoadenylate synthase
1 (OAS1) genes, among others. The use of dsRNA  30
bp, and specifically the use of 21-bp short-interfering
RNAs (siRNAs), was initially shown to evade stimulat-
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FIG. 2. Long hairpin RNAs mediate targeted suppression of HIV-1 subtype B and C LTR-driven Firefly luciferase reporter con-
structs. (A) LhRNAs were designed to be expressed as 60-bp transcripts from a U6 Pol III cassette containing G:U wobble mis-
matches within the sense strand of the duplex. (B) Two separate Firefly reporter constructs were generated by cloning the subtype
C (strain Du151) or subtype B (strain NL4-3) LTR promoter of HIV-1 upstream of a GL3 Firefly luciferase open reading frame. A
CMV Pol II cassette expressing Renilla luciferase was used as a background control in cotransfections. (C) Alignment and com-
parison between LTRb and LTRc sequences derived from isolates LAI and Du151, respectively. Long hairpins are shown with re-
spect to their cognate target sequence, and G:U wobbles are in bold text. Numbering is according to the molecular clone HXB2. 
(D and E) Three lhRNAs and controls were cotransfected with target reporter constructs in the presence and absence of exogenous
Tat in HEK293 cells. Data is expressed as a ratio of firefly to Renilla luciferase normalized to a nonspecific lhRNA HBV control
determined 48 hours posttransfection (n  3, SEM). (F) Three lhRNAs and controls were transfected in the presence of exoge-
nous Tat in HEK293 cells stably expressing subtype C LTR-driven Firefly luciferase. Data is expressed as an average Firefly lu-
ciferase value normalized to an empty vector control determined 48 hours posttransfection.
ing the type 1 IFN response (Elbashir, 2001; Sledz et al.,
2003). As an index of activation of an interferon response
by the lhRNAs used in this study, we assayed interferon
beta (IFN-) expression in the presence and absence of
Tat by quantitative real-time RT-PCR. None of the con-
structs elicited IFN- expression compared to a dsRNA
control (Fig. 3A), and moreover, cell viability and trans-
fection efficiencies were conserved in control and lhRNA-
treated cultures (Fig. 3B). These data suggest that the
lhRNAs are capable of inhibiting HIV-1 gene expression
without inducing an unwanted toxic cellular response.
The lhRNAs used here were generated to target 60
bp of cognate HIV-1 sequence. To characterize Dicer-
mediated processing of the lhRNAs, a knockdown assay
was performed on “tiled” segments of the lhRNA LTR 2
target sequence. Briefly, a set of target luciferase reporter
vectors were constructed that span either the complete
LTR 2 sequence or shorter overlapping segments that to-
gether cover the entire LTR 2 target site (Fig. 4A). These
sequences were placed in the 3 UTR of a Renilla lucifer-
ase reporter construct and Firefly luciferase was used as
an internal control (Fig. 4B). Following cotransfection
with either the complete lhRNAs or their sense or anti-
sense counterparts alone, suppression was only observed
when the entire LTR 2 Target site or Target A site was
present (Fig. 4C). Target A corresponds to the first 22 bp
of the complete sequence, suggesting that the majority of
siRNAs generated from the lhRNAs by Dicer occurs
from the 5 end of the lhRNA stem. These observations
are in accordance with our previously published results
that indicate that siRNAs are preferentially produced
from the stem region of a U6-generated lhRNA (Wein-
berg et al., 2007).
The ability of the various lhRNAs to suppress HIV-1
viral replication was determined using two different as-
says. First, LTR lhRNAs were cotransfected with a 
HIV-1 subtype B molecular clone (pNL4-3 Luc), and lu-
ciferase activity was measured. These results revealed a
similar pattern of suppression, with LTR lhRNA 2 again
proving to be the most effective lhRNA construct when
targeted to a subtype B LTR sequence (79% knock-
down). However, the knockdown efficiency was lower
than that observed for shRNA II, a previously described
shRNA that targets a conserved region of the Rev open
reading frame (Lee et al., 2002) (Fig. 5A). Second, LTR
lhRNAs were transfected into U87.CD4.CCR5 cells that
were subsequently challenged with a South African R5-
tropic subtype C HIV-1 isolate, FV5. Knockdown was
assessed by determining p24 antigen levels at day 4
postinfection. Both LTR lhRNA 2 and 3 inhibited HIV-1
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FIG. 3. Long hairpin RNAs targeted to the LTR of HIV-1 subtype C do not elicit a nonspecific interferon response. (A) As an in-
dex of the activation of interferon induction, quantitative real-time RT PCR was used to determine the expression of IFN- relative
to GAPDH expression 48 hours posttreatment in treated cell cultures. The dsRNA complex Poly I:C was used as a positive control
(n  3,  SEM). (B) HEK293 cells were cotransfected with the lhRNA expressing constructs and pCI–eGFP, a GFP expressing
plasmid, to verify equivalent transfection efficiencies between samples 48 hours posttransfection. Data is represented at 100
original magnification.
replication by 50% relative to a nonspecific lhRNA
control (Fig. 5B). Surprisingly, lhRNA LTR 1 also
showed some suppression, which may indicate that in the
context of a replicating virus, RNAi-refractory secondary
structures may become temporarily accessible for cleav-
age. Yoshinari et al. (2004) has previously shown that if
secondary structural elements in the TAR stem–loop are
relaxed, this region is sensitive to siRNA-mediated sup-
pression. These results are an encouraging proof of con-
cept because while the knockdown efficacy of the LTR-
specific lhRNAs is not as marked when compared to the
U6-expressed anti-Tat/Rev shRNA, these data were gen-
erated from a transfection assay. We plan to improve
knockdown by transducing cells with a lentiviral vector
carrying a LTR-specific lhRNA payload.
DISCUSSION
The lhRNAs generated in this study were specifically
designed to target pregenomic and viral mRNAs species
that include the first 180 nucleotides of transcribed se-
quences within the R/U5 5 UTR region of the HIV-1
LTR in an effort to block both early and late stages of the
viral life cycle. Although two out of the three lhRNAs
were capable of suppressing viral RNAs in vitro and in
vivo, there was a notable lack of suppression by LTR
lhRNA 1. This was probably due to the target site and not
the RNAi effector itself, as the LTR 1 sequence overlaps
completely with the TAR loop found in all HIV-1 tran-
scripts and the extensive secondary structure of this site
may cause this region to be refractory to RNAi mediated
inhibition (Yoshinari et al., 2004).
The use of shRNAs in concert involves the introduc-
tion of multiple expression cassettes into a cell, each of
which requires RNAi machinery to generate functional
siRNAs from the DNA based vector. This scenario may
lead to promoter occlusion either through competition for
transcription factors, or competitive inhibition of siRNA
precursors for RNAi processing machinery, or a combi-
nation of these two factors. Therefore, an advantage of
using long hairpin RNAs is that a single RNA Pol III pro-
moter expresses a single transcript that can be processed
by cellular Di into siRNAs that target multiple sites.
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FIG. 4. Silencing efficiency across the region spanning the lhRNA LTR 2 and 3 target sites. (A and B) The complete LTR2/3
target as well as 22-bp individual sequences (LTR 2 Targets A–E) that overlap to span only the LTR 2 sequence were inserted
downstream of the Renilla luciferase open reading frame within the pSiCheck vector. The tiled target sites (A–E) are depicted rel-
ative to the complete sequence (LTR). (C) Suppression efficiency of lhRNA 2, and controls were determined at 48 hours post-
transfection against the complete target and individual tile targets. Data is expressed as a ratio of Firefly to Renilla luciferase nor-
malized to an empty vector control (n  3, SEM).
Another advantage of using lhRNAs that can be
spliced into multiple siRNAs is their potential limitation
of the evolution of viral escape mutants. Certainly the in
vitro data presented here argues for some tolerance of se-
quence variation by the lhRNAs that may prove useful
when targeting various strains or subtypes of HIV-1.
However, a larger number of variant strains would need
to be tested to confirm these findings. Expression of both
HIV-1 subtype B and C LTR sequences were effectively
suppressed by the lhRNAs used here, although minor se-
quence variations in the targets, such as that seen in
lhRNA LTR 3 at position 575 (Fig. 2C), may have re-
sulted in the observed differences in inhibition.
At present, it remains unclear whether long dsRNAs
actively generate effective multiple siRNAs. We have
previously shown that RNA Pol III expressed lhRNAs
(between 50 and 100 bp) targeted to the HBV X open
reading frame are preferentially processed into siRNAs
at the duplex stem base, with processing and knockdown
efficacy tapering-off across the full length of the duplex
(Weinberg et al., 2007). These results are in accordance
with our LTR 2 “tiling” array studies (Fig. 4), which sug-
gest that multiple siRNAs may not be processed effi-
ciently from a single lhRNA template. These effects may
be due to inefficiencies in the processing of multiple
rounds by intracellular Dicer. Alternatively, siRNAs that
are processed along the duplex may not be functionally
active, because the incorrect strand could be selected into
RISC.
The two lhRNAs that showed the best suppressive ef-
fects exhibited knockdown in the presence and absence
of Tat when targeted to an episomal site. Furthermore, a
similar pattern was observed in the presence of an inte-
grated target. This may have important implications for
the treatment of latently infected pools of cells (Morris
and Rossi, 2006). Following integration of the viral ge-
nome into host chromosome, initial HIV-1 transcripts do
not elongate (nonprocessive transcription) unless Tat is
present to aid RNA Pol II. Current antiretrovirals are
only active against replicating forms of HIV-1, and thus,
any potential therapeutic that targets latent virus will be a
useful addition to existing antiretroviral regimens.
Progress on the use of RNAi as a single anti-HIV ther-
apeutic or in combination with other treatment strategies
has been slowed by concerns regarding the delivery of
large nucleic acid complexes to CD4 lymphocytes and
with the emergence of drug-resistant viral mutants (Mor-
ris, 2006). These problems have been exacerbated by the
recent observation that manipulation of the natural RNAi
pathway within mammalian cells can lead to saturation
of cellular RNAi components and serious off-target ef-
fects, leading in some cases to death in animal studies
(An et al., 2006; Grimm et al., 2006). Consequently, the
applicability of RNAi as an adjunctive anti-HIV therapy
will require a careful understanding of specific dosage re-
quirements. Nevertheless, the data presented here sug-
gest that off-target effects, as characterized by the IFN
response, is not being elicited in the presence of lhRNAs,
although further in vivo studies remain necessary.
Recently, a conserved HIV-1 int region was success-
fully targeted with a U6-expressed 50-bp lhRNA. This
study showed that lhRNAs were capable of suppressing
viral replication in a variant resistant to an anti-int
shRNA (Nishitsuji et al., 2006). However, it remains un-
clear whether these lhRNA constructs are capable of de-
laying the onset of viral escape. In addition, for some
longer hairpin duplexes (	100 bp and up to 1000 bp), the
silencing efficacy appears to be highly variable in a
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FIG. 5. Long hairpin RNA silencing of HIV-1 gene expres-
sion. (A) The three lhRNAs, control lhRNA HBV and a shRNA
control targeted to Tat were cotransfected with HIV-1 subtype
B clone pNL3-4 Luc in HEK293 cells and relative Firefly lucif-
erase expression determined 48 hours later. Data is expressed as
a ratio of Firefly to Renilla luciferase normalized to a nonspe-
cific lhRNA HBV control (n  3,  SEM). (B) Challenge as-
say testing all three lhRNAs against HIV-1 subtype C FV5
strain at a TCID50 1000. Viral p24 antigen was assayed 4 days
postinfection by ELISA. Data is expressed as a percentage
knockdown relative to a nonspecific lhRNA HBV control (n 
3, SEM).
mammalian cell context. Recently, a replication-compe-
tent nef-deleted HIV-1 variant with a 300-bp lhRNA tar-
geted to nef showed significant inhibition of HIV-1 in
trans, although, intriguingly through a non-RNAi-medi-
ated mechanism (Konstantinova et al., 2007). Unfortu-
nately, longer hairpin duplexes often result in lower
lentiviral titres due in part to the instability of hairpin
RNAs in the packaging RNA (Konstantinova et al.,
2007). These complications may be resolved in future by
packaging lentiviruses in cells defective in one or more
RNAi component, or by introducing mismatches such as
G:U wobbles within the long hairpin duplex.
In conclusion, lhRNAs might prove efficacious in sup-
pressing HIV-1 replication while avoiding the emergence
of viral variants. The lhRNAs described in this study are
functional in suppressing LTR-driven luciferase activity
across differing subtypes of HIV-1 that including sub-
type B and C sequences. Moreover, we have shown that
lhRNAs are active against processive and nonprocessive
transcripts, and do not induce a detectable IFN response.
Importantly, these anti-LTR lhRNAs showed knock-
down against a primary isolate of HIV-1. Future plans in-
clude the incorporation of these RNAi effectors into
lentiviral vectors. These will then be assessed for their ef-
ficacy against viral isolates following transduction into
HIV-1 permissive lymphocytes and followed longitudi-
nally to determine the ability of the lhRNAs at preventing
or delaying the emergence of escape mutants.
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